Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN PHARMACEUTICAL EXCIPIENTS AND FORMULATION PUBLISHED FROM 2006 TO 2007



Application No.: US20060002905A1  Published: 05/Jan/2006

Title: Mutant forms of EtxB and CtxB and their use as carriers

Applicant/Assignee: HUNTER IMMUNOLOGY LTD

Application No.: 10/743391   Filing Date: 22/Dec/2003

Abstract:The present invention describes the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity

but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.

Priority: GB20010015382 Applic. Date: 2001-06-22; WO2002GB02829 Applic. Date: 2002-06-20

Inventor: HIRST TIMOTHY R [AU]


Application No.: US20060002998A1  Published: 05/Jan/2006

Title: Pharmaceutical dosage forms of biguanide-sulfonylurea combinations

Applicant/Assignee:

Application No.: 10/534908   Filing Date: 13/May/2005

Abstract:The present invention relates to orally administered pharmaceutical compositions that include a combination of antidiabetic agents wherein one agent is present in an extended release form and the other agent is present in an immediate release form. For example, in one embodiment the dosage form includes an extended release layer that includes a biguanide

and an immediate release layer that includes a sulfonylurea.

Priority: IN2002DE01154 Applic. Date: 2002-11-15; WO2003IB05206 Applic. Date: 2003-11-17

Inventor: TREHAN ANUPAM [IN]; MADAN SUMIT [IN]; ARORA VINOD K [IN]; MALIK RAJIV [IN]


Application No.: US20060003010A1  Published: 05/Jan/2006

Title: Pharmaceutical formulations for the safe administration of drugs used in the treatment of drug addiction and processes for obtaining the same

Applicant/Assignee: IBSA INSTITUT BIOCHIMIQUE S.A

Application No.: 11/170314   Filing Date: 28/Jun/2005

Abstract:The present invention provides safe pharmaceutical formulations for drugs used in the treatment of drug addiction, namely formulations which render the abusive administration of the drug contained in these formulations not feasible, together with processes for obtaining said formulations.

Priority: IT2004MI01317 Applic. Date: 2004-06-30

Inventor: ECHANAGORRIA ANGEL M [IT]; BRAMBILLA LUIGI [IT]; IACCHETTI GIOVANNI [IT]


Application No.: US20060003962A1  Published: 05/Jan/2006

Title: Methods and products related to treatment and prevention of hepatitis C virus infection

Applicant/Assignee: COLEY PHARMACEUTICAL GMBH

Application No.: 11/183253   Filing Date: 15/Jul/2005

Abstract:The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.

Priority: WO2003IB05520 Applic. Date: 2003-10-29; US20020421987P Applic. Date: 2002-10-29

Inventor: AHLUWALIA NAVNEET K [CA]; EFLER SUSAN M [CA]; DAVIS HEATHER L [CA]; VOLLMER JORG [DE]


Application No.: US20060004207A1  Published: 05/Jan/2006

Title: Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methods

Applicant/Assignee: LEK PHARMACEUTICALS D.D

Application No.: 10/524993   Filing Date: 18/Feb/2005

Abstract:Pharmaceutically suitable crystalline and amorphous alkali and earth-alkali salts of 2-n-butyl-4-chloro-5-hidrox-ymethyl-1-[[2'-(1H-tetrazole-5-yl)[1.1'-biphenyl]-4-yl]-1 Himidazole have been prepared and new manufacturing, purification and isolation procedure for said salts in high purity have been described. Stable pharmaceutical compositions containing new crystalline potassium salts of 2-n-butyl-5-chloro-5hidroxymethyl-1-[[2'-(1H-tetrazole-5-yl)[1.1'-biphenyl]-44-yl]-1H-imidazole have been prepared.

Priority: SI20030000026 Applic. Date: 2003-01-30; SI20030000025 Applic. Date: 2003-01-30; SI20030000145 Applic. Date: 2003-06-12; SI20030000157 Applic. Date: 2003-06-26; SI20030000270 Applic. Date: 2003-11-05; WO2004SI00001 Applic. Date: 2004-01-29

Inventor: ANTONCIC LJUBOMIR [SI]; COPAR ANTON [SI]; SVETE PETER [SI]; HUSU-KOVACEVIC BREDA [SI]; HAM ZORAN [SI]; MAROLT BORIS [SI]


Application No.: US20060013869A1  Published: 19/Jan/2006

Title: Electrospun amorphous pharmaceutical compositions

Applicant/Assignee:

Application No.: 10/523835   Filing Date: 07/Feb/2005

Abstract:The present invention is directed to use of electrospinning, i.e. the process of making polymer nanofibers from either a solution or melt under electrical forces, to prepare stable, solid dispersions of amorphous drugs in polymer nanofibers.

Priority: US20020401726P Applic. Date: 2002-08-07; WO2003US24641 Applic. Date: 2003-08-07

Inventor: IGNATIOUS FRANCIS [US]; SUN LINGHONG [US]


Application No.: US20060013874A1  Published: 19/Jan/2006

Title: Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one

Applicant/Assignee: SOLVAY PHARMACEUTICALS B.V

Application No.: 11/178309   Filing Date: 12/Jul/2005

Abstract:The present invention relates to an extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one or a pharmaceutically acceptable salt thereof or a hydrate of said pharmaceutically acceptable salt thereof. The invention further relates to the preparation of these extended release formulations and their use in the prevention or treatment of disorders, especially pain and CNS disorders such as depression, anxiety and movement disorders.

Priority: US20040588036P Applic. Date: 2004-07-15

Inventor: BRUINS NICO [NL]; FRIJLINK HENDERIK W [NL]; DE VRIES MICHIEL H [NL]


Application No.: US20060013876A1  Published: 19/Jan/2006

Title: Novel floating dosage form

Applicant/Assignee:

Application No.: 10/518909   Filing Date: 01/Sep/2005

Abstract:Present invention relates to a novel pharmaceutical composition containing an active ingredient(s) which is retained in the stomach or upper part of gastrointestinal tract for controlled delivery of medicament for improved local treatment, and/or better absorption from upper parts of gastrointestinal tract for effective therapeutic results. Present invention also provides a method for preparation of the said dosage form preferably in the form of a bilayer tablet, in which one layer constitutes for spatial control and the other being for temporal control.

Priority: IN2002MU00565 Applic. Date: 2002-06-26; WO2003IN00229 Applic. Date: 2003-06-25

Inventor: LOHRAY BRAJ B [IN]; TIWARI SANDIP B [IN]; PAI RAVEENDRA M [IN]; MURTHY KRISHNA T [IN]; MEHTA PAVAK R [IN]


Application No.: US20060013887A1  Published: 19/Jan/2006

Title: Delayed release carnitine

Applicant/Assignee:

Application No.: 11/223086   Filing Date: 09/Sep/2005

Abstract:A sustained release, orally administered pharmaceutical composition comprising carnitine and an acceptable pharmaceutical excipient is described for the treatment of carnitine deficiency and other carnitine responsive conditions. The sustained release formulation avoids the characteristic problems of gastrointestinal invitation, dumping in the urine and bacterial degradation attendant previously known oral formulations of carnitine.

Priority: US2003-384085 Applic. Date: 2003-03-07; US1993-109159 Applic. Date: 1993-08-19; US1993-078985 Applic. Date: 1993-06-16

Inventor: SHUG AUSTIN L [US]; GULBRANDSEN CARL E [US]


Application No.: US20060013893A1  Published: 19/Jan/2006

Title: Bisphosphonates inorganic carriers

Applicant/Assignee:

Application No.: 11/157003   Filing Date: 20/Jun/2005

Abstract:Intercalated hydrotalcite-bisphosphonate compositions have improved bioavailability, less irritation in the GI tract and a more constant controlled delivery rate of the active component. These hybrid organic drug-inorganic carrier are useful to build-up skeleton bone and to incorporate into a dentifrice to strengthen the hydroxyapatite mineral on teeth. Added advantages in using hydrotalcite are that it is an excellent anti acid ingredient and certain anionic forms of analgesics vitamins, and pro-vitamins can be intercalated into the clay providing synergy to the bisphosphonate therapy. Other bioactive molecules in their anionic form can also be included, e.g., certain hormones, and nutritional supplements to name a few classes.

Priority: US20040589221P Applic. Date: 2004-07-19

Inventor: STOCKEL RICHARD F [US]


Application No.: US20060013896A1  Published: 19/Jan/2006

Title: Methods of treating acute pain using diclofenac

Applicant/Assignee:

Application No.: 11/180996   Filing Date: 13/Jul/2005

Abstract:New pharmaceutical compositions for oral use containing diclofenac preferably together with alkali metal bicarbonates in amounts of from about 20 to about 80 by weight with respect to diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other, side effects

in particular, these formulations permit to obtain in human patients higher Cmax of the active principle and shorter Tmax together with a lower coefficient of variation.

Priority: IT1996MI00992 Applic. Date: 1996-05-17; US2000-524747 Applic. Date: 2000-03-14; US1998-192493 Applic. Date: 1998-11-17; WO1997EP02709 Applic. Date: 1997-05-15

Inventor: REINER GIORGIO [IT]; REINER ALBERTO [IT]


Application No.: US20060013900A1  Published: 19/Jan/2006

Title: Use of betel leaf extract to induce IFN-gamma production from human peripheral blood T cells and as a Th1 type immunomodulator

Applicant/Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH ORGANISATION

Application No.: 11/222815   Filing Date: 12/Sep/2005

Abstract:This invention relates to use of betel leaf extract to induce IFNgamma from human peripheral blood mononuclear cells and as a Th1 type immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18-48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFNgamma specific known primers, and enhancement of IFNgamma as reflected by IFNgamma specific band.

Priority: US2002-319618 Applic. Date: 2002-12-16; US2000-746017 Applic. Date: 2000-12-26

Inventor: BANDYOPADHYAY SANTU [IN]; PAL BIKASH [IN]; BHATTACHARYA SAMIR [IN]; RAY MITALI [IN]; ROY KESHAB C [IN]


Application No.: US20060013902A1  Published: 19/Jan/2006

Title: Pharmaceutical products for treating neoplastic disease and inflammation

Applicant/Assignee: KGK SYNERGIZE INC

Application No.: 11/135694   Filing Date: 24/May/2005

Abstract:Disclosed in certain embodiments is a pharmaceutical formulation and a functional food comprising a pharmaceutical ingredient comprising an active agent combination comprising flavonoids and tocotrienols in a ratio of about 75:25 to about 95:5 and at least one pharmaceutically acceptable excipient and methods to treat neoplastic diseases and inflammation.

Priority: US20040574487P Applic. Date: 2004-05-26

Inventor: GUTHRIE NAJLA [CA]


Application No.: US20060014666A1  Published: 19/Jan/2006

Title: Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders

Applicant/Assignee: BEIJING JIANKAI TECHNOLOGY CO., LTD

Application No.: 10/514492   Filing Date: 01/Aug/2005

Abstract:The present invention relates to an active targeted water-solubility macromolecule polymer, conjugate With interferon and pharmaceutical composition comprising the conjugate. The targeted agent includes, for example, glucose, galatose and the like, as well as their derivates. The conjugate of the present invention is well in water-solubility and havc long physiological cycle half-life period, and have specific recognition to pathology organize, improved and increased medication effect of interferon to Hepatitis B, Hepatitis C etc. infectivity sickness and cancer, infect complication etc.

Priority: WO2002CN00331 Applic. Date: 2002-05-14; WO2002CN00919 Applic. Date: 2002-12-27

Inventor: JI SHISHAN [CN]; ZHU DEQUAN [CN]


Application No.: US20060014698A1  Published: 19/Jan/2006

Title: Nebulized pharmaceutical compositions for the treatment of bronchial disorders

Applicant/Assignee:

Application No.: 11/182279   Filing Date: 14/Jul/2005

Abstract:The present invention provides methods and pharmaceutical compositions for the treatment of bronchial disorders by inhalation therapy. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of a sulfated pentasaccharide and a peptidomemtic of a tripeptide. In various embodiments, the active ingredient of the pharmaceutical compositions is one or more of argatroban and fondaparinux.

Priority: US20040588154P Applic. Date: 2004-07-14

Inventor: O'CONNOR MICHAEL F [US]; NAURECKAS EDWARD T [US]; NOTH IMRE [US]


Application No.: US20060018962A1  Published: 26/Jan/2006

Title: Sustained release formulation of tramadol

Applicant/Assignee:

Application No.: 10/508615   Filing Date: 11/Aug/2005

Abstract:This invention relates to sustained release oral dosage forms comprising tramadol or a salt thereof dispersed in a matrix, wherein said matrix comprises xanthan gum.

Priority: EP20020076130 Applic. Date: 2002-03-22; WO2003EP03050 Applic. Date: 2003-03-21

Inventor: EIVASKHANI REZA [DE]; BRAUN CHRISTIAN [DE]; MERKLE STEFAN [DE]


Application No.: US20060018963A1  Published: 26/Jan/2006

Title: Extended release venlafaxine besylate tablets

Applicant/Assignee: SYNTHON IP INC

Application No.: 10/895984   Filing Date: 22/Jul/2004

Abstract:Venlafaxine besylate is formulated into an extended release tablet in high loading rates by use of a coating that contains ammonio methacrylate copolymer(s).

Priority:

Inventor: CUCALA ESCOI JOAN [ES]; GALLEGO LUENGO MONTSERRAT [ES]; MARGALLO LANA INOCENCIA [ES]


Application No.: US20060019902A1  Published: 26/Jan/2006

Title: PTH-like peptides

Applicant/Assignee: ABIOGEN PHARMA S.P.A

Application No.: 11/185906   Filing Date: 19/Jul/2005

Abstract:The present invention relates to peptides that are parathyroid hormone (PTH) analogs, useful for the treatment of hypoparathyroidism and diseases characterized by bone mass reduction, such as osteoporosis, and for stimulating bone repair or favoring the engraftment of a bone implant

to the pharmaceutical compositions comprising these PTH-like peptides and use thereof.

Priority: IT2004MI01440 Applic. Date: 2004-07-19

Inventor: CAPORALE ANDREA [IT]; FIORI NEREO [IT]; SCHIEVANO ELISABETTA [IT]; MAMMI STEFANO [IT]; PEGGION EVARISTO [IT]; CHOREV MICHAEL [US]; WITTELSBERGER ANGELA [US]


Application No.: US20060020007A1  Published: 26/Jan/2006

Title: Compositions containing policosanol and biotin and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/898889   Filing Date: 26/Jul/2004

Abstract:A composition is provided which contains policosanol and biotin and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol in humans and animals. The method comprises administering policosanol and biotin which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to biotin.

Priority:

Inventor: BERLIN ROGER [US]


Application No.: US20060020031A1  Published: 26/Jan/2006

Title: Compositions containing policosanol and omega-3 fatty acids and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/898897   Filing Date: 26/Jul/2004

Abstract:A composition is provided which contains policosanol and omega-3 fatty acids and which may be used for treating and or reducing hypercholesterolemic diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), sudden cardiac death, ventricular fibrillation, tachycardia, hypertension, inflammation, thrombosis, deep-vein thrombosis, stroke, macular degeneration, autoimmune and/or immunoregulatory diseases, cardiovascular diseases, anxiety, depression and/or neurodegenerative disorders, and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and omega-3 fatty acids which together effectively lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to omega-3 fatty acids.

Priority:

Inventor: BERLIN ROGER [US]


Application No.: US20060020116A1  Published: 26/Jan/2006

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/176830   Filing Date: 06/Jul/2005

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; GUYON THIERRY [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]


Application No.: US20060024361A1  Published: 02/Feb/2006

Title: Disintegrant assisted controlled release technology

Applicant/Assignee:

Application No.: 10/900415   Filing Date: 28/Jul/2004

Abstract:A disintegrant assisted controlled release device is disclosed. The device is a combination of a swelling disintegrant or super-disintegrant and water insoluble polymer or water soluble polymer, or both, and one or more water soluble or water insoluble active pharmaceutical ingredient(s). The said device is stabilized by a humectant or trehalose.

Priority:

Inventor: ODIDI ISA [CA]; ODIDI AMINA [CA]


Application No.: US20060024383A1  Published: 02/Feb/2006

Title: Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/900049   Filing Date: 27/Jul/2004

Abstract:A composition is provided which contains policosanol and chromium and/or chromium salts and which may be used for treating, preventing and or reducing metabolic syndrome, hypercholesterolemia and hypoglycemia related diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, triglycerides, coronary heart disease (heart attacks and strokes), inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, obesity, insulin resistance, dyslipidemia, raised blood pressure, fatigue, premenstrual syndrome, anxiety, depression and/or neurodegenerative disorders, and/or raising HDL cholesterol and/or lean body mass in humans and animals. The method comprises administering policosanol and chromium and/or chromium salts which together effectively lower blood glucose levels and lower the LDL/HDL cholesterol ratio. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to chromium and/or chromium salts.

Priority:

Inventor: BERLIN ROGER [US]


Application No.: US20060024394A1  Published: 02/Feb/2006

Title: Cancer cell growth inhibition by black bean (Phaseolus vulgaris L) extracts

Applicant/Assignee: INSTITUTO TECNOLOGICO Y DE ESTUDIOS SUPERIORES DEMONTERREY INSTITUTO TECHNOLOGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY

Application No.: 11/125782   Filing Date: 10/May/2005

Abstract:A group of phytochemical compounds extracted from whole germinated or not germinated black beans (Phaseolus vulgaris L) and/or their dry milled fractions such as seed coats or hulls and cotyledons is described. These phytochemicals are classified as phenolics, such as polyphenols, flavonoids, coumarins, and tannins, triterpenes such as saponins, phytosterols and other antioxidant compounds that proved to be effective to decrease cancer proliferation of hormone dependent mammary (MCF-7), hormone independent hepatic (HepG2) and colon (Caco2) cancer cells. They also effectively protect against chemical damage induced with DMBA and furthermore prevented cancer induced by this chemical in Wistar rats and also reduced tumor size when consumed after tumor detection.

Methanol, acetone, ethanol, water and mixtures of these solvents were used to obtain the extracts from raw, cooked, and germinated black beans of different varieties, both from the whole grain and the hulls. The black bean malting process produced extracts rich in aglycone forms of the previous mentioned compounds that were more biologically active against MCF-7 cancer cell proliferation. Both raw extracts, C-18 HPLC refined extracts and fractionated extracts may be used in the treatment, prophylaxis, amelioration or defense against a variety of hormone dependent and independent cancers.

The extracts and compounds have additional utilities, e.g., lower cholesterol or lower oxidation of LDL and/or inhibit cholesterol synthesis (or the enzyme therefor) and/or reduce liver fibrosis and/or reduce symptoms of menopause and/or stimulate calcium absorption and/or have estrogenic activity such as feminizing estrogenic activity and/or are antioxidants, for instance, as an active ingredient in a nutritional supplement and/or as a food, cosmetic or pharmaceutical antioxidants or colorants.

Priority: US20040570029P Applic. Date: 2004-05-10

Inventor: GUTIERREZ-URIBE JANET A [MX]; SERNA-SALDIVAR SERGIO R O [MX]; MORENO-CUEVAS JORGE E [MX]; HERNANDEZ-BRENES CARMEN [MX]; GUAJARDO-TOUCHE ELSA M [MX]


Application No.: US20060025475A1  Published: 02/Feb/2006

Title: Use of methyl pyruvate for the purpose of increasing muscle energy production.

Applicant/Assignee:

Application No.: 10/710710   Filing Date: 29/Jul/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing muscle energy production. When used as a dietary supplement, energizer or pharmaceutical, this anion can be formulated as a salt. The methyl pyruvate compounds which can be used in the present method include: (1) a salt using a monovalent cation (such as sodium or potassium methyl pyruvate) or (2) a divalent cation (such as calcium or magnesium methyl pyruvate) and analogs of these compounds which can act as substrates or substrate analogs for methyl pyruvate Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid" are used interchangeably.

Priority:

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]


Application No.: US20060025476A1  Published: 02/Feb/2006

Title: Use of methyl pyruvate for the purpose of reducing weight gain in mammals.

Applicant/Assignee:

Application No.: 10/710830   Filing Date: 05/Aug/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of reducing weight (fat) gain in mammals by orally administering therapeutically effective amounts of methyl pyruvate. The method also has the effect of increasing body protein concentration, improving insulin resistance, lower fasting insulin levels, preventing fat deposition and increasing cellular energy production. When used as a dietary supplement, energizer or pharmaceutical, this anion can be formulated as a salt. The methyl pyruvate compounds which can be used in the present method include: (1) a salt using a monovalent cation (such as sodium or potassium methyl pyruvate) or (2) a divalent cation (such as calcium or magnesium methyl pyruvate) and analogs of these compounds which can act as substrates or substrate analogs for methyl pyruvate Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid"are used interchangeably.

Priority: US2004-710710 Applic. Date: 2004-07-29

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]


Application No.: US20060025486A1  Published: 02/Feb/2006

Title: Compositions containing policosanol and B vitamins and their pharmaceutical uses

Applicant/Assignee:

Application No.: 10/900040   Filing Date: 27/Jul/2004

Abstract:A composition is provided which contains policosanol and B vitamins and which may be used for treating and or reducing hypercholesterolemia and hyperhomocysteinemia diseases, total cholesterol, LDL-cholesterol, LDL/HDL ratio, Lp(a), triglycerides, homocysteine, coronary heart disease (heart attacks and strokes), carotid artery disease, inflammation, deep-vein thrombosis, immunoregulatory diseases, cardiovascular diseases, anxiety, depression, neurodegenerative disorders (such as but not limited to Alzheimers), and/or raise HDL cholesterol in humans and animals. The method comprises administering policosanol and B vitamins which together effectively lower the risk of heart disease. Typically, the administered composition includes about 0.1-10:1 parts by weight of policosanol to B vitamins.

Priority:

Inventor: BERLIN ROGER [US]


Application No.: US20060025584A1  Published: 02/Feb/2006

Title: Crystallization of polyol compositions, crystalline polyol composition product and use thereof

Applicant/Assignee: DANISCO SWEETENERS OY

Application No.: 10/517692   Filing Date: 05/Jul/2005

Abstract:The present invention relates to a microcrystallized polyol comprising at least two polyols, wherein said polyols are selected from the group consisting of maltitol, xylitol and lactitol and wherein said composition contains at least 25% by weight of each of at least two of said polyols microcrystallized together into a solid microcrystalline product. The present invention also relates to a process for the microcrystallization of polyols into a polyol composition. The microcrystallized polyol composition can be used in confectionery, foodstuffs, oral hygiene products and pharmaceuticals and in dietetic products.

Priority: FI20020001312 Applic. Date: 2002-07-03; WO2003FI00533 Applic. Date: 2003-07-02

Inventor: EROMA OLLI-PEKKA [FI]; NYGREN JOHANNA [FI]; HEIKKILA HEIKKI [FI]; SORENSEN PER BO [DK]; SARKKI MARJA-LEENA [FI]; FAIRS IAN [GB]; GROS HAKAN [FI]


Application No.: US20060034776A1  Published: 16/Feb/2006

Title: Inhalable medicaments containing a new anticholinergic, corticosteroids, and betamimetics

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/182382   Filing Date: 15/Jul/2005

Abstract:A pharmaceutical formulation comprising: (a) at least one anticholinergic of formula 1 wherein X<-> is an anion with a single negative charge

(b) at least one corticosteroid (2)

and (c) at least one betamimetic (3), and the enantiomers, mixtures of the enantiomers, racemates, solvates, hydrates, or physiologically acceptable acid addition salts thereof, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: DE200410038886 Applic. Date: 2004-08-10; DE200410053023 Applic. Date: 2004-11-03

Inventor: PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]


Application No.: US20060034854A1  Published: 16/Feb/2006

Title: Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria

Applicant/Assignee:

Application No.: 10/523114   Filing Date: 02/Aug/2005

Abstract:The present invention relates to immunogenic compositions and vaccines for the prevention or treatment of Gram negative bacterial infection. Immunogenic compositions of the invention comprise transferrin binding protein and Hsf, and the combination of these two antigens have been shown to act synergistically to produce antibodies with high activity in a serum bactericidal assay. This combination of antigens is useful for use in vaccines against Neisseria meningitidis, Neisseria gonorrhoeae, Moraxella catarrhalis and Haemophilus influenzae.

Priority: GB20020018037 Applic. Date: 2002-08-02; GB20020018036 Applic. Date: 2002-08-02; GB20020018035 Applic. Date: 2002-08-02; GB20020018051 Applic. Date: 2002-08-02; GB20020020197 Applic. Date: 2002-08-30; GB20020020199 Applic. Date: 2002-08-30; GB20020025524 Applic. Date: 2002-11-01; GB20020025531 Applic. Date: 2002-11-01; GB20020030164 Applic. Date: 2002-12-24; GB20020030168 Applic. Date: 2002-12-24; GB20020030170 Applic. Date: 2002-12-24; GB20030005028 Applic. Date: 2003-03-05; WO2003EP08567 Applic. Date: 2003-07-31

Inventor: BERTHET FRANCOIS-XAVIER J [BE]; BIEMANS RALPH [BE]; DENOEL PHILIPPE [BE]; FERON CHRISTIANE [BE]; GORAJ CARINE [BE]; POOLMAN JAN [BE]; WEYNANTS VINCENT [BE]


Application No.: US20060034855A1  Published: 16/Feb/2006

Title: Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein

Applicant/Assignee: RAMOT AT TEL-AVIV UNIVERSITY LTD

Application No.: 10/506665   Filing Date: 07/Sep/2004

Abstract:The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AssPP epitope spanning the ss-secretase cleavage site of AssPP and a method for inducing an immune response against the ss-secretase cleavage site of AssPP using this immunizing composition. The present invention is also directed to antibodies against the ss-secretase cleavage site of AssPP and their use in a method for inhibiting the formation of amyloid ss.

Priority: US20020361344P Applic. Date: 2002-03-05; WO2003US06388 Applic. Date: 2003-03-04

Inventor: SOLOMON BEKA [IL]


Application No.: US20060034910A1  Published: 16/Feb/2006

Title: Pharmaceutical composition for extended release of phenytoin sodium

Applicant/Assignee:

Application No.: 11/199169   Filing Date: 09/Aug/2005

Abstract:The present invention provides an oral extended release solid pharmaceutical composition of phenytoin sodium or its pharmaceutically acceptable derivative thereof and the process of manufacturing the same the said extended release oral solid pharmaceutical composition comprising of at least one suitable pharmaceutically acceptable excipient alongwith phenytoin sodium. The said extended release oral solid pharmaceutical composition is manufactured by blending phenytoin sodium with at least one suitable pharmaceutically acceptable excipient and granulating the blend optionally using at least one suitable binder dissolved in an organic solvent or mixture of solvents.

Priority: US20040600114P Applic. Date: 2004-08-09

Inventor: PATEL SANJAY [US]; MUKHERJI GOUR [IN]; PATIL JAYADEV [IN]; MATE SIDHARTH [IN]


Application No.: US20060035857A1  Published: 16/Feb/2006

Title: Methods and compositions for the diagnosis and treatment of cancer

Applicant/Assignee:

Application No.: 11/200527   Filing Date: 09/Aug/2005

Abstract:Methods for the treatment of squamous cell carcinoma using a p53-expressing viral vector are disclosed. In particular embodiments, the vector is a replication-deficient adenovirus. In addition, there are provided methods for examining the development and treatment of microscopic residual disease in the context of post-surgical environments and in body cavities.

Priority: US1996-758033 Applic. Date: 1996-11-27; US19950007810P Applic. Date: 1995-11-30

Inventor: CLAYMAN GARY L [US]


Application No.: US20060035874A1  Published: 16/Feb/2006

Title: Pharmaceutical products and composition comprising specific anticholinergic agents, beta-2 agonists and corticosteroids

Applicant/Assignee: CIPLA LTD

Application No.: 10/525736   Filing Date: 06/Jun/2005

Abstract:This invention relates to pharmaceutical products and compositions for use in the treatment of asthma and related disorders, and especially but not exclusively for the treatment of chronic obstructive pulmonary disease (COPD). More particularly, the invention provides pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids.

Priority: GB20020020095 Applic. Date: 2002-08-29; GB20020027342 Applic. Date: 2002-11-22; WO2003GB03751 Applic. Date: 2003-08-29

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]


Application No.: US20060035975A1  Published: 16/Feb/2006

Title: Enteric coated oral pharmaceutical to erode kidney stones

Applicant/Assignee: MED FIVE, INC

Application No.: 11/066621   Filing Date: 25/Feb/2005

Abstract:A treatment protocol by which a renal stone patient is administered a chelating agent, generally once a day and preferably by mouth, during a treatment phase and is later administered the same chelating agent once a week, during a "maintenance" phase. The chelating agent is most preferably ethylene diamine tetraacetic acid (EDTA) and may be provided in a dosage form having an enteric coating and at least one external cathode and at least one external anode to create a galvanic current upon contact of the dosage form with the patient's intestinal contents.

Priority: US20040547909P Applic. Date: 2004-02-26

Inventor: KEITH ALEC D [US]; CRISP WILLIAM E [US]


Application No.: US20060036080A1  Published: 16/Feb/2006

Title: Conjugates of GM-CSF moiety and a polymer

Applicant/Assignee:

Application No.: 11/181692   Filing Date: 14/Jul/2005

Abstract:Conjugates of a GM-CSF moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient.

Priority: US20040588601P Applic. Date: 2004-07-16

Inventor: BOSSARD MARY J [US]; ZHANG PING [US]


Application No.: US20060039870A1  Published: 23/Feb/2006

Title: Pulmonary delivery of enzymatic medical countermeasures

Applicant/Assignee:

Application No.: 11/195041   Filing Date: 02/Aug/2005

Abstract:The present invention provides for non-invasive treatment of nerve agent poisoning by administering nerve agent neutralizing enzymes to the pulmonary epithelium of a subject, by inhalation, where they accumulate within the lungs. Localization of such enzymes in the pulmonary epithelium results in neutralization of the nerve agents at the lungs. As a result, nerve agents move by diffusion out of the blood through the pulmonary capillaries, duc to the organophosphorus nerve agents rapid diffusion across the cell membranes of the body via diffusion, down their concentration gradients. The present invention presents a practical method of administering nerve agent neutralizing enzymes, without requiring passage into the blood plasma, and without requiring blood plasma activity of the enzyme.

Priority: US20040603186P Applic. Date: 2004-08-20

Inventor: TURNER JEFFREY D [CA]


Application No.: US20060039981A1  Published: 23/Feb/2006

Title: Taste masked dosage forms and processes for their preparation

Applicant/Assignee:

Application No.: 10/526844   Filing Date: 27/Jul/2005

Abstract:The invention relates to taste masked dosage forms utilizing low amounts of taste masking polymer, and simple and economical processes for the preparation of the taste masked dosage forms. The taste-masked dosage form includes one or more drugs and one or more cationic polymers synthesized from dimethylaminoethyl methacrylate and neutral methacrylic acid esters. The wt/wt ratio of the drug to polymer is less than about one to two.

Priority: IN2002DE00903 Applic. Date: 2002-09-04; WO2003IB03779 Applic. Date: 2003-09-04

Inventor: MURPANI DEEPAK [IN]; ARORA VINOD K [IN]; MALIK RAJIV [AU]


Application No.: US20060039989A1  Published: 23/Feb/2006

Title: Pharmaceutical compositions of cell lysate and processes for the production and use thereof

Applicant/Assignee: INNOGENETICS N.V CELLTRAN LIMITED

Application No.: 10/537301   Filing Date: 02/Jun/2005

Abstract:The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.

Priority: EP20020447238 Applic. Date: 2002-12-03; US20020433912P Applic. Date: 2002-12-17; WO2003EP50891 Applic. Date: 2003-11-25

Inventor: VERVAET CHRIS [BE]; REMON JEAN-PAUL [BE]; DELAEY BERNARD [BE]; DE WAELE PETER [BE]


Application No.: US20060039999A1  Published: 23/Feb/2006

Title: Pharmaceutical composition for inhibition of tumor growth or metastasis

Applicant/Assignee: HEPAGUARD BIOTECHNOLOGY (INT'L) CO., LTD

Application No.: 11/156522   Filing Date: 21/Jun/2005

Abstract:A pharmaceutical composition for inhibition of tumor growth or metastasis which comprises an effective amount of Phyllanthus urinaria L. extracts, or the combination of the foregoing Phyllanthus urinaria L. extracts and pharmaceutical acceptable carries, adjuvants or excipients.

Priority: TW20040124644 Applic. Date: 2004-08-17

Inventor: LIN JUI Y [TW]; MACH WENDY B [TW]; CHEN PO-HSUN [TW]


Application No.: US20060040911A1  Published: 23/Feb/2006

Title: Method for preventing and/or treating the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered an effective amount of bioflavonoids extract derived from fructus crataegus (lipid metabolism and fructus crataegus)

Applicant/Assignee:

Application No.: 11/226862   Filing Date: 13/Sep/2005

Abstract:A method for treating and/or preventing the cardiovascular and hepatic diseases induced by hyperlipidemia which comprises administered thereto an effective amount of bioflavonoids extract derived from fructus crataegus such as

rutin, quercetin, kaempferol and vitexin or a mixture thereof.

Priority: US2003-337434 Applic. Date: 2003-01-06

Inventor: LIAO BENEDICT S [US]; LIAO JUDY F [US]; LIAO ALEX [US]; LIAO AUSTIN [US]; LIAO BURTON A [US]; LIAO-TUNG SU-HSIN [US]; LIAO-NIENG SUSAN [US]; NIENG CATHY [US]; LIAO-CHEN SU-LIEN [US]; LIAO SCHUE-YUAN [US]


Application No.: US20060045923A1  Published: 02/Mar/2006

Title: Composition containing tinospora cordifolia and process for obtaining same

Applicant/Assignee:

Application No.: 11/219117   Filing Date: 02/Sep/2005

Abstract:The present invention relates to a composition for use in a nutritional product, dietary supplement, food or pharmaceutical composition wherein such composition includes the plant Tinospora cordifolia or Tinospora cordifolia extract and is used to treat allergies, including but not limited to seasonal, perennial, or sporadic allergic rhinitis. The present invention further relates to an extraction process for obtaining such composition.

Priority: US20040606749P Applic. Date: 2004-09-02

Inventor: HINGORANI LAL [IN]; THAWANI VIJAY [IN]


Application No.: US20060045930A1  Published: 02/Mar/2006

Title: Purified Arabinogalactan-Protein (AGP) composition useful in the treatment psoriasis and other disorders

Applicant/Assignee: LUPIN LABORATORIES LIMITED LUPIN LIMITED

Application No.: 10/931814   Filing Date: 01/Sep/2004

Abstract:A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-gamma inhibition, or IL-10 induction

keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).

Priority:

Inventor: ARORA SUDERSHAN K [IN]; SRIVASTAVA VANDITA [IN]; WALUNJ SAMEER S [IN]


Application No.: US20060046974A1  Published: 02/Mar/2006

Title: N-acyl modified polysaccharides and pharmaceutical compositions comprising same

Applicant/Assignee:

Application No.: 11/214332   Filing Date: 28/Aug/2005

Abstract:This invention relates to novel N-acyl modified polysaccharides and pharmaceutical compositions comprising the modified polysaccharides. Further the invention relates to processes for using such compounds to inhibit lipases, to lower cholesterol, to lower the absorption of dietary fat, or as a dietary fiber supplement. In a preferred aspect of the invention the modified polysaccharides are capable of absorbing substantial amounts of oils or fats while dissipating in an aqueous solution. The invention also relates to a non-absorbable and essentially non-digestible polysaccharide fiber composition.

Priority: US20040605935P Applic. Date: 2004-08-30; US20040605931P Applic. Date: 2004-08-30

Inventor: GENTRY MULLINS JOHN J [US]


Application No.: US20060051412A1  Published: 09/Mar/2006

Title: Method for producing an immediately decomposing oral form of administration which releases active ingredients

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 10/542283   Filing Date: 15/Jul/2005

Abstract:The invention relates to a method for producing an oral form of administration which decomposes immediately and releases active ingredients in the mouth. According to said method, (a) an anionic pharmaceutical active ingredient is intensively mixed with (b) a copolymer consisting of radically polymerized C1-C4 esters of the acrylic acid or methacrylic acid and other (meth)acrylate monomers containing functional tertiary amino groups, and (c) between 5 and 50 wt. %, in relation to (b), of a C12-C22 carboxylic acid in the melted mass

the mixture is solidified and ground to form a powder containing active ingredients having an average particle size of 200 mum or less

and the powder is encapsulated in a water-soluble matrix consisting of pharmaceutically standard adjuvants, on the condition that no more than 3 wt. %, in relation to the copolymer, of emulsifiers with an HLB value of at least 14 must be contained therein. The invention also relates to the powder containing active ingredients and the uses of the same.

Priority: DE20031004403 Applic. Date: 2003-01-28; WO2003EP13059 Applic. Date: 2003-11-21

Inventor: PETEREIT HANS-ULRICH [DE]; MEIER CHRISTIAN [DE]; GRYCZKE ADREAS [DE]


Application No.: US20060051418A1  Published: 09/Mar/2006

Title: Pharmaceutical formulations of potassium ATP channel openers and uses thereof

Applicant/Assignee: ESSENTIALIS, INC

Application No.: 11/212130   Filing Date: 25/Aug/2005

Abstract:Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.

Priority: US20040604085P Applic. Date: 2004-08-25; US20050654571P Applic. Date: 2005-02-22; US20050668912P Applic. Date: 2005-04-06; US20040624219P Applic. Date: 2004-11-03

Inventor: COWEN NEIL M [US]; KASHKIN KENNETH B [US]


Application No.: US20060051422A1  Published: 09/Mar/2006

Title: Stabilised solid drug dispersions in an organic carrier and a process for preparing the same

Applicant/Assignee: EURAND S.P.A

Application No.: 10/540139   Filing Date: 21/Jun/2005

Abstract:New solid drug dispersions are described in which the drug is present in amorphous form and massively dispersed (in bulk) inside the particles of an organic carrier selected from cross-linked polymers and/or a complexing agents. These dispersions are obtainable by mixing together the drug and the carrier and applying an oscillating electromagnetic field to the mixture, to a frequency belonging to the microwave region

the microwaves are applied according to a specific heating cycle wherein the drug-carrier mixture is heated at a temperature higher than the melting point of the drug for at least 5 minutes. With respect to the known techniques, the present invention allows to increase in the amount of drug incorporated into the carrier in amorphous form, and to increase the physical stability of the amorphous phase. This is particularly useful in the preparation of pharmaceutical compositions based on drugs which are crystalline in nature, such as are notoriously sparingly soluble in water: thanks to the increased amounts and stability of the drug in amorphous form, the resulting formulations have a more rapid and intense effect, and are endowed with greater bioavailability.

Priority: IT2002MI02748 Applic. Date: 2002-12-23; WO2003EP14740 Applic. Date: 2003-12-22

Inventor: COLOMBO ITALO [IT]; GERVASONI DARIO [IT]


Application No.: US20060052306A1  Published: 09/Mar/2006

Title: GRAS composition for enhanced mucosal delivery of parathyroid hormone

Applicant/Assignee: NASTECH PHARMACEUTICAL COMPANY INC

Application No.: 11/246450   Filing Date: 06/Oct/2005

Abstract:What is described is an aqueous pharmaceutical composition for intranasal delivery of PTH, comprising a PTH molecule, and one or more excipients selected from the group consisting of a chelating agent, an alcohol, and a surface active agent, wherein the PTH molecule selected from the group consisting of SEQ NO: 1, SEQ NO: 2, and SEQ NO: 3.

Priority: US2005-126996 Applic. Date: 2005-05-10; US20040570113P Applic. Date: 2004-05-10

Inventor: COSTANTINO HENRY R [US]; LI CHING-YUAN [US]


Application No.: US20060052448A1  Published: 09/Mar/2006

Title: Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.

Applicant/Assignee:

Application No.: 10/711255   Filing Date: 04/Sep/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of treating diseases of the nervous system and/or to prevent against neuronal degeneration due to defective intracellular energy production. Methyl pyruvate compounds can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotropic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination, demyelination disorders, or cellular disorders which interfere with the energy metabolism of neurons and mitochondrial diseases. Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. Treatment can be effective even when administered after the onset of an ischemic event that triggers neurodegeneration. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid" are used interchangeably.

Priority:

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]


Application No.: US20060057073A1  Published: 16/Mar/2006

Title: Wet granulation process

Applicant/Assignee: PARI GMBH

Application No.: 10/517910   Filing Date: 08/Dec/2004

Abstract:The invention is in the field of pharmaceutical dosage forms, and more particularly in the field of pharmaceutical granules and processes for making granules. The invention provides a process for preparing pharmaceutical granules which contain an active ingredient in the form of a salt, said process comprising the steps of (a) providing a powder containing the active ingredient as a free base or acid, and (b) agglomerating the powder by adding a granulation liquid to form granules

wherein step (b) is conducted in the presence of a neutralization agent capable of neutralizing the active ingredient, and for a sufficient amount of time to allow the active ingredient to become at least partially converted into a salt. The invention also provides pharmaceutical granules obtainable by said process and pharmaceutical compositions comprising said granules. The invention further provides the use of pharmaceutical granules for the pulmonary delivery of an active ingredient.

Priority: EP20020025006 Applic. Date: 2002-11-08; WO2003EP11949 Applic. Date: 2003-10-28

Inventor: LINTZ FRANK-CHRISTOPHE [DE]; KELLER MANFRED [DE]


Application No.: US20060057199A1  Published: 16/Mar/2006

Title: Orally disintegrating tablets of atomoxetine

Applicant/Assignee:

Application No.: 11/223819   Filing Date: 09/Sep/2005

Abstract:A coated multi-particulate pharmaceutical dosage form such as an orally disintegrating tablet (ODT) presentation for delivering atomoxetine or a pharmaceutically acceptable salt thereof, a selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD, into the body to maintain a therapeutically effective amount of atomoxetine in the plasm. The dosage form may comprise one or more populations of coated atomoxetine-containing particles (beads, pellets, granules etc.) providing a pre-designed rapid release profile after a predesigned lag-time of about 0 to 6 hours following oral administration.

Priority: US20040609312P Applic. Date: 2004-09-13

Inventor: VENKATESH GOPI M [US]; HARMON TROY M [US]; TAYLOR JOHN [US]


Application No.: US20060057207A1  Published: 16/Mar/2006

Title: Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene

Applicant/Assignee: PFIZER INC

Application No.: 11/270766   Filing Date: 08/Nov/2005

Abstract:A fast disintegrating dosage form of varenicline comprising an effective amount of varenicline or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein the dosage form disintegrates in a patient's oral cavity in less than three minutes. Also provided are a method for reducing nicotine addiction, aiding in the cessation of, or lessening of tobacco use in a subject by administering to the subject an effective amount of the fast disintegrating dosage form of varenicline or pharmaceutically acceptable salts thereof

a method of treating a disorder or condition by administering an effective amount of the fast disintegrating dosage form of varenicline

and, various methods of manufacturing or forming an immediate dosage form of varenicline.

Priority: US2002-300608 Applic. Date: 2002-11-20; US20010334652P Applic. Date: 2001-11-30; US20050642083P Applic. Date: 2005-01-07

Inventor: ZIEGLER CARL B [US]; JOHNSON BARBARA A [US]


Application No.: US20060057218A1  Published: 16/Mar/2006

Title: Novel composition

Applicant/Assignee: LABORATOIRE GLAXOSMITHKLINE

Application No.: 11/203573   Filing Date: 09/Aug/2005

Abstract:A pharmaceutical composition comprising N-[(1-butyl-4-piperidinyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide (SB 207266) or a pharmaceutically acceptable salt thereof in combination with one or more pharmaceutically acceptable carriers, wherein at least some of the SB 207266 or salt thereof is in granulated form. Preferably, a filler and/or binder are also present.

Priority: GB20000019524 Applic. Date: 2000-08-08; GB20010018919 Applic. Date: 2001-08-02; GB20010019022 Applic. Date: 2001-08-03; US2002-055817 Applic. Date: 2002-01-23; WO2001GB03590 Applic. Date: 2001-08-08

Inventor: BUXTON PHILIP C [GB]; THOMSON SEONA [GB]; VAN-SCHIE DIRK M J [GB]


Application No.: US20060058390A1  Published: 16/Mar/2006

Title: D-methionine formulation with improved biopharmaceutical properties

Applicant/Assignee: MOLECULAR THERAPEUTICS, INC

Application No.: 11/225107   Filing Date: 14/Sep/2005

Abstract:The present invention provides pharmaceutical suspensions of D-methionine in which the aqueous solubility of D-methionine is exceeded, thereby allowing oral administration of higher doses. The present invention also provides processes for preparing these suspensions. The present invention further provides methods for preventing, treating, or ameliorating oral mucositis, hearing loss due to chemotherapy, antibiotics and noise, neuronal damage due to various CNS disorders and injuries, and anthracycline toxicity.

Priority: US20040609255P Applic. Date: 2004-09-14

Inventor: SUNKARA PRASAD [US]


Application No.: US20060062847A1  Published: 23/Mar/2006

Title: Pharmaceutical dosage forms with impeded extractability of a sympathomimetic

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 11/225176   Filing Date: 14/Sep/2005

Abstract:A solid oral pharmaceutical dosage form of a sympathomimetic with impeded extractability of the sympathomimetic, comprising I) a sympathomimetic (component I) II) an excipient mixture (component II) composed of a) 5 to 50% by weight of hydroxyalkylcelluloses or alkylcelluloses or mixtures thereof b) 5 to 70% by weight of xant

Priority: DE200410045037 Applic. Date: 2004-09-15

Inventor: KOLTER KARL [DE]; WICHTNER MARCUS [DE]; MEYER KATHRIN [DE]; EINIG HEINZ [DE]


Application No.: US20060062848A1  Published: 23/Mar/2006

Title: Formulation comprising itraconazole

Applicant/Assignee: NEKTAR THERAPEUTICS UK LIMITED

Application No.: 11/228541   Filing Date: 16/Sep/2005

Abstract:Formulations of azole antifungals such as itraconazole and particularly formulations, co-formulations and compositions of itraconazole with one or more oligomeric and/or polymeric excipients are disclosed. Methods for preparation of the formulations, co-formulations and compositions include co-precipitating the two materials from a common solvent or solvent mixture using a compressed (typically supercritical or near-critical) fluid anti-solvent as in the GAS (Gas Anti-Solvent) precipitation method. The formulations, co-formulations, compositions, methods of making and methods of delivering, are useful as pharmaceutical compositions and in medical treatment by virtue of their at least parity, preferably improved or enhanced solubility or dissolution characteristics, resulting in at least parity, preferably improved or enhanced bioavailability and/or pharmacokinetics.

Priority: US20040611102P Applic. Date: 2004-09-17

Inventor: GERMAN CAROLINE [GB]; SLOAN RAYMOND [GB]


Application No.: US20060063712A1  Published: 23/Mar/2006

Title: Pharmaceutical composition for inhibiting influenza virus infection and reproduction

Applicant/Assignee: FAR EAST MICROALGAE IND. CO., LTD

Application No.: 11/128189   Filing Date: 13/May/2005

Abstract:The present invention relates to a pharmaceutical composition for inhibiting influenza virus infection and reproduction, comprising a effective amount of C-phycocyanin (C-PC), allophycocyanin (APC), spirulina growth factor (SGF) or the mixture thereof. The present invention also provides a method for extracting said pharmaceutical composition, comprising the steps of: (a) adding hypotonic buffer solution to organic blue-green algae powder and mixing thoroughly

(b) incubating the mixture below room temperature overnight

(c) separating and purifying the mixture by a centrifuge

(d) collecting the suspending supernatant and detecting it by a spectrometer to determine ingredients and content

and (e) spray drying the supernatant

characterized in which low-temperature extraction is employed to maintain the bioactivity and nutrients of the pharmaceutical composition.

Priority: TW20040128553 Applic. Date: 2004-09-21

Inventor: CHIUEH CHUANG C [TW]; SHIH SHIN R [TW]


Application No.: US20060063723A1  Published: 23/Mar/2006

Title: Pharmaceutical composition comprising esterol derivatives for use in cancer therapy

Applicant/Assignee:

Application No.: 10/521040   Filing Date: 16/Aug/2005

Abstract:The present invention relates to a method of treating or preventing estrogen-sensitive tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula

Priority: EP20020077812 Applic. Date: 2002-07-12; EP20030075435 Applic. Date: 2003-02-14; WO2003NL00513 Applic. Date: 2003-07-11

Inventor: COELINGH BENNINK HERMAN JAN T [NL]; BUNSCHOTEN EVERT J [NL]


Application No.: US20060063832A1  Published: 23/Mar/2006

Title: Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof

Applicant/Assignee: PLIVA-LACHEMA A.S. A CZECH REPUBLIC CORPORATION

Application No.: 10/549296   Filing Date: 15/Sep/2005

Abstract:The invention relates to a pharmaceutical composition containing the platinum complex of formula (I) as an active substance where A, A', B, B', X and X' have specific meanings, in a mixture with at least one pharmaceutically acceptable excipient, characterized in that it is formed of a granulate with particles smaller than 0.5 mm in size prepared by wet granulation of a mixture of platinum complex of tetravalent platinum of formula (I) wetted by water, at least one neutral saccharide and at least one native and/or modified polysaccharide, being optionally contained in a capsule or a sack or being optionally pressed into the form of a tablet, while the surface of the granulate, the capsule or the tablet is optionally coated with a layer of at least one pharmaceutically acceptable substance enabling enterosolvent dissolution of the active substance in bowels only and/or at least one pharmaceutically acceptable substance enabling the controlled release of the active substance. The invention relates also the method of manufacturing of said pharmaceutical composition.

Priority: CZ20030000915 Applic. Date: 2003-03-31; CZ20040000235 Applic. Date: 2004-02-12; WO2004CZ00017 Applic. Date: 2004-03-30

Inventor: FRANC ALES [CZ]; SOVA PETER [CZ]


Application No.: US20060063938A1  Published: 23/Mar/2006

Title: Compounds to treat hiv infection and aids

Applicant/Assignee:

Application No.: 10/497898   Filing Date: 28/Mar/2005

Abstract:The present invention relates to compounds of formula I: useful HIV infection, AIDS, and other similar diseases. These compounds include inhibitors of the retroviral integrase enzyme that are useful in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce incorporation of a donor DNA into a receiving DNA.

Priority: US20010339137P Applic. Date: 2001-12-07; WO2002US39254 Applic. Date: 2002-12-06

Inventor: BURKE TERRENCE R [US]; ZHANG XUECHUN [US]; PAIS GODWIN C [US]; SVAROVSKAIA EVGUENIA [US]; PATHAK VINAY K [US]; MARCHAND CHRISTOPHE [US]; POMMIER YVES [US]


Application No.: US20060068015A1  Published: 30/Mar/2006

Title: Solid dosage form comprising a fibrate and a statin

Applicant/Assignee:

Application No.: 10/513778   Filing Date: 14/Jul/2005

Abstract:The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of a fibrate, notably fenofibrate, and a statin (also known as a HMG CoA reductase inhibitors), which compositions are manufactured without any need of addition of water or an aqueous medium and wherein at least 80% of the active substances (i.e. the fibrate and the statin) are present in the composition in dissolved form in order to ensure suitable bioavailability of both active ingredients upon oral administration

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; WO2004DK00668 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20060068019A1  Published: 30/Mar/2006

Title: Coated polyunsaturated fatty acid-containing particles and coated liquid pharmaceutical-containing particles

Applicant/Assignee:

Application No.: 10/523225   Filing Date: 31/Jan/2005

Abstract:A process for coating a polyunsaturated fatty acid (PUFA)-containing carrier particle or a PUFA matrix particle, or a liquid pharmaceutical-containing carrier particle or a liquid pharmaceutical matrix particle. Also disclosed are such particles made by the process of the invention and foods, pharmaceuticals, beverages, nutritional supplements, infant formula, pet food and animal feed with incorporate such particles.

Priority: US20020403598P Applic. Date: 2002-08-14; WO2003US25873 Applic. Date: 2003-08-14

Inventor: DALZIEL SEAN M [US]; FRIEDMANN THOMAS E [US]; SCHURR GEORGE A [US]


Application No.: US20060068411A1  Published: 30/Mar/2006

Title: Cancer specific gene MH15

Applicant/Assignee: MEDIGEN BIOTECHNOLOGY CORPORATION

Application No.: 11/074129   Filing Date: 07/Mar/2005

Abstract:MH15 (Hn1L) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MH15 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MH15 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MH15 expression or activity, thereby treating cancer, in vivo.

Priority: US20040551084P Applic. Date: 2004-03-08

Inventor: CHANG STANLEY [TW]; CHANG HSUN-LANG [TW]; KUO WEI-YING [TW]; CHEN KUO-YEN [TW]; LI NING-YI [TW]; HSU CHIH-PING [TW]; HO PEI-HSUN [TW]


Application No.: US20060069068A1  Published: 30/Mar/2006

Title: Methods and compositions for the treatment of diseases characterized by pathological calcification

Applicant/Assignee: NANOBAC PHARMACEUTICALS, INC

Application No.: 11/102798   Filing Date: 11/Apr/2005

Abstract:Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and/or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

Priority: US2004-891483 Applic. Date: 2004-07-15

Inventor: KAJANDER E O [US]; AHO K M [FI]; CIFTCIOGLU N [US]; MILLICAN B [US]


Application No.: US20060069073A1  Published: 30/Mar/2006

Title: Medicaments for inhalation comprising steroids and an anticholinergic

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/168619   Filing Date: 27/Jun/2005

Abstract:The present invention relates to novel pharmaceutical compositions based on steroids and salts of an anticholinergic, processes for preparing them and their use in the treatment of respiratory complaints.

Priority: EP20040015200 Applic. Date: 2004-06-29

Inventor: PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]


Application No.: US20060073174A1  Published: 06/Apr/2006

Title: Adherent and erodible film to treat a moist surface of a body tissue

Applicant/Assignee: ACCESS PHARMACEUTICALS, INC

Application No.: 11/192524   Filing Date: 29/Jul/2005

Abstract:A thin, flexible, bilayer or multi-layer film which when applied to a moist surface of a body tissue adheres and delivers an active agent, pharmaceutical compound, nutraceutical, flavor or other substance to the underlying surface and/or body cavity and erodes at a predetermined rate. In one application, the amount of time that the active agent remains in contact with the teeth surfaces is controlled by the composition and thickness of the backing layer of the composite film. This erosion or residence time can be regulated from one half hour to several hours, depending upon the desired therapeutic or cosmetic application.

Priority: US2001-931319 Applic. Date: 2001-08-16; US2003-444512 Applic. Date: 2003-05-23

Inventor: MORO DANIEL G [US]; NOWOTNIK DAVID P [US]; CALLAHAN ERNEST H JR [US]


Application No.: US20060073182A1  Published: 06/Apr/2006

Title: Conveniently implantable sustained release drug compositions

Applicant/Assignee:

Application No.: 11/236426   Filing Date: 27/Sep/2005

Abstract:This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

Priority: US20040614484P Applic. Date: 2004-10-01; US20050709665P Applic. Date: 2005-08-19

Inventor: WONG VERNON G [US]; WOOD LOUIS L [US]


Application No.: US20060073203A1  Published: 06/Apr/2006

Title: Dry polymer and lipid composition

Applicant/Assignee: CAMURUS AB

Application No.: 10/548588   Filing Date: 12/Sep/2005

Abstract:The present invention provides an orally administrable composition comprising a dry mixture of polymer, lipid and bioactive agent, being capable on contact with water or GI tract liquid of forming particles comprising said lipid and said bioactive agent and optionally also water. It is preferable that such particles have a liquid crystalline phase structure. The invention also provides a method for the formation of compositions comprising polymer, lipid and bioactive agent.

Priority: GB20030005941 Applic. Date: 2003-03-14; WO2004GB01099 Applic. Date: 2004-03-12

Inventor: LJUSBERG-WAHREN HELENA [SE]; JOABSSON FREDRIK [SE]; THURESSON KRISTER [SE]


Application No.: US20060074048A1  Published: 06/Apr/2006

Title: Mixed esters of hyaluronic acid with retinoic and butyric acids

Applicant/Assignee:

Application No.: 10/540939   Filing Date: 23/Jun/2005

Abstract:The present invention relates to mixed esters of hyaluronic acid, wherein the hydroxyl groups are partially esterified with retinoic and butyric acids. These mixed esters are characterized by specific degrees of esterification and by a high ratio between the degree of substitution with butyric acid and retinoic acid. They exhibit a high anti-proliferative activity associated with activation of cell differentiation, with consequent clinical relevance in the treatment of hyper-proliferative pathologies and in particular of solid and systemic tumors.

Priority: IT2002MI02745 Applic. Date: 2002-12-23; WO2003EP14732 Applic. Date: 2003-12-22

Inventor: PERBELLINI ALBERTO [IT]; CORADINI DANILA [IT]


Application No.: US20060074079A1  Published: 06/Apr/2006

Title: Solid pharmaceutical formulations comprising Diacereine and Meloxicam

Applicant/Assignee: LEOPOLDO ESPINOSA ABDALA

Application No.: 11/186031   Filing Date: 30/Sep/2005

Abstract:This invention relates to formulations in solid pharmaceutical forms containing diacereine and meloxicam. The present invention provides novel formulations comprising: (a) Diacereine, (b) Meloxicam, (c) one or more anti-adherent agents, (d) one or more disintegrating agents, (e) one or more binder agents, (f) one or more lubricants, (g) one or more diluents, (h) one or more solvents, and (i) any other additive which assists in formulation. The present invention also provides a method for treatment of osteoarthritis, rheumatoid arthritis, gout arthritis, multiple sclerosis, amyotrophic lateral sclerosis and related diseases, in addition of inflammatory processes originated from various etiologies, by administering suitable doses.

Priority: MX2004PA09698 Applic. Date: 2004-10-04

Inventor: ARMENTA MARIA ELENA G [MX]; MURILLO JOSEFINA S [MX]; OCHOA VICTOR GUILLERMO A [MX]; MENDOZA CONSUELO F [MX]


Application No.: US20060078542A1  Published: 13/Apr/2006

Title: Gel-based delivery of recombinant adeno-associated virus vectors

Applicant/Assignee:

Application No.: 11/055497   Filing Date: 10/Feb/2005

Abstract:Disclosed are water-soluble gel-based compositions for the delivery of recombinant adeno-associated virus (rAAV) vectors that express nucleic acid segments encoding therapeutic constructs including peptides, polypeptides, ribozymes, and catalytic RNA molecules, to selected cells and tissues of vertebrate animals. Also disclosed are gel-based rAAV compositions are useful in the treatment of mammalian, and in particular, human diseases, including for example, cardiac disease or dysfunction, and musculoskeletal disorders and congenital myopathies, including, for example, muscular dystrophy, acid maltase deficiency (Pompe's disease), and the like. In illustrative embodiments, the invention provides rAAV vectors comprised within a biocompatible gel composition for enhanced viral delivery/transfection to mammalian tissues, and in particular to vertebrate muscle tissues such as a human heart or diaphragm tissue.

Priority: US20040543508P Applic. Date: 2004-02-10

Inventor: MAH CATHRYN S [US]; FRAITES THOMAS J JR [US]; BYRNE BARRY J [US]


Application No.: US20060078614A1  Published: 13/Apr/2006

Title: Taste-masked pharmaceutical compositions

Applicant/Assignee:

Application No.: 11/248596   Filing Date: 12/Oct/2005

Abstract:There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

Priority: US20040617737P Applic. Date: 2004-10-12

Inventor: VENKATESH GOPI M [US]


Application No.: US20060078615A1  Published: 13/Apr/2006

Title: Bilayer tablet of telmisartan and simvastatin

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/236911   Filing Date: 28/Sep/2005

Abstract:A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for instant release of the HMG-CoA reductase inhibitor simvastatin from a disintegrating or eroding tablet matrix.

Priority: EP20040024239 Applic. Date: 2004-10-12

Inventor: KOHLRAUSCH ANJA [DE]


Application No.: US20060078623A1  Published: 13/Apr/2006

Title: Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent

Applicant/Assignee: EMISPHERE TECHNOLOGIES, INC

Application No.: 11/204778   Filing Date: 15/Aug/2005

Abstract:This invention relates to microparticles and/or nanoparticles containing a delivery agent and/or an active agent. This invention also relates to pharmaceutical formulations and solid dosage forms, including controlled release solid dosage forms of active agent and a delivery agent.

Priority: US20040601258P Applic. Date: 2004-08-13; US20040612810P Applic. Date: 2004-09-23

Inventor: DHOOT NIKHIL [US]; LEVCHIK HALINA [US]; MAJURU SHINGAI [US]; KLEIN GEORGE [US]; HARRIS JAMILA [US]; LIU PUCHUN [US]; DINH STEVEN [US]; LIAO JUN [US]; LEE JONGBIN [US]; ARBIT EHUD [US]; WANG NAI F [US]


Application No.: US20060079467A1  Published: 13/Apr/2006

Title: Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions

Applicant/Assignee: UNIGEN PHARMACEUTICALS, INC

Application No.: 11/254433   Filing Date: 19/Oct/2005

Abstract:The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds-Free-B-Ring flavonoids and flavans-for use in the prevention and treatment of diseases and conditions associated with mouth, gums and teeth. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity and reduces cytokine production at the mRNA level in normal, aged and damaged periodontal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the mouth, gums and teeth. The method for preventing and treating diseases and conditions of the mouth, teeth and gums is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria, Oroxylum, Acacia or Uncaria genus of plants and pharmaceutically and/or cosmetically acceptable carriers. Finally the present invention provides a method for the prevention and treatment of diseases and conditions of the mouth, teeth or gums, including but not limited to periodontal diseases, such as gingivitis, periodontitis, pulpitis, periodontal conditions caused by the physical implantation of oral dentures, trauma, injuries, bruxism, neoplastic and other degenerative processes

material alba, pellicles, dental plagues, calculus, and stains. Use of the composition described herein also affords the benefit of maintaining optimum saliva production and pH, minimizing bacterial growth, reducing the formation of pellicles and plague, inhibiting tooth decalcification and tooth caries (decay), promoting remineralization, which yields healthy gums, whitening teeth, maintaining healthy oral hygiene and reducing oral malodour (halitosis).

Priority: US2003-427746 Applic. Date: 2003-04-30; US2003-462030 Applic. Date: 2003-06-13; US2004-785704 Applic. Date: 2004-02-24; US2004-932571 Applic. Date: 2004-09-01; US20040620163P Applic. Date: 2004-10-19; US20020377168P Applic. Date: 2002-04-30; US20030450922P Applic. Date: 2003-02-26; US20030499742P Applic. Date: 2003-09-02

Inventor: JIA QI [US]; ZHAO YUAN [US]


Application No.: US20060079496A1  Published: 13/Apr/2006

Title: Agglomerates by crystallisation

Applicant/Assignee:

Application No.: 11/290185   Filing Date: 30/Nov/2005

Abstract:The present invention describes novel agglomerates in crystalline form of beta-lactum compounds, Furthermore, a process for the preparation of said agglomerates, wherein a solution or suspension of at least one beta-lactum compound in a solvent is mixed with one or more anti-solvents has been described.

Priority: EP19990201034 Applic. Date: 1999-04-01; US2002-937834 Applic. Date: 2002-02-13; WO2000EP02917 Applic. Date: 2000-04-03

Inventor: BOOIJ JOHANNES [NL]; LEFFERTS GEERTRUIDA A [NL]


Application No.: US20060079513A1  Published: 13/Apr/2006

Title: Methods and compositions including methscopolamine nitrate

Applicant/Assignee:

Application No.: 10/964252   Filing Date: 13/Oct/2004

Abstract:Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine nitrate is the preferred anticholinergic agent. The sedative agent may be a benzodiazepine or a barbiturate. Particularly, the sedative agent may be chlordiazepoxide hydrochloride, diazepam, or phenobarbital. Various methods using the compositions to alleviate gastrointestinal disorders or symptoms thereof are also provided.

Priority:

Inventor: PRESTON DAVID M [US]


Application No.: US20060079514A1  Published: 13/Apr/2006

Title: Methods and compositions including methscopolamine bromide

Applicant/Assignee: VICTORY PHARMA INCORPORATED

Application No.: 11/001748   Filing Date: 02/Dec/2004

Abstract:Therapeutic pharmaceutical compositions are provided that include an anticholinergic agent and a sedative agent. Particularly preferred anticholinergic agents include anticholinergic agents which do not substantially cross the blood-brain barrier. Methscopolamine bromide is the preferred anticholinergic agent. The sedative agent may be chlordiazepoxide hydrochloride or diazepam. Various methods using the compositions to alleviate gastrointestinal disorders or symptoms thereof are also provided.

Priority: US2004-964252 Applic. Date: 2004-10-13

Inventor: PRESTON DAVID M [US]


Application No.: US20060083718A1  Published: 20/Apr/2006

Title: Novel therapy for lysosomal enzyme deficiencies

Applicant/Assignee: UNIVERSITY OF MASSACHUSETTS

Application No.: 11/230017   Filing Date: 19/Sep/2005

Abstract:The present invention provides a therapeutic delivery system comprising an extracted yeast cell wall comprising beta-glucan, a payload trapping molecule and a payload molecule, wherein the payload molecule and the payload trapping molecule are soluble in the same solvent system wherein the payload molecule supplements the function of the deficient lysosomal enzyme. The invention further provides methods of making and methods of using the therapeutic delivery system.

Priority: US2004-869693 Applic. Date: 2004-06-16; US20040610872P Applic. Date: 2004-09-17

Inventor: GINNS EDWARD I [US]; OSTROFF GARY R [US]


Application No.: US20060083759A1  Published: 20/Apr/2006

Title: Stabilization of the profile of release of active substances from a formulation

Applicant/Assignee:

Application No.: 10/521295   Filing Date: 17/May/2005

Abstract:The invention discloses a method of a physical pre-treatment of an active substance, which modifies technologically important physical properties of the active substance so as to enable the manufacture of a formulation having a more stable release profile of the active substance over the whole shelf life of the medicine than the profile would be with the same composition, but without pre-treatment.

Priority: SI20020000179 Applic. Date: 2002-07-17; WO2003SI00025 Applic. Date: 2003-07-15

Inventor: RESMAN ALEKSANDER [SI]; FERCEJ-TEMELJOTOV DARJA [SI]; HUMAR VLASTA [SI]; OPRESNIK MARKO [SI]


Application No.: US20060083785A1  Published: 20/Apr/2006

Title: Large dose ribavirin formulations

Applicant/Assignee: THREE RIVERS PHARMACEUTICALS, LLC

Application No.: 11/201311   Filing Date: 11/Aug/2005

Abstract:The present invention is related to pharmaceutical dosage forms of ribavirin which are designed to increase patient compliance to a ribavirin therapy. Examples of such dosage forms include 400 mg to 600 mg tablets. These dosage forms are bioequivalent to multiple doses of tablets containing small amounts of ribavirin.

Priority: US20040619013P Applic. Date: 2004-10-18

Inventor: KERRISH DONALD J [US]; DHANANTWARI RAVINDRA [US]


Application No.: US20060083786A1  Published: 20/Apr/2006

Title: Taste masking pharmaceutical composition containing levocetirizine

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/193542   Filing Date: 29/Jul/2005

Abstract:A solid oral dosage composition is provided comprising a prophilactically or therapeutically effective amount of an active pharmaceutical ingredient comprising levocetirizine or a pharmaceutically acceptable salt thereof, the solid oral dosage composition having a coating thereon capable of providing taste masking of the levocetirizine or pharmaceutically acceptable salt thereof.

Priority: US20040592041P Applic. Date: 2004-07-29

Inventor: CHAUDHARI GHANSHYAM N [IN]; KHACHANE VASANT S [IN]; DESHMUKH VAIBHAV P [IN]; BHAMRE NITIN B [IN]


Application No.: US20060084628A1  Published: 20/Apr/2006

Title: Combination therapy for treating viral infections

Applicant/Assignee: ACHILLION PHARMACEUTICALS

Application No.: 11/252938   Filing Date: 18/Oct/2005

Abstract:A method of treating viral infections, particularly Hepatitis B (HBV) and Human Immunodeficiency Virus (HIV) infections, by administering Elvucitabine and a second active agent to a patient suffering viral infection is provided herein. The second active agent is, for example, an immunomodulatory compound, an anti-viral agent, or a combination comprising one or more of the foregoing active agents. For example the anti-viral agent may be a tyrosine kinase inhibitor, a CCR5 inhibitor, a non-nucleoside reverse transcriptase inhibitor, a protease inhibitor, an integrase inhibitor. Further provided herein are combination dosage forms comprising Elvucitabine and a second active agent. The combination dosage may be administered once per day. The Elvucitabine may be administered less frequently than the second active agent. Packaged pharmaceutical compositions comprising Elvucitabine, a second active agent, and instructions for using the composition for treating a viral infection by administering Elvucitabine and the second active agent are also provided.

Priority: US20040620023P Applic. Date: 2004-10-19

Inventor: POTTAGE JOHN [US]


Application No.: US20060088515A1  Published: 27/Apr/2006

Title: Methods and devices for sustained in-vivo release of an active agent

Applicant/Assignee:

Application No.: 11/238144   Filing Date: 27/Sep/2005

Abstract:The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.

Priority: US20040623150P Applic. Date: 2004-10-27; US2005-238104 Applic. Date: 2005-09-27

Inventor: HIGUCHI JOHN [US]; LI S K [US]; HIGUCHI WILLIAM I [US]; HASTINGS MATTHEW S [US]


Application No.: US20060088521ND  Published: ND

Title: ND

Applicant/Assignee: ND

Application No.: ND   Filing Date: ND

Abstract:ND

Priority: ND

Inventor: ND


Application No.: US20060088591A1  Published: 27/Apr/2006

Title: Tablets from a poorly compressible substance

Applicant/Assignee:

Application No.: 10/972095   Filing Date: 22/Oct/2004

Abstract:A solid composition suitable for forming into a tablet includes a pharmaceutically active substance in an amount sufficient to provide a therapeutic effect when administered

from about 0.2 to about 15 weight %, based on the total weight of the composition, of a water-soluble preparation of a fat-soluble vitamin

and from about 10 to 80 weight %, based on the total weight of the composition, of an excipient. Another aspect of the present invention is method for making the solid composition.

Priority:

Inventor: YUAN JINGHUA [US]; CLIPSE NANCY M [US]; WU STEPHEN H [US]


Application No.: US20060093589A1  Published: 04/May/2006

Title: Vp2-modified raav vector compositions and uses therefor

Applicant/Assignee:

Application No.: 10/513348   Filing Date: 17/Oct/2005

Abstract:Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells.

Priority: WO2004US05205 Applic. Date: 2004-02-19

Inventor: WARRINGTON KENNETH H [US]; OPIE SHAUN R [US]; MUZYCZKA NICHOLAS [US]


Application No.: US20060093619A1  Published: 04/May/2006

Title: Medicament for prevention and treatment of bone fracture and osteoporosis

Applicant/Assignee: SAGITTARIUS LIFE SCIENCE CORP

Application No.: 10/976599   Filing Date: 28/Oct/2004

Abstract:The present invention provides a pharmaceutical composition which can be used to prevent and treat bone fracture and osteoporosis. The composition is composed of Semen lactucae sativae 0.1-1, Lignum aquilariae resinatum 2-20, Fructus oryzae 1-5, Resina boswelliae carterii 0.1-1, Rhizoma atractylodis macrocephalae 0.1-1 and Semen cuscutae 0.1-1. The whole or the specific parts of the plants can be used to prepare the inventive pharmaceutical composition

preferred plants are Aquilariae lignum containing resin and Boswellia carterii containing resin. This pharmaceutical composition can be formulated into lozenge, tablet, film coated tablets, capsule, soft capsule, granule, powder, pill, solution, emulsion, injection solution, injection, ointment, cream, spray or inhalant.

Priority: WO2002CN00534 Applic. Date: 2002-08-02; CN20021019186 Applic. Date: 2002-05-14

Inventor: LIU SUYING [TW]; TSAL YIMING [TW]


Application No.: US20060093629A1  Published: 04/May/2006

Title: Dye-free pharmaceutical suspensions and related methods

Applicant/Assignee:

Application No.: 10/977655   Filing Date: 29/Oct/2004

Abstract:A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent having an average particle size of between about 10 and about 100 microns, an effective amount of non-reducing sweetener

an effective amount of water

and an effective amount of a suspending system

wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods.

Priority:

Inventor: BUEHLER GAIL K [US]


Application No.: US20060093630A1  Published: 04/May/2006

Title: Dye-free pharmaceutical suspensions and related methods

Applicant/Assignee:

Application No.: 10/977670   Filing Date: 29/Oct/2004

Abstract:A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent, an effective amount of non-reducing sweetener

an effective amount of water

and an effective amount of a suspending system

and an effective amount of an opacifier, wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods.

Priority:

Inventor: BUEHLER GAIL K [US]


Application No.: US20060093631A1  Published: 04/May/2006

Title: Dye-free pharmaceutical suspensions and related methods

Applicant/Assignee:

Application No.: 10/978035   Filing Date: 29/Oct/2004

Abstract:A dye-free pharmaceutical suspension having a therapeutically effective amount of a first active agent consisting essentially of a first substantially water insoluble active agent, an effective amount of non-reducing sweetener

an effective amount of water

and an effective amount of a suspending system

wherein the dye-free pharmaceutical suspension has a pH of from about 5 to about 6 and is substantially free of a reducing sugar and related methods.

Priority:

Inventor: BUEHLER GAIL K [US]


Application No.: US20060093666A1  Published: 04/May/2006

Title: Formulations for tyrosine kinase inhibitors

Applicant/Assignee:

Application No.: 10/544213   Filing Date: 02/Aug/2005

Abstract:The present invention is related to a powder, powder blend or granulation formulation of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one, a tyrosine kinase inhibitor, which is adapted for reconstitution with a diluent. This invention is also related to a prepared aqueous suspension, or dispersion, formulation, particularly to a stable oral pharmaceutical formulation, comprising granules of 3-[5-(4-methanesulfonyl-piperazin-1-ylmethyl)-1H-indol-2-yl]-1H-quinolin-2-one mixed with a diluent. Additionally, the present invention is related to the method of preparing these formulations.

Priority: US20030458094P Applic. Date: 2003-03-27; WO2004US08828 Applic. Date: 2004-03-23

Inventor: KARKI SHYAM B [US]; DESHPANDE SAMEER R [US]; THOMPSON KAREN C [US]; PAYNE ANNE H [US]; GANDEK THOMAS P [US]


Application No.: US20060093671A1  Published: 04/May/2006

Title: Controlled release galantamine composition

Applicant/Assignee:

Application No.: 11/304128   Filing Date: 15/Dec/2005

Abstract:The present invention is concerned with controlled release compositions for oral administration comprising galantamine

and with processes of preparing such controlled release compositions.

Priority: EP19980204447 Applic. Date: 1998-12-24; US2001-868991 Applic. Date: 2001-07-26; WO1999EP10257 Applic. Date: 1999-12-20

Inventor: MCGEE JOHN P [BE]; GILIS PAUL M V [BE]; DE WEER MARC MAURICE G [BE]; DE CONDE VALENTIN FLORENT V [BE]; DE BRUIJN HERMAN JOHANNES C [BE]; VAN DYCKE FREDERIC ANNE R [BE]


Application No.: US20060093677A1  Published: 04/May/2006

Title: Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Applicant/Assignee:

Application No.: 11/305461   Filing Date: 16/Dec/2005

Abstract:Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent

(ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles

(iii) blending the microparticles with the excipient to form a powder blend

and (iv) jet milling the powder blend to deagglomerate at least a portion of any of the microparticles which have agglomerated, while substantially maintaining the size and morphology of the individual microparticles. Jet milling advantageously can eliminate the need for more complicated wet deagglomeration processes, can lower residual moisture and solvent levels in the microparticles (which leads to better stability and handling properties for dry powder formulations), and can improve wettability, suspendability, and content uniformity of dry powder blend formulations.

Priority: US2002-324558 Applic. Date: 2002-12-19

Inventor: CHICKERING DONALD E III [US]; REESE SHAINA [US]; NARASIMHAN SRIDHAR [US]; STRAUB JULIE A [US]; BERNSTEIN HOWARD [US]; ALTREUTER DAVID [US]; HUANG ERIC K [US]


Application No.: US20060093678A1  Published: 04/May/2006

Title: Methods for making pharmaceutical formulations comprising deagglomerated microparticles

Applicant/Assignee:

Application No.: 11/305620   Filing Date: 16/Dec/2005

Abstract:Methods are provided for making a dry powder blend pharmaceutical formulation comprising (i) forming microparticles which comprise a pharmaceutical agent

(ii) providing at least one excipient in the form of particles having a volume average diameter that is greater than the volume average diameter of the microparticles

(iii) blending the microparticles with the excipient to form a powder blend

and (iv) jet milling the powder blend to deagglomerate at least a portion of any of the microparticles which have agglomerated, while substantially maintaining the size and morphology of the individual microparticles. Jet milling advantageously can eliminate the need for more complicated wet deagglomeration processes, can lower residual moisture and solvent levels in the microparticles (which leads to better stability and handling properties for dry powder formulations), and can improve wettability, suspendability, and content uniformity of dry powder blend formulations.

Priority: US2002-324558 Applic. Date: 2002-12-19

Inventor: CHICKERING DONALD E III [US]; REESE SHAINA [US]; NARASIMHAN SRIDHAR [US]; STRAUB JULIE A [US]; BERNSTEIN HOWARD [US]; ALTREUTER DAVID [US]; HUANG ERIC K [US]


Application No.: US20060093680A1  Published: 04/May/2006

Title: Coated particles and pharmaceutical dosage forms

Applicant/Assignee:

Application No.: 10/544920   Filing Date: 04/Nov/2005

Abstract:The present invention relates to coated particles and pharmaceutical dosage forms comprising the active substances sensitive to environmental influences. The coating of the present invention provides stability and protection of the active substance to environmental influences and in particular from oxidation and/or environmental humidity by coating.

Priority: SI20030000041 Applic. Date: 2003-02-12; WO2004SI00009 Applic. Date: 2004-02-11

Inventor: HUMAR VLASTA [SI]; BURJAK MATEJA [SI]; GRAHEK ROK [SI]; SALOBIR MATEJA [SI]; KERC JANEZ [SI]; KOCEVAR KLEMEN [SI]


Application No.: US20060099249A1  Published: 11/May/2006

Title: Modified release formulations of at least one form of tramadol

Applicant/Assignee:

Application No.: 10/517809   Filing Date: 11/Oct/2005

Abstract:The present invention provides for a modified release pharmaceutical composition comprising at least one form of tramadol selected from the group consisting of tramadol, enantiomers thereof, pharmaceutically acceptable salts thereof and combinations thereof, the composition exhibiting an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37 DEG C.) such that after 2 hours, from about 0% up to about 30% (by weight) of the at least one form of tramadol is released, after 4 hours, from about 5% to about 22% (by weight) of the at least one form of tramadol is released, after 6 hours, from about 15% to about 38% (by weight) of the at least one form of tramadol is released, after 8 hours, more than about 40% (by weight) of the at least one form of tramadol is released.

Priority: US20020357851P Applic. Date: 2002-02-21; WO2003US04866 Applic. Date: 2003-02-21

Inventor: SETH PAWAN [US]; MAES PAUL [US]


Application No.: US20060099251A1  Published: 11/May/2006

Title: Formulations of finasteride

Applicant/Assignee:

Application No.: 10/535826   Filing Date: 21/Nov/2005

Abstract:This invention relates to pharmaceutical formulations of finasteride that include Gelucire(R).

Priority: IS20020006633 Applic. Date: 2002-11-22; WO2003IS00034 Applic. Date: 2003-11-21

Inventor: JOHANNSSON FJALAR [IS]


Application No.: US20060099260A1  Published: 11/May/2006

Title: Methods and formulations for making pharmaceutical compositions containing bupropion

Applicant/Assignee: BIOKEY, INC

Application No.: 11/265918   Filing Date: 03/Nov/2005

Abstract:Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include from about 5% to about 99% by weight of the coating of a pharmaceutically acceptable pH-independent polymer. The coating may further include from about 0.001% to about 30% by weight of the coating of a surfactant. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.

Priority: US20040626317P Applic. Date: 2004-11-08

Inventor: CHOW SAN-LAUNG [US]; WONG DAVID [US]; GARCIA DAMIAN [US]


Application No.: US20060099261A1  Published: 11/May/2006

Title: Methods and formulations for making controlled release oral dosage form

Applicant/Assignee: BIOKEY, INC

Application No.: 11/295851   Filing Date: 06/Dec/2005

Abstract:Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating antidepressant or smoking cessation. In one aspect, the invention provides a pharmaceutical formulation comprising a core, including bupropion and its salt derivatives, and a coating. The coating may include one or more surfactants and aqueous dispersions of one or more insoluble pharmaceutical acceptable polymers. The core may also include aqueous dispersions of one or more insoluble pharmaceutical acceptable polymers. In another aspect, the invention provides methods for preparing and administering a pharmaceutical composition in oral dosage form, such as a tablet.

Priority: US20040626317P Applic. Date: 2004-11-08; US2005-265918 Applic. Date: 2005-11-03

Inventor: CHOW SAN-LAUNG [US]; WONG DAVID [US]; GARCIA DAMIAN [US]


Application No.: US20060099267A1  Published: 11/May/2006

Title: High-dosage extended-release formulation of gepirone

Applicant/Assignee: FABRE-KRAMER PHARMACEUTICALS, INC

Application No.: 10/981663   Filing Date: 05/Nov/2004

Abstract:The present invention relates to high-dosage extended-release formulation of gepirone and methods of treating major depression by administering the same to a subject in need thereof. More specifically, the present invention relates to a high-dosage extended-release tablet form of gepirone. The present invention also relates to a method of treating depression in mammals by administering to a subject in need thereof an effective amount the high-dosage extended-release formulation of gepirone in accordance with the present invention.

Priority:

Inventor: KRAMER STEPHEN J [US]; FABRE LOUIS F [US]


Application No.: US20060099284A1  Published: 11/May/2006

Title: Composition containing an extract of fructus psoraleae for inhibiting anxiety and depression, improving memory and treating dementia

Applicant/Assignee:

Application No.: 11/271317   Filing Date: 10/Nov/2005

Abstract:Disclosed is a composition comprising of an extract of Fructus Psoraleae for inhibiting anxiety and depression and improving memory. The composition can be used in medicaments and health care foods for preventing and treating anxiety and depression of modern people suffering from brain impairment caused by environmental factors, such as various stresses, drinking, smoking and so on, improving memory, and preventing and treating dementia.

Priority: KR20040091252 Applic. Date: 2004-11-10

Inventor: KIM SUNG-JIN [KR]


Application No.: US20060100182A1  Published: 11/May/2006

Title: Pharmaceutical compositions for the treatment of urinary incontinence

Applicant/Assignee:

Application No.: 10/524131   Filing Date: 13/Sep/2005

Abstract:Pharmaceutical compositions for the treatment of urinary incontinence with a cholinergic and musulotropic substance, combined or not combined with a little resorbed estrogen agent, by local route, wherein the cholinergic and musculotropic substance is oxybutynin, or one of its salts, and the little resorbed estrogen agent is chosen from estriol, 16-epiestriol or estradiol in free, esterified and/or etherified form suited for vaginal or rectal administration and a method of treating urinary incontinence.

Priority: FR20020010058 Applic. Date: 2002-08-07; WO2003FR02471 Applic. Date: 2003-08-06

Inventor: ROUGAIGNON CAROLINE [MC]; LANQUETIN MICHEL [FR]


Application No.: US20060104997A1  Published: 18/May/2006

Title: Monoterpene compositions and uses thereof

Applicant/Assignee:

Application No.: 10/498566   Filing Date: 17/Nov/2005

Abstract:The present invention relates to pharmaceutical compositions and methods for the mucosal and oral administration of monoterpenes and derivatives thereof. The compositions of this invention further comprise one or more surfactants and cosolvents and are in the form of self-emulsifying compositions. The compositions of the invention may further comprise water-insoluble therapeutic agents, vaccines and diagnostics. Such agents include but are not limited to taxanes, steroids, topoisomerase inhibitors such as etoposide and other water-insoluble or lipophilic drugs.

Priority: US20010339778P Applic. Date: 2001-12-11; US20020378900P Applic. Date: 2002-05-07; WO2002US39545 Applic. Date: 2002-12-11

Inventor: CONSTANTINIDES PANAYIOTIS P [US]; PATIL REENA T [US]; BOLOTIN ELIJAH M [US]; LIANG LIKAN [US]


Application No.: US20060105000A1  Published: 18/May/2006

Title: Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil

Applicant/Assignee: J.P.M.E.D. LTD

Application No.: 10/535961   Filing Date: 20/May/2005

Abstract:The invention provides a composition of matter for treating infected skin and mucousal membranes, said composition comprising at least one anti-microbial drug

and at least one essential oil, in combination with a substantially, alcohol-free carrier system, said carrier being selected from a liquid carrier or a semi-solid carrier, said carrier system being selected from isotonic system and a moderately hypertonic system.

Priority: IL20020152993 Applic. Date: 2002-11-21; IL20030158901 Applic. Date: 2003-11-17; WO2003IL00980 Applic. Date: 2003-11-19

Inventor: FRIEDMAN DORON I [IL]


Application No.: US20060105035A1  Published: 18/May/2006

Title: Sustained release heterodisperse hydrogel systems for insoluble drugs

Applicant/Assignee: PENWEST PHARMACEUTICALS CO

Application No.: 11/333027   Filing Date: 17/Jan/2006

Abstract:A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.

Priority: US2004-798225 Applic. Date: 2004-03-11; US2000-654691 Applic. Date: 2000-09-05; US1998-207298 Applic. Date: 1998-12-08; US1997-843573 Applic. Date: 1997-04-18; US1996-651901 Applic. Date: 1996-05-21; US1995-447236 Applic. Date: 1995-05-22; US1993-118924 Applic. Date: 1993-09-09

Inventor: BAICHWAL ANAND R [US]


Application No.: US20060105038A1  Published: 18/May/2006

Title: Taste-masked pharmaceutical compositions prepared by coacervation

Applicant/Assignee: EURAND PHARMACEUTICALS LIMITED

Application No.: 11/213266   Filing Date: 26/Aug/2005

Abstract:There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredients, rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates rapidly with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing one or more actives) with a taste-masking membrane applied by a modified solvent coacervation process comprising a water-insoluble polymer and at least one gastrosoluble inorganic or organic pore-former, exhibit a pleasant taste when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Priority: US20040627525P Applic. Date: 2004-11-12

Inventor: LAI JIN-WANG [US]; QIAN KEN K [US]; VENKATESH GOPI M [US]


Application No.: US20060105039A1  Published: 18/May/2006

Title: Taste-masked pharmaceutical compositions with gastrosoluble pore-formers

Applicant/Assignee:

Application No.: 11/256653   Filing Date: 21/Oct/2005

Abstract:There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active), coated with a taste-masking membrane comprising a water-insoluble polymer and one or more gastrosoluble inorganic or organic pore-formers (practically insoluble in water and saliva, but soluble in an acidic buffer), exhibit acceptable taste-masking when placed in the oral cavity and provide rapid, substantially-complete release of the dose on entry into the stomach.

Priority: US20040621144P Applic. Date: 2004-10-21

Inventor: LAI JIN-WANG [US]; VENKATESH GOPI M [US]; QIAN KEN K [US]


Application No.: US20060105044A1  Published: 18/May/2006

Title: Sustained release formulations of sotalol

Applicant/Assignee:

Application No.: 11/134089   Filing Date: 20/May/2005

Abstract:Sustained release compositions of sotalol, or a pharmaceutically acceptable salt thereof, are provided. In certain examples, sotalol, or a pharmaceutically acceptable salt thereof, may be administered in an effective amount to provide a therapeutic effect to a patient, such as, for example, a patient suffering from a cardiac disorder. In some examples, sotalol combined with a sustained release system may be administered to provide a sustained release of sotalol for a desired period, e.g., at least about 24 hours.

Priority: US20040573367P Applic. Date: 2004-05-20

Inventor: SINGH BRAMAH N [US]


Application No.: US20060105050A1  Published: 18/May/2006

Title: Compositions comprising fenofibrate and simvastatin

Applicant/Assignee:

Application No.: 10/988828   Filing Date: 15/Nov/2004

Abstract:The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor simvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCsimvastatin) of between about 800 and about 29,300. The solid compositions are manufactured without any need of addition of water or aqueous medium and comprise at least 80% of the active substances fenofibrate and simvastatin in dissolved form, or, optionally, atorvastatin in micronized form, in order to ensure suitable bioavailability.

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; WO2004DK00668 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20060106000A1  Published: 18/May/2006

Title: Use of inositol-tripyrophosphate in treating tumors and diseases

Applicant/Assignee:

Application No.: 11/175979   Filing Date: 06/Jul/2005

Abstract:Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate to enhance PO2 in hypoxic tumors.

Priority: US20040585804P Applic. Date: 2004-07-06

Inventor: NICOLAU CLAUDE [US]; GREFERATH RUTH [DE]; FYLAKTAKIDOU KONSTANTINA C [GR]; LEHN JEAN-MARIE [FR]


Application No.: US20060110329A1  Published: 25/May/2006

Title: Inhalable pharmaceutical compositions containing an anticholinergic, salmeterol, and a steroid

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/273782   Filing Date: 15/Nov/2005

Abstract:A pharmaceutical composition comprising an anticholinergic of formula 1 wherein X<-> is an anion

salmeterol xinafoate, or a hydrate, solvate, enantiomer, or mixtures of enantiomers thereof

and a steroid selected from ciclesonide, budesonide, and mometasone furoate, or a solvate or hydrate thereof.

Priority: DE200410056579 Applic. Date: 2004-11-23

Inventor: PIEPER MICHAEL P [DE]


Application No.: US20060110330A1  Published: 25/May/2006

Title: Inhalable pharmaceutical compositions containing an anticholinergic, formoterol, and a steroid

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/274648   Filing Date: 15/Nov/2005

Abstract:A pharmaceutical composition containing an anticholinergic of formula 1 wherein X<-> is an anion

a formoterol salt selected from formoterol fumarate and formoterol hemifumarate, or a hydrate, solvate, enantiomer, or mixtures of enantiomers thereof

and a steroid selected from ciclesonide, budesonide, and mometasone furoate, or a solvate or hydrate thereof.

Priority: DE200410056578 Applic. Date: 2004-11-23

Inventor: PIEPER MICHAEL P [DE]


Application No.: US20060110331A1  Published: 25/May/2006

Title: Compositions comprising azelastine and methods of use thereof

Applicant/Assignee: MEDPOINTE HEALTHCARE INC

Application No.: 11/284109   Filing Date: 22/Nov/2005

Abstract:The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders. The compositions and methods of the present invention provide significant value in terms of patient acceptability, convenience, and compliance.

Priority: US20040630274P Applic. Date: 2004-11-24

Inventor: DANG PHUONG G [US]; LAWRENCE BRIAN D [US]; BALWANI GUL [US]; D ADDIO ALEXANDER D [US]


Application No.: US20060110444A1  Published: 25/May/2006

Title: Solid dosage form comprising a fibrate

Applicant/Assignee: LIFECYCLE PHARMA A/S

Application No.: 10/513807   Filing Date: 08/Nov/2004

Abstract:The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; DK20040001006 Applic. Date: 2004-06-25; WO2004DK00667 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20060110450A1  Published: 25/May/2006

Title: Bilayer tablet of telmisartan and amlodipine

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/265722   Filing Date: 02/Nov/2005

Abstract:A bilayer tablet comprises a first layer formulated for instant release of the angiotensin II receptor antagonist telmisartan from a dissolving tablet matrix and a second layer formulated for instant release of the calcium channel blocker amlodipine from a disintegrating or eroding tablet matrix.

Priority: EP20040026234 Applic. Date: 2004-11-05

Inventor: EISENREICH WOLFRAM [DE]


Application No.: US20060110452A1  Published: 25/May/2006

Title: Dosage forms of risedronate

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: 11/286875   Filing Date: 23/Nov/2005

Abstract:Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food.

Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies.

Priority: US2005-106816 Applic. Date: 2005-04-15; US20040573881P Applic. Date: 2004-05-24

Inventor: DANSEREAU RICHARD J [US]; BURGIO DAVID E JR [US]


Application No.: US20060110454A1  Published: 25/May/2006

Title: Extended release formulation of pramipexole dihydrochloride

Applicant/Assignee:

Application No.: 11/260066   Filing Date: 27/Oct/2005

Abstract:An extended release composition of Pramipexole or a pharmaceutical acceptable salt thereof, wherein the active agent is coated on a non pareil inert core, the drug loaded core is further coated with a polymeric layer which enables the release of the active agent over an extended period and optionally the extended release pellets being further blended with suitable excipients and compressed into a multi unit tablet and processes for the preparation of the said composition.

Priority: IN2004MU01153 Applic. Date: 2004-10-27

Inventor: KSHIRSAGAR RAJESH [IN]; JOSHI MAYANK [IN]; KUMAR AMRESH [IN]


Application No.: US20060111343A1  Published: 25/May/2006

Title: Oxcarbazepine dosage forms

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/264836   Filing Date: 01/Nov/2005

Abstract:Dosage forms of oxcarbazepine or a pharmaceutically acceptable salt thereof and a pH modifying agent for use in oral administration are provided.

Priority: US20040623926P Applic. Date: 2004-11-01

Inventor: KRISHNAN ANANDI [IN]; KANNAN MUTHAIYYAN E [IN]; PATIL ATUL V [IN]


Application No.: US20060111442A1  Published: 25/May/2006

Title: Use of methyl pyruvate to increase cellular energy production downstream of glycolysis for the PARP-1 ablation of HIV without necrotic cell death caused by continuous, chronic PARP-1 activation through the concomitant depletion of ATP and NAD.

Applicant/Assignee:

Application No.: 10/904648   Filing Date: 20/Nov/2004

Abstract:The present invention relates to the use of methyl pyruvic acid (a methyl ester of pyruvic acid) and/or methyl pyruvate (methyl pyruvate is the ionized form of methyl pyruvic acid) for the purpose of increasing cellular energy production thereby providing energy for the continuous activation of PARP-1 and up-regulation of PPAR. It is well known that chronic activation of PARP causes ATP and NAD depletion with concomitant cell death. PARP is known to prevent HIV replication by competitive receptor inhibition. Use of methyl pyruvate and/or methyl pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. In the following text, the terms "methyl pyruvate, methyl pyruvate compounds, methyl pyruvic acid" are used interchangeably.

Priority:

Inventor: ANTOSH STANLEY C [US]; MEDURI ANTHONY J [US]


Application No.: US20060115529A1  Published: 01/Jun/2006

Title: Fast-melting tablets having taste-masking and sustained release properties

Applicant/Assignee:

Application No.: 11/267568   Filing Date: 04/Nov/2005

Abstract:Fast-melting tablets contain particles of an active ingredient and ion-exchange resin complex to mask unpleasant taste associated with the active ingredient. The resin complex particles can be coated or uncoated to impart sustained release properties to the active ingredient. A fast-melting tablet also comprises a dry binder and bulk diluent to form highly plastic granules that are subsequently compressed into tablets.

Priority: US2004-841979 Applic. Date: 2004-05-07; US20040624959P Applic. Date: 2004-11-04; US20030468449P Applic. Date: 2003-05-07

Inventor: JEONG SEONGHOON [US]; KIMURA SUSUMU [JP]; FU YOURONG [US]; PARK KINAM [US]


Application No.: US20060115530A1  Published: 01/Jun/2006

Title: Gastric acid secretion inhibiting composition

Applicant/Assignee: OREXO AB

Application No.: 10/531598   Filing Date: 25/Nov/2005

Abstract:An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Priority: SE20020003065 Applic. Date: 2002-10-16; WO2003SE01598 Applic. Date: 2003-10-15

Inventor: PETTERSSON ANDERS [SE]; NYSTROM CHRISTER [SE]; HAKANSSON YVONNE [SE]


Application No.: US20060121040A1  Published: 08/Jun/2006

Title: Compositions and methods for treating neuroendocrine tumors

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 11/296404   Filing Date: 08/Dec/2005

Abstract:Methods and pharmaceutical compostions for treating or suppressing symptoms of neuroendocrine (NE) tumors comprising inhibiting the activities of GSK-3beta of the cancer cells. Also disclosed are pharmaceutical compositions for the methods. Preferably, the pharmaceutical composition comprises Li+, SB216763, SB415286, indirubins, Paullones, Hymenialdisine, Azakenpaullone, Thienyl and phenyl alpha-halomethyl ketones, CHR 99021, AR-A014418, Bis-7-azaindolylmaleimides, CHR 98023, CHR-98014, and ZM336372, or a pharmaceutically acceptable salt or derivative thereof.

Priority: US20040634082P Applic. Date: 2004-12-08

Inventor: KUNNIMALAIYAAN MUTHUSAMY [US]; CHEN HERBERT [US]


Application No.: US20060121092A1  Published: 08/Jun/2006

Title: Methods of producing coated products including active agent and products regarding same

Applicant/Assignee:

Application No.: 11/273941   Filing Date: 15/Nov/2005

Abstract:Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the products. The products include a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a consumable center. By chewing the product, the medicament or agent is released from the product within the buccal cavity.

Priority: US2002-044113 Applic. Date: 2002-01-09; US2000-631326 Applic. Date: 2000-08-03; US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06

Inventor: REAM RONALD L [US]; MATULEWICZ LEONARD [US]; WOKAS WILLIAM J [US]


Application No.: US20060121093A1  Published: 08/Jun/2006

Title: Tableted products including active agent

Applicant/Assignee:

Application No.: 11/273942   Filing Date: 15/Nov/2005

Abstract:Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the products. The products include a coating having a medicament or agent. The medicament or agent is present within the coating that surrounds a consumable center. By chewing the products, the medicament or agent is released from the product within the buccal cavity.

Priority: US2002-044113 Applic. Date: 2002-01-09; US2000-631326 Applic. Date: 2000-08-03; US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06

Inventor: REAM RONALD L [US]; MATULEWICZ LEONARD [US]; WOKAS WILLIAM J [US]


Application No.: US20060121114A1  Published: 08/Jun/2006

Title: Method of manufacturing sustained release microbeads containing venlafaxine HCL

Applicant/Assignee:

Application No.: 11/149527   Filing Date: 10/Jun/2005

Abstract:A sustained release Venlafaxine composition that includes a plurality of non-agglomerated, uniformly-shaped and sized microbeads of inert core particles having a first coating layer. The first coating layer includes an active agent of Venlafaxine or a pharmaceutical acceptable salt thereof, a binder, and an anti-tack agent. The active agent is present in the first coating layer in a concentration of at least about 5% to about 70% by weight of the composition, the binder is present in an amount of at least 35% by weight of the active agent, or in a further layer located upon or below the first coating layer, or as an alternating layer between plural first layers, wherein the binder is present in an amount of less than about 2.5% by weight of the composition, and the anti-tack agent is present in the first coating layer in a concentration of about 2.5% to about 20% by weight based on the weight of the active agent. The composition is also substantially free of organic acid.

Priority: IN2002MU01054 Applic. Date: 2002-11-28; US2005-138913 Applic. Date: 2005-05-27; WO2003IB05194 Applic. Date: 2003-11-17

Inventor: ANTARKAR AMIT K [IN]; VARDAM POONAM P [IN]; SHAH MAYA J [IN]; LALA RAJENDRA G [IN]


Application No.: US20060122158A1  Published: 08/Jun/2006

Title: Pharmaceutical application of 15- or 16-substituted testosterone analogues

Applicant/Assignee:

Application No.: 10/526730   Filing Date: 16/Sep/2005

Abstract:The invention relates to pharmaceutical dosage units for oral, transmucosal or transdermal administration containing 15- or 16-substituted testosterone analogues, as well as to therapeutic methods that employ these testosterone analogues. More particularly, the invention is concerned with such pharmaceutical dosage units containing at least 10 mug of an androgenic steroid selected from the group consisting of 15-hydroxytestosterones, 16-hydroxytestosterones, precursors thereof and mixtures of these hydroxytestosterones and/or their precursors

and a pharmaceutically acceptable excipient. The term "15-hydroxytestosterones" encompasses both 15beta-hydroxytestosterone (15alpha, 17beta-dihydroxy-4-androsten-3-one) and 15beta-hydroxytestosterone (15beta, 17beta-dihydroxy-4-androsten-3-one). Similarly, the term "16-hydroxytestosterones" encompasses both 16alpha-hydroxytestosterone hydroxytestosterone (16alpha, 17beta-dihydroxy-4-androsten-3-one) and 16alpha-hydroxytestosterone (16beta, 17beta-dihydroxy-4-androsten-3-one). The androgenic steroids according to the invention are advantageously employed in e.g. a method of treating or preventing androgen deficiency or a method of hormonal contraception.

Priority: EP20020078643 Applic. Date: 2002-09-05; WO2003NL00621 Applic. Date: 2003-09-05

Inventor: BUNSCHOTEN EVERT J [NL]; COELINGH BENNINK HERMAN JAN T [NL]; VAN DER LINDEN RENE F [NL]


Application No.: US20060122162A1  Published: 08/Jun/2006

Title: Methods of using temozolomide formulation intrathecally in the treatment of cancers

Applicant/Assignee: SCHERING CORPORATION

Application No.: 11/290779   Filing Date: 30/Nov/2005

Abstract:Methods are disclosed for treating cancer in a patient in need of such treating comprising intrathecally administering temozolomide in a pharmaceutical formulation in a therapeutically effective amount.

Priority: US20040632675P Applic. Date: 2004-12-02

Inventor: CUTLER DAVID L [US]


Application No.: US20060122194A1  Published: 08/Jun/2006

Title: Tablet comprising efletirizine and pseudoephedrine

Applicant/Assignee: UCB FARCHIM S.A

Application No.: 10/537553   Filing Date: 12/Nov/2003

Abstract:The present invention concerns a tablet comprising two distinct segments. More particularly the invention relates to combinations of two pharmaceutical substances and methods of treatment of allergic disorders.

Priority: EP20020080127 Applic. Date: 2002-12-06; WO2003EP12627 Applic. Date: 2003-11-12

Inventor: BERWAER MONIQUE [BE]; GUICHAUX ANTHONY [BE]; CUYPERS SERGE [BE]; DELEERS MICHEL [BE]; FANARA DOMENICO [IT]


Application No.: US20060122208A1  Published: 08/Jun/2006

Title: Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Applicant/Assignee: TARO PHARMACEUTICALS INDUSTRIES LTD

Application No.: 11/201024   Filing Date: 10/Aug/2005

Abstract:The present invention relates to a composition and a method of delivering a barbituric acid derivative to the central nervous system of a mammal in need of treatment for neurological conditions. In particular, the present invention relates to a method of administering an oral dosage form of a sodium salt of 5,5-diphenyl barbituric acid to enhance the bioavailability of 5,5-diphenyl barbituric acid and brain delivery of same.

Priority: US2003-735514 Applic. Date: 2003-12-11; US2003-354146 Applic. Date: 2003-01-30; US2004-865428 Applic. Date: 2004-06-10; US2003-333957 Applic. Date: 2003-01-27; WO2001US23420 Applic. Date: 2001-07-26; US20040600327P Applic. Date: 2004-08-10; US20020432470P Applic. Date: 2002-12-11; US20020352273P Applic. Date: 2002-01-30; US20000221672P Applic. Date: 2000-07-26

Inventor: GUTMAN DANIELLA [IL]; MOROS DANIEL [US]; YACOBI AVRAHAM [US]; RUTMAN HOWARD [US]


Application No.: US20060122273A1  Published: 08/Jun/2006

Title: Use for deferiprone

Applicant/Assignee: APOTEX INC

Application No.: 11/331101   Filing Date: 13/Jan/2006

Abstract:A method of treating iron induced cardiac disease in a patient with iron overload, such as in thalassemia or the like comprising administering to the patient a therapeutically effective amount of deferiprone or a physiologically acceptable salt thereof sufficient to treat induced cardiac disease normally associated with iron overload.

Priority: WO2001CA00956 Applic. Date: 2001-06-28; US2003-311814 Applic. Date: 2003-04-04; CA20002313270 Applic. Date: 2000-06-30

Inventor: SPINO MICHAEL [CA]; PIGA ANTONIO [IT]


Application No.: US20060122274A1  Published: 08/Jun/2006

Title: Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Applicant/Assignee: OSTEOLOGIX A/S

Application No.: 11/269289   Filing Date: 07/Nov/2005

Abstract:Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

Priority: DK20030001820 Applic. Date: 2003-12-09; DK20030000932 Applic. Date: 2003-06-20; DK20030000691 Applic. Date: 2003-05-07; WO2004DK00328 Applic. Date: 2004-05-06; WO2005DK00140 Applic. Date: 2005-02-28; WO2005DK00404 Applic. Date: 2005-06-17; WO2005DK00401 Applic. Date: 2005-06-17; US20030528442P Applic. Date: 2003-12-09

Inventor: HANSEN CHRISTIAN [DK]; NILSSON HENRIK [DK]; CHRISTGAU STEPHAN [DK]; ANDERSEN JENS E [DK]


Application No.: US20060122275A1  Published: 08/Jun/2006

Title: Agentfor reducing side effects of diclofenac

Applicant/Assignee:

Application No.: 10/524857   Filing Date: 21/Sep/2005

Abstract:The present invention relates to reduction of side effects of diclofenac or a salt thereof An agent for reducing side effects of diclofenac or a salt thereof which comprises ornoprostil. It is expected that a combination agent of diclofenac or a non-toxic salt thereof and ornoprostil is comparable to even superior to marketed diclofenac tablets or Arthrotec tables in effects and fast-acting property while showing little side effects (particularly digestive disorders, gastric ulcer, diarrhea/vomiting and renal disorder) and exerting excellent antipyretic, analgesic and antiinlfammatory effects. Also, by formulating the combination agent into a preparation of separation type pharmaceutical preparation, the stability of ornoprostil can be improved.

Priority: JP20020241271 Applic. Date: 2002-08-22; WO2003JP10562 Applic. Date: 2003-08-21

Inventor: SAKAI YOSHIKI [JP]; KATSUBE NOBUO [JP]; NISHIURA AKIO [JP]; YAMAMOTO MASANOBU [JP]; SUGISHITA KEN-ICHI [JP]


Application No.: US20060127354A1  Published: 15/Jun/2006

Title: Phosphorylated polymers and conjugates thereof

Applicant/Assignee:

Application No.: 11/342209   Filing Date: 27/Jan/2006

Abstract:The present invention is directed to absorbable polyesters comprising one or more monophosphate functionality

a conjugate comprising the foregoing polyester and a peptide and/or a bioactive agent

microparticles comprising an absorbable polyester

a conjugate comprising the microparticles and a peptide and/or a bioactive agent

an acylated or alkylated polysaccharide having one or more monophosphate functionality

a conjugate comprising the acylated or alkylated polysaccharide and a peptide and/or a bioactive agent

and pharmaceutical compositions thereof.

Priority: US2001-762431 Applic. Date: 2001-05-22; WO1999US18146 Applic. Date: 1999-08-10

Inventor: SHALABY SHALABY W [US]; CORBETT JOEL T [US]


Application No.: US20060127357A1  Published: 15/Jun/2006

Title: Rapamycin and il-10 for the treatment of immune diseases

Applicant/Assignee:

Application No.: 10/536316   Filing Date: 27/Nov/2003

Abstract:The invention discloses a combined preparation containing IL-10 and rapamucin able to induce immunosuppression and antigen-specific immune tolerance, and the use thereof in the treatment of diseases involving an excessive, dysfunctional or uncontrolled immune response mediated by T cells.

Priority: US20020429561P Applic. Date: 2002-11-29; WO2003EP13351 Applic. Date: 2003-11-27

Inventor: RONCAROLO MARIA G [IT]; BATTAGLIA MANUELA [IT]


Application No.: US20060127472A1  Published: 15/Jun/2006

Title: Taste-masked prednisolone oral formulations

Applicant/Assignee:

Application No.: 11/010472   Filing Date: 13/Dec/2004

Abstract:An improved taste-masked pharmaceutical prednisolone composition contains prednisolone sodium phosphate taste-masked with an effective taste-masking amount of rum ether.

Priority:

Inventor: WHITEHEAD KEITH [US]


Application No.: US20060127480A1  Published: 15/Jun/2006

Title: Pharmaceutical excipients comprising inorganic particles in association with an organic polymeric material and forming a solid reticulated matrix, compositions, manufacturing and use thereof

Applicant/Assignee:

Application No.: 10/531073   Filing Date: 16/Dec/2005

Abstract:A pharmaceutical excipient comprising a solid, reticulated matrix, wherein the matrix comprises an aggregation of inorganic particles in association with an organic polymeric material, defines a plurality of pores with a mean width in the range of about 0.01-500 m, and has a specific surface area of at least about 1 m2/g is described, as are products comprising such excipients, methods of making them and use thereof.

Priority: US20020418055P Applic. Date: 2002-10-11; WO2003GB04463 Applic. Date: 2003-10-10

Inventor: TOBYN MICHAEL [GB]; STANIFORTH JOHN N [GB]; CLINCH CHERYL [GB]; HEARN MATTHEW P [GB]; WALSH DOMINIC [GB]; HALL SIMON R [GB]


Application No.: US20060127487A1  Published: 15/Jun/2006

Title: Antiviral compositions

Applicant/Assignee:

Application No.: 11/347071   Filing Date: 03/Feb/2006

Abstract:The present invention is concerned with pharmaceutical compositions of antiviral compounds which can be administered to a mammal, in particular a human, suffering from a viral infection. These compositions comprise particles obtainable by melt-extruding a mixture comprising one or more antiviral compounds and one or more appropriate water-soluble polymers and subsequently milling said melt-extruded mixture.

Priority: EP19990203128 Applic. Date: 1999-09-24; US2002-088805 Applic. Date: 2002-03-21; WO2000EP08522 Applic. Date: 2000-08-31

Inventor: VERRECK GEERT [BE]; BAERT LIEVEN [BE]


Application No.: US20060128809A1  Published: 15/Jun/2006

Title: Rapidly absorbed liquid compositions

Applicant/Assignee:

Application No.: 11/342186   Filing Date: 27/Jan/2006

Abstract:The present invention provides a method which provides for a faster absorption of pharmaceutically acceptable amines. The method provides a pharmaceutically acceptable amine in combination with a non-steroidal anti-inflammatory drug in a liquid form. A preferred embodiment employs pseudoephedrine and ibuprofen.

Priority: US2003-608170 Applic. Date: 2003-06-26; US2002-323433 Applic. Date: 2002-12-19; US2001-777086 Applic. Date: 2001-02-05; US1999-329900 Applic. Date: 1999-06-10

Inventor: GELOTTE CATHY K [US]; HILLS JOANNA F [US]; PENDLEY CHARLES E II [US]; SHAH MANOJ N [US]


Application No.: US20060134190A1  Published: 22/Jun/2006

Title: Formulations of bisphosphonate drugs with improved bioavailability

Applicant/Assignee: BANNER PHARMACAPS INC

Application No.: 11/014252   Filing Date: 16/Dec/2004

Abstract:This invention relates to formulations of bisphosphonates such as alendronate. The formulations taught herein enhance bioavailability of bisphosphonates and reduce esophageal and gastric ulcerations associated with them. Also taught herein are methods of preparing the formulations and their clinical use in the treatment of osteoporosis and other bone diseases.

Priority:

Inventor: KIM TAE K [US]; FATMI AQEEL A [US]


Application No.: US20060134200A1  Published: 22/Jun/2006

Title: Pharmaceutical composition based on agonist of benzodiazepine

Applicant/Assignee:

Application No.: 10/559290   Filing Date: 02/Dec/2005

Abstract:The present invention describes the use of pharmaceutical compounds in pharmaceutical compositions for sublingual administration, including as active ingredient thereof, an agonist of the central receptor of benzodiazepinics chosen among diazepam, lorazepam, bromazepam, triazolam, alprazolam, flunitrazepam, nitrazepam and midazolam maleate, in a mixture with a pharmaceutical excipient consisting of, at least, 70% of the weight of the final formulation containing 40-45% by weight of lactose, 15-27% by weight of sorbitol and 12-16% by weight of cellulose.

Priority: BR20030002017 Applic. Date: 2003-06-02; WO2004BR00076 Applic. Date: 2004-05-26

Inventor: VANDONI GUIDO [IT]; OLIANI CARLO [BR]; COELHO ADRIANO [BR]; ZANIBONI HENY [BR]


Application No.: US20060134213A1  Published: 22/Jun/2006

Title: Stabilized ramipril compositions and methods of making

Applicant/Assignee:

Application No.: 11/269388   Filing Date: 07/Nov/2005

Abstract:The present invention relates to ramipril compositions with improved stability. More particularly, the present invention is directed to pharmaceutical compositions comprising ramipril that are stabilized against decomposition into degradation products, namely, ramipril-diketopiperazine and ramipril-diacid, during formulation and storage conditions. The present invention also relates to methods for making and methods of manufacturing stabilized ramipril compositions.

Priority: US20040625270P Applic. Date: 2004-11-05

Inventor: WILSON EDWARD S [US]; BEASLEY MARTIN W [US]


Application No.: US20060134217A1  Published: 22/Jun/2006

Title: Leukotriene and integrin inhibitor combination and treatment method

Applicant/Assignee:

Application No.: 11/314487   Filing Date: 19/Dec/2005

Abstract:The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of montelukast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms are useful in the treatment or control of asthma. The present invention also provides a method for treating asthma employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

Priority: US20040638214P Applic. Date: 2004-12-22

Inventor: SANDHU HARPREET K [US]; VALACER DAVID J [US]


Application No.: US20060134422A1  Published: 22/Jun/2006

Title: Composition comprising a mixture of active principles, and method of preparation

Applicant/Assignee: ETHYPHARM

Application No.: 10/544311   Filing Date: 21/Jan/2004

Abstract:Active principle-based coated particle, in which both the core and the coating contain active principle, includes a core which contains a first active principle while the coating contains a second active principle, which is different in nature.

Priority: FR20030001308 Applic. Date: 2003-02-05; US20030447198P Applic. Date: 2003-02-13; WO2004EP50035 Applic. Date: 2004-01-21

Inventor: CHENEVIER PHILIPPE [CA]; MARECHAL DOMINIQUE [CA]


Application No.: US20060135427A1  Published: 22/Jun/2006

Title: Formulations of human growth hormone comprising a non-naturally encoded amino acid

Applicant/Assignee: AMBRX, INC

Application No.: 11/316483   Filing Date: 21/Dec/2005

Abstract:Formulations of modified human growth hormone polypeptides are provided.

Priority: US20040638616P Applic. Date: 2004-12-22; US20050680617P Applic. Date: 2005-05-13; US20050728035P Applic. Date: 2005-10-17

Inventor: HAYS ANNA-MARIA [US]; BUECHLER YING [US]; LITZINGER DAVID C [US]


Application No.: US20060135586A1  Published: 22/Jun/2006

Title: Stabilized polymeric thiol reagents

Applicant/Assignee:

Application No.: 11/316051   Filing Date: 21/Dec/2005

Abstract:Disclosed are water soluble polymeric reagents comprising the structure POLY-[Y-S-W]x, where POLY is a water soluble polymer

Y is a hydrocarbon-based spacer group, x is 1 to 25, and S-W is a thiol, protected thiol, or thiol-reactive derivative. Preferably, the water soluble polymer is a PEG polymer. Also disclosed are conjugates of such polymeric reagents with pharmaceutically relevant molecules, and methods of their formation and use.

Priority: US20040639823P Applic. Date: 2004-12-21; US20050705968P Applic. Date: 2005-08-04

Inventor: KOZLOWSKI ANTONI [US]; MCMANUS SAMUEL [US]


Application No.: US20060140984A1  Published: 29/Jun/2006

Title: Cosmetic and pharmaceutical foam

Applicant/Assignee: FOAMIX LTD

Application No.: 10/532618   Filing Date: 22/Dec/2005

Abstract:The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

Priority: IL20020152486 Applic. Date: 2002-10-25; US20020429546P Applic. Date: 2002-11-29; WO2003IB05527 Applic. Date: 2003-10-24

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; EINI MEIR [IL]


Application No.: US20060140986A1  Published: 29/Jun/2006

Title: Anesthetic composition for topical administration

Applicant/Assignee:

Application No.: 10/562392   Filing Date: 01/Jun/2004

Abstract:It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base

1.5% of prilocaine base

4% of tetracaine base

10% of methylpynrolidone

2% of dimethyl sulfoxide

0.08% of topical hyaluronidase

1.5% of guar gum

1% of Tween-20

0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

Priority: ES20030001548 Applic. Date: 2003-06-19; WO2004EP50967 Applic. Date: 2004-06-01

Inventor: FITA FERNANDO B [ES]


Application No.: US20060141008A1  Published: 29/Jun/2006

Title: Over-coated product including consumable center and medicament

Applicant/Assignee:

Application No.: 11/269980   Filing Date: 09/Nov/2005

Abstract:Methods and products for delivering a medicament or agent to an individual are provided as well as methods for producing the product. The product includes one or more coatings having a medicament or agent. The coatings can further comprise one or more fat-based confectioneries to provide a coated product that has an improved aesthetic and taste appeal to a consumer. The medicament or agent is present within a coating that surrounds a consumable center. By chewing the coated product, the medicament or agent is released from the product within the buccal cavity.

Priority: US2002-044113 Applic. Date: 2002-01-09; US2000-631326 Applic. Date: 2000-08-03; US2000-510878 Applic. Date: 2000-02-23; US1999-286818 Applic. Date: 1999-04-06

Inventor: REAM RONALD L [US]; MATULEWICZ LEONARD [US]; WOKAS WILLIAM J [US]; REAM BRIAN [US]


Application No.: US20060141023A1  Published: 29/Jun/2006

Title: Pharmaceutical compositions containing abiguanide-glitazone combination

Applicant/Assignee:

Application No.: 10/534909   Filing Date: 16/Nov/2005

Abstract:The present invention relates to an orally administered pharmaceutical composition that is a combination of two or more antidiabetic agents in which one of the antidiabetic agents is present in an extended release form and the other antidiabetic agent is present in an immediate release form.

Priority: IN2002DE01155 Applic. Date: 2002-11-15; WO2003IB05140 Applic. Date: 2003-11-13

Inventor: TREHAN ANUPAM [IN]; MADAN SUMIT [IN]; ARORA VINOD K [IN]; MALIK RAJIV [AT]


Application No.: US20060141027A1  Published: 29/Jun/2006

Title: Sublingual administration of non-steroidal anti-inflammatory pharmacological substances

Applicant/Assignee:

Application No.: 10/560337   Filing Date: 09/Dec/2005

Abstract:The present invention relates to a sublingual administration method of non-steroidal ant-inflammatory, referred as FANS, which allows to considerably reduce the therapeutic dose, with the additional advantage of increasing the quickness of the effects and improving the tolerability.

Priority: IT2003RM00288 Applic. Date: 2003-06-10; WO2004IB01755 Applic. Date: 2004-05-28

Inventor: CIOLI VALERIO [IT]


Application No.: US20060141030A1  Published: 29/Jun/2006

Title: Method and composition for stable and controlled delivery of (-)-hydroxycitric acid

Applicant/Assignee:

Application No.: 11/287905   Filing Date: 28/Nov/2005

Abstract:The present invention provides stable encapsulated (-)-hydroxycitric acid ("HCA")-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption.

Priority: WO2004US17187 Applic. Date: 2004-05-28; US2003-447992 Applic. Date: 2003-05-29

Inventor: CLOUATRE DALLAS L [US]; DUNN JAMES M [US]; DUNN CAROLINE [US]


Application No.: US20060141037A1  Published: 29/Jun/2006

Title: Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof

Applicant/Assignee: J. B. CHEMICALS & PHARMACEUTICALS LTD

Application No.: 11/314890   Filing Date: 21/Dec/2005

Abstract:Bilayer tablet comprising an immediate release first layer comprising an effective amount of oxcarbazepine and at least one pharmaceutically acceptable excipients and a controlled release second layer comprising an effective amount of oxcarbazepine and pharmaceutically acceptable excipients wherein the total amount of oxcarbazepine impurities is less than or equal to about 2% by weight. A process for preparation of controlled release bilayer tablets is capable of delivering oxcarbazepine from one layer immediately followed by a controlled delivery of oxcarbazepine from a matrix forming layer, and a process for preparation of oxcarbazepine bilayer tablets. Bilayer tablets of oxcarbazepine, which maintain a therapeutically effective blood concentration of oxcarbazepine with once a day administration.

Priority: IN2004MU01425 Applic. Date: 2004-12-29

Inventor: MEHTA BHARAT P [IN]; SHAH RAJEN [IN]; JOSHI MILIND D [IN]


Application No.: US20060141040A1  Published: 29/Jun/2006

Title: Injectable non-aqueous suspension

Applicant/Assignee:

Application No.: 11/305938   Filing Date: 19/Dec/2005

Abstract:The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions.

Priority: US20040638448P Applic. Date: 2004-12-23

Inventor: CHEN GUOHUA [US]; HOUSTON PAUL R [US]; LUK ANDREW S [US]


Application No.: US20060141566A1  Published: 29/Jun/2006

Title: Virus preparations and methods

Applicant/Assignee: AURX, INC

Application No.: 11/021275   Filing Date: 23/Dec/2004

Abstract:Methods are disclosed for the preparation of herpesvirus, such as herpes simplex virus type 2 for vaccine use. Such viruses can be grown on serum free or serum containing media and can be prepared from the virus containing culture supernatant or virus containing cells. The virus is prepared for subsequent pharmaceutical formulation by methods which may include treatment with solid phase affinity reagents containing sulfate- or sulfonate-comprising binding groups. Such sulfated polysaccharide groups as heparin or dextran sulfate may be used, and eluted with salt solutions. The process can be combined with other culture, harvesting and formulation steps.

Priority:

Inventor: CALTON GARY J [US]; FISHELEVICH RITA [US]


Application No.: US20060141598A1  Published: 29/Jun/2006

Title: Promotion of peroxisomal catalase function in cells

Applicant/Assignee: WAYNE STATE UNIVERSITY

Application No.: 10/533124   Filing Date: 27/Dec/2005

Abstract:The molecular mechanisms of peroxisome biogenesis have begun to emerge: in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor. Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H2O2, and this increased load of reactive oxygen species (ROS) may further reduce peroxisomal protein import and exacerbate the effects of aging.

Disclosed are novel compositions and methods for restoring catalase in peroxisomes by use of targeted catalase modified at its C-terminus and/or N-terminus, optionally in combination with polypeptides which promote cellular uptake of proteins, to prevent or overcome the changes that follows aging or that are associated with a number of diseases or disorders.

Priority: US20020422100P Applic. Date: 2002-10-30; WO2003US34512 Applic. Date: 2003-10-30

Inventor: TERLECKY STANLEY R [US]; WALTON PAUL A [CA]


Application No.: US20060142221A1  Published: 29/Jun/2006

Title: Vaccine

Applicant/Assignee:

Application No.: 10/533841   Filing Date: 23/Nov/2005

Abstract:The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. Preferably the HIV envelope molecule is non-glycosylated in mammalian cells.

Priority: GB20020025786 Applic. Date: 2002-11-05; WO2003EP12429 Applic. Date: 2003-11-03

Inventor: ERTL PETER F [GB]


Application No.: US20060142234A1  Published: 29/Jun/2006

Title: Injectable non-aqueous suspension

Applicant/Assignee:

Application No.: 11/305947   Filing Date: 19/Dec/2005

Abstract:The present invention relates generally to compositions and methods for administering a biologically active agent, and more specifically to injectable non-aqueous suspensions.

Priority: US20040638486P Applic. Date: 2004-12-23

Inventor: CHEN GUOHUA [US]; HOUSTON PAUL R [US]; LUK ANDREW S [US]


Application No.: US20060142308A1  Published: 29/Jun/2006

Title: Synergistic combination comprising roflumilast and formoterol

Applicant/Assignee: ATLANTA PHARMA AG

Application No.: 10/535816   Filing Date: 26/Nov/2003

Abstract:The invention relates to the combined administration of roflumilast and formoterol for the treatment of respiratory tract disorders.

Priority: EP20020026505 Applic. Date: 2002-11-27; WO2003EP13275 Applic. Date: 2003-11-26

Inventor: KOLASSA NORBERT [AT]; WEIMAR CHRISTIAN [DE]; BUNDSCHUH DANIELA [CH]; BEUME ROLF [DE]; MARX DEGENHARD [DE]


Application No.: US20060147382A1  Published: 06/Jul/2006

Title: Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 10/550192   Filing Date: 21/Sep/2005

Abstract:The invention relates to the administration of roflumilast and an anticholinergic agent selected from the group of an ipratropium, oxitropium or tiotropium salt for the treatment of respiratory diseases.

Priority: EP20030007104 Applic. Date: 2003-03-28; WO2004EP50376 Applic. Date: 2004-03-26

Inventor: BUNDSCHUH DANIELA [CH]; WOLLIN STEFAN-LUTZ [DE]; WEIMAR CHRISTIAN [DE]


Application No.: US20060147388A1  Published: 06/Jul/2006

Title: Pharmaceutical compositions for nasal delivery

Applicant/Assignee:

Application No.: 10/547030   Filing Date: 01/Mar/2004

Abstract:According to the invention there is provided a powdered pharmaceutical formulation suitable for nasal delivery which is a freeze-dried blend of active material and excipient(s) containing: 0.5-50% by wt of active material 50-99.5% by wt of excipient(s), and in which at least 0.1% by wt of the blend is an amorphous state, which can be directly obtained by freeze drying without the need for milling and without containing the pronounced low particles defined as finings. Such powders retain free-flowing properties on storage, are physically and chemically stable and are readily soluble.

Priority: GB20030004636 Applic. Date: 2003-02-28; WO2004GB00846 Applic. Date: 2004-03-01

Inventor: MERKUS FRANCISCUS W H [BE]; LAMBERT PETER A [GB]; ADAMS GERALD [GB]


Application No.: US20060147516A1  Published: 06/Jul/2006

Title: Taste masking system for alprazolam

Applicant/Assignee: CIMA LABS INC

Application No.: 11/325038   Filing Date: 04/Jan/2006

Abstract:The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and alprazolam in a solvent, granulating using that material or forming layers over a solid support therewith. This can be followed with the use of an overcoating layer.

Priority: US20050641807P Applic. Date: 2005-01-06; US20050642619P Applic. Date: 2005-01-10

Inventor: HABIB WALID [US]; MOE DEREK [US]


Application No.: US20060147517A1  Published: 06/Jul/2006

Title: Taste masking system for non-plasticizing drugs

Applicant/Assignee: CIMA LABS INC

Application No.: 11/325673   Filing Date: 04/Jan/2006

Abstract:The present invention relates to taste masking system, taste masked formulations, dosage forms made from those formulations and methods of making those formulations that involve dissolving or dispersing a pH dependant polymer and a non-plasticizing active pharmaceutical ingredient in a solvent, granulating using that material or forming layers over a solid support therewith. This can be followed with the use of a taste masking overcoating layer.

Priority: US20050641807P Applic. Date: 2005-01-06; US20050642619P Applic. Date: 2005-01-10

Inventor: HABIB WALID [US]; MOE DEREK [US]


Application No.: US20060147518A1  Published: 06/Jul/2006

Title: Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it

Applicant/Assignee: PIERRE FABRE MEDICAMENT

Application No.: 11/025348   Filing Date: 30/Dec/2004

Abstract:This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30 000.

Priority:

Inventor: BOUGARET JOEL [FR]; LEVERD ELIE [FR]; IBARRA MARIE-DOMINIQUE [FR]


Application No.: US20060147529A1  Published: 06/Jul/2006

Title: Granulate comprising an oily substance, corresponding production method and tablet

Applicant/Assignee: HEXAL AG

Application No.: 10/541894   Filing Date: 02/Dec/2005

Abstract:The invention relates to a process for the preparation of granules comprising an oily substance. It relates also to granules for a pharmaceutical formulation and to a tablet as a product of further processing.

Priority: DE20031000325 Applic. Date: 2003-01-09; WO2003EP14097 Applic. Date: 2003-12-11

Inventor: KLOKKERS KARIN [DE]; OTTO INA E [DE]; MEYER HEIDEMARIE E E [DE]


Application No.: US20060147531A1  Published: 06/Jul/2006

Title: Tamsulosin core with a coating of polyvinylpyrrolidone and polyfinylacetate

Applicant/Assignee:

Application No.: 10/562737   Filing Date: 30/Jun/2004

Abstract:The present invention is directed to a sustained/release pharmaceutical composition containing Tamsulosin and having a reduced food effect.

Priority: DE20031029812 Applic. Date: 2003-07-01; DE20031033497 Applic. Date: 2003-07-22; WO2004EP07131 Applic. Date: 2004-06-30

Inventor: SEGULA MOJCA [SI]; PISEK ROBERT [SI]; VRECER FRANC [SI]; BREZNIK MARJANCA [SI]; CERNOSA LIDIA [SI]; BANKO IVANKA [SI]


Application No.: US20060148756A1  Published: 06/Jul/2006

Title: Amphiphilic macrocyclic derivatives and their analogues

Applicant/Assignee: UNIVERSITY COLLEGE DUBLIN

Application No.: 11/295724   Filing Date: 07/Dec/2005

Abstract:Soluble amphiphilic macrocycle analogues having lipophilic groups attached to one side of the units making up the macrocycle and hydrophilic groups attached to the other side. These amphiphilic macrocyclic derivatives have the ability to self-assemble in aqueous solvent forming micelles or vesicles and can be used as hosts for the solubilisation and/or stabilisation of various compounds. Embodiments of the present invention utilise macrocyclic oligosaccharides and preferably cyclodextrin as the macrocyclic derivatives to be modified.

Priority: IE20000000326 Applic. Date: 2000-04-28; US2002-281070 Applic. Date: 2002-10-25; WO2001IE00057 Applic. Date: 2001-04-30

Inventor: DARCY RAPHAEL [IE]; PENKLER LAWRENCE J [ZA]; RAVOO BART J [IE]


Application No.: US20060148839A1  Published: 06/Jul/2006

Title: New pharmaceutical compositions based on anticholinergics and tace-inhibitors

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 10/544238   Filing Date: 07/Feb/2004

Abstract:The present invention relates to novel pharmaceutical compositions based on anticholinergics and TACE (TNF alpha converting enzyme) inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: EP20030002986 Applic. Date: 2003-02-11; WO2004EP01144 Applic. Date: 2004-02-07

Inventor: MEADE CHRISTOPHER J M [DE]; PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]


Application No.: US20060148903A1  Published: 06/Jul/2006

Title: Capsaicinoid gel formulation and uses thereof

Applicant/Assignee: ALGORX PHARMACEUTICALS, INC

Application No.: 11/286059   Filing Date: 23/Nov/2005

Abstract:The present invention provides capsaicinoid gel formulations and methods for relieving pre- and post-surgical pain at a site in a human or animal by administering at a surgical site in a human or animal in need thereof a dose of capsaicinoid gel in an amount effective to attenuate post-surgical pain at the surgical site, the dose of capsaicin ranging from 100 mug to 10,000 mug.

Priority: US20040630577P Applic. Date: 2004-11-24

Inventor: BURCH RONALD M [US]; ANDERSON TIMOTHY A [US]; LAZAR JEFF [US]


Application No.: US20060151574A1  Published: 13/Jul/2006

Title: Formulations useful against hepatitis C virus infections

Applicant/Assignee: GPC BIOTECH AG

Application No.: 10/536950   Filing Date: 16/Nov/2005

Abstract:The present invention relates generally to chemical compounds and substances which are effective against Hepatitis C virus (HCV) infections. Moreover, the present invention relates to compositions comprising said compounds and/or substances, to methods for preventing HCV infections as well use of the compounds and/or substances for the preparation of compositions useful for the prophylaxis and/or treatment of HCV infections. Useful compounds and substances according to the invention are selenium, selenium salts, Vitamin D3 and retinoids, like all trans retinoic acid and salts thereof, C1-C alkyl amides of all trans retinoic acid and salts thereof, C1-C10 alkyl esters of all trans retinoic acid and salts thereof, 9-cis retinoic acid and salts thereof, C1-C10 alkyl amides of 9-cis retinoic acid and salts thereof, C1-C10 alkyl esters of 9-cis retinoic acid and salts thereof, (E)-4-[2(5,6,7,8-tetrahydro-5,5,8,8-tetra methyl-2-naphthalenyl-1-propenyl)benzoic acid (TTNPB), (4-[5,6,7,8-tetrahydro5,5,8,8-tetramethyl-2-naphthalenyl)carboxamido]benzoic acid (AM-580), N-(4-hydroxyphenyl)retinamide (4-HPR), and 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (AHPN).

Priority: DE20021055861 Applic. Date: 2002-11-29; DE20031005138 Applic. Date: 2003-02-07; US20020430367P Applic. Date: 2002-12-03; US20030446246P Applic. Date: 2003-02-11; WO2003EP13514 Applic. Date: 2003-12-01

Inventor: HERGET THOMAS [DE]; KLEBL BERT [DE]


Application No.: US20060153791A1  Published: 13/Jul/2006

Title: Repeat sequence protein polymer active agent congjugates, methods and uses

Applicant/Assignee: GENENCOR INTERNATIONAL, INC

Application No.: 11/351712   Filing Date: 10/Feb/2006

Abstract:Biomolecular conjugates are provided which comprise the conjugation product of a repeat sequence protein polymer and at least one active agent. Additional aspects provide methods for their manufacture and various industrial and consumer applications.

Priority: US2004-845936 Applic. Date: 2004-05-14; US20030470464P Applic. Date: 2003-05-14

Inventor: COLLIER KATHERINE D [US]; CUEVAS WILLIAM A [US]; KUMAR MANOJ [US]


Application No.: US20060153918A1  Published: 13/Jul/2006

Title: Dosage forms with an enterically coated core tablet

Applicant/Assignee:

Application No.: 11/190766   Filing Date: 26/Jul/2005

Abstract:The present invention provides a pharmaceutical dosage form for oral administration to a patient comprising an enterically coated core tablet sheathed in an annular body of compressed powder or granular material. The present invention also provides a pharmaceutical dosage form for co-administration of two or more active pharmaceutical ingredients. The present invention also provides a method comprising administering the dosage form of the present invention to a patient with impaired gastric motility, such as a patient with Parkinson's disease.

Priority: US20040591482P Applic. Date: 2004-07-26; US20040591820P Applic. Date: 2004-07-27

Inventor: LERNER E I [IL]; ROSENBERGER VERED [IL]; AQUA OFER [IL]; FLASHNER-BARAK MOSHE [IL]


Application No.: US20060153925A1  Published: 13/Jul/2006

Title: Novel solid pharmaceutical composition comprising amisulpride

Applicant/Assignee: SANOFI-AVENTIS

Application No.: 11/327603   Filing Date: 06/Jan/2006

Abstract:The invention relates to a solid pharmaceutical composition for oral administration of amisulpride, which comprises at least one coated amisulpride particle and at least one pharmaceutically acceptable excipient suitable for an orodispersible administration of the composition.

Priority: FR20030008409 Applic. Date: 2003-07-09; WO2004FR01792 Applic. Date: 2004-07-08

Inventor: ANDRE FREDERIC [FR]; CRUZ HENRI D [FR]; DENNI MICHEL [FR]; LEWIS GARETH [FR]; MIGNONNEAU JEROME [FR]; RIBARDIERE AGNES [FR]


Application No.: US20060154934A1  Published: 13/Jul/2006

Title: Combinations comprising antimuscarinic agents and PDE4 inhibitors

Applicant/Assignee:

Application No.: 11/375308   Filing Date: 14/Mar/2006

Abstract:Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2005-141169 Applic. Date: 2005-05-31

Inventor: ESCARDO JORDI G [ES]; CALVO JESUS L [ES]; RYDER HAMISH [ES]; DIAZ PIO O [ES]


Application No.: US20060154941A1  Published: 13/Jul/2006

Title: Novel amorphous form of erlotinib hydrochloride and its solid amorphous dispersion

Applicant/Assignee: MAI DE LTD

Application No.: 11/033523   Filing Date: 12/Jan/2005

Abstract:The present invention relates to novel amorphous form of [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl) (erlotinib hydrochloride), to solid amorphous dispersion of erlotinib hydrochloride and a carrier such as PVP or solid PEG, to processes for their preparations, to pharmaceutical compositions containing them and to method of treatment using the same. The amorphous form or solid amorphous dispersion of erlotinib hydrochloride obtained in this invention is useful in preparing pharmaceutical dosage forms.

Priority:

Inventor: HUANG LE [CN]


Application No.: US20060154953A1  Published: 13/Jul/2006

Title: Amorphous tacrolimus and preparation thereof

Applicant/Assignee:

Application No.: 11/326724   Filing Date: 05/Jan/2006

Abstract:The present invention provides amorphous tacrolimus in a free drug particulate form. Also provided are methods for preparing amorphous tacrolimus, and a tablet containing amorphous tacrolimus.

Priority: US20050641868P Applic. Date: 2005-01-05; US20050705681P Applic. Date: 2005-08-03

Inventor: KERI VILMOS [HU]; KOVACSNE-MEZEI ADRIENNE [HU]; CSORVASI ANDREA [HU]; MESZAROS SOS ERZSEBET [HU]


Application No.: US20060159713A1  Published: 20/Jul/2006

Title: Bendamustine pharmaceutical compositions

Applicant/Assignee: CEPHALON, INC

Application No.: 11/330868   Filing Date: 12/Jan/2006

Abstract:The present invention provides pharmaceutical formulations of lyophilized bendamustine suitable for pharmaceutical use. The present invention further provides methods of producing lyophilized bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Priority: US20050644354P Applic. Date: 2005-01-14

Inventor: BRITTAIN JASON E [US]; FRANKLIN JOE C [US]


Application No.: US20060159741A1  Published: 20/Jul/2006

Title: Pharmaceutical compositions comprising amoxicillin and clavulanic acid

Applicant/Assignee:

Application No.: 10/536543   Filing Date: 28/Jun/2005

Abstract:The present invention relates to the formed particles comprising amoxicillin and clavulanic acid, the particles being obtained wet granulation. The invention also relates to the procedure for the preparation of these particles and to the pharmaceutical compositions comprising them.

Priority: SI20020000282 Applic. Date: 2002-11-26; SI20030000247 Applic. Date: 2003-09-24; WO2003SI00043 Applic. Date: 2003-11-25

Inventor: KERC JANEZ [SI]; SALOBIR MATEJA [SI]


Application No.: US20060159742A1  Published: 20/Jul/2006

Title: Stabilized individually coated ramipril particles, compositions and methods

Applicant/Assignee: KING PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC

Application No.: 11/269387   Filing Date: 07/Nov/2005

Abstract:The present invention relates to novel ramipril crystalline particles with improved stability and bioavailability. More particularly, the present invention is directed to individually coated, single ramipril crystalline particles for pharmaceutical and biopharmaceutical applications in oral therapies that are stabilized against decomposition into degradation products, namely, ramipril-DKP and ramipril-diacid, during formulation and storage conditions. The present invention also relates to stabilized ramipril pharmaceutical compositions, novel anhydrous pharmaceutical grade ramipril powders, methods for improving ramipril bioavailability, and methods of manufacture and stabilization of ramipril formulations. The novel, anhydrous pharmaceutical grade ramipril powders and ramipril compositions and dosage forms formed therewith are useful in the treatment of cardiovascular disorders and have the advantage that they provide greater stability against decomposition into ramipril-DKPs and ramipril-diacids under formulation and storage conditions. In addition, they maintain consistent label ramipril potency over extended shelf-life and provide reduced in vivo variability in the bioavailability of ramipril among subjects when administered orally.

Priority: US20040625270P Applic. Date: 2004-11-05

Inventor: WILSON EDWARD S [US]; SILLS KEVIN H [US]; JOLLY M K [US]; BEASLEY MARTIN W [US]; HAUSE DAVID P [US]


Application No.: US20060159747A1  Published: 20/Jul/2006

Title: Telmisartan and hydrochlorothiazide combination therapy

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/300947   Filing Date: 15/Dec/2005

Abstract:A pharmaceutical composition comprising about 80 mg of telmisartan or a salt thereof and about 25 mg of hydrochlorothiazide or about 160 mg of telmisartan or a salt thereof and about 50 mg of hydrochlorothiazide, and methods of treating hypertension in patients with such combination.

Priority: US20040637042P Applic. Date: 2004-12-17

Inventor: SCHUMACHER HELMUT E [DE]; RIEDEL AXEL [DE]; BOEHM PETER [DE]


Application No.: US20060159749A1  Published: 20/Jul/2006

Title: Controlled release and taste masking oral pharmaceutical composition

Applicant/Assignee: COSMO TECHNOLOGIES LIMITED

Application No.: 11/378378   Filing Date: 20/Mar/2006

Abstract:Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract.

Priority: IT1999MI01317 Applic. Date: 1999-06-14; IT2000MI00422 Applic. Date: 2000-03-03; US2001-009532 Applic. Date: 2001-12-12; WO2000EP05356 Applic. Date: 2000-06-09

Inventor: VILLA ROBERTO [IT]; PEDRANI MASSIMO [IT]; AJANI MAURO [IT]; FOSSATI LORENZO [IT]


Application No.: US20060159751A1  Published: 20/Jul/2006

Title: Controlled release pharmaceutical compositions of carbidopa and levodopa

Applicant/Assignee:

Application No.: 10/510468   Filing Date: 11/Apr/2003

Abstract:The present invention relates to controlled release pharmaceutical compositions of carbidopa and levodopa that include a combination of different molecular weight cellulose ethers and in particular, hydroxypropyl cellulose ether.

Priority: IN2002DE00447 Applic. Date: 2002-04-11; WO2003IB01361 Applic. Date: 2003-04-11

Inventor: GOGIA MONA [IN]; MATHUR RAJEEV S [IN]; SETHI SANJEEV [IN]


Application No.: US20060159758A1  Published: 20/Jul/2006

Title: Coating composition for taste masking coating and methods for their application and use

Applicant/Assignee:

Application No.: 10/538354   Filing Date: 11/Dec/2003

Abstract:The present invention relates to coating compositions for taste masking and methods for applying the coating compositions to dosage forms to mask the taste of a medicinal substance. The taste masking coating compositions generally include a copolymer of acrylate and methacrylate with a quaternary ammonium group in combination with sodium carboxymethylcellulose and a polyvinyl alcohol-polyethylene glycol copolymer.

Priority: IN2002DE01240 Applic. Date: 2002-12-11; WO2003IB05877 Applic. Date: 2003-12-11

Inventor: GANDHI RAJESH [IN]; ISSA CHAYAPATHY [IN]; MALIK RAJIV [AU]


Application No.: US20060159762A1  Published: 20/Jul/2006

Title: Stable pharmaceutical composition comprising an active substance in the form of solid solution

Applicant/Assignee:

Application No.: 11/317769   Filing Date: 23/Dec/2005

Abstract:The present invention relates to a novel pharmaceutical comprising an active substance in the form of solid solution. The stability of active substance in the pharmaceutical composition is significantly improved relative to the stability of non-formulated active substance.

Priority: SI20040000351 Applic. Date: 2004-12-24

Inventor: STANIC LJUBIN TIJANA [SI]; SIRCA JUDITA [SI]


Application No.: US20060160702A1  Published: 20/Jul/2006

Title: Compositions comprising anti-proliferative agents and use thereof

Applicant/Assignee:

Application No.: 11/289156   Filing Date: 28/Nov/2005

Abstract:The invention relates to anti-proliferative agents derived from plants, wherein the agents are capable of inducing a plant organ into a state of dormancy or maintaining the organ in the state of dormancy. The invention further discloses compositions comprising the anti-proliferative agents and the use of said compositions to inhibit undesired or deleterious cell proliferation in plant or mammal tissue.

Priority: US2003-465911 Applic. Date: 2003-06-20; US2001-915768 Applic. Date: 2001-07-27; US1999-367898 Applic. Date: 1999-11-29; WO1998IL00085 Applic. Date: 1998-02-23

Inventor: SOUDANT ETIENNE [FR]; OPPEN-BEZALEL LEA V [DE]; ZIV MEIRA [IL]; PERRY INON [IL]


Application No.: US20060160888A1  Published: 20/Jul/2006

Title: Room-temperature stable dronabinol formulations

Applicant/Assignee: INSYS THERAPEUTICS, INC

Application No.: 11/299183   Filing Date: 09/Dec/2005

Abstract:A room temperature stable cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation is dronabinol in an oil-based carrier contained within a hard gelatin capsule.

Priority: US20040634474P Applic. Date: 2004-12-09

Inventor: KOTTAYIL S G [US]; ZHU ZHONGYUAN [US]; GOSKONDA VENKAT R [US]


Application No.: US20060160948A1  Published: 20/Jul/2006

Title: Polymer-von Willebrand factor-conjugates

Applicant/Assignee:

Application No.: 11/317582   Filing Date: 23/Dec/2005

Abstract:The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.

Priority: US20040639244P Applic. Date: 2004-12-27; US20050668378P Applic. Date: 2005-04-04; US20050671901P Applic. Date: 2005-04-15; US20050685086P Applic. Date: 2005-05-26

Inventor: SCHEIFLINGER FRIEDRICH [AT]; TURECEK PETER [AT]; SIEKMANN JUERGEN [AT]


Application No.: US20060165776A1  Published: 27/Jul/2006

Title: Antidepressant oral pharmaceutical compositions

Applicant/Assignee:

Application No.: 11/215911   Filing Date: 31/Aug/2005

Abstract:Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its pharmaceutical derivatives thereof compressed together, an intermediate and an enteric layer. Duloxetine or its pharmaceutical derivatives thereof may be any pharmaceutically acceptable prodrug, salt, solvate or derivative of Duloxetine. The novel compositions prepared according to the present invention have enhanced stability and bioavailability.

Priority:

Inventor: SESHA RAMESH [US]


Application No.: US20060165780A1  Published: 27/Jul/2006

Title: Anticoagulant composition

Applicant/Assignee: LTP LIPID TECHNOLOGIES PROVIDER AB

Application No.: 10/516858   Filing Date: 21/Jul/2005

Abstract:A solid heparin tablet composition has a melting point of 25 DEG C. or higher and is a continuous lipid component containing one or more polar lipids, one or more non-polar lipids, optionally one or several of water and mono- to trivalent alcohol in an amount of up to 15% by weight of the composition, and native heparin or fractionated heparin. Also described is a corresponding tablet, processes for production of the composition and the tablet, and a method of preventing or treating conditions amenable to preventive or therapeutic treatment by administration of the tablet.

Priority: SE20020001922 Applic. Date: 2002-06-20; WO2003SE00973 Applic. Date: 2003-06-12

Inventor: HERSLOF BENGT [SE]; TINGVALL PER [SE]


Application No.: US20060165822A1  Published: 27/Jul/2006

Title: Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment of neurological diseases

Applicant/Assignee: PHYTRIX AG

Application No.: 10/533135   Filing Date: 18/Nov/2005

Abstract:The present invention provides pharmaceutical compositions comprising Mucuna pruriens seeds or one or more Mucuna pruriens seed components, substances, fractions or mixtures or substances obtained therefrom. Furthermore, the invention relates to the use of Mucuna pruriens seed powder or one or more Mucuna pruriens components, substances, fractions or mixtures or substances obtained therefrom for the preparation of a pharmaceutical composition for preventing, alleviating or treating neurological diseases. Additionally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for neuroprotection or neurostimulation and to methods of preparing extracts of Mucuna pruriens which can be used for the preparation of a pharmaceutical composition for treating neurological diseases.

Finally, the invention relates to the use of Mucuna pruriens seeds for the preparation of a pharmaceutical composition for the treatment of Parkinson's Disease to obtain a broader therapeutic window in L-Dopa therapy, to delay a need for combination therapy, to obtain an earlier onset and longer duration of L-Dopa efficacy, and to prevent or alleviate acute and chronic L-Dopa toxicity.

Priority: EP20020024475 Applic. Date: 2002-10-30; WO2003EP10975 Applic. Date: 2003-10-02

Inventor: VAN DER GIESSEN ROB [CH]; OLANOW C W [US]; LEES ANDREW [GB]; WAGNER HILDEBERT [DE]


Application No.: US20060172010A1  Published: 03/Aug/2006

Title: Process for preparing particles containing an antiviral

Applicant/Assignee:

Application No.: 10/564845   Filing Date: 19/Jul/2004

Abstract:A process for preparing a particle comprising a co-precipitate surrounding a neutral hydrophilic carrier, said process comprising spraying an organic solution on a neutral hydrophilic carrier, said solution comprising at least one triazine or pyrimidine active ingredient having HIV inhibiting properties, one surface active agent, and one hydrophilic polymer, wherein the spraying of whole of the solution occurs in at least two separate steps, each of these steps followed by a grinding step of the product obtained at the end of the preceding step.

Priority: FR20030008720 Applic. Date: 2003-07-17; EP20040103156 Applic. Date: 2004-07-02; WO2004EP51545 Applic. Date: 2004-07-19

Inventor: LAMOUREUX GAEL [FR]; COUSIN GERARD [FR]; THORNE DANIEL JOSEPH C [BE]


Application No.: US20060173067A1  Published: 03/Aug/2006

Title: Small molecules for the treatment of atherosclerosis

Applicant/Assignee: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION

Application No.: 11/201004   Filing Date: 09/Aug/2005

Abstract:This invention provides novel small molecules that ameliorate one or more symptoms of atherosclerosis. The small molecules are highly stable and readily administered via an oral route. The small molecules are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a small molecule in a mammal. In addition, the small molecules inhibit osteoporosis. When administered with a statin, the small molecules enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

Priority: US20040600925P Applic. Date: 2004-08-11

Inventor: FOGELMAN ALAN M [US]; ANANTHARAMAIAH GATTADAHALLI M [US]; NAVAB MOHAMAD [US]


Application No.: US20060173081A1  Published: 03/Aug/2006

Title: Treating morning migraines with propranolol

Applicant/Assignee:

Application No.: 11/239687   Filing Date: 30/Sep/2005

Abstract:This invention relates to a method for preventing and treating morning migraine headaches. Pursuant to this method, a therapeutic amount of beta-adrenergic-blocking agent is administered nightly to a person that suffers from migraine attacks such that the blocking agent is first released during morning hours when the person is most susceptible to morning migraine.

Priority: US20040614545P Applic. Date: 2004-10-01

Inventor: ROTENBERG KEITH S [US]; BOBOTAS GEORGE [US]


Application No.: US20060177381A1  Published: 10/Aug/2006

Title: Opiopathies

Applicant/Assignee:

Application No.: 11/395200   Filing Date: 03/Apr/2006

Abstract:The present invention provides novel methods for classifying, diagnosing and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture of pharmaceutical and veterinary formulations therefor. The invention also relates to neuropathic, polyneuropathic, neurologic and neurogenic ailments typically characterized by paresis/paralysis. These ailments can involve an abnormal concentration of one or more endogenous opioids, or the blockade, underexpression or overexpression of one or more opioid receptors. In that regard, the invention encompasses therapeutic uses, methods and compositions employing opiates and/or their receptors. In particular, the invention relates to certain laboratory testing methods, clinical testing methods, research and development methods, business methods, methods of treatment, novel therapeutic uses, and human and veterinary pharmaceutical dosage forms, dosing regimens and formulations, especially those pertaining to opiopathy (particularly hypo-opiopathy).

Priority: US2003-367386 Applic. Date: 2003-02-14; US20020357389P Applic. Date: 2002-02-15

Inventor: BROOKS-KORN HOWARD [US]


Application No.: US20060177496A1  Published: 10/Aug/2006

Title: Pharmaceutical formulations

Applicant/Assignee:

Application No.: 10/565462   Filing Date: 21/Jul/2004

Abstract:The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form by a weld between parts of the assembled dosage form.

Priority: US20030489159P Applic. Date: 2003-07-21; WO2004US23542 Applic. Date: 2004-07-21

Inventor: MCALLISTER STEPHEN M [US]; RABY JR RONALD K [US]; BROWN ADRIAN [US]


Application No.: US20060177498A1  Published: 10/Aug/2006

Title: Solid pharmaceutical composition comprising ramipril

Applicant/Assignee:

Application No.: 10/542675   Filing Date: 11/Aug/2005

Abstract:The present invention relates to solid pharmaceutical compositions comprising ramipril with a suitably low water content, and processes for preparing said compositions.

Priority: GB20030001471 Applic. Date: 2003-01-22; DE20031054862 Applic. Date: 2003-11-24; NL20031024899 Applic. Date: 2003-11-27; WO2004EP00456 Applic. Date: 2004-01-21

Inventor: BHARATRAJAN RAMASWAMI [IN]; ZEISL ERICH [AU]; KOFLER NIKLAUS [AU]; PATIL MANISHA R [IN]; SAHASRABUDHE PARFULLA S [IN]


Application No.: US20060177499A1  Published: 10/Aug/2006

Title: Method for the manufacture of a pharmaceutical composition in the form of tablets containing a fibrate and tablets obtained according to the method

Applicant/Assignee:

Application No.: 10/546999   Filing Date: 26/Aug/2005

Abstract:A method for the manufacture of a pharmaceutical composition containing the active ingredient fenofibrate or one of its derivatives, optionally in combination with a second active ingredient, in the form of tablets, characterized in that it comprises a compression step of the active ingredient and excipients by means of a dry method of granulation

Priority: FR20030002520 Applic. Date: 2003-02-28; WO2004FR50090 Applic. Date: 2004-02-27

Inventor: BESSE JEROME [FR]


Application No.: US20060177502A1  Published: 10/Aug/2006

Title: Sustained release pharmaceutical formulations

Applicant/Assignee:

Application No.: 11/326965   Filing Date: 05/Jan/2006

Abstract:Disclosed are novel ranolazine sustained release pharmaceutical formulations.

Priority: US20050642168P Applic. Date: 2005-01-06

Inventor: SASTRY SRIKONDA [US]; NYSHADHAM JANAKI [US]


Application No.: US20060177503A1  Published: 10/Aug/2006

Title: Bambuterol and integrin inhibitor combination and treatment method

Applicant/Assignee:

Application No.: 11/348386   Filing Date: 06/Feb/2006

Abstract:The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of bambuterol, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms are useful in the treatment or control of asthma. The present invention also provides a method for treating asthma employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

Priority: US20050650664P Applic. Date: 2005-02-07

Inventor: RAMES ALEXIS [FR]; SANDHU HARPREET K [US]; VALACER DAVID J [US]


Application No.: US20060177510A1  Published: 10/Aug/2006

Title: Dual controlled release osmotic device

Applicant/Assignee:

Application No.: 11/321736   Filing Date: 29/Dec/2005

Abstract:A pharmaceutical composition and dosage form for the treatment of incontinence with oxybutynin and a second drug is provided. The second drug can be darifenacin or tolterodine. Depending upon the route of administration, the dosage form used, and the second drug used, the dosage form may independently include therapeutic or sub-therapeutic amounts of the oxybutynin and the second drug. Particular embodiments include a dosage form that provides a controlled release of oxybutynin and the second drug to maintain therapeutically effective levels oxybutynin and/or the second in a mammal for an extended period of time. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. A method of treating urinary (stress or urge) incontinence with the pharmaceutical composition and dosage form is provided. Together, oxybutynin and the second drug provide an overall improved therapeutic benefit over either agent alone when administered at approximately the same dose.

Priority: US2001-992488 Applic. Date: 2001-11-06

Inventor: VERGEZ JUAN A [AR]; RICCI MARCELO A [AR]


Application No.: US20060182711A1  Published: 17/Aug/2006

Title: Conjugates of an EPO moiety and a polymer

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: 11/357936   Filing Date: 16/Feb/2006

Abstract:Conjugates of an EPO moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making conjugates, and methods of administering compositions comprising such conjugates to a patient.

Priority: US20050653451P Applic. Date: 2005-02-16

Inventor: BOSSARD MARY J [US]; STEPHENSON GAYLE [US]


Application No.: US20060182716A1  Published: 17/Aug/2006

Title: Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same

Applicant/Assignee:

Application No.: 11/330917   Filing Date: 11/Jan/2006

Abstract:The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention further provides oral formulations of protease-resistant or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, the protease-resistant polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, a protease-resistant polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

Priority: US2005-200531 Applic. Date: 2005-08-08; US20040600202P Applic. Date: 2004-08-09; US20040600134P Applic. Date: 2004-08-09; US20040604280P Applic. Date: 2004-08-24; US20040604415P Applic. Date: 2004-08-24

Inventor: HONG JIN [US]; SEIWERT SCOTT D [US]; BLATT LAWRENCE M [US]


Application No.: US20060182796A1  Published: 17/Aug/2006

Title: Taste masked pharmaceutical compositions

Applicant/Assignee: ABRIKA PHARMACEUTICALS, INC

Application No.: 11/346700   Filing Date: 03/Feb/2006

Abstract:A pharmaceutical composition for oral administration containing a pharmaceutically active ingredient coated with an amount of a polymer combination of an enteric polymer and an ammonio methacrylate copolymer to effectively mask the taste of the medicament. In a preferred embodiment, the ratio of the enteric polymer to the ammonio methacrylate copolymer is about 40:60 to about 90:10, preferably about 60:40, by weight of polymer. The pharmaceutical coating composition is soluble in the acidic environment of the stomach, which generally has a pH value of about 1.0 to 3.0, but relatively insoluble at higher pH values of the mouth. The coatings provide for rapid release and absorption of the drug after it passes through the mouth, and is particularly desirable in the case of liquid dosage forms.

Priority: US20050649644P Applic. Date: 2005-02-03

Inventor: WU CHUANBIN [US]; INJETY HAROLD [US]; WENG TIM [US]


Application No.: US20060182806A1  Published: 17/Aug/2006

Title: Extended-release propranolol composition

Applicant/Assignee:

Application No.: 11/268060   Filing Date: 07/Nov/2005

Abstract:An extended-release pharmaceutical composition comprising a core and a coating, wherein said core comprises propranolol or a pharmaceutically acceptable salt thereof and at least one excipient, and said coating comprises at least one water-soluble polymer and at least one water-insoluble polymer, wherein said coating is heated at a temperature of about 30 DEG C. to about 70 DEG C. after being applied to said core.

Priority: US20040625866P Applic. Date: 2004-11-08

Inventor: GUO MINTONG [US]; PALANISWAMY SURESH [US]; PATEL ASHISH A [US]; GASSERT CHAD M [US]; DAVILA PABLO [US]


Application No.: US20060183746A1  Published: 17/Aug/2006

Title: Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds

Applicant/Assignee:

Application No.: 11/292300   Filing Date: 02/Dec/2005

Abstract:Certain compounds, such as at least one chemical entity choen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, may in certain embodiments be used to treat patients suffering from one or more diseases responsive to inhibition of tyrosine kinase activity. The diseases may, for instance, be responsive to inhibition of Btk activity and/or B-cell proliferation. Example diseases include cancer, an autoimmune and/or inflammatory disease, and an acute inflammatory reaction.

Priority: US2004-861791 Applic. Date: 2004-06-04; US20030475634P Applic. Date: 2003-06-04; US20030519311P Applic. Date: 2003-11-11; US20040633378P Applic. Date: 2004-12-06

Inventor: CURRIE KEVIN S [US]; DESIMONE ROBERT W [US]; MITCHELL SCOTT A [US]; PIPPIN DOUGLAS A I [US]; DARROW JAMES W [US]; QIAN XIAOBING [US]; VELLECA MARK [US]; QIAN DAPENG [US]


Application No.: US20060183855A1  Published: 17/Aug/2006

Title: Segmented polymers and their conjugates

Applicant/Assignee: NEKTAR THERAPEUTICS AL, CORPORATION NEKTAR THERAPEUTICS

Application No.: 11/402350   Filing Date: 11/Apr/2006

Abstract:Segmented water soluble polymers, containing a higher molecular weight segment linked to a lower molecular weight segment, are described. In one embodiment, the polymer segments are poly(ethylene glycol) segments. The segmented polymers are functionalized and are useful for conjugation to various moieties such as pharmacologically active substances. Also described are conjugates of such polymers and methods of their preparation.

Priority: US2003-734858 Applic. Date: 2003-12-11; US2001-024357 Applic. Date: 2001-12-18; US20000256801P Applic. Date: 2000-12-18

Inventor: KOZLOWSKI ANTONI [US]; SHEN XIAOMING [US]; BENTLEY MICHAEL D [US]; FANG ZHIHAO [US]; SANDER TONY L [US]


Application No.: US20060183886A1  Published: 17/Aug/2006

Title: Ligands to enhance cellular uptake of biomolecules

Applicant/Assignee: CELL WORKS THERAPEUTICS, INC., A DELAWARE CORPORATION

Application No.: 11/256476   Filing Date: 21/Oct/2005

Abstract:The present invention relates to the design and synthesis of homogeneous A-L-P constructs, which contain a hepatic ligand to direct an oligomer or "payload" to a hepatocyte intracellularly via a receptor-mediated, ligand-directed pathway.

Priority: US2001-888164 Applic. Date: 2001-06-22; US1999-282455 Applic. Date: 1999-03-31; US1996-755062 Applic. Date: 1996-11-22; US19950007480P Applic. Date: 1995-11-22

Inventor: TSO PAUL O [US]; DUFF ROBERT [US]; ZHOU YUANZHONG [US]; DEAMOND SCOTT [US]; ROBY CLINTON [US]


Application No.: US20060188569A1  Published: 24/Aug/2006

Title: Stable pharmaceutical formulations of zonisamide and methods for their manufacture

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 11/336546   Filing Date: 20/Jan/2006

Abstract:One of the embodiments of the present invention is directed toward a process for preparing a stable zonisamide pharmaceutical composition, comprising subjecting zonisamide to wet granulation with a granulation liquid to form a granulated mixture as the stable zonisamide pharmaceutical composition, wherein the granulation liquid is selected from purified water, alcohol and mixtures thereof. The stable zonisamide pharmaceutical composition can be used to fill capsule shells to prepare stable zonisamide capsules. Another embodiment of the invention concerns a for preparing a stable zonisamide pharmaceutical capsule, comprising (i) forming an intimate mixture with zonisamide powder and an effective amount of at least one pharmaceutically acceptable excipient by compressing, co-milling, co-micronization and/or co-compaction of the components, or subjecting the components to a similarly intensive process

and (ii) filling capsule shells with the intimate mixture to obtain the stable zonisamide pharmaceutical capsule.

Priority: US20050645030P Applic. Date: 2005-01-21

Inventor: HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]


Application No.: US20060189527A1  Published: 24/Aug/2006

Title: Methods of treating disease with random copolymers

Applicant/Assignee: PEPTIMMUNE, INC

Application No.: 11/283406   Filing Date: 17/Nov/2005

Abstract:The invention relates to novel methods and kits for treating or preventing disease through the administration of random copolymers. The invention also relates to the treatment of autoimmune diseases, such as multiple sclerosis, and to the administration of random copolymers in treatment regimen comprising formulations that are administered at intervals greater than 24 hours, or to sustained release formulations which administer the copolymer over a period greater than 24 hours. The invention further relates to methods for conducting a pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the formulations or dosing regimens of random copolymer described herein.

Priority: WO2005US16340 Applic. Date: 2005-05-09; WO2005US16344 Applic. Date: 2005-05-09; US20040569292P Applic. Date: 2004-05-07; US20050663333P Applic. Date: 2005-03-18

Inventor: RASMUSSEN JAMES [US]; ZHANG JIANXIN [US]; BALDWIN SAM [US]; ZANELLI ERIC [US]; YU BEI [US]; BONNIN DUSTAN [US]; JOHNSON KEITH [US]


Application No.: US20060189529A1  Published: 24/Aug/2006

Title: Modified human growth hormone

Applicant/Assignee: AMBRX, INC

Application No.: 11/316534   Filing Date: 21/Dec/2005

Abstract:Modified growth hormone polypeptide and uses thereof are provided.

Priority: US20040638616P Applic. Date: 2004-12-22; US20050727996P Applic. Date: 2005-10-17

Inventor: CHO HO S [US]; DANIEL THOMAS O [US]; DIMARCHI RICHARD D [US]; HAYS ANNA-MARIA [US]; WILSON TROY E [US]; SIM BEE-CHENG [US]; LITZINGER DAVID C [US]


Application No.: US20060189558A1  Published: 24/Aug/2006

Title: Delivery of substances to cells

Applicant/Assignee: PHOGEN LIMITED

Application No.: 11/223449   Filing Date: 09/Sep/2005

Abstract:Aggregates comprising VP22 protein and oligonucleotides or polynucleotides can be used together with a disaggregating agent (simultaneously or sequentially) to treat target cells by delivery of molecules to the cells and/or to prevent cell proliferation and/or to kill cells.

Priority: GB20000022101 Applic. Date: 2000-09-08; US2001-949093 Applic. Date: 2001-09-07

Inventor: O'HARE PETER FRANCIS [GB]; BREWIS NEIL D [GB]; NORMAND NADIA M [FR]; SUNASSEE KAVITHA R [GB]


Application No.: US20060189565A1  Published: 24/Aug/2006

Title: Pharmaceutical compositions of ganciclovir

Applicant/Assignee:

Application No.: 10/532024   Filing Date: 22/Oct/2003

Abstract:The technical field of the invention relates to pharmaceutical compositions of 9-(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir) that are stable and contain more than 1% water content. One pharmaceutical composition includes ganciclovir having more than about 1% water content, and one or more pharmaceutically acceptable excipients. The ganciclovir retains at least about 97% of its initial purity after one month, at least about 96% of its initial purity after two months, and at least about 95% of its initial purity after three months when stored at 40 DEG C. and 75% RH. In particular, the water content may be between about 2% and about 6%.

Priority: IN2002DE01058 Applic. Date: 2002-10-22; WO2003IB04664 Applic. Date: 2003-10-22

Inventor: MATHUR RAJEEV S [IN]; KUMAR PANANCHUKUNNATH M [IN]; ROY SUNILENDU B [IN]; MALIK RAJIV [AT]


Application No.: US20060189633A1  Published: 24/Aug/2006

Title: Preparation of amorphous form of indiplon

Applicant/Assignee: MAI DE LTD

Application No.: 11/347753   Filing Date: 06/Feb/2006

Abstract:The present invention is directed to amorphous form of indiplon, to processes for preparing said amorphous form, to pharmaceutical compositions containing the same, and to method of treatment using the same. Additionally, the present invention also relates to the preparation of solid amorphous dispersion of indiplon and a carrier which includes PVP and solid PEG etc.

Priority: CN20051033218 Applic. Date: 2005-02-18

Inventor: HUANG LE [CN]; HUANG HUI M H [US]


Application No.: US20060189651A1  Published: 24/Aug/2006

Title: Combinations comprising antimuscarinic agents and beta-adrenergic agonists

Applicant/Assignee:

Application No.: 11/409157   Filing Date: 21/Apr/2006

Abstract:Combinations comprising (a) a beta2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2005-141428 Applic. Date: 2005-05-31

Inventor: GRAS ESCARDO JORDI [ES]; LLENAS CALVO JESUS [ES]; RYDER HAMISH [ES]; ORVIZ DIAZ PIO [ES]


Application No.: US20060189685A1  Published: 24/Aug/2006

Title: Formulations of ladostigil tartrate

Applicant/Assignee:

Application No.: 11/361379   Filing Date: 24/Feb/2006

Abstract:Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.

Priority: US20050656477P Applic. Date: 2005-02-24

Inventor: LICHT DANIELLA [IL]; LOVINGER IOANA [IL]; CACIULARU FANNY [IL]; GILBERT ADRIAN [IL]


Application No.: US20060191534A1  Published: 31/Aug/2006

Title: Dry powder inhaler devices, multi-dose dry powder drug packages, control systems, and associated methods

Applicant/Assignee:

Application No.: 11/294681   Filing Date: 05/Dec/2005

Abstract:Dry powder inhalers with integrated active energy patient assist dispersal systems are configured with control systems which provide adjustable energy output responsive to the user's inspiratory capabilities and/or the flowability of the dry powder drug being administered. The multi-dose dry drug package includes a piezoelectric polymer substrate (such as PVDF) which flexes to deform and provide mechanical oscillation in a selected region of the package corresponding to the dry powder drug dose in the exit flow path and is thus actively dispersed into the exit flow path of the inhaler during the user's inspiratory activity. Control systems employ fuzzy logic models of the flowability of particular drug formulations (also being able to compensate or allow for the particular type of excipient used) and/or adjust for the real-time measured inspiratory efforts of the user. Manufacturing process control systems can adjust certain parameters in response to a fuzzy logic model of the flowability of the dry powder and other conditions associated with the dry powder drug being produced and/or dispensed.

Priority: US2003-204609 Applic. Date: 2003-01-29; WO2001US02262 Applic. Date: 2001-01-24; US20000188543P Applic. Date: 2000-03-10

Inventor: HICKEY ANTHONY J [US]; CROWDER TIMOTHY M [US]


Application No.: US20060193908A1  Published: 31/Aug/2006

Title: Extended release formulations of poorly soluble antibiotics

Applicant/Assignee:

Application No.: 11/267943   Filing Date: 04/Nov/2005

Abstract:An extended release pharmaceutical compressed composition and dosage form comprising poorly water soluble macrolide antibiotic, surfactant and non-lipophilic, non-polymeric excipient is disclosed. The composition releases the macrolide antibiotic over an extended period of time, generally at least over 12 hours, even in the absence of a release rate-retarding polymer, release rate-retarding coating or release rate-retarding lipophilic excipient. The composition is suitable for once daily or twice daily oral administration for the treatment of many different types of bacterial infections. One embodiment of the compressed composition includes a drug-containing granular composition and a binding composition, wherein the two are mixed together and then compressed into a tablet or pill. The surfactant is in admixture with or coated onto the macrolide antibiotic, and it can be included in the granular composition and/or the binding composition. The non-polymeric, non-lipophilic excipient is included in the granular composition and/or the binding composition.

Priority: US20040626277P Applic. Date: 2004-11-09

Inventor: BURNSIDE BETH A [US]; ROWLINGS COLIN [US]; WASSINK SANDRA E [US]; TREACY DONALD J JR [US]; KOLENG JOHN J [US]


Application No.: US20060193910A1  Published: 31/Aug/2006

Title: Tablets with improved drug substance dispersibility

Applicant/Assignee:

Application No.: 11/357303   Filing Date: 17/Feb/2006

Abstract:The present invention relates to a method for the preparation of pharmaceutical compositions in the form of tablets with improved drug substance dispersibility, which method comprises a) preparing a dispersion of at least one pharmaceutically active drug substance and at least one surfactant and/or binder in a liquid

b) preparing a carrier by dry blending at least one porous carrier and one or more excipient(s)

and c) spray granulating the dispersion prepared in step a) onto the carrier prepared in step b) to obtain a spray-granulated product.

Priority: EP20050101458 Applic. Date: 2005-02-25

Inventor: BERNIGAL NATHALIE [FR]; GARCIA ERIC [FR]; PAGE SUSANNE [DE]; TARDIO JOSEPH [FR]


Application No.: US20060193911A1  Published: 31/Aug/2006

Title: Controlled release venlafaxine formulations

Applicant/Assignee: PENWEST PHARMACEUTICALS CO.,

Application No.: 11/363760   Filing Date: 28/Feb/2006

Abstract:In certain embodiments, the present invention is directed to a controlled release oral solid dosage form comprising a matrix comprising a therapeutically effective amount of venlafaxine, an active metabolite of venlafaxine, or a pharmaceutically acceptable salt thereof, dispersed in a cross-linked gelling agent, the matrix providing a controlled release of venlafaxine, active metabolite of venlafaxine, or salt thereof to provide 24 hour therapeutic plasma levels after oral administration to human patients.

Priority: US20050657035P Applic. Date: 2005-02-28; US20050750594P Applic. Date: 2005-12-14

Inventor: KETSELA SARA [US]; DINICOLA DEAN [US]; BAICHWAL ANAND R [US]


Application No.: US20060194826A1  Published: 31/Aug/2006

Title: Pharmaceutical combinations of hydrocodone and naltrexone

Applicant/Assignee: EURO-CELTIQUE S.A

Application No.: 10/562494   Filing Date: 09/Sep/2004

Abstract:Disclosed is a pharmaceutical composition comprising from about 5 to about 20 mg of hydrocodone or a pharmaceutically acceptable salt thereof and from 0.055 to about 0.56 mg naltrexone or pharmaceutically acceptable salt thereof.

Priority: WO2004US29521 Applic. Date: 2004-09-09; US20030506222P Applic. Date: 2003-09-25

Inventor: OSHLACK BENJAMIN [US]; WRIGHT CURTIS [US]; BREDER CHRIS [US]


Application No.: US20060198838A1  Published: 07/Sep/2006

Title: Combination enzyme for cystic fibrosis

Applicant/Assignee:

Application No.: 11/232180   Filing Date: 21/Sep/2005

Abstract:A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. A further object of this invention is to provide a stabilized preparation of a combination medicant which resists degradation by light, heat, humidity or association with commonly used excipients.

Priority: US20040613666P Applic. Date: 2004-09-28

Inventor: FALLON JOAN M [US]


Application No.: US20060198848A1  Published: 07/Sep/2006

Title: Methods and compositions for treating herpes infections

Applicant/Assignee:

Application No.: 11/367772   Filing Date: 03/Mar/2006

Abstract:A method of treatment or prophylaxis of herpes infections and associated disease states by administration of compositions comprising immunoglobulins. Methods comprising intravenous and topical administration of immunoglobulins are provided.

Priority: WO2004US28559 Applic. Date: 2004-09-01; US2003-656781 Applic. Date: 2003-09-05

Inventor: BETZ ULRICH [DE]; RADTKE KLAUS-PETER [US]


Application No.: US20060198850A1  Published: 07/Sep/2006

Title: Pharmaceutical formulation and a method of making same

Applicant/Assignee:

Application No.: 10/542032   Filing Date: 12/Dec/2003

Abstract:The methods of the present invention and the formulations made from those methods, allow the stable integration of multiple actives within a single formulation. The solubilisation of an active in a suitable solvent and the subsequent adsorption onto a sorbing medium provide effective protection for the active from any adverse conditions within the liquid in which the active-loaded sorbing medium is dispersed. As a result the liquid can be formulated to suit the requirements of the actives that may include therein. As a result the actives may be stably integrated within the formulation.

Priority: NZ20020523128 Applic. Date: 2002-12-12; WO2003NZ00272 Applic. Date: 2003-12-12

Inventor: RAZZAK MAJID HAMEED A [NZ]


Application No.: US20060198889A1  Published: 07/Sep/2006

Title: Roflumilast and integrin inhibitor combination and treatement method

Applicant/Assignee:

Application No.: 11/365569   Filing Date: 01/Mar/2006

Abstract:The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a therapeutically active amount of roflumilast, or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of N-(2-chloro-6-methylbenzoyl)-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine-2-(diethylamino)ethyl ester, or a pharmaceutically acceptable thereof, and one or more pharmaceutically acceptable excipients. These novel solid pharmaceutical dosage forms are useful in the treatment or control of asthma. The present invention also provides a method for treating asthma employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.

Priority: US20050658719P Applic. Date: 2005-03-04

Inventor: SANDHU HARPREET K [US]; VALACER DAVID J [US]


Application No.: US20060199849A1  Published: 07/Sep/2006

Title: Solid lercanidipine free base

Applicant/Assignee: RECORDATI IRELAND LIMITED

Application No.: 11/364861   Filing Date: 27/Feb/2006

Abstract:The invention provides substantially pure lercanidipine free base, having a purity of at least 95%, preferably at least 97%, more preferably at least 99%, and still more preferably at least 99.5%. The lercanidipine free base of the present invention is formed as an amorphous solid that is easily handled and particularly well suited to the formulation of pharmaceutical compositions.

Priority: US20050656741P Applic. Date: 2005-02-25

Inventor: BERLATI FABIO [IT]; LEONARDI AMEDEO [IT]; MOTTA GIANNI [IT]; CANDIANI ILARIA [IT]; CORCELLA FRANCESCO [IT]


Application No.: US20060199860A1  Published: 07/Sep/2006

Title: Salts of (-)-O-desmethylvenlafaxine

Applicant/Assignee:

Application No.: 11/418137   Filing Date: 05/May/2006

Abstract:Methods of preparing, and compositions comprising, derivatives of (-)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

Priority: US2004-806423 Applic. Date: 2004-03-23; US2002-222815 Applic. Date: 2002-08-19; US2001-014592 Applic. Date: 2001-12-14; US1999-450690 Applic. Date: 1999-11-30; US19980110488P Applic. Date: 1998-12-01

Inventor: JERUSSI THOMAS P [US]; SENANAYAKE CHRISANTHA H [US]; BHONGLE NANDKUMAR N [US]


Application No.: US20060204451A1  Published: 14/Sep/2006

Title: Chewing gum in the form of multi-layer tablets

Applicant/Assignee:

Application No.: 10/545348   Filing Date: 20/Jan/2004

Abstract:Disclosed are tablets having a sandwich-like structure comprising at least one inner layer of gum base containing one or more active pharmaceutical, dietetic or nutritional ingredients and two non-contigous outer layers comprising antiadhesion excipients and compression adjuvants preventing the adhesion to the punches of the tabletting machine and possibly active ingredients which are the same as or different from those present in the inner layer. Said tablets are obtainable by direct compression of mixtures or granulates of the various components of each layer.

Priority: EP20030003813 Applic. Date: 2003-02-20; WO2004EP00371 Applic. Date: 2004-01-20

Inventor: SALINI ALBERTO [CH]


Application No.: US20060204473A1  Published: 14/Sep/2006

Title: Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same

Applicant/Assignee: ALIOS BIOPHARMA, INC

Application No.: 11/351163   Filing Date: 08/Feb/2006

Abstract:The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same.

The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic.

The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

Priority: US2006-330917 Applic. Date: 2006-01-11; US2005-200531 Applic. Date: 2005-08-08; US20040600202P Applic. Date: 2004-08-09; US20040600134P Applic. Date: 2004-08-09; US20040604280P Applic. Date: 2004-08-24; US20040604415P Applic. Date: 2004-08-24

Inventor: BLATT LAWRENCE M [US]; SEIWERT SCOTT D [US]; HONG JIN [US]


Application No.: US20060204559A1  Published: 14/Sep/2006

Title: Fast dissolving orally consumable films containing an ion exchange resin as a taste masking agent

Applicant/Assignee: MCNEIL-PPC, INC

Application No.: 11/429547   Filing Date: 05/May/2006

Abstract:Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods for producing the films are also disclosed.

Priority: US2000-535005 Applic. Date: 2000-03-23

Inventor: BESS WILLIAM S [US]; KULKARNI NEEMA [US]; AMBIKE SUHAS H [CA]; RAMSAY MICHAEL P [CA]


Application No.: US20060204571A1  Published: 14/Sep/2006

Title: Stable compositions of bupropion or its pharmaceutically acceptable salts

Applicant/Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED

Application No.: 11/373480   Filing Date: 10/Mar/2006

Abstract:A stable oral pharmaceutical composition comprising a therapeutically effective amount of bupropion or its pharmaceutically acceptable salt intimately blending with one or more compatible excipients selected from the group consisting of talc and potassium chloride, additional pharmaceutically acceptable excipients and total impurities are present in amounts from 0% to not more than 3.3% w/w of the bupropion hydrochloride, when the composition is stored at 40 DEG C. at 75% relative humidity for three months in closed containers with silica gel as dessicant.

Priority: IN2005MU00240 Applic. Date: 2005-03-12

Inventor: DHAVSE VAISHALI V [IN]; DHARMADHIKARI NITIN B [IN]


Application No.: US20060204573A1  Published: 14/Sep/2006

Title: Control release formulation containing a hydrophobic material as the sustained release agent

Applicant/Assignee: NOSTRUM PHARMACEUTICALS, INC

Application No.: 11/355346   Filing Date: 16/Feb/2006

Abstract:The present invention is directed to a sustained release pharmaceutical composition in oral dosage form consisting essentially of a pharmaceutically effective amount of a medicament and a hydrophobic material in the absence of a lactose or hydrophobic carbohydrate polymer, said medicament being present in an amount greater than about 25% of the pharmaceutical composition and having a water solubility greater than about 1 gram per 10 mL of water at 25 DEG C., said hydrophobic material having a melting point ranging from at least about 40 DEG C. to about 100 DEG C. at 1 atm pressure, and being present in an amount ranging from about 3% to about 20% by weight of the pharmaceutical composition and in an amount less than the of the medicament, and said hydrophobic material not being present in coating of said pharmaceutical composition

said pharmaceutical composition being prepared by direct compression in the absence of or melting the hydrophobic material or the use of high shear mixer. The present invention is also directed to a method of preparing said pharmaceutical composition.

Priority: US2002-167368 Applic. Date: 2002-06-10; US20010297140P Applic. Date: 2001-06-08

Inventor: MULYE NIRMAL [US]


Application No.: US20060204578A1  Published: 14/Sep/2006

Title: Dual controlled release dosage form

Applicant/Assignee:

Application No.: 11/355315   Filing Date: 15/Feb/2006

Abstract:A dosage form that provides a controlled release of at least two different active agents is provided. Particular embodiments include a dosage form that provides therapeutically effective levels of a first active agent and a second active agent in a mammal for an extended period of time following oral administration. An osmotic device containing a bi-layered core is provided. The osmotic device provides a dual controlled release of both drugs from the core. The layers of the core are in stacked, substantially concentric or substantially eccentric arrangement.

Priority: US2005-321736 Applic. Date: 2005-12-29; US2001-992488 Applic. Date: 2001-11-06

Inventor: VERGEZ JUAN A [AR]; RICCI MARCELO A [AR]


Application No.: US20060204582A1  Published: 14/Sep/2006

Title: Multiple phase cross-linked compositions and uses thereof

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 11/434023   Filing Date: 15/May/2006

Abstract:The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.

Priority: US2001-883842 Applic. Date: 2001-06-18; US20000212511P Applic. Date: 2000-06-19

Inventor: STEIN STANLEY [US]; QIU BO [US]


Application No.: US20060204587A1  Published: 14/Sep/2006

Title: Use of film coating as taste-masking coating of oral dosage forms

Applicant/Assignee:

Application No.: 11/218533   Filing Date: 06/Sep/2005

Abstract:The present invention relates to the use of a film coating consisting of a) polyvinyl acetate b) hydrophilic additives c) other conventional coating ingredients d) and, where appropriate, a physiologically tolerated acid as taste-masking coating for oral dosage forms, and to a process for producing such dosage forms.

Priority: DE19991061897 Applic. Date: 1999-12-20; US2000-729460 Applic. Date: 2000-12-05

Inventor: KOLTER KARL [DE]; SCHEIFFELE SILKE [DE]; EINIG HEINZ [DE]; BODMEIER ROLAND [DE]


Application No.: US20060204597A1  Published: 14/Sep/2006

Title: Method and means for improving bowel health

Applicant/Assignee: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION LIMAGRAIN CEREALES INGREDIENTS SA

Application No.: 11/324063   Filing Date: 30/Dec/2005

Abstract:A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30% and/or the grain comprises a reduced level of SBEIIa enzyme activity and/or protein relative to wild-type grain.

Priority: AU20040907350 Applic. Date: 2004-12-30; US20050688944P Applic. Date: 2005-06-08

Inventor: BIRD ANTHONY R [AU]; MANN GULAY S [AU]; RAHMAN SADEQUR [AU]; REGINA AHMED [AU]; LI ZHONGYI [AU]; TOPPING DAVID L [AU]; MORELL MATTHEW K [AU]


Application No.: US20060205669A1  Published: 14/Sep/2006

Title: G-type peptides and other agents to ameliorate atherosclerosis and other pathologies

Applicant/Assignee: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION

Application No.: 11/229042   Filing Date: 16/Sep/2005

Abstract:This invention provides novel peptides, and other agents, that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The peptides are highly stable and readily administered via an oral route.

Priority: US20040610711P Applic. Date: 2004-09-16

Inventor: FOGELMAN ALAN M [US]; NAVAB MOHAMAD [US]; ANANTHARAMAIAH GATTADAHALLI M [US]


Application No.: US20060205679A1  Published: 14/Sep/2006

Title: Topical and oral formulations of cardiac glycosides for treating skin diseases

Applicant/Assignee: AZAYA THERAPEUTICS, INC

Application No.: 11/255596   Filing Date: 21/Oct/2005

Abstract:The present invention provides method, preparation and use of a variety of pharmaceutical compositions containing at least one digitalis glycoside such as oleandrin, odoroside-A, neriifolin, proscillaridin-A, methyl-proscillaridin-A, digitoxin, digoxin alone or at least one digitalis glycoside complexed with cyclodextrins. In another aspect, the present invention provides an effective method to treat diseases in mammals. In yet another aspect, the present invention provides an effective method for treating skin diseases in a human or non-human animal.

Priority: US20040621102P Applic. Date: 2004-10-22

Inventor: STREEPER ROBERT [US]; SINGH CHANDRA U [US]


Application No.: US20060205793A1  Published: 14/Sep/2006

Title: Flupirtine preparation for the treatment of neurodegenerative diseases of the visual apparatus and diabetes mellitus

Applicant/Assignee:

Application No.: 11/316570   Filing Date: 21/Dec/2005

Abstract:The invention relates to the use of flupirtine in manufacture of a pharmaceutical preparation for therapy and/or prophylaxis of diabetes mellitus, diabetic retinopathy, diabetic maculopathy, genetically related maculopathies, apoptosis of the visual apparatus and/or human glaucomas and also a combination preparation comprising flupirtine and at least one further active ingredient for therapy and/or prophylaxis of said diseases.

Priority: DE20031028260 Applic. Date: 2003-06-23; WO2004EP06738 Applic. Date: 2004-06-22

Inventor: SCHMIDT KARL-GEORG [DE]


Application No.: US20060205822A1  Published: 14/Sep/2006

Title: 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect

Applicant/Assignee: FOREST LABORATORIES, INC

Application No.: 11/315581   Filing Date: 21/Dec/2005

Abstract:The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane.

Priority: US20040638423P Applic. Date: 2004-12-22

Inventor: JONAS JEFFREY [US]; MANN ALLISON [US]


Application No.: US20060210573A1  Published: 21/Sep/2006

Title: Peptide useful in immunomodulation

Applicant/Assignee: MOR-RESEARCH APPLICATIONS LTD., CURETECH LTD MOR-RESEARCH APPLICATIONS LTD

Application No.: 11/411832   Filing Date: 27/Apr/2006

Abstract:The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.

Priority: IL20010145926 Applic. Date: 2001-10-15; US2004-821283 Applic. Date: 2004-04-09; WO2002IL00831 Applic. Date: 2002-10-15

Inventor: HARDY BRITTA [IL]; RAITER ANNAT [IL]; KLAPPER LEAH [IL]


Application No.: US20060210620A1  Published: 21/Sep/2006

Title: Co-precipitated amorphous losartan and dosage forms comprising the same

Applicant/Assignee:

Application No.: 10/542587   Filing Date: 21/Jan/2004

Abstract:The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers

and spray drying the aqueous solution of losartan and one or more hydrophilic polymers to form a mixture. The amorphous losartan and one or more hydrophilic polymers are co-precipitated from the aqueous solution.

Priority: IN2003DE00054 Applic. Date: 2003-01-21; WO2004IB00144 Applic. Date: 2004-01-21

Inventor: KUMRA PANNANCHUKUNNATH M [IN]; MANIKANDAN RAMALINGAM [IN]; SINGH ROMI B [IN]; NAGAPRASAD VISHNUBHOTLA [IN]


Application No.: US20060210622A1  Published: 21/Sep/2006

Title: Surface modified particulate compositions of biologically active substances

Applicant/Assignee: SKYEPHARMA CANADA INC

Application No.: 11/272902   Filing Date: 14/Nov/2005

Abstract:This invention disclosure relates to compositions for the delivery of stable surface modified sub-micron and micron sized particles of water-insoluble biologically active substances from a non-aqueous medium that self-disperses on exposure to an aqueous environment.

Priority: US2000-667328 Applic. Date: 2000-09-21; US19990154964P Applic. Date: 1999-09-21

Inventor: PACE GARY W [US]; MISHRA AWADHESH K [CA]; SNOW ROBERT A [US]


Application No.: US20060210623A1  Published: 21/Sep/2006

Title: Sustained release delivery of isradipine

Applicant/Assignee:

Application No.: 11/377648   Filing Date: 17/Mar/2006

Abstract:Sustained release oral formulations of israpidine, methods of preparing same, and methods of using sustained release oral formulations to provide controlled delivery of israpidine. The sustained release oral formulations include israpidine and a sustained release polymer, and provide substantially zero order release of israpidine over an extended period.

Priority: US20050662370P Applic. Date: 2005-03-17

Inventor: STACH PAUL E [US]; KADRI BALAJI V [US]; BOBOTAS GEORGE [US]; FAWZY ABDEL A [US]


Application No.: US20060210630A1  Published: 21/Sep/2006

Title: Controlled release compositions of gamma-hydroxybutyrate

Applicant/Assignee:

Application No.: 11/239638   Filing Date: 30/Sep/2005

Abstract:The present invention is directed to oral pulse-release pharmaceutical dosage form containing an immediate release component of gamma-hydroxybutyric acid, and one or more delayed/controlled release components of gamma-hydroxybutyric acid.

Priority: US20040614622P Applic. Date: 2004-09-30

Inventor: LIANG LIKAN [US]; SHAH NIRAJ [US]; BHATT PADMANABH P [US]; IBRAHIM SCOTT [US]


Application No.: US20060210631A1  Published: 21/Sep/2006

Title: Multi-particulate, modified-release composition

Applicant/Assignee:

Application No.: 11/085671   Filing Date: 21/Mar/2005

Abstract:A multi-particulate, modified-release pharmaceutical composition for the oral administration of an active ingredient to the colon, wherein said particles comprise: (a) a core comprising an active ingredient or a pharmaceutically acceptable salt or ester thereof, and optionally one or more excipients

(b) a first coating applied to the surface of the core, wherein said first coating is insoluble in gastric juice and in intestinal juice below pH 7, but soluble in colonic intestinal juice

and (c) a second coating applied to the surface of the first coating.

Priority:

Inventor: PATEL ASHISH A [US]; PALANISWAMY SURESH [US]; DAVILA PABLO [US]


Application No.: US20060211668A1  Published: 21/Sep/2006

Title: Use of ciclesonide for the treatment of inflammatory bowel diseases

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 10/570986   Filing Date: 28/Mar/2006

Abstract:The invention relates to the novel use of ciclesonide in the treatment of inflammatory bowel disease.

Priority: EP20030020871 Applic. Date: 2003-09-15; WO2004EP52170 Applic. Date: 2004-09-15

Inventor: ABEL FLORIAN [DE]; BRUECK ANTJE [DE]; DIETZEL KLAUS [DE]; EISTETTER KLAUS [DE]; NAVE RUEDIGER [DE]; POSTIUS STEFAN [DE]; VON RICHTER OLIVER [DE]


Application No.: US20060211742A1  Published: 21/Sep/2006

Title: Amorphous lercanidipine hydrochloride and uses thereof

Applicant/Assignee: RECORDATI IRELAND LIMITED

Application No.: 11/364862   Filing Date: 27/Feb/2006

Abstract:The invention provides a substantially pure amorphous lercanidipine hydrochloride having a purity of at least 95% pure, preferably at least about 97% pure, more preferably at least about 99% pure, and still more preferably at least about 99.5% pure. The invention further relates to methods of preparing substantially pure amorphous lercanidipine, as well as methods of providing rapid relief from hypertension by administering the substantially pure amorphous lercanidipine hydrochloride of the present invention to a patient in need of such treatment.

Priority: US20050656836P Applic. Date: 2005-02-25

Inventor: LEONARDI AMEDEO [IT]; MOTTA GIANNI [IT]; BERLATI FABIO [IT]


Application No.: US20060216294A1  Published: 28/Sep/2006

Title: Method of modulation

Applicant/Assignee:

Application No.: 11/229415   Filing Date: 16/Sep/2005

Abstract:Disclosed are methods for modulating neuron activity, and in particular, for modulating motor neuron function and activity, particularly for use in the treatment, prevention, and/or amelioration of symptoms of one or more motor neuron conditions or diseases in a mammal. Also disclosed are compositions comprising one or more agonists or antagonists of a mammalian Müllerian Inhibitory Substance receptor polypeptide, as well as pharmaceutical formulations, isolated host cells, and therapeutic and/or diagnostic kits that comprises such agonists or antagonists.

Priority: NZ20050539036 Applic. Date: 2005-03-24

Inventor: MCLENNAN IAN S [NZ]; KOISHI KYOKO [NZ]; WANG PEI-YU [NZ]


Application No.: US20060216343A1  Published: 28/Sep/2006

Title: Pharmaceutical compositions comprising an oligonucleotide as an active agent

Applicant/Assignee:

Application No.: 11/266999   Filing Date: 04/Nov/2005

Abstract:A pharmaceutical composition is disclosed, which composition comprises an oligonucleotide as an active agent, the oligonucleotide being adapted to target nucleic acids encoding CD40 thereby to modulate the expression of CD40 in mammalian cells, and a liposome as an excipient. Said liposome is an amphoteric liposome. Also disclosed is a method for the treatment or prophylaxis of a disease or condition associated with the expression of CD40 in a human or non-human animal patient by administering to said patient a therapeutically or prophylactically effective amount of such a composition.

Priority: DE200410054731 Applic. Date: 2004-11-05; DE200410056659 Applic. Date: 2004-11-19; EP20050020218 Applic. Date: 2005-09-15; US20040625195P Applic. Date: 2004-11-05; US20040629600P Applic. Date: 2004-11-19; US20050717293P Applic. Date: 2005-09-15

Inventor: PANZNER STEFFEN [DE]; RAUCHHAUS UNA [DE]; ENDERT GEROLD [DE]; FANKHAENEL STEFAN [DE]


Application No.: US20060216347A1  Published: 28/Sep/2006

Title: Tablet punches and methods for tableting

Applicant/Assignee:

Application No.: 10/567055   Filing Date: 16/Aug/2004

Abstract:A tablet punch having a punch cup having a non-stick polymeric coating which may comprise a fluoropolymer such as polytetrafluoroethylene.

Priority: US20030497580P Applic. Date: 2003-08-25; WO2004IB02668 Applic. Date: 2004-08-16

Inventor: STROPPOLO FEDERICO [CH]; LEPORI SANDRO [CH]; CICCARELLO FRANCO [CH]; MILANI RITA [CH]


Application No.: US20060216348A1  Published: 28/Sep/2006

Title: AGGLOMERATED STARCH COMPOSITIONS

Applicant/Assignee: BPSI HOLDINGS, INC

Application No.: 11/376855   Filing Date: 16/Mar/2006

Abstract:Agglomerated starch compositions containing native starch and pre-compacted starch powder is disclosed. The agglomerated starch compositions have superior flow and less pH sensitivity than simple blends of the two components at equivalent ratios.

Priority: US20050664447P Applic. Date: 2005-03-23

Inventor: CUNNINGHAM CHARLES R [US]


Application No.: US20060216351A1  Published: 28/Sep/2006

Title: Pharmaceutical Compositions of Dispersions of Drugs and Neutral Polymers

Applicant/Assignee: PFIZER INC

Application No.: 11/383520   Filing Date: 16/May/2006

Abstract:In one aspect, pharmaceutical compositions comprising dispersions of an acid-sensitive drug and a neutral dispersion polymer are disclosed. The acid-sensitive drug has improved chemical stability relative to dispersions of the drug and acidic polymers. In another aspect, pharmaceutical compositions of low-solubility drugs and amphiphilic, hydroxy-functional vinyl copolymers are disclosed.

Priority: US2002-175132 Applic. Date: 2002-06-18; US20010300255P Applic. Date: 2001-06-22

Inventor: FRIESEN DWAYNE T [US]; GUMKOWSKI MICHAEL J [US]; KETNER RODNEY J [US]; LORENZ DOUGLAS A [US]; NIGHTINGALE JAMES A [US]; SHANKER RAVI M [US]; WEST JAMES B [US]


Application No.: US20060216358A1  Published: 28/Sep/2006

Title: Controlled release composition containing a strontium salt

Applicant/Assignee:

Application No.: 10/556150   Filing Date: 06/May/2004

Abstract:A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for preventing a cartilage and/or bone condition in a subject, and for the treatment and/or prophylaxis of secondary osteoporosis.

Priority: DK20030000691 Applic. Date: 2003-05-07; DK20030001043 Applic. Date: 2003-07-08; DK20030001821 Applic. Date: 2003-12-09; US20030528409P Applic. Date: 2003-12-09; WO2004DK00326 Applic. Date: 2004-05-06

Inventor: HANSEN CHRISTIAN [DK]; NILSSON HENRIK [DK]; ANDERSEN JENS E [DK]; CHRISTGAU STEPHAN [DK]


Application No.: US20060217309A1  Published: 28/Sep/2006

Title: Novel cyclosporine analog formulations

Applicant/Assignee: ISOTECHNIKA INC., A CANADA CORPORATION ISOTECHNIKA INC

Application No.: 11/375532   Filing Date: 13/Mar/2006

Abstract:The present invention relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations.

Priority: US2002-274419 Applic. Date: 2002-10-17; US20020370597P Applic. Date: 2002-04-05; US20010346201P Applic. Date: 2001-10-19

Inventor: NAICKER SELVARAJ A [CA]; YATSCOFF RANDALL W [CA]; FOSTER ROBERT T [CA]


Application No.: US20060222703A1  Published: 05/Oct/2006

Title: Pharmaceutical composition and preparation method thereof

Applicant/Assignee: IPRBOX OY

Application No.: 11/097969   Filing Date: 01/Apr/2005

Abstract:The invention relates to an oral solid pharmaceutical composition comprising pharmacologically effective amounts of entacapone, levodopa and carbidopa, or a pharmaceutically acceptable salt or hydrate thereof, and one or more pharmaceutically acceptable excipients, wherein the excipients are long-chain polymers having an equilibrium moisture content of at least 2%, and to a preparation method thereof. The compositions can be used for the treatment of Parkinson's disease.

Priority:

Inventor: POLITI GIOVANNI [FI]


Application No.: US20060222706A1  Published: 05/Oct/2006

Title: Formulations of Fenofibrate

Applicant/Assignee:

Application No.: 11/323886   Filing Date: 29/Dec/2005

Abstract:The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol or a surfactant mixture, wherein the menthol can be menthol or menthol surfactant mixture, and wherein the surfactant mixture can be a mixture of a polyethylene glycol and a poloxamer such as PGE 1000 and poloxamer 407. The invention also provides a method for the treatment of elevated levels of triglycerides in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of fenofibrate or another fibrate drug and menthol or a surfactant mixture, wherein the fenofibrate or the other fibrate drug is in intimate association with the menthol or surfactant mixture, wherein the menthol can be menthol or menthol surfactant mixture, and wherein the surfactant mixture can be a mixture of a polyethylene glycol and a poloxamer such as PGE 1000 and poloxamer 407.

Priority: US20050666192P Applic. Date: 2005-03-30

Inventor: FLASHNER-BARAK MOSHE [IL]; LERNER E I [IL]


Application No.: US20060222713A1  Published: 05/Oct/2006

Title: Extended release pharmaceutical composition of phenytoin sodium

Applicant/Assignee:

Application No.: 10/539129   Filing Date: 16/Dec/2003

Abstract:The present invention relates to extended release pharmaceutical composition of phenytoin sodium that includes a blend of phenytoin sodium and one or more hydrophilic polymers. The blend forms a matrix after contacting an aqueous media and the matrix retains at least about 20% of the phenytoin after 1 hour. It also relates to a process for preparing the extended release pharmaceutical composition.

Priority: IN2002DE01264 Applic. Date: 2002-12-16; WO2003IB06007 Applic. Date: 2003-12-16

Inventor: MURPANI DEEPAK [IN]; MADAN ASHISH [IN]


Application No.: US20060222715A1  Published: 05/Oct/2006

Title: Particles containing an acitve agent in the form of a co-precipitate

Applicant/Assignee:

Application No.: 10/564786   Filing Date: 16/Jul/2004

Abstract:The invention relates to particles containing an active agent in the form of a co-precipitate, to a method for producing said particles and to pharmaceutical forms containing said particles.

Priority: FR20030008720 Applic. Date: 2003-07-17; WO2004FR01878 Applic. Date: 2004-07-16

Inventor: COUSIN GERARD [FR]; LAMOUREUX GAEL [FR]


Application No.: US20060223787A1  Published: 05/Oct/2006

Title: Modified release formulations and methods of treating inflammatory bowel disease

Applicant/Assignee: AGI THERAPEUTICS LTD

Application No.: 11/371958   Filing Date: 10/Mar/2006

Abstract:Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.

Priority: US2004-930743 Applic. Date: 2004-09-01; US20030499365P Applic. Date: 2003-09-03

Inventor: DEVANE JOHN [IE]; BUTLER JACKIE [IE]


Application No.: US20060228348A1  Published: 12/Oct/2006

Title: Targeting of glycoprotein therapeutics

Applicant/Assignee: GENZYME CORPORATION

Application No.: 11/398949   Filing Date: 05/Apr/2006

Abstract:Methods of making ligand-decorated polymer conjugates of therapeutic glycoproteins are described. Improved targeting of glycoproteins to specific tissues is achieved by masking the natural carbohydrate and other surface determinants with high molecular weight polymers, such as, e.g., PEG, polysialic acid, etc., which in turn are decorated with target-specific ligands. In some embodiments, acid-labile linkages in such conjugates or rapidly degradable masking groups allow for the intracellular release of the polymer from the glycoprotein, for example, under conditions found in lysosomes.

Priority: US20050668920P Applic. Date: 2005-04-06

Inventor: STEFANO JAMES [US]


Application No.: US20060228399A1  Published: 12/Oct/2006

Title: Taste masked veterinary formulation

Applicant/Assignee: BAYER HEALTHCARE LLC

Application No.: 11/102426   Filing Date: 08/Apr/2005

Abstract:A method of producing a self-take anthelmintic that includes active components that are undesirable to at least one sense of a target animal. The active ingredients including praziquantel are mixed with artificial beef and yeast components and subjected to a first compression. The resulting rough tablet is then ground to increase the density of the material by approximately 100% of the original density. Thereafter, the material is subjected to a second compression to form a final self-take tablet.

Priority:

Inventor: ROSE JOHN [US]; RUETER JOCHEM [US]


Application No.: US20060228410A1  Published: 12/Oct/2006

Title: Flavored taste-masked pharmaceutical formulation made using a one-step coating process

Applicant/Assignee:

Application No.: 10/565609   Filing Date: 10/Aug/2004

Abstract:The present invention encompasses a flavored and taste-masked pharmaceutical composition comprising a plurality of pharmaceutically acceptable cores, such as microspheres, said pharmaceutically acceptable cores comprising etoricoxib, wherein the pharmaceutically acceptable cores are coated with a flavored taste-masking coating solution in a convenient one-step process.

Priority: US20030494370P Applic. Date: 2003-08-11; WO2004CA01483 Applic. Date: 2004-08-10

Inventor: DUMONT HUBERT [CA]; THIBERT ROCH [CA]


Application No.: US20060228422A1  Published: 12/Oct/2006

Title: Polysaccharide double-layer microcapsules as carriers for biologically active substance oral administration

Applicant/Assignee:

Application No.: 10/567699   Filing Date: 03/Aug/2004

Abstract:The present invention relates to microcapsules with a double-layer of natural polysaccharides-chitosan and alginate-gelified and stabilized by means of a divalent ion containing inside at least one biologically active substance. The microcapsules of the invention can be employed as carriers for the oral administration of biologically active substances, also associated with an adjuvant of the biological response of the same, administered for a preventive or therapeutic purpose. These substances can be chosen, for example, from antigens and adjuvants, suitable for immune response stimulation against infective and non-infective agents, or from chemotherapeutics and adjuvants with therapeutic type effects. According to the type of biologically active substance encapsulated in the microcapsules, there can be a variety of uses for oral vaccination or therapy in the human and veterinary field.

Priority: IT2003MI01617 Applic. Date: 2003-08-06; WO2004EP51693 Applic. Date: 2004-08-03

Inventor: SAVA GIANNI [IT]; ZORZIN LAURA [IT]


Application No.: US20060228452A1  Published: 12/Oct/2006

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386469   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20060228453A1  Published: 12/Oct/2006

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386498   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US20050727196P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050726878P Applic. Date: 2005-10-14; US20050727080P Applic. Date: 2005-10-14; US20050664328P Applic. Date: 2005-03-23; US19970060015P Applic. Date: 1997-09-25; US20030453555P Applic. Date: 2003-03-10; US1998-159945 Applic. Date: 1998-09-24; US1999-433001 Applic. Date: 1999-11-02; US2001-950307 Applic. Date: 2001-09-10; US2002-235572 Applic. Date: 2002-09-06; US2004-977288 Applic. Date: 2004-10-29; US2004-769243 Applic. Date: 2004-01-30

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20060228570A1  Published: 12/Oct/2006

Title: Reactor coated with a polymer

Applicant/Assignee:

Application No.: 10/554967   Filing Date: 27/Oct/2005

Abstract:The invention relates to the use of a coated manufacturing vessel in pharmaceutical production. A polymer coating (ECTFE, PVDF, PFA) avoids the adhesion or sticking of compounds within the vessel.

Priority: SE20030001260 Applic. Date: 2003-04-29; WO2004GB01775 Applic. Date: 2004-04-26

Inventor: BURNS STEPHEN J [GB]; FLETCHER IAN M [GB]; METCALF STEPHEN P [GB]


Application No.: US20060229258A1  Published: 12/Oct/2006

Title: Steroidal compositions containing hydroxycarboxylic acids and methods of using the same

Applicant/Assignee:

Application No.: 10/566079   Filing Date: 30/Jul/2003

Abstract:Pharmaceutical compositions suitable for topical administration comprising two active ingredients, a hydroxycarboxylic acid and prednicarbate, and a pyrrolidone carboxylate salt moisturizing agent. In a particular aspect, the two active ingredients in the present inventive compositions have a purity of at least 90% and a concentration of degradation product(s) less than about 10% of the starting concentration of the active ingredients. These compositions are used for topical medical applications, particularly to treat steroid responsive dermatoses.

Priority: WO2003US23723 Applic. Date: 2003-07-30

Inventor: SERIKAKU DANIELA [BR]


Application No.: US20060233740A1  Published: 19/Oct/2006

Title: Conjugates of an hGH moiety and a polymer

Applicant/Assignee:

Application No.: 11/388784   Filing Date: 23/Mar/2006

Abstract:Conjugates of an hGH moiety and one or more non-peptidic water-soluble polymers are provided. Typically, the non-peptidic water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising such conjugates, methods of making the conjugates, and methods of administering compositions comprising such conjugates to a mammalian subject.

Priority: US20050664401P Applic. Date: 2005-03-23

Inventor: BOSSARD MARY J [US]; ZHANG PING [US]


Application No.: US20060233743A1  Published: 19/Oct/2006

Title: Compositions and methods of therapy

Applicant/Assignee:

Application No.: 10/532291   Filing Date: 21/Oct/2003

Abstract:A method of inducing tolerance to an antigen in a patient, the method comprising administering to the patient an agent which raises the effective cAMP concentration in a monocyte cell and GMCSF or a derivative thereof. Preferably, the agent which raises the effective cAMP concentration in a monocyte cell is a prostaglandin or agonist thereof which stimulates cAMP production in a monocyte. Optionally, the antigen to which it is desired to induce tolerance, or a derivative thereof, may also be administered.

Priority: GB20020024415 Applic. Date: 2002-10-21; WO2003GB04537 Applic. Date: 2003-10-21

Inventor: KELLY RODNEY W [GB]


Application No.: US20060233747A1  Published: 19/Oct/2006

Title: Polymer-modified synthetic proteins

Applicant/Assignee: AMYLIN PHARMACEUTICALS, INC

Application No.: 11/446419   Filing Date: 05/Jun/2006

Abstract:The present invention relates to methods and compositions for modifying peptides, polypeptides and proteins with polymers, especially glyco-mimetic polymers, so as to improve their biological activity or pharmacokinetic properties. The invention further provides methods and uses for such polymer-modified peptides, polypeptides and proteins. The invention is particularly suitable for use in the synthesis of polymer-modified, synthetic bioactive proteins, and of pharmaceutical compositions that contain such proteins.

Priority: US2003-332385 Applic. Date: 2003-01-08; WO2001US21930 Applic. Date: 2001-07-12; US20000236377P Applic. Date: 2000-09-29; US20000231339P Applic. Date: 2000-09-08

Inventor: KOCHENDOERFER GERD G [US]; BOTTI PAOLO [IT]; BRADBURNE JAMES A [US]; CHEN SHIAH-YUN [US]; CRESSMAN SONYA [CA]; HUNTER CHRISTIE L [US]; KENT STEPHEN B [US]; LOW DONALD W [US]; WILKEN JILL G [US]


Application No.: US20060233764A1  Published: 19/Oct/2006

Title: Skin regeneration system

Applicant/Assignee:

Application No.: 10/565616   Filing Date: 28/Jul/2004

Abstract:A cell culture medium and system are provided which eliminate or at least reduce the requirement for exogenous components such as serum and feeder cells. The cell culture medium comprises an IGF and vitronectin or fibronectin and, optionally an IGFBP, and is particularly suitable for propagating keratinocytes for subsequent use in skin growth and regeneration. This invention also relates to compositions and methods for skin growth and regeneration in situ, which utilize aerosol delivery of cultured keratinocytes.

Priority: AU20030903896 Applic. Date: 2003-07-28; WO2004AU01006 Applic. Date: 2004-07-28

Inventor: UPTON ZEE [AU]; HARKIN DAMIEN [AU]; LEAVESLEY DAVID [AU]


Application No.: US20060233873A1  Published: 19/Oct/2006

Title: Dispersion of taste masked crystals or granules of active substances, chewable soft capsules filled with said dispersion, and process for preparing same

Applicant/Assignee:

Application No.: 10/543084   Filing Date: 21/Jan/2004

Abstract:The present invention concerns a dispersion of crystals or granules of active substance in a lipophilic vehicle, said crystals or granules being coated by a coating for taste masking purposes. The invention also it concerns unit dosage forms and preferentially chewable or fast dissolving soft gelatin capsules filled with said dispersion as well as process for manufacturing same.

Priority: FR20030000824 Applic. Date: 2003-01-24; WO2004US01463 Applic. Date: 2004-01-21

Inventor: MEISSONNIER JULIEN [FR]; ROSE FABRICE [FR]; BOHN MARIE M [FR]


Application No.: US20060233875A1  Published: 19/Oct/2006

Title: Taste masked sumatriptan tablets and processes for their preparation

Applicant/Assignee:

Application No.: 10/521402   Filing Date: 17/Jul/2003

Abstract:The technical field of the present invention relates to uncoated, taste masked sumatriptan tablets for oral administration and processes for their preparation. It also relates to wax polished sumatriptan tablets and processes for their preparation.

Priority: IN2002DE00759 Applic. Date: 2002-07-19; WO2003IB02838 Applic. Date: 2003-07-17

Inventor: MATHUR RAJEEV S [IN]; KUMAR T V [IN]; ROY SUNILENDU B [IN]; MALIK RAJIV [AT]


Application No.: US20060233878A1  Published: 19/Oct/2006

Title: Extended release formulation of beta-lactam antibiotics

Applicant/Assignee: LUPIN LIMITED

Application No.: 10/568325   Filing Date: 16/Feb/2006

Abstract:A pharmaceutical composition for controlled drug delivery comprising a beta-lactam antibiotic or its pharmaceutically acceptable hydrates, salts or esters, and one or more carbomers. The above beta-lactam antibiotics formulation avoids the limitations of known beta-lactam controlled release form which are found to be either complex and/or cost-extensive to obtain requiring multiphase and/or selective coatings or fail to achieve the desired controlled release for once daily dosage form. Importantly, in the beta-lactam antibiotic form of the above the rate-controlling polymer wherein the Cmax of the formulation is substantially the same as that of a single dose of the immediate release formulation. Also advantageously the formulation achieves a rate controlling polymer wherein the T>MIC for the formulation is more than 17 hours when the MIC is 0.25 mcg/ml and more than 10 hours when the MIC is 2 mcg/ml. The above beta-lactam antibiotic form is thus directed to serve as the much desired simple and cost-effective controlled release form suitable for once daily administration.

Priority: WO2003IN00326 Applic. Date: 2003-09-30

Inventor: BHAMARE SHAILESH [IN]; BHUSHAN INDU [IN]; SEN HIMADRI [IN]


Application No.: US20060234919A1  Published: 19/Oct/2006

Title: Use

Applicant/Assignee:

Application No.: 10/488166   Filing Date: 01/Mar/2004

Abstract:The present invention relates to the use of substances with oxytocin for the preparation of pharmaceutical composition against inflamation. It also relates to a pharmaceutical composition comprising at least one substance with oxytocin activity against inflamation.

Priority: SE20010002910 Applic. Date: 2001-08-31; WO2002SE01560 Applic. Date: 2002-09-02

Inventor: UVNAES-MOBERG KERSTIN [SE]; LUNDEBERG THOMAS [SE]


Application No.: US20060239908A1  Published: 26/Oct/2006

Title: COMPOSITIONS FOR INHALATION

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/379721   Filing Date: 21/Apr/2006

Abstract:The present invention relates to new pharmaceutical compositions for inhalation containing one or more, preferably one anticholinergic 1 in combination with one or more betamimetics 2 and one or more steroids 3, processes for preparing them and their use in the treatment of respiratory complaints.

Priority: EP20050008956 Applic. Date: 2005-04-23

Inventor: BOUYSSOU THIERRY [DE]; KONETZKI INGO [DE]; PIEPER MICHAEL P [DE]; SCHNAPP ANDREAS [DE]


Application No.: US20060239924A1  Published: 26/Oct/2006

Title: COMPOSITIONS FOR DELIVERY OF THERAPEUTICS AND OTHER MATERIALS, AND METHODS OF MAKING AND USING THE SAME

Applicant/Assignee: PHARMAIN CORPORATION

Application No.: 11/428803   Filing Date: 05/Jul/2006

Abstract:In part, the present invention is directed to biocompatible compositions comprising a carrier with a first metal binding domain, a metal ion, an active agent with second metal binding domain and optionally a protective chain covalently attached to the polymeric carrier.

Priority: US2003-378100 Applic. Date: 2003-02-27; US20020360350P Applic. Date: 2002-02-27

Inventor: BOLOTIN ELIJAH M [US]


Application No.: US20060239960A1  Published: 26/Oct/2006

Title: Polymer-based compositions and conjugates of antimicrobial agents

Applicant/Assignee: NEKTAR THERAPEUTICS AL, CORPORATION

Application No.: 11/402641   Filing Date: 11/Apr/2006

Abstract:Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions.

Priority: US20050671000P Applic. Date: 2005-04-12

Inventor: BOSSARD MARY J [US]; MITCHELL STACY [US]


Application No.: US20060240068A1  Published: 26/Oct/2006

Title: Pharmaceutical composition as solid dosage form and method for manufacturing thereof

Applicant/Assignee: FERRING B.V

Application No.: 11/396899   Filing Date: 04/Apr/2006

Abstract:The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein the pharmaceutical composition is composed of a compressed granulate and contains lubricant in an amount of from 0.05 to less than 0.50 percent by weight of said pharmaceutical composition.

Priority: US2003-626857 Applic. Date: 2003-07-25

Inventor: LOMRYD HAKAN [SE]; NICKLASSON HELENA [SE]; OLSSON LARS-ERIK [SE]


Application No.: US20060240070A1  Published: 26/Oct/2006

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee:

Application No.: 11/386587   Filing Date: 22/Mar/2006

Abstract:An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2004-769243 Applic. Date: 2004-01-30; US2004-796243 Applic. Date: 2004-03-09; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02; US1998-159945 Applic. Date: 1998-09-24; US20030453555P Applic. Date: 2003-03-10; US20050664328P Applic. Date: 2005-03-23; US20050727080P Applic. Date: 2005-10-14; US20050726878P Applic. Date: 2005-10-14; US20050732577P Applic. Date: 2005-10-17; US20050727196P Applic. Date: 2005-10-14

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Application No.: US20060240095A1  Published: 26/Oct/2006

Title: Pharmaceutical composition comprising a combination of metformin and a statin

Applicant/Assignee:

Application No.: 10/568523   Filing Date: 15/Feb/2006

Abstract:A pharmaceutical composition comprising: (i) metformin, optionally in the form of one of its pharmaceutically acceptable salts, (ii) a statin, optionally in the form one of its pharmaceutically acceptable salts, and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of hyperglycemia non-insulin-dependent diabetes, dyslipidemia, hyperlipidemia, hypercholesterolemia, and obesity.

Priority: EP20030292077 Applic. Date: 2003-08-22; WO2004EP09337 Applic. Date: 2004-08-20

Inventor: JUNIEN JEAN-LOUIS [FR]; EDGAR ALAN [FR]


Application No.: US20060240101A1  Published: 26/Oct/2006

Title: Orally disintegrating pharmaceutical tablet formulations of olanzapine

Applicant/Assignee:

Application No.: 11/402416   Filing Date: 11/Apr/2006

Abstract:This invention provides orally disintegrating pharmaceutical tablet formulations comprising per tablet the following ingredients in the following percentages by weight: olanzapine as an active ingredient in an amount from about 2.5% to about 10%

mannitol in an amount from about 75% to about 95%

a disintegrating agent in an amount from about 1.0% to about 10%

and one or more excipient in a total amount of about 0.1% to about 10%. This invention also provides a method of treating a patient in need of treatment with olanzapine which comprises administering to the patient a therapeutically effective dose of the above pharmaceutical tablet formulations. Finally, this invention provides a method of producing the above pharmaceutical tablet formulation which comprises combining the ingredients in the appropriate relative percentages by weight.

Priority: US20050674077P Applic. Date: 2005-04-22

Inventor: CHUNGI SHUBHA [US]; BARNES CLAUDE R [US]; LONESKY STEVEN M [US]


Application No.: US20060240107A1  Published: 26/Oct/2006

Title: Controlled-release compositions

Applicant/Assignee:

Application No.: 11/111996   Filing Date: 22/Apr/2005

Abstract:A solid dosage formulation having a core with a pharmacological agent dispersed in a first controlled-release matrix from which release of the agent is relatively slow

and a coat formed over the core and having the agent dispersed in a second controlled-release matrix from which release of the agent is relatively fast. The first matrix can be a cross-linked high amylose starch and the second matrix can be a mixture of polyvinyl acetate and polyvinylpyrrolidone.

Priority: WO2003CA01637 Applic. Date: 2003-10-27; US20020509062P Applic. Date: 2002-10-25; US20030510000P Applic. Date: 2003-10-10

Inventor: LENAERTS VINCENT [CA]; OUADJI-NJIKI LAURE P [CA]; BACON JOHNATAN [FR]; OUZEROUROU RACHID [CA]; GERVAIS SONIA [CA]; RAHMOUNI MILOUD [CA]; SMITH DAMON [CA]


Application No.: US20060241181A1  Published: 26/Oct/2006

Title: Alpha-ketoglutarates of active ingredients and compositions containing same

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A

Application No.: 11/443458   Filing Date: 31/May/2006

Abstract:Novel stable and pharmacologically acceptable salts of L-carnitine and lower alkanoyl L-carnitines with alpha-ketoglutaric acid are disclosed as well as the compositions useful as dietary and dietetic supplements, nutraceuticals or drugs containing same.

Priority: IT2001RM00445 Applic. Date: 2001-07-25; US2004-484927 Applic. Date: 2004-04-07; WO2001IT00549 Applic. Date: 2001-10-29

Inventor: POLA PIETRO [IT]


Application No.: US20060246095A1  Published: 02/Nov/2006

Title: Multiepitope polypeptides for cancer immunotherapy

Applicant/Assignee: GAVISH-GALILEE-BIO APPLICATIONS LTD

Application No.: 11/388794   Filing Date: 24/Mar/2006

Abstract:Disclosed are recombinant multiple epitope polypeptides (MEPs) consisting of T cell epitopes derived from tumor-associated antigens capable of being presented by an antigen presenting cell (APC), the recombinant nucleic acid sequences and expression vectors encoding them, and host cells transfected with said expression vectors. Further described are LTB-MEP fusion proteins comprising the E. Coli heat labile enterotoxin subunit B (LTB) peptide fused to a MEP by a synthetic linker, the recombinant nucleic acid sequences and expression vectors encoding them and host cell transfected with said expression vectors. Further included are compositions for inducing an immune response against malignancies, pharmaceutical compositions and a transdermal drug delivery system for the treatment of malignant disorders. Also disclosed are methods for conferring immunity against malignancies and for the treatment of malignant disorders.

Priority: IL20030158140 Applic. Date: 2003-09-25; WO2004IL00894 Applic. Date: 2004-09-26

Inventor: PERETZ TAMAR [IL]; LOTEM MICHAL [IL]; FRANKENBURG SHOSHANA [IL]; PITCOVSKI JACOB [IL]; LEVI ADVA [IL]; MARGALIT HANAH [IL]; ALTUVIA YAEL [IL]


Application No.: US20060246130A1  Published: 02/Nov/2006

Title: Compositions and methods for combination antiviral therapy

Applicant/Assignee:

Application No.: 10/540794   Filing Date: 13/Jan/2004

Abstract:The present invention relates to therapeutic combinations of [2-(6-amino-purin-9 yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester (tenofovir disoproxil fumarate, Viread(R)) and (2R,5S,cis)-4-amino-5-fluoro-1-(2 hydroxymethyl-1,3-oxathiolan-5-yl)-( 1 H)-pyrimidin-2-one (emtricitabine, Emtriva(TM), (-)-cis FTC) and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is also concerned with pharmaceutical compositions and formulations of said combinations of tenofovir disoproxil fumarate and emtricitabine, and their physiologically functional derivatives, as well as therapeutic methods of use of those compositions and formulations.

Priority: US20030440308P Applic. Date: 2003-01-14; US20030440246P Applic. Date: 2003-01-14; WO2004US00832 Applic. Date: 2004-01-13

Inventor: DAHL TERRENCE C [US]; MENNING MARK M [US]; OLIYAI REZA [US]


Application No.: US20060246132A1  Published: 02/Nov/2006

Title: Sustained release formulations of venlafaxine

Applicant/Assignee:

Application No.: 10/544624   Filing Date: 09/Feb/2004

Abstract:The present invention relates to sustained release tablet formulations of venlafaxine. Kollidon SR proved to be an excellent sustained release agent for venlafaxine, that is an extremely soluble drug.

Priority: IS20030006710 Applic. Date: 2003-02-07; IS20040007143 Applic. Date: 2004-02-05; WO2004IS00003 Applic. Date: 2004-02-09

Inventor: JOHANNSSON FJALAR [IS]


Application No.: US20060246162A1  Published: 02/Nov/2006

Title: Antiestrogenic glyceollins suppress human breast and ovarian carcinoma proliferation and tumorigenesis

Applicant/Assignee:

Application No.: 11/118431   Filing Date: 29/Apr/2005

Abstract:The flavonoid family of phytochemicals, particularly those derived from soy, has received attention regarding their hormonal activity and their effects on human health and disease. The types and amounts of these compounds in soy and other plants are controlled by both constitutive expression and stress-induced biosynthesis. The health benefits of soy may therefore be dependent upon the amounts of the various hormonally active phytochemicals present. We have identified increased biosynthesis of the isoflavonoid phytoalexin compounds, Glyceollins I, II and III, in soy plants grown under stressed conditions (elicited soy), which exhibit marked anti-estrogenic effects on ER function. Here we demonstrate that specific glyceollins, isolated from elicited soy, displayed anti-estrogenic activity, suppressing basal and estrogen stimulated colony formation of ER-positive estrogen dependent breast cancer cells and inhibiting ER-dependent gene expression of progesterone receptor (PgR) and stromal derived factor-1 (SDF1/CXCL12). Examining the effects of glyceollin on in vivo tumor formation/growth we demonstrate the ability of glyceollins to significantly suppress basal and estrogen-stimulated tumor growth of ER-positive MCF-7 breast and BG-1 ovarian carcinoma cells in ovariectomized female nude mice. We further demonstrate that the effects of glyceollins on suppression of tumor growth correlate with inhibition of estrogen stimulated PgR expression. In contrast to the uterotropic activity of tamoxifen the glyceollins displayed no uterine agonist activity. The Glyceollin (I-III) compounds may represent an important component of the health effects of soy as well as represent novel anti-estrogens useful in the prevention or treatment of breast and ovarian carcinoma.

Priority:

Inventor: CLEVELAND THOMAS E [US]; BOUE STEPHEN M [US]; BUROW MATTHEW E [US]; MCLACHLAN JOHN A [US]


Application No.: US20060246192A1  Published: 02/Nov/2006

Title: Use of debranched starch in extrusion-spheronization pharmaceutical pellets

Applicant/Assignee:

Application No.: 11/410375   Filing Date: 25/Apr/2006

Abstract:This patent pertains to the use of debranched starch in the preparation of pharmaceutical pellets by extrusion spheronization. Such excipients are useful in any dry dosage form, including tablets and capsules, for either immediate or sustained release.

Priority: US20050677182P Applic. Date: 2005-05-02

Inventor: DUKIC ALEKSANDRA [YU]; VERVAET CHRIS [BE]; REMON JEAN P [BE]; ALTIERI PAUL A [US]; FOREMAN PAUL B [US]


Application No.: US20060247221A1  Published: 02/Nov/2006

Title: Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy

Applicant/Assignee:

Application No.: 10/532320   Filing Date: 23/Oct/2003

Abstract:The present invention relates to a method of treating or preventing estrogen-suppressed tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (I) in which formula R1, R2, R3, R4, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms

precursors capable of liberating a substance according to the aforementioned formula when used in the present method

and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.

Priority: EP20020079414 Applic. Date: 2002-10-23; WO2003NL00718 Applic. Date: 2003-10-23

Inventor: COELINGH BENNINK HERMAN J T [NL]; BUNSCHOTEN EVERT J [NL]


Application No.: US20060251619A1  Published: 09/Nov/2006

Title: Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides

Applicant/Assignee:

Application No.: 11/429100   Filing Date: 04/May/2006

Abstract:Provided are modified interferon-gamma (IFN-gamma) polypeptides and methods of generating modified interferon-gamma polypeptides. Also provided are methods of treatment using modified interferon-gamma polypeptides.

Priority: US20050678031P Applic. Date: 2005-05-04; US20050733835P Applic. Date: 2005-11-04

Inventor: BORRELLY GILLES [FR]; GUYON THIERRY [FR]; DRITTANTI LILA [FR]


Application No.: US20060251656A1  Published: 09/Nov/2006

Title: New pharmaceutical compositions based on anticholinergics and anti-tnf antibodies

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 10/544235   Filing Date: 16/May/2006

Abstract:The present invention relates to novel pharmaceutical compositions based on anticholinergies and anti-TNF antibodies, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: EP20030002968 Applic. Date: 2003-02-11; WO2004EP01142 Applic. Date: 2004-02-07

Inventor: MEADE CHRISTOPHER J M [DE]; PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]


Application No.: US20060251679A1  Published: 09/Nov/2006

Title: Ferritin fusion proteins for use in vaccines and other applications

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 11/374066   Filing Date: 14/Mar/2006

Abstract:An isolated ferritin fusion protein is provided in which ferritin is fused with a protein or peptide capable of being fused to ferritin without interfering with the polymeric self-assembly of the resulting fusion protein, and the protein may be of the endocapsid form when fused at the C terminus or an exocapsid form when fused at the N terminus. These fusion proteins may self-assemble into a variety of useful higher polymeric forms, e.g., capsid or other polymeric aggregate, and they are advantageous in that they are useful in a variety of applications, including human and veterinary vaccines and therapeutics, blood substitutes, image contrast agents, metal chelating agents, gelling agents, protein purification platforms, and therapeutic receptor-binding proteins.

Priority: US2003-435666 Applic. Date: 2003-05-12; US20020379145P Applic. Date: 2002-05-10

Inventor: CARTER DANIEL C [US]; LI CHESTER Q [US]


Application No.: US20060252689A1  Published: 09/Nov/2006

Title: Factor VII or VIIa - Like Molecules

Applicant/Assignee: MAXYGEN HOLDINGS, LTD

Application No.: 11/426394   Filing Date: 26/Jun/2006

Abstract:Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.

Priority: DK20000000218 Applic. Date: 2000-02-11; US2004-950747 Applic. Date: 2004-09-27; US2001-782587 Applic. Date: 2001-02-12; US20000184036P Applic. Date: 2000-02-22; US20000241916P Applic. Date: 2000-10-18; DK20000001558 Applic. Date: 2000-10-18

Inventor: PEDERSEN ANDERS H [DK]; ANDERSEN KIM V [DK]; BORNAES CLAUS [DK]


Application No.: US20060252696A1  Published: 09/Nov/2006

Title: Pharmaceutical composition as solid dosage form and method for manufacturing thereof

Applicant/Assignee: FERRING B. V

Application No.: 11/486214   Filing Date: 14/Jul/2006

Abstract:The present invention relates to a novel pharmaceutical composition as a solid dosage form comprising desmopressin as a therapeutically active ingredient, and to a method for manufacturing thereof. The invention relates to a pharmaceutical composition as a solid dosage form comprising desmopressin, or a pharmaceutically acceptable salt thereof, as a therapeutically active ingredient together with a pharmaceutically acceptable excipient, diluent or carrier, or mixture thereof, wherein at least one of said excipient, diluent and carrier is a substance selected from a monosaccharide, disaccharide, oligosaccharide and a polysaccharide, wherein the said substance has an average particle size in the range of from 60 to 1,000 mum. A method according to the present invention provides an improved production of solid dosage forms of desmopressin.

Priority: US2003-425993 Applic. Date: 2003-04-30

Inventor: LOMRYD HAKAN [SE]; NICKLASSON HELENA [SE]; OLSSON LARS-ERIK [SE]


Application No.: US20060252745A1  Published: 09/Nov/2006

Title: Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use

Applicant/Assignee:

Application No.: 11/123205   Filing Date: 06/May/2005

Abstract:The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

Priority:

Inventor: ALMEIDA JOSE L D [PT]; SOARES-DA-SILVA PATRICIO MANUE [PT]


Application No.: US20060254583A1  Published: 16/Nov/2006

Title: Dry powder inhaler system

Applicant/Assignee:

Application No.: 10/549124   Filing Date: 17/Mar/2004

Abstract:An improved dry powder inhalation system comprising: at least one micronized active ingredient in an hydroxypropylmethylcellulose capsule ( 10 ), and an dry powder inhaler device equipped with piercing systems ( 12 ) having an equivalent diameter of not less than 0.8 mm.

Priority: WO2003BE00048 Applic. Date: 2003-03-20; WO2004BE00039 Applic. Date: 2004-03-17

Inventor: DEBOECK ARTHUR [US]; BAUDUER PHILIPPE [BE]


Application No.: US20060257327A1  Published: 16/Nov/2006

Title: Medical product

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/448773   Filing Date: 08/Jun/2006

Abstract:The invention discloses a medical product for use in a treatment of respiratory disorders, and comprises a metered dose of a tiotropium dry powder formulation, directly loaded and sealed into a container made to act as a dry high barrier seal to prevent the capture and ingress of moisture into the tiotropium powder. The dose of tiotropium is further adapted for inhalation and the container is so tight that the efficacy of the dose when delivered is unaffected by moisture. In a further aspect of the invention a type of inhaler is illustrated, which may accept at least one sealed, moisture-tight container of a dose of tiotropium, to deliver the dose with a consistent fine particle dose, over the expected shelf life of the product.

Priority: SE20030003269 Applic. Date: 2003-12-03; US2003-728986 Applic. Date: 2003-12-08

Inventor: ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]


Application No.: US20060257391A1  Published: 16/Nov/2006

Title: Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions

Applicant/Assignee: BAUSCH & LOMB INCORPORATED

Application No.: 11/126625   Filing Date: 11/May/2005

Abstract:A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

Priority:

Inventor: BARTELS STEPHEN P [US]; MCINTIRE GREGORY L [US]; COMSTOCK TIMOTHY L [US]; LEVY BRIAN [US]


Application No.: US20060257471A1  Published: 16/Nov/2006

Title: Pharmaceutical tablets of crystalline Type II aripiprazole

Applicant/Assignee:

Application No.: 11/377400   Filing Date: 17/Mar/2006

Abstract:Crystalline aripiprazole Type II can be formulated into pharmaceutical tablets having reduced dissolution profile variability upon storage.

Priority: US20050662552P Applic. Date: 2005-03-17; US20050692557P Applic. Date: 2005-06-22; US20050739640P Applic. Date: 2005-11-26

Inventor: ETTEMA GERRIT J [NL]; WESTHEIM RAYMOND J [NL]; KALMOUA FAYSAL [NL]; JANSEN KORINDE A [NL]; DORKOOSH FARID A [NL]


Application No.: US20060257475A1  Published: 16/Nov/2006

Title: Stable Sertraline Hydrochloride Formulation and Method

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/465427   Filing Date: 17/Aug/2006

Abstract:Pharmaceutically stable solid pharmaceutical dosage forms of sertraline hydrochloride Form II and Form V polymorphs formed by direct compression.

Priority:

Inventor: ECONOMOU JULIA [US]; MCPHILLIPS ANDREA M [US]; SMOLIGA JOHN A [US]; WILSON RANDALL S [US]


Application No.: US20060257482A1  Published: 16/Nov/2006

Title: Modified release, multiple unit drug delivery systems

Applicant/Assignee:

Application No.: 10/517101   Filing Date: 09/Jun/2003

Abstract:The invention relates to novel modified release multiple unit systems, and methods of preparing these systems, which can be easily compressed into tablets or filled into capsules or sachets without affecting the desired release characteristics of the pharmaceutical active ingredients incorporated within the systems. The multiple unit tablet includes multiple units. Each unit includes at least one core having an outer surface, a first coating layer surrounding at least a portion of the outer surface of the core and having an outer surface, one or more rate controlling polymers, and one or more one active pharmaceutical ingredients. The coating layer includes one or both of the one or more active pharmaceutical ingredients and the one or more rate controlling polymers. The tablet may further include an outer layer on the outer surface of the unit which includes a material that is one or both of elastic and compressible. The material may be a wax materials, such as polyethylene glycol's (PEGS).

Priority: IN2002DE00617 Applic. Date: 2002-06-07; IN2002DE01157 Applic. Date: 2002-11-15; IN2003DE00234 Applic. Date: 2003-03-06; WO2003IB02186 Applic. Date: 2003-06-09

Inventor: KUMAR PATRIK [IN]; JAIN GIRISH K [IN]; RAMPAL ASHOK [IN]; NITHYANANDAM RAVIKUMAR [IN]; RAGHUVANSHI RAJEEV S [IN]


Application No.: US20060257483A1  Published: 16/Nov/2006

Title: Controlled release bupropion dosage forms

Applicant/Assignee: ABRIKA PHARMACEUTICALS

Application No.: 11/125857   Filing Date: 10/May/2005

Abstract:A controlled release pharmaceutical dosage form comprising bupropion or pharmaceutically acceptable salt thereof.

Priority:

Inventor: YANG TIANRUN [US]; WENG TIMOTHY [US]


Application No.: US20060257494A1  Published: 16/Nov/2006

Title: Coated tablets

Applicant/Assignee:

Application No.: 11/492373   Filing Date: 24/Jul/2006

Abstract:Disclosed is a pharmaceutically acceptable oral dosage form comprising fenofibrate, phospholipid, a buffer salt, a water-soluble bulking agent selected from maltodextrin, mannitol, and combinations thereof, a cellulosic additive, beads or crystals of a pharmaceutically acceptable water-soluble excipient support material, a polyvinylpyrrolidone or crospovidone, croscarmellose sodium, granular mannitol, sodium dodecyl sulfate, silicon dioxide, and a stearate, wherein the fenofibrate is in the form of microparticles, and wherein at least a portion of the phospholipid is coated on the surfaces of the fenofibrate microparticles, the phospholipid coated microparticles are embedded in a matrix comprising the water-soluble bulking agent, phospholipid that is not coated on the microparticles, the buffer salt and the cellulosic additive, and the matrix is coated on up to 100% of the surfaces of the beads or crystals of the excipient support material.

Priority: US2003-428007 Applic. Date: 2003-05-02; US2001-838541 Applic. Date: 2001-04-20; US20020377237P Applic. Date: 2002-05-03; US20000234186P Applic. Date: 2000-09-20; US20000241761P Applic. Date: 2000-10-20

Inventor: VACHON MICHAEL [CA]; MISHRA AWADHESH K [US]; SNOW ROBERT A [US]; GUIVARC H POL-HENRI [CA]


Application No.: US20060258626A1  Published: 16/Nov/2006

Title: Use of inositol-tripyrophosphate in treating tumors and diseases

Applicant/Assignee:

Application No.: 11/396338   Filing Date: 31/Mar/2006

Abstract:Inositol-tripyrophosphate is an allosteric effector of hemoglobin due to its ability to cross the plasma membrane of red blood cells and deliver oxygen to solid tumors, by lowering the oxygen affinity of the hemoglobin of red blood cells. The present invention is directed to the use of inositol-tripyrophosphate to reduce hemoglobin's affinity for oxygen in circulating red blood cells. The present invention is further directed to the use of inositol-tripyrophosphate to inhibit angiogenesis and enhance radiation sensitivity of hypoxic tumors. The present invention is further directed to the use of inositol-tripyrophosphate for the treatment of various types of cancers, Alzheimer's disease, stroke and osteoporosis.

Priority: US2005-175979 Applic. Date: 2005-07-06; US2006-384012 Applic. Date: 2006-03-17; US20040585804P Applic. Date: 2004-07-06; US20050663491P Applic. Date: 2005-03-18

Inventor: NICOLAU CLAUDE [US]; GREFERATH RUTH [DE]; LEHN JEAN-MARIE [FR]; FYLAKTAKIDOU KONSTANTINA C [GR]


Application No.: US20060263340A1  Published: 23/Nov/2006

Title: Treating gastrointestinal diseases with modulators of retinoic acid

Applicant/Assignee:

Application No.: 11/413874   Filing Date: 28/Apr/2006

Abstract:T cells are programmed to target the gastrointestinal tract by activation with dendritic cells capable of producing and/or transporting retinoic acid. Methods for using the programmed dendritic cells and/or T and/or B cells to treat a variety of pathogens and infectious agents residing in the intestine are also disclosed. Similarly, inhibitors of retinoic acid synthesis by dendritic cells or other cells in the gut, and inhibitors of retinoic acid receptors in T and/or B cells or other cells in the intestinal mucosa, are disclosed for treating a variety of gastrointestinal autoimmune diseases such as inflammatory bowel disease and celiac disease.

Priority: US20050676249P Applic. Date: 2005-04-29

Inventor: ANDRIAN ULRICH H V [US]; MORA RODRIGO [US]


Application No.: US20060263397A1  Published: 23/Nov/2006

Title: Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same

Applicant/Assignee:

Application No.: 11/494131   Filing Date: 27/Jul/2006

Abstract:A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 per cent by weight of the drug, 5 to 60 per cent by weight of a surfactant, 10 to 40 per cent by weight of water

1 to 20 per cent by weight of unsaturated fatty acid ester, 0 to 50 per cent by weight water miscible pharmaceutically acceptable polyol and 1 to 10 per cent by weight of phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixture. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form.

Priority: US2002-317657 Applic. Date: 2002-12-12

Inventor: LI WENJI [US]; ALOSIO EDWARD [US]; DEMA-ALA BRICINI F [US]; NGUYEN AMY [US]


Application No.: US20060263429A1  Published: 23/Nov/2006

Title: Compressible mixture, compressed pharmaceutical compositions, and method of preparation thereof

Applicant/Assignee:

Application No.: 11/133864   Filing Date: 20/May/2005

Abstract:A compressible mixture prepared from a waxy filler, cellulose filler, or a mixture thereof and a disintegrant is disclosed for the preparation of compressed pharmaceutical compositions containing coated pellets. The resulting compressed compositions exhibit substantially the same dissolution profiles as the pellets in the absence of the compressible mixture.

Priority:

Inventor: FENG HENGSHENG [US]


Application No.: US20060263436A1  Published: 23/Nov/2006

Title: Antifungal compositions with improved bioavailability

Applicant/Assignee:

Application No.: 11/445849   Filing Date: 01/Jun/2006

Abstract:The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.

Priority: EP19960201430 Applic. Date: 1996-05-20; EP19970200698 Applic. Date: 1997-03-07; US2002-218851 Applic. Date: 2002-08-14; US1998-194480 Applic. Date: 1998-11-19; WO1997EP02507 Applic. Date: 1997-05-12

Inventor: BAERT LIEVEN E C [BE]; VERRECK GEERT [BE]; THONE DANY [BE]


Application No.: US20060264423A1  Published: 23/Nov/2006

Title: Methylene Blue Therapy of Viral Disease

Applicant/Assignee: BIOENVISION, INC

Application No.: 11/419426   Filing Date: 19/May/2006

Abstract:A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, alone or in combination with low levels of light or other drugs, to selectively inactivate or inhibit hepatitis infection, has been developed. Clinical trial results demonstrate efficacy in a human clinical trial for treatment of hepatitis C by oral administration of methylene blue immediate release formulation, in a dosage of 65 mg twice daily, over a period of at least 100 days. A method for using thiazine dyes, especially methylene blue or methylene blue derivatives, in an immediate or controlled release formulation, along or in combination with low levels of light or other drugs, to prevent or decrease reactivation of viruses, is also described. The preferred class of patient is infected with, or has been exposed to, viruses such as Herpes simplex virus type 1 & 2, Varicella zoster virus, Epstein-Barr virus, Cytomegalovirus, and Herpes virus type 6 & 7, Adenovirus, and Human polyoma viruses, e.g. JC virus and BK virus. In one embodiment the thiazine dye is administered to a patient experiencing symptoms or disease caused by reactivation of a virus. In a preferred embodiment the thiazine dye is administered to a patient at risk for or experiencing symptoms or disease caused by reactivation of a virus, prior to or during immunosuppression or chemotherapy.

Priority: US20050682891P Applic. Date: 2005-05-20; US20050718804P Applic. Date: 2005-09-20; US20050697094P Applic. Date: 2005-07-07; US20050720066P Applic. Date: 2005-09-23; US20050720147P Applic. Date: 2005-09-23; US20050720058P Applic. Date: 2005-09-23

Inventor: WOOD CHRISTOPHER [GB]; HABIB NAGY [EG]


Application No.: US20060269601A1  Published: 30/Nov/2006

Title: Oral modified release formulations containing 8-prenylnaringenin for continuous estrogen support

Applicant/Assignee:

Application No.: 11/366947   Filing Date: 02/Mar/2006

Abstract:This invention is directed to an oral modified release formulation of the phytoestrogen 8-prenylnaringenin and methods for the treatment of symptoms of estrogen deficiency.

Priority: EP20050090049 Applic. Date: 2005-03-02; EP20050076899 Applic. Date: 2005-08-12

Inventor: HUEMPEL MICHAEL [DE]; KRANZ HEIKO [DE]


Application No.: US20060269605A1  Published: 30/Nov/2006

Title: Multilayer pharmaceutical dosage form containing a substance that acts in a modulatory manner with regard to the release of active substances

Applicant/Assignee: ROEHM GMBH & CO. KG

Application No.: 10/572963   Filing Date: 21/Mar/2006

Abstract:The invention relates to a multilayer pharmaceutical dosage form for the controlled release of active substances, containing: a) a core layer containing a substance that acts in a modulatory manner with regard to the release of active substances, optionally a neutral core and/or an active substance

b) an inner control layer that influences the release of the substance that acts in a modulatory manner and of the optionally contained active substance from the core layer, containing pharmaceutically useable polymers, waxes, resins and/or proteins

c) an active substance layer containing a pharmaceutical active substance and, optionally, a substance that acts in a modulatory manner

d) an outer control layer containing a (meth)acrylate copolymer or a mixture consisting of a number of (meth)acrylate copolymers comprised of 98 to 85 C1-C4 alkyl esters of (meth)acrylic acid and 2 to 15% by weight of methacrylate monomers with a quaternary ammonium group in the alkyl radical and optionally containing pharmaceutically useable polymers that are insoluble in water, whereby the layers can contain, in addition and in a known manner, pharmaceutically conventional adjuvants.

Priority: DE20031053186 Applic. Date: 2003-11-13; WO2004EP10297 Applic. Date: 2004-09-15

Inventor: LIZIO ROSARIO [DE]; PETEREIT HANS-ULRICH [DE]; ASSMUS MANFRED [DE]; RAVISHANKAR HEMA [IN]


Application No.: US20060269607A1  Published: 30/Nov/2006

Title: Timed, sustained release systems for propranolol

Applicant/Assignee: EURAND, INC

Application No.: 11/500892   Filing Date: 09/Aug/2006

Abstract:A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.

Priority: US2003-453848 Applic. Date: 2003-06-02; US2002-334052 Applic. Date: 2002-12-30; US2001-971167 Applic. Date: 2001-10-04

Inventor: PERCEL PHILLIP J [US]; VISHNUPAD KRISHNA S [US]; VENKATESH GOPI M [US]


Application No.: US20060269608A1  Published: 30/Nov/2006

Title: Pharmaceutical formulation

Applicant/Assignee:

Application No.: 10/543289   Filing Date: 02/Feb/2004

Abstract:The present invention provides processes for making and forms of solid dispersions of pharmaceutical active ingredients.

Priority: US20030444602P Applic. Date: 2003-02-03; WO2004EP00925 Applic. Date: 2004-02-02

Inventor: ABU SHMEIS-ZIADEH RAMA A [US]; KOWALSKI JAMES [US]; KRILL STEVEN L [US]; PARTHIBAN LAKSHMAN J [US]; WANG ZEREN [US]


Application No.: US20060269622A1  Published: 30/Nov/2006

Title: Formulations and methods of administration of cephalotaxines, including homoharringtonine

Applicant/Assignee: CHEMGENEX PHARMACEUTICALS, INC

Application No.: 11/497739   Filing Date: 01/Aug/2006

Abstract:The present invention is directed to compositions and methods for the treatment of patients with cephalotaxines, for example, homoharringtonine. The invention is also directed to improvements in the purity, manufacturing process, formulation and administration of homoharringtonine for the treatment of cancer and other aberrant cellular diseases. The invention also provides methods and compositions for antiparasitic, antifungal, antiviral and antibacterial treatments.

Priority: US2003-617927 Applic. Date: 2003-07-10; US20020396926P Applic. Date: 2002-07-17

Inventor: BROWN DENNIS M [US]


Application No.: US20060269629A1  Published: 30/Nov/2006

Title: Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof

Applicant/Assignee: POMWONDERFUL LLC POM WONDERFUL, LLC

Application No.: 11/137248   Filing Date: 24/May/2005

Abstract:Processes for producing an extract containing phytochemicals from pomegranates are disclosed. The processes generally comprise providing pomegranate solids, such as the pericarp, inner membrane and seeds

creating a mixture comprising the pomegranate solids in an aqueous solution

adding enzymes to the mixture in an amount sufficient to at least partially degrade the pomegranate solids

heating the mixture to a temperature that permits the maximum rate of catalysis of the enzyme

maintaining the temperature of the heated mixture for a time sufficient to allow at least partial degradation of the pomegranate solids

and removing residual insoluble solid materials from the mixture. Compositions containing the extract may be used as a food product, beverage, pharmaceutical preparations, nutritional supplements, vitamin supplements, food additives, and food supplements.

The composition may also be used for preventing or ameliorating disease conditions by administering an effective amount of the composition to a subject in need thereof.

Priority:

Inventor: BATES BYRON [US]; FRITZ ERICH A [US]; HENIG YAIR S [US]; LIKER HARLEY R [US]


Application No.: US20060270717A1  Published: 30/Nov/2006

Title: Therapeutic combination

Applicant/Assignee:

Application No.: 11/499753   Filing Date: 07/Aug/2006

Abstract:This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

Priority: WO1998IB01225 Applic. Date: 1998-08-11; US2002-214058 Applic. Date: 2002-08-07; US2000-512914 Applic. Date: 2000-02-25; US19970057275P Applic. Date: 1997-08-29

Inventor: BUCH JAN [US]


Application No.: US20060275360A1  Published: 07/Dec/2006

Title: Oral dosage forms comprising progesterone and methods of making and using the same

Applicant/Assignee:

Application No.: 11/441447   Filing Date: 26/May/2006

Abstract:The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.

Priority: US20050684557P Applic. Date: 2005-05-26

Inventor: AHMED SALAH U [US]; DILIBERTI CHARLES E [US]; VATTIKONDA CHANDRA [US]; GORUKANTI SUDHIR R [US]; GUPTA SANJEEV K [US]


Application No.: US20060275362A1  Published: 07/Dec/2006

Title: Rapidly-dissolving pharmaceutical composition for inhibiting ovulation

Applicant/Assignee:

Application No.: 11/146314   Filing Date: 03/Jun/2005

Abstract:A rapidly-dissolving oral dosage pharmaceutical composition for inhibiting ovulation in a mammal, said composition comprising drospirenone or a pharmaceutically acceptable salt or ester thereof, optionally ethinyl estradiol or a pharmaceutically acceptable salt, ester or ether thereof, a surfactant and at least one pharmaceutically acceptable excipient, wherein the drospirenone has a surface area of less than 10,000 cm<2>/g.

Priority:

Inventor: DAVILA PABLO [US]; PANIAGUA MARCOS PAOLA H [ES]; PAJUELO BENITO L [ES]


Application No.: US20060275365A1  Published: 07/Dec/2006

Title: Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof

Applicant/Assignee:

Application No.: 11/447303   Filing Date: 06/Jun/2006

Abstract:The invention relates to immediate-release and high-drug-load solid pharmaceutical formulations comprising micronised (4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl] as well as pharmaceutically acceptable salts thereof.

Priority: EP20050090167 Applic. Date: 2005-06-07; US20050698522P Applic. Date: 2005-07-12

Inventor: BACKENSFELD THOMAS [DE]; JUERGENS KAI [DE]; WAGNER THORSTEN [DE]; FUNKE ADRIAN [DE]; THODE KAI [DE]; KRANZ HEIKO [DE]


Application No.: US20060276392A1  Published: 07/Dec/2006

Title: Treatments employing neuronal exocytosis-inhibiting peptides

Applicant/Assignee: LIPOTEC, S.A

Application No.: 11/327952   Filing Date: 09/Jan/2006

Abstract:The peptide has a sequence of 3 to 30 adjacent aminoacids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain said peptide and optionally one or more peptides from the carboxyl end of SNAP-25. Said compositions are suitable for the treatment of facial wrinkles and asymmetry and pathological neuronal exocytosis-mediated pathological disorders and alterations.

Priority: ES19990000844 Applic. Date: 1999-04-23; US2002-030485 Applic. Date: 2002-06-17; WO2000ES00058 Applic. Date: 2000-02-18

Inventor: MIRA MA C B [ES]; HERNANDEZ MA MERCEDES L [ES]; TEBAR ANA I G [ES]; BALLESTER GREGORIO J F [ES]; GUTIERREZ LUIS M [ES]; CASTELLO TERESA C [ES]; PAYA ENRIQUE P [ES]; CASES ROSA M P [ES]; MONTIEL ANTONIO V F [ES]; BOVER SALVADOR V [ES]


Application No.: US20060276441A1  Published: 07/Dec/2006

Title: Medicaments comprising steroids and a novel anticholinergic

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/407735   Filing Date: 20/Apr/2006

Abstract:A pharmaceutical composition comprising: (a) a salt of formula 1 wherein: X<-> is an anion with a single negative charge

and (b) a steroid 2, processes for preparing such pharmaceutical composition, and their use in the treatment of respiratory complaints.

Priority: DE20021016429 Applic. Date: 2002-04-12; US2003-391735 Applic. Date: 2003-03-19; US20020386790P Applic. Date: 2002-06-07

Inventor: BANHOLZER ROLF [DE]; MEISSNER HELMUT [DE]; MORSCHHAEUSER GERD [DE]; PIEPER MICHAEL P [DE]; POHL GERALD [DE]; REICHL RICHARD [DE]; SPECK GEORG [DE]; MEADE CHRISTOPHER J M [DE]; PAIRET MICHEL [DE]


Application No.: US20060276483A1  Published: 07/Dec/2006

Title: Aerosolized fluoroquinolones and uses thereof

Applicant/Assignee: MPEX PHARMACEUTICALS, INC

Application No.: 11/436875   Filing Date: 18/May/2006

Abstract:Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.

Priority: US20050682530P Applic. Date: 2005-05-18; US20050696160P Applic. Date: 2005-07-01; US20060773300P Applic. Date: 2006-02-13; US20060773301P Applic. Date: 2006-02-13

Inventor: SURBER MARK W [US]; BOSTIAN KEITH A [US]; DUDLEY MICHAEL N [US]; LOMOVSKAYA OLGA [US]; GRIFFITH DAVID C [US]


Application No.: US20060276500A1  Published: 07/Dec/2006

Title: COMPOSITIONS AND METHODS FOR TREATING NOCTURNAL ACID BREAKTHROUGH AND OTHER ACID RELATED DISORDERS

Applicant/Assignee:

Application No.: 11/380177   Filing Date: 25/Apr/2006

Abstract:The present invention relates to, inter alia, pharmaceutical compositions comprising an acid labile proton pump inhibitor and a buffering agent

to methods for manufacture of such compositions, and to use of such compositions in treating and preventing diseases and/or disorders.

Priority: US20050675123P Applic. Date: 2005-04-26

Inventor: PHILLIPS JEFFREY O [US]


Application No.: US20060276551A1  Published: 07/Dec/2006

Title: Exo-S-Mecamylamine Formulation and Use in Treatment

Applicant/Assignee:

Application No.: 11/278770   Filing Date: 05/Apr/2006

Abstract:A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer) atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder. Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome. Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.

Priority: US2003-441947 Applic. Date: 2003-09-23; US2001-882935 Applic. Date: 2001-06-15; WO1999US30153 Applic. Date: 1999-12-16; US19980112534P Applic. Date: 1998-12-16

Inventor: SHYTLE DOUGLAS [US]; SANBERG PAUL [US]; NEWMAN MARY [US]; SILVER ARCHIE A [US]


Application No.: US20060280798A1  Published: 14/Dec/2006

Title: Nanoparticles for delivery of a pharmacologically active agent

Applicant/Assignee: ISTITUTO SUPERIORE DI SANITA

Application No.: 10/577973   Filing Date: 26/Jun/2006

Abstract:Core-shell nanoparticles comprising: (a) a core which comprises a water insoluble polymer or copolymer, and (b) a shell which comprises a hydrophilic polymer or copolymer

said nanoparticles being obtainable by emulsion polymerization of a mixture comprising, in an aqueous solution, at least one water-insoluble styrenic, acrylic or methacrylic monomer and specific hydrophylic monomers or copolymers.

Priority: GB20030025625 Applic. Date: 2003-11-03; WO2004EP12420 Applic. Date: 2004-11-03

Inventor: ENSOLI BARBARA [IT]


Application No.: US20060280809A1  Published: 14/Dec/2006

Title: Anti-infective iodine based compositions for otic and nasal use

Applicant/Assignee:

Application No.: 11/452372   Filing Date: 14/Jun/2006

Abstract:Otic and nasal compositions containing any iodine-containing derivatives, including, free iodine and iodoform, are disclosed. lodoform is a potent germicidal agent which provides anti-infective benefits. The composition also contains one or more anti-inflammatory agents and one or more natural or synthetic compounds which provide analgesic benefits. The composition preferably also contains one or more natural or synthetic compounds which provides aromatic benefits. The composition may be utilized to treat otic and nasal conditions, including otitis media, by topically applying the composition to the affected tissue.

Priority: US20050689946P Applic. Date: 2005-06-14

Inventor: LESHCHINER ADELE K [US]; LARSEN NANCY E [US]; PARENT EDWARD G [US]


Application No.: US20060281072A1  Published: 14/Dec/2006

Title: Agonistic Binding Molecules to the Human OX40 Receptor

Applicant/Assignee: CRUCELL HOLLAND B.V

Application No.: 10/517941   Filing Date: 13/Dec/2004

Abstract:The present invention provides binding molecules, such as human binding molecules, that bind to and stimulate the human OX40-receptor. The invention also provides nucleic acids encoding such binding molecules. Methods for producing such binding molecules are also provided by the present invention. The binding molecules and nucleic acids are useful in the stimulation of human T-cells and can be used to enhance antigen-specific immune responses.

Priority: WO2002NL00389 Applic. Date: 2002-06-13; WO2003EP06341 Applic. Date: 2003-06-13

Inventor: BAKKER ALEXANDER BERTHOLD H [NL]


Application No.: US20060281152A1  Published: 14/Dec/2006

Title: Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity and process for their preparation

Applicant/Assignee:

Application No.: 11/440749   Filing Date: 24/May/2006

Abstract:Glycosaminoglycans derived from the K5 polysaccharide having high anticoagulant and antithrombotic activity obtained by a process comprising the preparation of the K5 polysaccharide from Escherichia coli, N-deacetilation/N-sulfation, C-5 epimerization, supersulfation, selective O-desulfation, selective 6-O sulfation and N-sulfation, wherein said epimerization is carried out using the glucuronosyl C-5 epimerase enzyme in solution or in immobilized form in presence of specific divalent cations.

Priority: IT2000MI00665 Applic. Date: 2000-03-30; US2002-240606 Applic. Date: 2002-12-21; WO2001EP03461 Applic. Date: 2001-03-27

Inventor: ZOPPETTI GIORGIO [IT]; ORESTE PASQUA [IT]; CIPOLLETTI GIOVANNI [IT]


Application No.: US20060281675A1  Published: 14/Dec/2006

Title: Somatogenic therapy using a 20kda placental variant of growth hormone

Applicant/Assignee: NEUREN PHARMACEUTICALS LIMITED

Application No.: 10/568573   Filing Date: 10/Aug/2006

Abstract:Embodiments of the present invention provide improved methods of treating conditions requiring human growth hormone (hGH) therapy, whereby the beneficial effects of hGH such as growth promotion and lipolysis are retained and unwanted properties are reduced or eliminated. In particular, it is directed at a method of treatment whereby the lactogenic side effects of hGH treatment are reduced. Said enhanced method includes the use of a growth hormone variant

20 kDa hGH-V in the treatment of conditions that are currently treated with hGH or that have the potential to be treated with hGH.

Priority: US20030496970P Applic. Date: 2003-08-20; WO2004US27187 Applic. Date: 2004-08-19

Inventor: GLUCKMAN PETER [NZ]; GILMOUR ROBERT S [GB]; VICKERS MARK H [NZ]; BREIER BERNHARD H H [NZ]


Application No.: US20060281716A1  Published: 14/Dec/2006

Title: Alkaloid formulations

Applicant/Assignee:

Application No.: 10/551203   Filing Date: 03/Mar/2005

Abstract:There is provided an alkaloid formulation comprising the reaction product of one or more alkaloids with one or more phosphate derivatives of one or more electron transfer agents.

Priority: AU20040901107 Applic. Date: 2004-03-03; AU20040904367 Applic. Date: 2004-08-03; WO2005AU00307 Applic. Date: 2005-03-03

Inventor: WEST SIMON M [AU]; OGRU ESRA [AU]; GIANELLO ROBERT [AU]


Application No.: US20060281887A1  Published: 14/Dec/2006

Title: PH-sensitive polymer

Applicant/Assignee: UNIVERSITE DE MONTREAL

Application No.: 11/476182   Filing Date: 28/Jun/2006

Abstract:A pH-sensitive polymer which has cytotoxic or membranolytic properties at pH values below pH 6.5. Carriers for natural or synthetic biomolecules or active pharmaceutical ingredients using such a pH-sensitive polymer.

Priority: DE20021019505 Applic. Date: 2002-04-30; DE20021020470 Applic. Date: 2002-05-07; US2004-510371 Applic. Date: 2004-10-05; WO2002EP11791 Applic. Date: 2002-10-22

Inventor: PETEREIT HANS-ULRICH [DE]; MEIER CHRISTIAN [DE]; SCHULTES KLAUS [DE]; YESSINE MARIE-ANDREE [CA]; LEROUX JEAN-CHRISTOPHE [CA]


Application No.: US20060286162A1  Published: 21/Dec/2006

Title: Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof

Applicant/Assignee: HELM AG

Application No.: 11/156576   Filing Date: 21/Jun/2005

Abstract:The present invention relates to an adsorbate, comprising an adsorbent and bicalutamide adsorbed on said adsorbent, a process for preparing same, and a pharmaceutical composition thereof.

Priority:

Inventor: GLANZER KLAUS [DE]


Application No.: US20060286163A1  Published: 21/Dec/2006

Title: PHARMACEUTICAL COMPOSITION OF TOPIRAMATE

Applicant/Assignee:

Application No.: 11/467298   Filing Date: 25/Aug/2006

Abstract:The invention is directed to a pharmaceutical composition of topiramate, an anticonvulsant which is useful for treating epilepsy. More specifically, the present invention provides a solid dosage formulation of topiramate intended primarily for use by pediatric patients, or for patients who have difficulty swallowing tablets. Processes for preparing the pharmaceutical composition are also described.

Priority: US2003-748764 Applic. Date: 2003-12-30; US1999-259718 Applic. Date: 1999-03-01; US19980076770P Applic. Date: 1998-03-04

Inventor: THAKUR MADHAV S [US]; KOTWAL PRAMOD M [US]; GIBBS IRWIN S [US]


Application No.: US20060286186A1  Published: 21/Dec/2006

Title: Method and means for improving bowel health

Applicant/Assignee:

Application No.: 11/417330   Filing Date: 02/May/2006

Abstract:A method and composition for improving one or more indicators of bowel health or metabolic health in a mammalian animal. This comprises the delivering to the gastrointestinal tract of the animal an effective amount of an altered wheat starch in the form of or derived from the grain of a wheat plant. The proportion of amylose in the starch of the grain is at least 30%.

Priority: AU20040907350 Applic. Date: 2004-12-30; US2005-324063 Applic. Date: 2005-12-30; US20050688944P Applic. Date: 2005-06-08

Inventor: BIRD ANTHONY R [AU]; MANN GULAY S [AU]; RAHMAN SADEQUR [AU]; REGINA AHMED [AU]; LI ZHONGYI [AU]; TOPPING DAVID L [AU]; MORELL MATTHEW K [AU]


Application No.: US20060287352A1  Published: 21/Dec/2006

Title: Modified release compositions comprising tacrolimus

Applicant/Assignee:

Application No.: 10/569862   Filing Date: 13/Jun/2006

Abstract:A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating

and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents

and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Priority: DK20030001232 Applic. Date: 2003-08-29; DK20030001837 Applic. Date: 2003-12-11; DK20040000079 Applic. Date: 2004-01-21; DK20040000463 Applic. Date: 2004-03-23; DK20040000467 Applic. Date: 2004-03-23; US20030529793P Applic. Date: 2003-12-15; WO2004DK00573 Applic. Date: 2004-08-30

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20060292186A1  Published: 28/Dec/2006

Title: Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs

Applicant/Assignee: NOVAGALI PHARMA SA

Application No.: 10/569316   Filing Date: 22/Feb/2006

Abstract:A pharmaceutical composition in a form of an anhydrous self-nanoemulsifying oily formulation comprising: one or more therapeutic agent(s) which have low solubility in water or are water-insoluble, vitamin E, one co-solvent selected from propylene glycol and ethanol and mixture thereof one surfactant selected from tyloxapol and from mixture of tyloxapol and TPGS, and optionally, a bioenhancer.

Priority: EP20030292141 Applic. Date: 2003-08-29; US20030498663P Applic. Date: 2003-08-29; WO2004IB03077 Applic. Date: 2004-08-27

Inventor: GARRIGUE JEAN-SEBASTIEN [FR]; LAMBERT GREGORY [FR]; RAZAFINDRATSITA ALAIN [FR]; BENITA SIMON [FR]; YANG SHICHENG [US]; GURSOY NESLIHAN [IL]


Application No.: US20060292224A1  Published: 28/Dec/2006

Title: Pharmaceutical composition

Applicant/Assignee:

Application No.: 10/541786   Filing Date: 09/Jan/2004

Abstract:This invention relates to pharmaceutical formulations comprising particles with a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule. The invention also relates to methods of forming particles comprising a substantially non-hygroscopic inner crystalline core and an outer coating comprising at least one bioactive molecule.

Priority: GB20030000427 Applic. Date: 2003-01-09; WO2004GB00044 Applic. Date: 2004-01-09

Inventor: MOORE BARRY D [GB]; PARKER MARIE C [GB]; PARTRIDGE JOHANN [GB]; VOS JAN [GB]; KREINER MICHAELA M [GB]; STEVEN HOWARD N E [GB]; FLORES MARIA V [GB]; ROSS ALISTAIR [GB]


Application No.: US20060293293A1  Published: 28/Dec/2006

Title: Salmeterol and ciclesonide combination

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 10/556863   Filing Date: 15/Nov/2005

Abstract:The invention relates to pharmaceutical compositions containing combinations of salmeterol and ciclesonide and the use of such pharmaceutical compositions in medicine, in particular, the prophylaxis and treatment of respiratory disease.

Priority: US20030472466P Applic. Date: 2003-05-22; WO2004EP50846 Applic. Date: 2004-05-19

Inventor: MULLER HELGERT [DE]; SHAH TUSHAR P [US]


Application No.: US20060293499A1  Published: 28/Dec/2006

Title: Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates

Applicant/Assignee:

Application No.: 11/454971   Filing Date: 16/Jun/2006

Abstract:The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. The conjugates as well as the polymeric reagents used to form the conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.

Priority: US20050691516P Applic. Date: 2005-06-16; US20050705968P Applic. Date: 2005-08-04; US20050751082P Applic. Date: 2005-12-16; US20050751121P Applic. Date: 2005-12-16; US20050752825P Applic. Date: 2005-12-21

Inventor: BENTLEY MICHAEL D [US]; CULBERTSON SEAN [US]; MCMANUS SAMUEL P [US]


Application No.: US20070003487A1  Published: 04/Jan/2007

Title: Composition, method and pharmaceutical preparation for pharmaceutical spray suspensions

Applicant/Assignee:

Application No.: 10/553389   Filing Date: 16/Apr/2004

Abstract:A pharmaceutical composition, constituting a spray suspension includes at least one liquid excipient and at least one solid excipient substantially insoluble in the liquid excipient, and at least one pharmaceutical active ingredient. A method of preparing porous suspension particles includes: a) wet-milling or dry-milling the solid excipient(s) or a mixture of at least one active ingredient and a solid excipient(s) in a milling equipment inducing essentially compression and shear forces, resulting in fine particulate quality, where more than 90% by weight is smaller than 5 m

b) drying and aggregating the product of step a) alone or with the addition of at least one active ingredient, in fine particulate form, which will produce essentially isodiametrical aggregate particles. A suspension particles obtainable by the method pharmaceutical preparation, utilising the composition or porous suspension particles and a method for treatment of disorders using the preparation are disclosed.

Priority: US20030463326P Applic. Date: 2003-04-17; WO2004SE00591 Applic. Date: 2004-04-16

Inventor: EK RAGNAR [SE]


Application No.: US20070003541A1  Published: 04/Jan/2007

Title: Methods and compositions for therapeutics

Applicant/Assignee:

Application No.: 11/257928   Filing Date: 24/Oct/2005

Abstract:The invention encompasses composition and methods for cell culture and for therapeutic and cosmetic use. The compositions and methods utilize collagenase, e.g., bacterial collagenase, other isolated collagenase, or synthetic collagenase, e.g., recombinant collagenase. One form of collagenase that can be used in some embodiments of the invention is matrix metalloproteinase-1. The compositions and methods of the invention also optionally utilize a cAMP-elevating agent.

Priority: US20050695956P Applic. Date: 2005-07-01

Inventor: FAUDOA RODOLFO [US]; MEDINA MARIA L [US]


Application No.: US20070003585A1  Published: 04/Jan/2007

Title: Topical skin treating compositions

Applicant/Assignee: STIEFEL LABORATORIES, INC

Application No.: 11/476558   Filing Date: 29/Jun/2006

Abstract:Topical compositions and methods of using same for treating various skin disorders or conditions. In a particular aspect, these compositions comprise a storage-stable mixture of a benzoyl peroxide-containing composition, an antibiotic or a pharmaceutically acceptable salt or ester thereof, and a retinoid or a pharmaceutically acceptable salt thereof. In an alternative embodiment, these compositions comprise a storage-stable mixture of a retinoid or a pharmaceutically acceptable salt thereof and either a benzoyl peroxide-containing composition or an antibiotic or a pharmaceutically acceptable salt or ester thereof.

Priority: US20050694799P Applic. Date: 2005-06-29

Inventor: CLARK KATHLEEN L [US]; REYNOLDS JEFFREY S [US]


Application No.: US20070003617A1  Published: 04/Jan/2007

Title: Morphine controlled release system

Applicant/Assignee: EGALET A/S

Application No.: 10/550453   Filing Date: 26/Mar/2004

Abstract:A composition for controlled release of an opioid from a pharmaceutical composition, the method comprises controlling the release of at least one opioid into an aqueous medium by erosion of at least one surface of a pharmaceutical composition comprising I) a matrix composition comprising a) polymer or a mixture of polymers, b) an opioid and, optionally, c) one or more pharmaceutically acceptable excipients, and (i) a coating. The matrix composition has a conus-like shape so the surface area exposed to the aqueous medium increases at least during initial erosion of the matrix composition, and the dissolution of the opioid-when tested in a Dissolution Test as described herein with or without application of sinkers-results in a zero order release of at least 80% of the opioid contained in the composition. Such compositions are especially suitable for controlled release of an opioid to obtain a delayed pead concentration and a prolonged therapeutically effective plasma concentration upon oral administration. Once or twice daily administration is possible. The matrix typically comprises PEO and the active substance is typically an opioid such as morphine or a glucuronide thereof.

Priority: DK20030000463 Applic. Date: 2003-03-26; WO2004DK00215 Applic. Date: 2004-03-26

Inventor: FISCHER GINA [DK]; BAR-SHALOM DAMEL [DK]; SLOT LILLIAN [DK]; ANDERSEN CHRISTINE [DK]


Application No.: US20070003626A1  Published: 04/Jan/2007

Title: Sterile in-situ microcarrier forming gelled polymeric dispersions and processes to manufacture the same

Applicant/Assignee:

Application No.: 10/574233   Filing Date: 31/Mar/2006

Abstract:These inventions is in the field of drug delivery systems comprising of sterile gelling agents and in-situ polymeric gelled dispersions which maybe microparticulate for parentral administration and contain a therapeutically active component. They may release the active agent immediately or over a period of time.

Priority: WO2004IB00003 Applic. Date: 2004-01-06

Inventor: HENDRIX DANIEL [DE]


Application No.: US20070004623A1  Published: 04/Jan/2007

Title: Use of hydroxylated amino acids for treating diabetes

Applicant/Assignee: INNODIA INC

Application No.: 10/577512   Filing Date: 10/Jul/2006

Abstract:This invention relates to methods and compositions for treating diabetes, which involve the use of hydroxylated amino acids, such as 4-hydroxyisoleucine, and one or more additional antidiabetic agents.

Priority: US20030514738P Applic. Date: 2003-10-27; WO2004CA01883 Applic. Date: 2004-10-27

Inventor: BELLINI FRANCESCO [CA]; VEZEAU CLAUDE [CA]; RIBES GERARD [FR]; CHAPAL NICOLAS [CA]; PRENTKI MARK [CA]


Application No.: US20070004653A1  Published: 04/Jan/2007

Title: Stable lyophilized anthracycline glycosides

Applicant/Assignee:

Application No.: 11/433026   Filing Date: 11/May/2006

Abstract:The present invention provides lyophilized and stable lyophilized anthracycline glycoside salts, in particular, the hydrochloride salt. Also, the present invention provides methods of stabilizing these anthracycline glycoside salts, and methods for producing stable lyophilized anthracycline glycoside salts, such as for example the antineoplastic compound idarubicin hydrochloride, or the compounds doxorubicin hydrochloride, and epirubicin hydrochloride.

Priority: US20050680139P Applic. Date: 2005-05-11

Inventor: AROSIO ROBERTO [IT]; VILLA MARCO [IT]; AMATI SIMONETTA [IT]


Application No.: US20070004693A1  Published: 04/Jan/2007

Title: Estrogen compositions for vaginal administration

Applicant/Assignee: WARNER CHILCOTT COMPANY INC

Application No.: 11/454473   Filing Date: 16/Jun/2006

Abstract:Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.

Priority: US20050691440P Applic. Date: 2005-06-16

Inventor: WOOLFSON DAVID [IE]; GILLIGAN CLAIRE [IE]


Application No.: US20070004694A1  Published: 04/Jan/2007

Title: Estrogen compositions for vaginal administration

Applicant/Assignee: WARNER CHILCOTT COMPANY INC

Application No.: 11/454697   Filing Date: 16/Jun/2006

Abstract:Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.

Priority: US20050691442P Applic. Date: 2005-06-16

Inventor: WOOLFSON DAVID [IE]; MALCOLM KARL [IE]


Application No.: US20070004795A1  Published: 04/Jan/2007

Title: Antidepressant oral pharmaceutical compositions

Applicant/Assignee:

Application No.: 11/158158   Filing Date: 21/Jun/2005

Abstract:The invention provides a pharmaceutical composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof and at least one buffering agent. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg

and the buffering agent is present in an amount of approximately 0.1 mEq to approximately 2.5 mEq per mg of duloxetine. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.

Priority:

Inventor: SESHA RAMESH [US]


Application No.: US20070009491A1  Published: 11/Jan/2007

Title: Platelet-derived growth factor-responsive neural precursor cells and progeny thereof

Applicant/Assignee: STEM CELL THERAPEUTICS CORP

Application No.: 11/292326   Filing Date: 01/Dec/2005

Abstract:This invention provides platelet-derived growth factor-responsive neural precursor (PRP) cells and methods of producing such cells in vivo or in vitro. These cells can further be used to generate neurons, oligodendrocytes and/or astrocytes.

Priority: US20040632751P Applic. Date: 2004-12-01; US20050738735P Applic. Date: 2005-11-21

Inventor: WEISS SAMUEL [CA]; CHOJNACKI ANDREW [CA]


Application No.: US20070009564A1  Published: 11/Jan/2007

Title: Drug/polymer composite materials and methods of making the same

Applicant/Assignee:

Application No.: 11/158724   Filing Date: 22/Jun/2005

Abstract:A method of forming a drug/polymer composite material is carried out by combining a drug material with a polymer material under pressure in the presence of a compressed gas solvent (e.g., carbon dioxide) to form the drug/polymer composite material. Drug/polymer composite materials and shaped articles (e.g., subcutaneous drug depots) which may be produced by a process are also described, along with methods of use thereof.

Priority:

Inventor: MCCLAIN JAMES B [US]; DEYOUNG JAMES P [US]


Application No.: US20070009589A1  Published: 11/Jan/2007

Title: EXTENDED RELEASE COMPOSITIONS

Applicant/Assignee:

Application No.: 11/428936   Filing Date: 06/Jul/2006

Abstract:Pharmaceutical compositions of metoprolol or a salt have water-insoluble inorganic cores such as dibasic calcium phosphate having the drug deposited thereon, optionally with one or more hydrophilic or hydrophobic polymers or mixtures thereof, and an outer coating of a polymer blend utilizing groups of polymers having opposing wettability characteristics.

Priority: IN2005CH00889 Applic. Date: 2005-07-07; US20050718785P Applic. Date: 2005-09-20

Inventor: RAGHUPATHI KANDARAPU [IN]; PASHA MOHAMMAD B [IN]; NASARE VIJAY D [IN]; BHUSHAN INDU [IN]; MOHAN MAILATUR S [IN]


Application No.: US20070009596A1  Published: 11/Jan/2007

Title: Controlled drug release composition resistant to in vivo mechanic stress

Applicant/Assignee:

Application No.: 10/556734   Filing Date: 14/Nov/2005

Abstract:The controlled release units of the present invention are capable of maintaining the drug/s sustained release properties along the gastro-intestinal tract without losing their mechanical resistance induced by the in vivo peristalsis. The formulations object of the present invention are based on a matrix consisting in a glyceryl ester in combination with ethers of cellulose. Such a matrix composition further incorporates the drug/s. The matrix units of the present invention may be obtained by known granulation methods or by direct compression according to the rheological properties of the drug/s. The drug release profile in vitro matches very well with release in vivo, i.e. the controlled release matrix is not damaged by in vivo peristalsis. The present compositions show good drug release properties, even at very early stages after administration, and ensure a constant and complete release of drug within acceptable times.

Priority: IE20030000366 Applic. Date: 2003-05-14; WO2004EP50814 Applic. Date: 2004-05-14

Inventor: BRUSCHI STEFANO D L [IT]; PENGO SERGIO [IT]


Application No.: US20070009598A1  Published: 11/Jan/2007

Title: Sustained-release microgranules containging gingko biloba extract and the process for manufacturing these

Applicant/Assignee: ETHYPHARM

Application No.: 10/574923   Filing Date: 19/May/2006

Abstract:The subject of the present invention is a new stable herbal drug formulation in the form of sustained-release microgranules containing Gingko Biloba extract as well as the process for preparing it.

Priority: EP20030292512 Applic. Date: 2003-10-10; WO2004IB03542 Applic. Date: 2004-10-11

Inventor: MARECHAL DOMINIQUE [CA]


Application No.: US20070009603A1  Published: 11/Jan/2007

Title: Compositions comprising fenofibrate and atorvastatin

Applicant/Assignee:

Application No.: 10/988917   Filing Date: 15/Nov/2004

Abstract:The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compositions are manufactured without any need of addition of water or aqueous medium and comprise at least 80% of the active substances fenofibrate and atorvastatin in dissolved form, or, optionally, atorvastatin in micronized form, in order to ensure suitable bioavailability.

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; WO2004DK00668 Applic. Date: 2004-10-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20070010517A1  Published: 11/Jan/2007

Title: Pharmaceutical salts of reboxetine

Applicant/Assignee:

Application No.: 10/588808   Filing Date: 08/Aug/2006

Abstract:The present invention relates to novel crystalline, water-soluble salts of the 2S,3S enantiomer of reboxetine, which are the fumarate and succinate salts thereof, to a process for their preparation, to their utility in therapy and to pharmaceutical corn-positions containing them.

Priority: EP20020077366 Applic. Date: 2002-06-17; WO2003EP05261 Applic. Date: 2003-06-04

Inventor: AIROLDI ANNALISA [IT]; MARTINI ALESSANDRO [IT]; ZAMPIERI MASSIMO [IT]


Application No.: US20070010525A1  Published: 11/Jan/2007

Title: Method and compositions for modulating neuropeptide hormone secretion

Applicant/Assignee:

Application No.: 11/475010   Filing Date: 27/Jun/2006

Abstract:Methods for increasing the release of oxytocin or vasopressin or both from the posterior pituitary of a mammal in need thereof, comprising administering to the mammal an effective amount of a cyclic guanosine 3',5'-monophosphate phosphodiesterase type five (cGMP PDE5) inhibitor to the mammal. The method is particularly useful to treat pregnant female or postnatal mammal wherein labor, fetal expulsion, or milk let-down or production needs to be induced, enhanced or augmented. Also provided are pharmaceutical compositions suitable for the inventive method.

Priority: US20050693939P Applic. Date: 2005-06-27

Inventor: JACKSON MEYER [US]


Application No.: US20070014846A1  Published: 18/Jan/2007

Title: PHARMACEUTICAL COMPOSITIONS COMPRISING FENOFIBRATE AND ATORVASTATIN

Applicant/Assignee: LIFECYCLE PHARMA A/S

Application No.: 11/456566   Filing Date: 11/Jul/2006

Abstract:Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compositions are manufactured without any need of addition of water or aqueous medium. Atorvastatin is optionally provided as a controlled release or a delayed release formulation resulting in a maintained LDL-lowering effect at a reduced dosage, and fenofibrate is provided in a formulation having increasing bioavailability and reduced food effect.

Priority: DK20030001503 Applic. Date: 2003-10-10; DK20040000464 Applic. Date: 2004-03-23; DK20040001506 Applic. Date: 2004-10-01; DK20040001761 Applic. Date: 2004-11-15; DK20050000196 Applic. Date: 2005-02-09; DK20050000534 Applic. Date: 2005-04-13; WO2005DK05001 Applic. Date: 2005-10-03; WO2005DK05004 Applic. Date: 2005-10-03; US2004-988917 Applic. Date: 2004-11-15; WO2004DK00668 Applic. Date: 2004-10-01; US20060790449P Applic. Date: 2006-04-07

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20070014853A1  Published: 18/Jan/2007

Title: Pharmaceutical dosage form containing novel pharmaceutical granulate

Applicant/Assignee:

Application No.: 11/181821   Filing Date: 15/Jul/2005

Abstract:One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture

(b) drying the combined mixture of step (a)

and (c) comminuting the product of step (b) to obtain the granulate.

Priority:

Inventor: ZALIT ILAN [IL]; HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]; SHALOM-KLEIN SAGIT [IL]


Application No.: US20070014854A1  Published: 18/Jan/2007

Title: Novel granulation process

Applicant/Assignee:

Application No.: 11/181822   Filing Date: 15/Jul/2005

Abstract:One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture

(b) drying the combined mixture of step (a)

and (c) comminuting the product of step (b) to obtain the granulate.

Priority:

Inventor: ZALIT ILAN [IL]; HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]; SHALOM-KLEIN SAGIT [IL]


Application No.: US20070014857A1  Published: 18/Jan/2007

Title: PHARMACEUTICAL FORMULATION HAVING A MASKED TASTE AND METHOD FOR THE PRODUCTION THEREOF

Applicant/Assignee: AVENTIS PHARMA S.A

Application No.: 11/533573   Filing Date: 20/Sep/2006

Abstract:The invention relates to a pharmaceutical formulation in the form of a powder which is administered orally in an aqueous suspension, having a masked taste, and comprising at least one cellulose polymer, a methacrylic polymer and an active ingredient which is distributed in a homogeneous manner in a molecular state in an atomized matrix, in addition to an alkaline agent and an adsorbing agent, a method for the production thereof and a method for masking the taste of pharmaceutical products.

Priority: FR20010008157 Applic. Date: 2001-06-21; US2003-735538 Applic. Date: 2003-12-12; WO2002FR02158 Applic. Date: 2002-06-21

Inventor: BECOURT PHILIPPE [FR]; CHAUVIN JOSIANE [FR]; SCHWABE DETLEV [DE]


Application No.: US20070014864A1  Published: 18/Jan/2007

Title: Novel pharmaceutical granulate

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES, LTD

Application No.: 11/181820   Filing Date: 15/Jul/2005

Abstract:One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar, wherein the active pharmaceutically ingredient has a water solubility less than about 20 mg/ml. The at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar is selected from the group consisting of disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The at least one pharmaceutically acceptable sugar is preferably selected from pyranosyl pyranoses, such as lactose. Another object of the invention relates to a process for preparing a pharmaceutical granulate, comprising (a) combining an API having poor water solubility with a solution comprising at least one pharmaceutically acceptable sugar, for example a pyranosyl pyranose such as lactose, and a solvent, and optionally at least one pharmaceutically acceptable excipient other than the at least one pharmaceutically acceptable sugar to form a combined mixture

(b) drying the combined mixture of step (a)

and (c) comminuting the product of step (b) to obtain the granulate.

Priority:

Inventor: ZALIT ILAN [IL]; HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]; SHALOM-KLEIN SAGIT [IL]


Application No.: US20070015721A1  Published: 18/Jan/2007

Title: Hiv-gag codon-optimised dna vaccines

Applicant/Assignee:

Application No.: 10/490011   Filing Date: 25/Oct/2004

Abstract:The invention provides a nucleotide sequence that encodes an HIV-1 gag protein or fragment thereof containing a gag epitope and a second HIV antigen or a fragment encoding an epitope of said second HIV antigen, operably linked to a heterologous promoter. Preferred polynucleotide sequences further encodes nef or a fragment thereof and RT or a fragment thereof.

Priority: WO2001GB04207 Applic. Date: 2001-09-20; GB20010029604 Applic. Date: 2001-12-11; GB20020006462 Applic. Date: 2002-03-19; WO2002EP10592 Applic. Date: 2002-09-18

Inventor: BEATON ANDREW [US]; ERTL PETER F [GB]; GOUGH GERALD W [GB]; LEAR ANDREW [GB]; TITE JOHN P [GB]; VAN WELY CATHERINE A [GB]


Application No.: US20070015833A1  Published: 18/Jan/2007

Title: Formulations of fenofibrate containing menthol

Applicant/Assignee:

Application No.: 11/182777   Filing Date: 18/Jul/2005

Abstract:The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with menthol, optionally in the presence of at least one surfactant mixture. The invention also provides a method for the treatment of elevated levels of triglycerides in a subject, comprising administering to the subject a composition comprising a therapeutically effective amount of fenofibrate or another fibrate drug and menthol, wherein the fenofibrate or the other fibrate drug is in intimate association with the menthol, wherein the menthol can be menthol or menthol surfactant mixture.

Priority:

Inventor: FLASHNER-BARAK MOSHE [IL]; LERNER E I [IL]; ROSENBERGER VERED [IL]; MOLDAVSKI NAOMI [IL]


Application No.: US20070015834A1  Published: 18/Jan/2007

Title: Formulations of fenofibrate containing PEG/Poloxamer

Applicant/Assignee:

Application No.: 11/182778   Filing Date: 18/Jul/2005

Abstract:The invention provides at least a composition for the treatment of elevated levels of triglycerides, comprising a therapeutically effective amount of fenofibrate or another fibrate drug intimately associated with a polyethylene glycol and a poloxamer, preferably PEG 1000 and Poloxamer 407. The invention also provides a method for the treatment of elevated levels of triglycerides in a subject, comprising administering to the subject the fenofibrate composition of the invention.

Priority:

Inventor: FLASHNER-BARAK MOSHE [IL]; LERNER E I [IL]; ROSENBERGER VERED [IL]; MOLDAVSKI NAOMI [IL]


Application No.: US20070020198A1  Published: 25/Jan/2007

Title: Medical product containing tiotropium

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/448766   Filing Date: 08/Jun/2006

Abstract:The invention discloses a medical product that may be used in a treatment of respiratory disorders.

Priority: SE20030003269 Applic. Date: 2003-12-03; SE20030003571 Applic. Date: 2003-12-22; US2004-921192 Applic. Date: 2004-08-19

Inventor: NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]


Application No.: US20070020329A1  Published: 25/Jan/2007

Title: Methods of formulating linezolid

Applicant/Assignee:

Application No.: 11/333906   Filing Date: 17/Jan/2006

Abstract:A method of formulating linezolid to provide a pharmaceutical composition comprising linezolid wherein the linezolid is linezolid Form IV substantially free of linezolid Form II, a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II and povidone, methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV substantially free of linezolid Form II, and methods of treating a condition responsive to linezolid in a patient comprising administering to the patient a solid pharmaceutical composition comprising linezolid form IV and povidone.

Priority: US20050701438P Applic. Date: 2005-07-20

Inventor: TENENGAUZER RUTH [IL]; LEIBOVICI MINUTZA [IL]; SOLOMON BEN-ZION [IL]


Application No.: US20070020332A1  Published: 25/Jan/2007

Title: Tannate compositions, methods of making and methods of use

Applicant/Assignee:

Application No.: 11/501649   Filing Date: 09/Aug/2006

Abstract:Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.

Priority: US2004-921438 Applic. Date: 2004-08-19; US2002-119285 Applic. Date: 2002-04-09; US2002-269027 Applic. Date: 2002-10-10; US20010282969P Applic. Date: 2001-04-10; US20010328990P Applic. Date: 2001-10-12

Inventor: KIEL JEFFREY S [US]; THOMAS H G [US]; MANI NARASIMHAN [US]


Application No.: US20070020333A1  Published: 25/Jan/2007

Title: Controlled release of hypnotic agents

Applicant/Assignee:

Application No.: 11/186348   Filing Date: 20/Jul/2005

Abstract:The application relates to the controlled release of a hypnotic agent with extended release profiles. The pharmaceutical composition and processes for manufacturing, and methods of using the controlled release formulation are provided.

Priority:

Inventor: CHIANG CHIN-CHIH [US]; CHANG TING-WEI [TW]


Application No.: US20070020334A1  Published: 25/Jan/2007

Title: Benzimidazole formulation

Applicant/Assignee:

Application No.: 11/483736   Filing Date: 11/Jul/2006

Abstract:A dry manufacturing process for the production of a pharmaceutical formulation of a benzimidazole and an alkaline substance is described. A tablet is compressed directly from a dry powder or a dry particulate matter avoiding any liquid or excipient conventionally used as a wet binder. The manufacturing process has the advantage of being simple and cost efficient. At the same time an expensive drying step is superfluous. The resulting pharmaceutical formulation has a good stability and a good dissolution profile.

Priority: DK20050001019 Applic. Date: 2005-07-11; US20050727855P Applic. Date: 2005-10-19

Inventor: BERTELSEN POUL [DK]; OLSEN PEDER M [DK]


Application No.: US20070021333A1  Published: 25/Jan/2007

Title: Pharmaceutical compositions based on anticholinergics and soluble tnf receptor fusion proteins

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 10/544250   Filing Date: 07/Feb/2004

Abstract:The present invention relates to novel pharmaceutical compositions based on anticholinergics and soluble TNF receptor fusion proteins, processes for preparing them and their use in the treatment of respiratory diseases.

Priority: EP20030002975 Applic. Date: 2003-02-11; WO2004EP01143 Applic. Date: 2004-02-07

Inventor: MEADE CHRISTOPHER J M [DE]; PIEPER MICHAEL P [DE]; PAIRET MICHEL [DE]


Application No.: US20070021499A1  Published: 25/Jan/2007

Title: CRYSTALLINE BASE OF ESCITALOPRAM AND ORODISPERSIBLE TABLETS COMPRISING ESCITALOPRAM BASE

Applicant/Assignee: H. LUNDBECK A/S

Application No.: 11/425522   Filing Date: 21/Jun/2006

Abstract:The present invention relates to the crystalline base of the well known antidepressant drug escitalopram, S-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, formulations of said base, a process for the preparation of purified salts of escitalopram, such as the oxalate, using the base, the salts obtained by said process and formulations containing such salts, and a process for the preparation of purified escitalopram free base or salts of escitalopram, such as the oxalate, using the hydrobromide, the salts obtained by said process and formulations containing such salts.

Finally the present invention relates to an orodispersible tablet having a hardness of at least 22 N and an oral-disintegration time of less than 120 s and comprising an active pharmaceutical ingredient adsorbed onto a water soluble filler wherein the active pharmaceutical ingredient has a melting point in the range of 40-100 DEG C., as well as a method for making such an orodispersible tablet.

Priority: US20050693214P Applic. Date: 2005-06-22

Inventor: DANCER ROBERT [DK]; PETERSEN HANS [DK]; NIELSEN OLE [DK]; ROCK MICHAEL H [DK]; ELIASEN HELLE [DK]; LILJEGREN KEN [DK]


Application No.: US20070025923A1  Published: 01/Feb/2007

Title: Use of ciclesonide for the treatment of respiratory diseases

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 10/571311   Filing Date: 09/Mar/2006

Abstract:The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.

Priority: US20030502984P Applic. Date: 2003-09-16; WO2004EP52172 Applic. Date: 2004-09-15

Inventor: WURST WILHELM [DE]; BETHKE THOMAS [DE]; ENGELSTAETTER RENATE [DE]


Application No.: US20070025956A1  Published: 01/Feb/2007

Title: Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs

Applicant/Assignee: NEKTAR THERAPEUTICS AL, CORPORATION

Application No.: 11/454998   Filing Date: 15/Jun/2006

Abstract:Provided herein are water-soluble polymer conjugates and polymer-based compositions of non-steroidal anti-inflammatory drugs. Also provided are methods for synthesizing and administering such conjugates and compositions.

Priority: US20050691846P Applic. Date: 2005-06-17

Inventor: BURTON KEVIN [US]; ZHAO XUAN [CN]; BENTLEY MICHAEL [US]


Application No.: US20070026065A1  Published: 01/Feb/2007

Title: Solid, modified-release pharmaceutical dosage forms which can be administered orally

Applicant/Assignee: BAYER HEALTHCARE AG

Application No.: 11/317720   Filing Date: 23/Dec/2005

Abstract:The present invention relates to solid, modified-release pharmaceutical dosage forms which can be administered orally and comprise 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide, and process for their production, their use as medicaments, their use for the prophylaxis, secondary prophylaxis and/or treatment of disorders, and their use for producing a medicament for the prophylaxis, secondary prophylaxis and/or treatment of disorders.

Priority: DE200410062475 Applic. Date: 2004-12-24

Inventor: BENKE KLAUS [DE]; HENCK JAN-OLAV [US]


Application No.: US20070026072A1  Published: 01/Feb/2007

Title: Benzoquinones of enhanced bioavailability

Applicant/Assignee:

Application No.: 11/495991   Filing Date: 28/Jul/2006

Abstract:Benzoquinone compositions of enhanced solubility and bioavailability are described that contain at least one benzoquinone with at least one solubility-enhancing polymer. In one embodiment, the benzoquinone is coenzyme Q1O. Described methods to produce the bioenhanced products comprise dry blending and solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising benzoquinone, a solubility-enhancing polymer and a solvent and removing the solvent to form amorphous benzoquinone. Products made by the invention's compositions and methods include pharmaceuticals, nutraceuticals, cosmetic, and personal care products for man and animal.

Priority: US20060756454P Applic. Date: 2006-01-05; US20050703374P Applic. Date: 2005-07-28

Inventor: OLSEN STEPHEN [US]; DONEY JOHN A [US]; SHORES CHRISTOPHER S [US]


Application No.: US20070026073A1  Published: 01/Feb/2007

Title: Amorphous efavirenz and the production thereof

Applicant/Assignee:

Application No.: 11/496030   Filing Date: 28/Jul/2006

Abstract:Efavirenz compositions of enhanced bioavailability are described that contain efavirenz with at least one solubility-enhancing polymer. Described methods to produce the bioenhanced products comprise solvent spray drying. One aspect of the method includes the steps of providing a mixture comprising efavirenz, a solubility-enhancing polymer and a single solvent, a solvent blend or solvent/non-solvent blend removing and then evaporating the mixture to form amorphous efavirenz.

Priority: US20050703374P Applic. Date: 2005-07-28

Inventor: DONEY JOHN A [US]


Application No.: US20070026082A1  Published: 01/Feb/2007

Title: Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form

Applicant/Assignee: ROEHM GBMH & KG

Application No.: 10/564096   Filing Date: 15/Jul/2004

Abstract:The invention relates to an oral, multiparticle pharmaceutical dosage form containing pellets, the size of which ranges from 50 to 2500 mum and which essentially consist of: a) an inner matrix layer containing an active substance which is a peptide or a protein, including the derivatives or conjugates thereof, and which is embedded in a matrix consisting of a polymer with mucoadhesive effect, and b) an outer film coating essentially consisting of an anionic polymer or copolymer, which can be optionally formulated with pharmaceutically conventional adjuvants, more particularly softening agents.

Priority: DE20031032160 Applic. Date: 2003-07-15; WO2004EP07882 Applic. Date: 2004-07-15

Inventor: LIZIO ROSARIO [DE]; PETEREIT HANS-ULRICH [DE]; ROTH ERNA [DE]; ANDRES INES [IT]; DAMM MICHAEL [DE]


Application No.: US20070026119A1  Published: 01/Feb/2007

Title: Edible product with masked bitter, sour and/or astringent taste

Applicant/Assignee:

Application No.: 10/553760   Filing Date: 22/Apr/2004

Abstract:The present invention relates to edible products with masked bitter, sour and/or astringent taste. The new products comprise a sweetening agent and from 0.2 to 25% by weight plant sterol ester, wherein the amount of sweetening agent is reduced as compared to a regular product.

Priority: FI20030000610 Applic. Date: 2003-04-22; WO2004FI00250 Applic. Date: 2004-04-22

Inventor: HONKANEN ANNIINA [FI]; KUUSISTO PAIVI [FI]; LAHTINEN RITVA [FI]; KOPONEN LEENA [FI]


Application No.: US20070031339A1  Published: 08/Feb/2007

Title: Contrast agents

Applicant/Assignee:

Application No.: 10/560065   Filing Date: 08/Dec/2005

Abstract:The present invention relates to particles comprising cores of tungsten or tungsten in mixture with other metallic elements as the contrast enhancing material wherein said core are coated, to pharmaceuticals containing such particles, and to the use of such pharmaceuticals specifically as contrast agents in diagnostic imaging, in particular in X-ray imaging.

Priority: NO20030005294 Applic. Date: 2003-11-28; NO20040004622 Applic. Date: 2004-10-26; WO2004NO00364 Applic. Date: 2004-11-26

Inventor: AXELSSON OSKAR [SE]; LEUNBACH IB [SE]; KARLSSOV MAGNUS [SE]


Application No.: US20070031342A1  Published: 08/Feb/2007

Title: Sustained release microparticles for pulmonary delivery

Applicant/Assignee: NEKTAR THERAPEUTICS

Application No.: 11/430665   Filing Date: 09/May/2006

Abstract:A composition of microparticles for delivery to the pulmonary system provides sustained release of a pharmaceutical agent. The microparticles comprise a lipid structural matrix comprising a multilamellar structure of lipid bilayers having lipid chains ordered in an LbetaL phase. The lipid matrix at least partially encapsulates the pharmaceutical agent at a bilayer interface formed between head groups of adjacent lipid layers. The microparticles are prepared by heating a precursor formulation comprising a solvent, matrix-forming excipient and pharmaceutical agent to a temperature above the liquid-crystalline transition temperature Tc of the matrix-forming excipient and below the melting or denaturation point of the pharmaceutical agent. The solvent is then removed to form microparticles with partially encapsulated pharmaceutical agent.

Priority: US20050651489P Applic. Date: 2005-06-22

Inventor: TZANNIS STELIOS T [US]; SADRZADEH NEGAR [US]; SCHIAVONE HELEN [US]; LABIRIS RENEE [CA]


Application No.: US20070031397A1  Published: 08/Feb/2007

Title: Compositions and methods for enhancing axon regeneration

Applicant/Assignee:

Application No.: 11/442676   Filing Date: 25/May/2006

Abstract:As described below, the present invention generally features compositions and methods for the treatment of CNS disease or injury. In particular, the invention provides methods and compositions for enhancing axonal outgrowth in a subject. In one embodiment, the invention enhances the success of CNS restorative surgery.

Priority: US20050684340P Applic. Date: 2005-05-25

Inventor: SCHNAAR RONALD L [US]; YANG LYNDA J [US]; SCHRAMM LAWRENCE P [US]


Application No.: US20070031459A1  Published: 08/Feb/2007

Title: ORAL SUSPENSION OF PREDNISOLONE ACETATE

Applicant/Assignee: TARO PHARMACEUTICAL NORTH AMERICA, INC

Application No.: 11/457197   Filing Date: 13/Jul/2006

Abstract:The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Priority: US20050705370P Applic. Date: 2005-08-04

Inventor: ASOTRA SATISH [CA]; GAO SHEN [CA]; YACOBI AVRAHAM [US]


Application No.: US20070031485A1  Published: 08/Feb/2007

Title: Pharmaceutical composition having a cationic excipient

Applicant/Assignee:

Application No.: 10/577836   Filing Date: 01/May/2006

Abstract:The invention relates to a pharmaceutical composition comprising a pharmaceutically effective amount of a pharmaceutically active substance and a pharmaceutically acceptable carrier comprising a cationic excipient, wherein said cationic excipient is a labile ester of betaine and a lipophilic alcohol having at least one primary hydroxyl group. The invention also relates to the use of a labile ester of betaine and a lipophilic alcohol having at least a primary hydroxyl group as a cationic excipient in a carrier for a pharmaceutical composition comprising a pharmaceutically active substance.

Priority: SE20030002924 Applic. Date: 2003-11-05; WO2004SE01569 Applic. Date: 2004-10-29

Inventor: LJUSBERG-WAHREN HELENA [SE]; LUNDBERG DAN [SE]; HOLMBERG KRISTER [SE]


Application No.: US20070031488A1  Published: 08/Feb/2007

Title: Method of administering a partial dose of a segmented pharmaceutical tablet

Applicant/Assignee: ACCU-BREAK PHARMACEUTICALS, INC

Application No.: 11/441456   Filing Date: 25/May/2006

Abstract:A drug-containing pharmaceutical tablet adapted for accurate breaking which has two or more segments with at least one segment containing a drug.

Priority: WO2005US18633 Applic. Date: 2005-05-23; WO2005US18638 Applic. Date: 2005-05-23; WO2005US18639 Applic. Date: 2005-05-23; US20040573042P Applic. Date: 2004-05-21; US20040573134P Applic. Date: 2004-05-21

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Application No.: US20070031497A1  Published: 08/Feb/2007

Title: Gastric acid secretion inhibiting composition

Applicant/Assignee: OREXO AB

Application No.: 11/544750   Filing Date: 10/Oct/2006

Abstract:An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.

Priority: SE20020003065 Applic. Date: 2002-10-16; US2005-531598 Applic. Date: 2005-11-25; WO2003SE01598 Applic. Date: 2003-10-15

Inventor: PETTERSSON ANDERS [SE]; NYSTROM CHRISTER [SE]; HAKANSSON YVONNE [SE]


Application No.: US20070032430A1  Published: 08/Feb/2007

Title: Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA THE UAB RESEARCH FOUNDATION

Application No.: 11/407390   Filing Date: 18/Apr/2006

Abstract:This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of atherosclerosis and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route.

Priority: US2003-423830 Applic. Date: 2003-04-25; US2002-273386 Applic. Date: 2002-10-16; US2002-187215 Applic. Date: 2002-06-28; US2001-896841 Applic. Date: 2001-06-29; US2000-645454 Applic. Date: 2000-08-24; US20050697495P Applic. Date: 2005-07-07; US20050676431P Applic. Date: 2005-04-29

Inventor: FOGELMAN ALAN M [US]; NAVAB MOHAMAD [US]


Application No.: US20070032511A1  Published: 08/Feb/2007

Title: Amorphous ziprasidone mesylate

Applicant/Assignee:

Application No.: 11/354325   Filing Date: 13/Feb/2006

Abstract:Provided is amorphous form of ziprasidone mesylate and process for its preparation. Also provided is a process for preparing ziprasidone mesylate dihydrate needle crystals.

Priority: US20050652356P Applic. Date: 2005-02-11

Inventor: ARONHIME JUDITH [IL]; MENDELOVICI MARIOARA [IL]; LEVI SIGALIT [IL]; MAINFELD ALEX [IL]; GOLD AMIR [IL]


Application No.: US20070036805A1  Published: 15/Feb/2007

Title: Compositions comprising large and small binding fragments of antibodies against the same toxin

Applicant/Assignee: THE SECTETARY OF STATE FOR DEFENCE

Application No.: 10/559148   Filing Date: 03/Jun/2004

Abstract:A pharmaceutical composition comprising (i) a first specific binding agent selected from an antibody or a large binding fragment of an antibody which specifically binds a target toxin, and (ii) a second specific binding agent which comprises a small binding fragment of an antibody which binds said toxin. The compositions are used in the treatment of toxin poisoning, for example following exposure to toxins such as Botulinum toxins.

Priority: GB20030012642 Applic. Date: 2003-06-03; WO2004GB02351 Applic. Date: 2004-06-03

Inventor: HOLLEY JANE L [GB]; MAYERS CARL N [GB]; WHITFIELD DAVID [GB]; BROOKS TIMOTHY J G [GB]


Application No.: US20070036843A1  Published: 15/Feb/2007

Title: Non-ionic non-aqueous vehicles for topical and oral administration of carrier-complexed active agents

Applicant/Assignee: COLLEGIUM PHARMACEUTICAL, INC

Application No.: 11/341016   Filing Date: 27/Jan/2006

Abstract:An improved controlled release composition for non-parenteral administration of active agents and other therapeutics, particularly for oral or topical administration, has been developed. The composition is made by dispersing a complex formed of an active agent bound to an ion-exchange resin or to another form of resin or carrier, in a non-ionic non-aqueous ("NINA") vehicle. The complexes are optionally coated with one or more layers of coating material to provide a controlled pattern of release of active agent from the carrier. Replacing the usual aqueous vehicle with a NINA vehicle, such as an oil or an ointment, allows the active agent-carrier complexes, with or without coatings, to be both orally and topically administered. The compositions can be formulated as powders, liquids, liquid suspensions, gels, capsules, soft gelatin capsules, tablets, chewable tablets, topical ointments, lotions, pourable or pumpable fluids, semisolid, crushable tablets, and unit-of-use sachets or capsules for reconstitution or direct application. The combination of multiple active agents is possible with this system, in which one or more active agents are bound to particles and one or more active agents are dissolved or dispersed in the NINA vehicle. This allows the combination of two or more active agents, which are otherwise incompatible, into a single dosage form.

Priority: US2005-046608 Applic. Date: 2005-01-28; US2005-128947 Applic. Date: 2005-05-13; US20050648172P Applic. Date: 2005-01-28

Inventor: HIRSH JANE [US]; RARIY ROMAN V [US]; TRUMBORE MARK W [US]; FLEMING ALISON [US]; HIRSH MARK [US]


Application No.: US20070036852A1  Published: 15/Feb/2007

Title: Rapidly dispersing/disintegrating compositions

Applicant/Assignee:

Application No.: 11/500139   Filing Date: 07/Aug/2006

Abstract:The present invention relates to a rapidly dispersing/disintegrating, taste masked oral ondansetron dosage forms and a simple and economic process for their manufacture which can be easily scaled up. In particular, the present invention relates to a compressed dosage form for oral administration capable of being rapidly disintegrated comprising a bitter active pharmaceutical ingredient, a pharmaceutically acceptable polymer of methacrylic acid with divinylbenzene, and at least one further excipient, a process for the manufacture of such a compressed dosage form, compressed dosage forms obtainable from such a process and the use of Polacrillin potassium for the purpose of taste masking in a rapidly disintegrating dosage form.

Priority: GB20050016604 Applic. Date: 2005-08-12

Inventor: DABHADE HARSHA M [IN]; ATTARDE PANKAJ U [IN]


Application No.: US20070036861A1  Published: 15/Feb/2007

Title: Orally-dispersible multilayer tablet

Applicant/Assignee: ETHYPHARM

Application No.: 10/559350   Filing Date: 04/Jun/2004

Abstract:The present invention relates to a multilayer orodispersible tablet and to the process for preparing it.

Priority: FR20030006900 Applic. Date: 2003-06-06; US2003-610668 Applic. Date: 2003-06-30; WO2004FR01400 Applic. Date: 2004-06-04

Inventor: OURY PASCAL [FR]; LAMOUREUX GAEL [FR]; HERRY CATHERINE [FR]; PREVOST YANN [FR]


Application No.: US20070037781A1  Published: 15/Feb/2007

Title: Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/424558   Filing Date: 16/Jun/2006

Abstract:Disclosed are medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups X, R, R, R<1>, R<1'>, R<2>, R<2'>, R<2''>, R<2'''>, V and n may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

Priority: DE200510030733 Applic. Date: 2005-07-01

Inventor: KONETZKI INGO [DE]; BOUYSSOU THIERRY [DE]; PESTEL SABINE [DE]; SCHNAPP ANDREAS [DE]


Application No.: US20070037843A1  Published: 15/Feb/2007

Title: Zolpidem hemitartrate

Applicant/Assignee:

Application No.: 11/588122   Filing Date: 25/Oct/2006

Abstract:The present invention provides for novel polymorphs of zolpidem hemitartrate and the preparation of the polymorphs.

Priority: US2001-841025 Applic. Date: 2001-04-24; US20000199298P Applic. Date: 2000-04-24; US20000206025P Applic. Date: 2000-05-22; US20000225364P Applic. Date: 2000-08-14

Inventor: ARONHIME JUDITH [IL]; LEONOV DAVID [IL]; MESZAROS-SOS ERZEBET [HU]; SALYI SZABOLES [HU]; SZABO CSABA [HU]; ZAVUROV SHLOMO [IL]


Application No.: US20070041987A1  Published: 22/Feb/2007

Title: Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development

Applicant/Assignee:

Application No.: 10/549809   Filing Date: 19/Mar/2004

Abstract:An isolated fusion protein is provided which is a conjugate of a therapeutic polypeptide and an albumin fragment, such as a fragment including an individual domain or subdomain of albumin, or a polymer of albumin (e.g., dimers, trimers, etc.) and which is used to optimize the half-life of that therapeutic agent in the bloodstream in a tunable fashion based on the molecular weight of the fragment or polymer. Albumin fragments useful in the invention include fragments containing any of the individual domains and subdomains of human serum albumin, as well as fragments including specific combinations of binding regions or subdomains. The present invention thus provides fragments or polymers which will allow for optimizing half-lives of therapeutic polypeptides depending on their molecular weight, and this will optimizes protein and vaccine therapeutics to have desired half lives for their greatest effectiveness.

Priority: US20030455566P Applic. Date: 2003-03-19; WO2004US08696 Applic. Date: 2004-03-19

Inventor: CARTER DANIEL [US]; MCKENZIE SIMON R [US]; RUKER FLORIAN [US]


Application No.: US20070042034A1  Published: 22/Feb/2007

Title: High drug load formulations and dosage forms

Applicant/Assignee: MYRIAD GENETICS, INCORPORATED

Application No.: 11/491771   Filing Date: 24/Jul/2006

Abstract:The invention relates to high drug load formulations containing (R)-2-(2-fluoro-4-biphenylyl)propionic acid as an active pharmaceutical ingredient.

Priority: US20050701710P Applic. Date: 2005-07-22; US20050706344P Applic. Date: 2005-08-08

Inventor: ZENTNER GAYLEN M [US]; MCREA JAMES C [US]; WILLIAMS MARK S [US]; OEHRTMAN GREGORY T [US]; POWERS TRACY A [US]


Application No.: US20070042044A1  Published: 22/Feb/2007

Title: Matrix compositions for controlled delivery of drug substances

Applicant/Assignee: EGALET A/S

Application No.: 10/550685   Filing Date: 26/Mar/2004

Abstract:A novel matrix composition for pharmaceutical use. The matrix composition has been designed so that it is especially suitable in those situation where an improved bioavailability is desired and/or in those situation where a slightly or insoluble active substance is employed. Accordingly, a controlled release pharmaceutical composition for oral use is provided in the form of a coated matrix composition, the matrix composition comprising i) a mixture of a first and a second polymer that have plasticizing properties and which have melting points or melting intervals of a temperature of at the most 200 DEG C., the first polymer being selected from the group consisting of polyethylene glycols and polyethylene oxides, and the second polymer being selected form block copolymer of ethylene oxide and propylene oxide including poly(ethylene-glycol-b-(DL-lactic acid-co-glycolic acid)

-b-ethylene glycol (PEG-PLGA PEG), poly((DL-lactic acid-co-glycolic acid)-g-ethylene glycol) (PLGA-g-PEG), poloxamers and polyethylene oxide-polypropylene oxide (PEO-PPO), ii) a therapeutically, prophylactically and/or diagnostically active substance, the matrix composition being provided with a coating having at least one opening exposing at one surface of said matrix, wherein the active substance is released with a substantially zero order release.

Priority: DK20030000464 Applic. Date: 2003-03-26; WO2003DK00765 Applic. Date: 2003-11-07; WO2004DK00217 Applic. Date: 2004-03-26

Inventor: FISCHER GINA [DK]; BAR-SHALOM DANIEL [DK]; SLOT LILLIAN [DK]; LADEMANN ANNE-MARIE [DK]


Application No.: US20070042045A1  Published: 22/Feb/2007

Title: Multilayer dosage form comprising a matrix that influences release of a modulatory substance

Applicant/Assignee: ROEHM GBMH & CO. KG

Application No.: 10/573019   Filing Date: 15/Sep/2004

Abstract:The invention relates to a multilayer pharmaceutical form for controlled active ingredient release, essentially comprising a) optionally a neutral core (nonpareilles), b) an inner controlling layer comprising a substance having a modulating effect, which is embedded in a matrix which influences the delivery of the modulatory substance and which comprises pharmaceutically usable polymers, waxes, resins and/or proteins, and where appropriate an active ingredient, c) an active ingredient layer comprising an active pharmaceutical ingredient and, where appropriate, a substance having a modulating effect, d) an outer controlling layer comprising at least 60% by weight of one or a mixture of a plurality of (meth)acrylate copolymers composed of 98 to 85 C1 to C4 alkyl esters of (meth)

acrylic acid and 2 to 15% by weight of methacrylate monomers with a quaternary ammonium group in the alkyl radical, and, where appropriate, further water-insoluble pharmaceutically usable polymers, where the layers may additionally and in a manner known per se comprise pharmaceutically usual excipients.

Priority: DE20031053196 Applic. Date: 2003-11-13; WO2004EP10300 Applic. Date: 2004-09-15

Inventor: LIZIO ROSARIO [DE]; PETEREIT HANS-ULRICH [DE]; ASSMUS MANFRED [DE]; RAVISHANKAR HERNA [IN]


Application No.: US20070042977A1  Published: 22/Feb/2007

Title: Vaccine

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: 10/533734   Filing Date: 03/Nov/2003

Abstract:The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative, which is non-glycosylated when expressed in a mammalian target cell, operably linked to a heterologous promoter. Preferably the HIV envelope molecule, such as gp120 or gp140 or gp160, lacks a functional secretion signal. It may be fused to additional HIV proteins such as Nef, Gag, RT or Tat.

Priority: GB20020025788 Applic. Date: 2002-11-05; WO2003EP12402 Applic. Date: 2003-11-03

Inventor: ERTL PETER F [GB]


Application No.: US20070042993A1  Published: 22/Feb/2007

Title: Polysaccharides derivatives with high antithrombotic activity in plasma

Applicant/Assignee: INALCO S.P.A

Application No.: 10/557584   Filing Date: 07/Jul/2004

Abstract:The present invention relates to a process for the preparation of sulphated glycosaminoglycans derived from N-acetylheparosan which comprises: a) N-deacetylation and N-sulphation of the N-acetylheparosan polysaccharide prepared from natural or recombinant bacterial strain, preferably K5 E. coli, b) enzymatic epimerization with the glucuronyl C5-epimerase enzyme, c) partial O-sulphation followed by a partial O-desulphation, d) partial 6-0-sulphation, e) N-sulphation and an intermediate step of controlled depolimerization characterised by the fact that both 0-sulphations (0-sulphation and 60-sulphation) are partial.

Furthermore the invention relates to the products obtained according to the process which show a ratio between the anti-Xa activity and anti-Ila activity equal to or higher than 1 and to compositions comprising said products in combination with suitable and pharmaceutically acceptable excipients and/or diluent.

Priority: IT2003MI01618 Applic. Date: 2003-08-06; WO2004EP51391 Applic. Date: 2004-07-07

Inventor: MANONI MARCO [IT]; SALSINI LIANA [IT]; CHINI JACOPO [IT]; CIPOLLETTI GIOVANNI [IT]


Application No.: US20070043327A1  Published: 22/Feb/2007

Title: Drug delivery device comprising a mesh sleeve

Applicant/Assignee:

Application No.: 10/550965   Filing Date: 26/Mar/2004

Abstract:This invention concerns drug delivery by way of mesh sleeves for use with devices adapted for insertion into the vagina, rectum, nasal or buccal cavity. The resulting apparatus exploit the highly vascularised nature of the tissue of bodily cavities such as the vagina, nose, rectum and mouth to deliver pharmaceutical agents to localised areas and/or into underlying tissues.

Priority: GB20030006977 Applic. Date: 2003-03-26; WO2004GB01311 Applic. Date: 2004-03-26

Inventor: KNOX PETER [GB]


Application No.: US20070048370A1  Published: 01/Mar/2007

Title: Pharmaceutical formulation for salts of monobasic acids with clopidogrel

Applicant/Assignee:

Application No.: 11/392824   Filing Date: 30/Mar/2006

Abstract:A pharmaceutical formulation in the form of a tablet which contains, as active substance, a salt of a monobasic acid with clopidogrel is disclosed herein.

Priority: DE200520013839U Applic. Date: 2005-09-01

Inventor: DOSER KARL-HEINZ [DE]; GLANZER KLAUS [DE]; LOFFLER UWE [DE]


Application No.: US20070048373A1  Published: 01/Mar/2007

Title: Dried milled granulate and methods

Applicant/Assignee: CIMA LABS INC

Application No.: 11/507240   Filing Date: 21/Aug/2006

Abstract:The present invention relates to a method of producing a dried wet granulate having a desirable average particle size and particle size distribution and dosage forms made from that granulate.

Priority: US20050712580P Applic. Date: 2005-08-30

Inventor: CHASTAIN SARA J [US]; HABIB WALID [US]; MOE DEREK [US]


Application No.: US20070048374A1  Published: 01/Mar/2007

Title: Bazedoxifene acetate formulations

Applicant/Assignee: WYETH WYETH LLC

Application No.: 11/508801   Filing Date: 23/Aug/2006

Abstract:The present invention is directed to formulations of bazedoxifene acetate that have reduced polymorph conversion, compositions containing the same, preparations thereof, and uses thereof.

Priority: US20050710761P Applic. Date: 2005-08-24

Inventor: SHAH SYED M [US]; DIORIO CHRISTOPHER R [US]; EHRNSPERGER ERIC C [US]; ALI KADUM A [US]


Application No.: US20070053843A1  Published: 08/Mar/2007

Title: Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same

Applicant/Assignee:

Application No.: 10/595449   Filing Date: 22/Oct/2004

Abstract:Pharmaceutical formulations suitable for inhalation comprise at least one pharmaceutically active medicament and lactose anhydrate.

Priority: US20030515077P Applic. Date: 2003-10-28; WO2004US35129 Applic. Date: 2004-10-22

Inventor: DAWSON MICHELLE L [GB]; ROCHE TREVOR C [GB]; WHITAKER MARK [GB]; CHIDAVAENZI OWEN C [GB]


Application No.: US20070053868A1  Published: 08/Mar/2007

Title: Solvent system for enhancing the solubility of pharmaceutical agents

Applicant/Assignee: BANNER PHARMACAPS, INC

Application No.: 11/367238   Filing Date: 03/Mar/2006

Abstract:Liquid and semi-solid pharmaceutical compositions, which can be administered in liquid form or can be used for preparing capsules, are described herein. The composition comprises the salt of one ore more active agents, polyethylene glycol, 0.2-1.0 mole equivalents of a de-ionizing agent per mole of active agent, and water. The pH of the composition is adjusted within the range of 2.5-7.5. The de-ionizing agent causes partial de-ionization (neutralization) of the salt of the active agent resulting in enhanced bioavailability of salts of weakly acidic, basic or amphoteric active agents as well as lesser amounts of polyethylene glycol (PEG) esters.

Priority: US20050659679P Applic. Date: 2005-03-08

Inventor: CHIDAMBARAM NACHIAPPAN [US]; FATMI AQEEL [US]


Application No.: US20070053869A1  Published: 08/Mar/2007

Title: Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents

Applicant/Assignee:

Application No.: 11/509355   Filing Date: 24/Aug/2006

Abstract:The present invention relates to a method of enhancing absorption of a pharmaceutical agent by administering the agent in combination with an inhibitor of BCRP/ABCG2 wherein the amount of the inhibitor is about the critical micelle concentration of the inhibitor or less than the critical micelle concentration. The invention also relates to a formulation suitable for use to enhance absorption of a pharmaceutical agent. The pharmaceutical agent can be a chemotherapeutic agent. The invention also relates to capsules containing the formulation.

Priority: US20050713343P Applic. Date: 2005-09-02

Inventor: SUGIYAMA YUICHI [JP]; MORISHIA MARIKO [JP]; BENAMEUR HASSAN [FR]; DAUMESNIL ROLAND [FR]


Application No.: US20070053982A1  Published: 08/Mar/2007

Title: Sustained release oral formulations

Applicant/Assignee:

Application No.: 11/592853   Filing Date: 03/Nov/2006

Abstract:Pharmaceutical composition capable of releasing a therapeutically effective dose of active agent, e.g., rivastigamine, in a time-controlled manner.

Priority: GB19980021298 Applic. Date: 1998-10-01; GB19980021299 Applic. Date: 1998-10-01; GB19980026654 Applic. Date: 1998-12-03; GB19980027624 Applic. Date: 1998-12-16; GB19990007822 Applic. Date: 1999-04-06; GB19990007823 Applic. Date: 1999-04-06; US2005-105967 Applic. Date: 2005-04-14; US2003-403146 Applic. Date: 2003-03-31; US2002-118183 Applic. Date: 2002-04-08; US2001-818690 Applic. Date: 2001-03-27; WO1999EP07298 Applic. Date: 1999-10-01

Inventor: OGORKA JORG [DE]; KALB OSKAR [DE]; SHAH RAJEN [IN]; KHANNA SATISH C [CH]


Application No.: US20070053983A1  Published: 08/Mar/2007

Title: Extended release compositions of metoprolol succinate

Applicant/Assignee:

Application No.: 11/339676   Filing Date: 26/Jan/2006

Abstract:The present invention relates to sustained release solid pharmaceutical composition comprising antihypertensives, in particular, Metoprolol succinate or pharmaceutically acceptable derivatives thereof and a process for preparing such a formulation. The present invention is a composition comprising Metoprolol succinate or its pharmaceutically acceptable derivatives thereof and the composition releases the drug over 24 hours. The composition further comprises hydrophilic polymer matrix based tablets. The present invention describes a sustained release tablet comprising sustained release matrix comprising of gelling agents comprising at least one hydrophilic polymer with one or more gum and gum derivatives.

Priority: IN2005MU01084 Applic. Date: 2005-09-06

Inventor: JAIN GIRISH [IN]; KONDAPATURU MOHAN K [IN]; BHADRA UTATHYA [IN]


Application No.: US20070054843A1  Published: 08/Mar/2007

Title: Methods for treatment of headaches by administration of oxytocin

Applicant/Assignee:

Application No.: 11/511997   Filing Date: 28/Aug/2006

Abstract:The present invention relates to methods for the treatment of headache and headache disorders. The methods comprise administration of an oxytocin peptide for the treatment of primary and secondary headaches or trigeminal neuralgia.

Priority: US20050711950P Applic. Date: 2005-08-26; US20060794004P Applic. Date: 2006-04-21

Inventor: YEOMANS DAVID C [US]; ANGST MARTIN S [US]; FREY WILLIAM H II [US]; JACOBS DANIEL I [US]


Application No.: US20070059249A1  Published: 15/Mar/2007

Title: Acute treatment of social phobia

Applicant/Assignee:

Application No.: 11/223882   Filing Date: 09/Sep/2005

Abstract:Methods and compositions for the treatment of social phobia are provided, including administering a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid to an individual in need of treatment and a pharmaceutical composition for the treatment of social phobia having a therapeutically effective amount of an androsta-4,16-dien-3-ol steroid. Therapeutically effective amounts may be, for example, between about 100 picograms and about 100 micrograms, or between about 1 nanogram and about 10 microgram, or between about 10 nanograms and about 1 microgram of an androsta-4,16-dien-3-ol steroid. Administration of the androsta-4,16-dien-3-ol compound is preferably intranasal administration to the nasal passages and the vomeronasal organ of the individual. A preferred androsta-4,16-dien-3-ol steroid is [3beta]-androsta-4,16-dien-3-ol. In some embodiments of the methods, both [3beta}-androsta-4,16-dien-3-ol and [3alpha],-androsta-4,16-dien-3-ol are administered to a patient, and are included in a pharmaceutical composition for the treatment of social phobia.

Priority:

Inventor: MONTI-BLOCH LOUIS [US]


Application No.: US20070059359A1  Published: 15/Mar/2007

Title: Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof

Applicant/Assignee:

Application No.: 11/448136   Filing Date: 07/Jun/2006

Abstract:The invention relates to immediate-release and high-drug-load solid pharmaceutical formulations comprising non-micronized (4-chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl] as well as pharmaceutically acceptable salts thereof.

Priority: EP20050090166 Applic. Date: 2005-06-07; US20050689521P Applic. Date: 2005-06-13

Inventor: BACKENSFELD THOMAS [DE]; FUNKE ADRIAN [DE]; JUERGENS KAI [DE]; THODE KAI [DE]; WAGNER TORSTEN [DE]


Application No.: US20070059360A1  Published: 15/Mar/2007

Title: WATER-DISPERSIBLE ANTI-RETROVIRAL PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 11/461057   Filing Date: 31/Jul/2006

Abstract:Provided herein are water-dispersible pharmaceutical compositions comprising a combination of one or more anti-retroviral drugs useful for the treatment of Human Immunodeficiency Virus (HIV) infections. Also provided are processes for preparing such water-dispersible pharmaceutical compositions.

Priority: IN2005DE02019 Applic. Date: 2005-07-29

Inventor: JAISWAL ASHISH [IN]; GARG MUKESH [IN]; SINGLA AJAY K [IN]


Application No.: US20070059361A1  Published: 15/Mar/2007

Title: FAST-DISINTEGRATING EPINEPHRINE TABLETS FOR BUCCAL OR SUBLINGUAL ADMINISTRATION

Applicant/Assignee: UNIVERSITY OF MANITOBA

Application No.: 11/530360   Filing Date: 08/Sep/2006

Abstract:Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations similar to those achieved by an approximately 0.3 mg epinephrine dose in the thigh (Epi-Pen).

Priority: US20050715180P Applic. Date: 2005-09-09; US20060759039P Applic. Date: 2006-01-17

Inventor: RAWAS-QALAJI MUTASEM [CA]; SIMONS KEITH [CA]; GU XIAOCHEN [CA]; SIMONS ESTELLE [CA]


Application No.: US20070059365A1  Published: 15/Mar/2007

Title: Novel formulation of ropinirole

Applicant/Assignee:

Application No.: 10/569398   Filing Date: 19/Aug/2004

Abstract:The present invention relates to novel formulations of ropinirole for oral administration and to their use in the treatment of diseases which can prevent or disturb sleep, particularly Restless Legs Syndrome (RLS).

Priority: GB20030019874 Applic. Date: 2003-08-22; WO2004EP09356 Applic. Date: 2004-08-19

Inventor: POLLOCK PETA E [GB]; WESTRUP JULIAN [GB]; YATES DAVID J [GB]


Application No.: US20070059681A1  Published: 15/Mar/2007

Title: Method for production of bioresorable microparticles, microparticles thus obtained and use thereof

Applicant/Assignee: BIOMERIEUX

Application No.: 10/570948   Filing Date: 21/Sep/2004

Abstract:The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: (i) preparing said microparticles from at least one bioresorbable polymer without stabilizer and without surfactant, and (ii) bonding said protein substances to the microparticles obtained in step (i) without surfactant. It further relates to the bioresorbable microparticles thus obtained and use thereof in diagnosis and therapy.

Priority: FR20030011057 Applic. Date: 2003-09-22; WO2004FR50447 Applic. Date: 2004-09-21

Inventor: ATAMAN-ONAL YASEMIN [FR]; DELAIR THIERRY [FR]; INCHAUSPE GENEVIEVE [FR]; JEANNIN PASCALE [FR]; PARANHOS-BACCALA GLAUCIA [FR]; VERRIER BERNARD [FR]


Application No.: US20070060513A1  Published: 08/Sep/2005

Title: Method for increasing the serum half-life of a biologically active molecule

Applicant/Assignee:

Application No.: 11/113592   Filing Date: 25/Apr/2005

Abstract:A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased serum half-life, e.g., human urokinase plasminogen activator (human "uPA" or "hUPA") or a fragment or derivative thereof. Pharmaceutical compositions containing such molecules and methods of using them to treat uPA-mediated and uPA receptor-mediated disorders are also provided.

Priority: US2002-123092 Applic. Date: 2002-04-11; US1999-263117 Applic. Date: 1999-03-05; US19980076964P Applic. Date: 1998-03-05

Inventor: DRUMMOND ROBERT J [US]; ROSENBERG STEVE [US]


Application No.: US20070060527A1  Published: 15/Mar/2007

Title: Orally administered small peptides synergize statin activity

Applicant/Assignee: THE UNIVERSITY OF ALABAMA RESEARCH FOUNDATION

Application No.: 11/485620   Filing Date: 11/Jul/2006

Abstract:This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention also provides a method of tracking a peptide in a mammal. In addition, the peptides inhibit osteoporosis. When administered with a statin, the peptides enhance the activity of the statin permitting the statin to be used at significantly lower dosages and/or cause the statins to be significantly more anti-inflammatory at any given dose.

Priority: US2003-649378 Applic. Date: 2003-08-26; US2003-423830 Applic. Date: 2003-04-25; US2002-273386 Applic. Date: 2002-10-16; US2002-187215 Applic. Date: 2002-06-28; US2001-896841 Applic. Date: 2001-06-29; US2000-645454 Applic. Date: 2000-08-24; US20030494449P Applic. Date: 2003-08-11

Inventor: FOGELMAN ALAN M [US]; ANANTHARAMAIAH GATTADAHALLI M [US]; NAVAB MOHAMAD [US]


Application No.: US20070065369A1  Published: 22/Mar/2007

Title: NOVEL METHODS AND COMPOSITION FOR DELIVERING MACROMOLECULES TO OR VIA THE RESPIRATORY TRACT

Applicant/Assignee:

Application No.: 11/551166   Filing Date: 19/Oct/2006

Abstract:A composition comprises a lipid-based microstructure with at least one bioactive macromolecule. The composition provides improved bioavailability and is capable of rapidly releasing a bioactive macromolecule. It is believed that the improved bioavailability is due, at least in part, to the reduction of scavenging by bronchoalveolar macrophages and/or mucociliary clearance.

Priority: US2002-132215 Applic. Date: 2002-04-26; US2001-919477 Applic. Date: 2001-07-30; US20000221544P Applic. Date: 2000-07-28

Inventor: BOT ADRIAN I [US]; DELLAMARY LUIS A [US]; SMITH DAN J [US]


Application No.: US20070065505A1  Published: 22/Mar/2007

Title: Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Applicant/Assignee:

Application No.: 10/564259   Filing Date: 09/Jul/2004

Abstract:Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent

a crospovidone or povidone

and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

Priority: US20030486495P Applic. Date: 2003-07-11; WO2004EP07584 Applic. Date: 2004-07-09

Inventor: LI SHOUFENG [US]; GHOSH ANASUYA A [US]; BATEMAN SIMON D [US]; AZRIA MOISE [CH]; ROYCE ALAN E [US]


Application No.: US20070066554A1  Published: 22/Mar/2007

Title: Immunostimulatory nucleic acids

Applicant/Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION

Application No.: 11/507079   Filing Date: 18/Aug/2006

Abstract:The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.

Priority: US2000-669187 Applic. Date: 2000-09-25; US20000227436P Applic. Date: 2000-08-23; US19990156135P Applic. Date: 1999-09-27; US19990156113P Applic. Date: 1999-09-25

Inventor: KRIEG ARTHUR M [US]; SCHETTER CHRISTIAN [DE]; VOLLMER JORG [DE]


Application No.: US20070066643A1  Published: 22/Mar/2007

Title: Methods of treating middle-of-the-night insomnia

Applicant/Assignee: TRANSORAL PHARMACEUTICALS, INC

Application No.: 11/439874   Filing Date: 23/May/2006

Abstract:The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.

Priority: US20050684842P Applic. Date: 2005-05-25; US20050741673P Applic. Date: 2005-12-01; US20060788340P Applic. Date: 2006-03-31; US20060788249P Applic. Date: 2006-03-31

Inventor: SINGH NIKHILESH [US]; PATHER SATHASIVAN I [US]


Application No.: US20070071689A1  Published: 29/Mar/2007

Title: Advantageous combination for inhalation of nacystelyn and bronchodilators

Applicant/Assignee: GALEPHAR M/F

Application No.: 10/567408   Filing Date: 06/Aug/2003

Abstract:pharmaceutical combination or composition for inhalation a fixed combination (A) L-lysine N-acetylcysteinate and (B) a bronchodilator agent for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory or obstructive respiratory disease.

Priority: WO2003BE00134 Applic. Date: 2003-08-06

Inventor: DEBOECK ARTHUR M [US]; BAUDIER PHILIPPE [BE]; VANDERBIST FRANCIS [BE]


Application No.: US20070071691A1  Published: 29/Mar/2007

Title: Composition

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: 10/576461   Filing Date: 22/Oct/2004

Abstract:Dry powder pharmaceutical compositions having improved storage stability, dry powder inhalers comprising the same and their use in the treatment of respiratory disorders by inhalation.

Priority: GB20030024918 Applic. Date: 2003-10-24; WO2004GB04492 Applic. Date: 2004-10-22

Inventor: BROWN ANDREW B [US]; VAN OORT MICHIEL M [US]


Application No.: US20070071806A1  Published: 29/Mar/2007

Title: Tansmucosal drug delivery system

Applicant/Assignee:

Application No.: 10/545774   Filing Date: 24/Feb/2004

Abstract:Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.

Priority: US20030449647P Applic. Date: 2003-02-24; WO2004US05490 Applic. Date: 2004-02-24

Inventor: MCCARTY JOHN A [US]


Application No.: US20070071811A1  Published: 29/Mar/2007

Title: Stable combinations of amlodipine besylate and benazepril hydrochloride

Applicant/Assignee:

Application No.: 11/238496   Filing Date: 28/Sep/2005

Abstract:The present invention provides a pharmaceutical composition comprising benazepril and amlodipine wherein the benazepril and the amlodipine are in physical contact with one another, and methods for making the same.

Priority:

Inventor: KADOSH MALI [IL]; LESKA FANNY [IL]


Application No.: US20070071819A1  Published: 29/Mar/2007

Title: MULTIPLE UNIT MODIFIED RELEASE COMPOSITIONS OF CARBAMAZEPINE AND PROCESS FOR THEIR PREPARATION

Applicant/Assignee:

Application No.: 11/420957   Filing Date: 30/May/2006

Abstract:The present invention relates to multiple-unit modified release carbamazepine compositions for oral administration which include: (i) at least one extended release unit, and (ii) at least one enteric release unit. Also provided are processes for the preparation of multiple-unit modified release compositions of carbamazepine.

Priority: IN2005DE01380 Applic. Date: 2005-05-30; IN2005DE01382 Applic. Date: 2005-05-30

Inventor: KESARWANI AMIT K [IN]; CHAWLA MANISH [IN]; RAGHUVANSHI RAJEEV S [IN]; RAMPAL ASHOK [IN]


Application No.: US20070071820A1  Published: 29/Mar/2007

Title: Delayed release pharmaceutical formulations

Applicant/Assignee: EURO-CELTIQUE S.A

Application No.: 11/603766   Filing Date: 22/Nov/2006

Abstract:Delivery of a drug is controlled to impart a delay before release after administration by formulating the drug with a disruption agent to provide a core, and coating the core with a regulatory membrane comprising a water-soluble gel-forming polymer and a water-insoluble film-forming polymer.

Priority: GB20000025208 Applic. Date: 2000-10-13; US2003-399077 Applic. Date: 2003-09-30; WO2001GB04423 Applic. Date: 2001-10-04

Inventor: PRATER DEREK A [GB]; HASSAN MOHAMMED [GB]; BLAND CHRISTOPHER R [GB]


Application No.: US20070071824A1  Published: 29/Mar/2007

Title: Treatment of mucositis using N-acetylcysteine

Applicant/Assignee:

Application No.: 11/540357   Filing Date: 29/Sep/2006

Abstract:This present invention provides a therapeutic composition for use in the treatment of mucositis and a method for using such a therapeutic composition. The therapeutic composition includes a pharmaceutical substance effective for treating mucositis formulated with a biocompatible polymer, such as a biocompatible reverse-thermal gelation polymer.

Priority: US2003-728277 Applic. Date: 2003-12-04; US2001-993383 Applic. Date: 2001-11-21; US2000-721516 Applic. Date: 2000-11-22

Inventor: ROSENTHAL GARY J [US]; ETTER JEFFREY B [US]; RODELL TIMOTHY C [US]; SCHAUER WREN H [US]; SAMANIEGO ADRIAN [US]


Application No.: US20070071835A1  Published: 29/Mar/2007

Title: Administering pharmaceutical compositions to the mammalian central nervous system

Applicant/Assignee:

Application No.: 11/527900   Filing Date: 26/Sep/2006

Abstract:Methods, compositions and systems are provided for the non-invasive transnasal and transocular drug delivery to the central nervous system using eriodictyon fluid extract technology. By administration through the olfactory nerve or the optical nerve, the delivery of a biologically active substance of interest into the CNS and CSF can be enhanced through bypassing the blood-brain barrier. The invention involves the use of eriodictyon fluid extract as an excipient in compositions and systems for administering drugs to the olfactory or optical nerve.

Priority: US2006-460194 Applic. Date: 2006-07-26; US20050720797P Applic. Date: 2005-09-26

Inventor: PARNELL FRANCIS W [US]


Application No.: US20070072247A1  Published: 29/Mar/2007

Title: METHODS AND REAGENTS FOR THE ANALYSIS AND PURIFICATION OF POLYSACCHARIDES

Applicant/Assignee: ACADEMIA SINICA

Application No.: 11/469270   Filing Date: 31/Aug/2006

Abstract:The disclosure provides fusion proteins comprising a carbohydrate recognition domain of an innate immunity receptor and a heterologous polypeptide. The fusion proteins of the disclosure may be used, for example, to fingerprint polysaccharide compositions and to purify polysaccharide compositions. Polysaccharide compositions include those isolated from Ganoderma lucidum (Reishi). The methods and reagents of the disclosure may also be used to identify innate immunity receptors and cell types that bind to polysaccharide compositions (including polysaccharide compositions associated with pathogens), whereupon modulators of the identified receptors can then be obtained. The fusion proteins also may be used to inhibit the interaction between a polysaccharide composition and an innate immunity receptor on a cell surface. The methods and reagents of the disclosure are used in one example to determine that the DLVR1 innate immunity receptor on macrophages interacts with Dengue virus (DV), and that DLVR1 is responsible for DV-mediated secretion of proinflammatory cytokines from macrophages. The disclosure also provides DVLR1 antibodies that prevent the secretion of proinflammatory cytokines by DV-infected macrophages.

Priority: US20050713463P Applic. Date: 2005-08-31

Inventor: WONG CHIE-HUEY [US]; HSIEH SHIE-LIANG [TW]; HSU TSUI-LING [TW]; CHENG SHIH-CHIN [TW]; CHEN SZU-TING [TW]


Application No.: US20070077279A1  Published: 05/Apr/2007

Title: Novel compositions containing polyphenols

Applicant/Assignee: DSM IP ASSETS B.V

Application No.: 11/540955   Filing Date: 02/Oct/2006

Abstract:The present invention is directed to compositions containing at least a polyphenol and polyethylenglycol, to products such as food, beverages, dietary supplements, feed, pharmaceuticals and personal care products containing such a composition as well as to the use of polyethylenglycol for masking the bitter taste of such polyphenols. The polyphenols are preferably selected from the group consisting of epigallocatechin gallate, resveratrol, hydroxytyrosol, oleuropein, polyphenols present in green tea extracts, catechins, polyphenols present in extracts of red grape skin, polyphenols present in olives and/or olive waste water, and their mixtures.

Priority: US20050721993P Applic. Date: 2005-09-30

Inventor: SCHWEIKERT LONI [CH]; STEINKE PETER [DE]


Application No.: US20070081949A1  Published: 12/Apr/2007

Title: Buccal drug delivery

Applicant/Assignee: ARROW NO. 7 LIMITED

Application No.: 10/570697   Filing Date: 06/Sep/2004

Abstract:A lozenge is provided that has stable pH and stable levels of active ingredient over time. It comprises a combination of (i) at least one gum and (ii) at least one non-crystallising sugar or non-crystallising sugar alcohol in a matrix designed for controlled buccal delivery of a drug. The lozenge also contains water and optional components selected from flavourings, taste masking agents, colourings, buffer components, pH adjusting agents, excipients, stabilizers and sweeteners. Methods of preparing the lozenge are also provided.

Priority: GB20030020854 Applic. Date: 2003-09-05; GB20040003373 Applic. Date: 2004-02-16; WO2004GB03811 Applic. Date: 2004-09-06

Inventor: DAM ANDERS [DK]; MAJOR JANOS [DK]; TASKO PETER [GB]


Application No.: US20070081992A1  Published: 12/Apr/2007

Title: Fusion proteins for blood-brain barrier delivery

Applicant/Assignee:

Application No.: 11/245546   Filing Date: 07/Oct/2005

Abstract:The invention provides compositions, methods, and kits for increasing transport of agents across the blood brain barrier while allowing their activity once across the barrier to remain substantially intact. The agents are transported across the blood brain barrier via one or more endogenous receptor-mediated transport systems. In some embodiments the agents are therapeutic, diagnostic, or research agents.

Priority: US2005-245710 Applic. Date: 2005-10-07

Inventor: PARDRIDGE WILLIAM M [US]; BOADO RUBEN J [US]


Application No.: US20070082842A1  Published: 12/Apr/2007

Title: Therapeutic applications for c-peptide

Applicant/Assignee:

Application No.: 10/575701   Filing Date: 13/Oct/2004

Abstract:The present invention relates to administration of C-peptide in a once daily dose for use in the treatment of diabetes and diabetic complications.

Priority: GB20030023979 Applic. Date: 2003-10-13; WO2004GB04341 Applic. Date: 2004-10-13

Inventor: EKBERG KARIN [SE]; WAHREN JOHN [SE]; SIMA ANDERS [US]


Application No.: US20070086974A1  Published: 19/Apr/2007

Title: CETIRIZINE COMPOSITIONS

Applicant/Assignee:

Application No.: 11/539406   Filing Date: 06/Oct/2006

Abstract:Stable and palatable taste masked pharmaceutical compositions of substituted benzhydrylpiperazines and processes for preparing them.

Priority: IN2005CH01418 Applic. Date: 2005-10-06; US20060745249P Applic. Date: 2006-04-20

Inventor: GAWANDE RAHUL S [IN]; RAVINDER KODIPYAKA [IN]; B S PRAVEEN K [IN]; BHUSHAN INDU [IN]; MOHAN MAILATUR S [IN]


Application No.: US20070087050A1  Published: 19/Apr/2007

Title: Orally Disintegratable Simvastatin Tablets

Applicant/Assignee:

Application No.: 11/465418   Filing Date: 17/Aug/2006

Abstract:An orally disintegratable tablet containing simvastatin and silicified microcrystalline cellulose is provided with a non-alkaline lubricant.

Priority: US20050708773P Applic. Date: 2005-08-17

Inventor: JANSEN KORINDE A [NL]


Application No.: US20070087970A1  Published: 19/Apr/2007

Title: Use of C-reactive protein to treat immune complex-mediated renal disease

Applicant/Assignee: STC.UNM

Application No.: 11/604416   Filing Date: 27/Nov/2006

Abstract:The present invention relates to a method of treating or preventing kidney disease in an animal subject including administering an effective amount of C-reactive protein to the animal subject. The kidney disease may be associated with systemic lupus erythematosus.

Priority: US2004-947267 Applic. Date: 2004-09-23; US20030514122P Applic. Date: 2003-10-23

Inventor: DU CLOS TERRY [US]; MOLD CAROLYN [US]


Application No.: US20070087975A1  Published: 19/Apr/2007

Title: Compound useful for the prevention and treatment of left ventricular hypertrophy in dialysed patients

Applicant/Assignee: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA

Application No.: 11/250634   Filing Date: 17/Oct/2005

Abstract:Is described a method of treating left ventricular hypertrophy comprising administering an effective amount of propionyl L-carnitine, or a pharmaceutical salt thereof, to ESRD or dialysed patients in need of such treatment.

Priority:

Inventor: CARMINATI PAOLO [IT]; CORSI MARCO [IT]


Application No.: US20070092524A1  Published: 26/Apr/2007

Title: Method for the treatment and prophylaxis of avian influenza infection

Applicant/Assignee:

Application No.: 11/584568   Filing Date: 23/Oct/2006

Abstract:This invention relates to methods and compositions for treatment and prevention of Avian Influenza. Specifically, the invention relates to the use of immunoglobulins obtained from a subject immune to Avian Influenza in the preparation and use of pharmaceutical preparations for the treatment of Avian Influenza.

Priority: US20050728764P Applic. Date: 2005-10-21; US20050729196P Applic. Date: 2005-10-24

Inventor: NUSBACHER JACOB [IL]; CAPLAN VERED [IL]


Application No.: US20070092553A1  Published: 26/Apr/2007

Title: Compositions and methods of making rapidly dissolving lonically masked formulations

Applicant/Assignee: PFAB LP

Application No.: 11/255555   Filing Date: 21/Oct/2005

Abstract:The present invention includes compositions and methods for reduce the taste of the drug in the drug resin complex. The composition may include one or more drug-resin complexes and a highly compressible, free-flowing pharmaceutical excipient. The resin is present in an amount effective to reduce the taste of the drug in the drug resin complex relative to an otherwise identical pharmaceutical composition without the resin

and wherein the highly compressible, free-flowing pharmaceutical excipient causes release of the drug-resin complex in the mouth.

Priority:

Inventor: TENGLER MARK [US]; MCMAHEN RUSSELL L [US]


Application No.: US20070093503A1  Published: 26/Apr/2007

Title: METHODS AND KIT FOR TREATING PARKINSON'S DISEASE

Applicant/Assignee: THOMAS JEFFERSON UNIVERSITY

Application No.: 11/565831   Filing Date: 01/Dec/2006

Abstract:The efficacy of levodopa therapy in patients being treated for Parkinson's disease is enhanced by administering high doses of a partial glycine agonist. The frequency and severity of levodopa-induced side effects in Parkinson's disease patients are also reduced by administration of a partial glycine agonist.

Priority: US2003-660090 Applic. Date: 2003-09-11; US20020410512P Applic. Date: 2002-09-13

Inventor: SCHNEIDER JAY S [US]


Application No.: US20070098649A1  Published: 03/May/2007

Title: Method and composition for controlling oral pathogens

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Application No.: 10/551639   Filing Date: 22/Mar/2004

Abstract:A composition and method of controlling oral and other human pathogens is disclosed. The composition and method utilize an antimicrobial or antibiotic and a berberine as active agents to treat mammals, including humans.

Priority: WO2004US08616 Applic. Date: 2004-03-22

Inventor: WU CHRISTINE D [US]; KIINGHORN A D [US]; ROBERTS SARA K [NZ]


Application No.: US20070098765A1  Published: 03/May/2007

Title: Method of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof

Applicant/Assignee: NASHAI BIOTECH, LLC

Application No.: 11/640917   Filing Date: 19/Dec/2006

Abstract:The present invention discloses methods of making a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate, pharmaceutical compositions of the above mixture of theaflavins, diet supplement compositions of the above mixture of theaflavins and methods for using the above mixtures of theaflavin and pharmaceutical compositions thereof to treat or prevent various diseases. The present invention also discloses methods of making theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate, each as a separate compound, pharmaceutical compositions of the above compounds, diet supplement compositions of the above compounds and methods for using the above compounds to treat or prevent various diseases.

Priority: CN20021011512 Applic. Date: 2002-04-26; US2003-601314 Applic. Date: 2003-06-20; US2002-306204 Applic. Date: 2002-11-27; US20010333515P Applic. Date: 2001-11-28; US20020413576P Applic. Date: 2002-09-24

Inventor: ZHAO JIAN [US]; ZHOU RUI [CN]; CHEN HU [CN]


Application No.: US20070098792A1  Published: 03/May/2007

Title: OXYMORPHONE CONTROLLED RELEASE FORMULATIONS

Applicant/Assignee:

Application No.: 11/425966   Filing Date: 22/Jun/2006

Abstract:The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.

Priority: US2002-190192 Applic. Date: 2002-07-03; US20010329445P Applic. Date: 2001-10-15; US20010329432P Applic. Date: 2001-10-15; US20010303357P Applic. Date: 2001-07-06; US20010329444P Applic. Date: 2001-10-15

Inventor: KAO HAUI-HUNG [US]; BAICHWAL ANAND R [US]; MCCALL TROY [US]; LEE DAVID [US]


Application No.: US20070098794A1  Published: 03/May/2007

Title: OXYMORPHONE CONTROLLED RELEASE FORMULATIONS

Applicant/Assignee:

Application No.: 11/427438   Filing Date: 29/Jun/2006

Abstract:The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.

Priority: US2002-190192 Applic. Date: 2002-07-03; US20010329445P Applic. Date: 2001-10-15; US20010329432P Applic. Date: 2001-10-15; US20010303357P Applic. Date: 2001-07-06; US20010329444P Applic. Date: 2001-10-15

Inventor: KAO HAUI-HUNG [US]; BAICHWAL ANAND R [US]; MCCALL TROY [US]; LEE DAVID [US]


Application No.: US20070098797A1  Published: 03/May/2007

Title: Modified release composition of at least one form of venlafaxine

Applicant/Assignee: BIOVAIL LABORATORIES INTERNATIONAL S.R.L

Application No.: 11/445198   Filing Date: 02/Jun/2006

Abstract:The present invention relates to a modified release composition of at least one form of venlafaxine, which is a delayed controlled release composition. The composition comprises a core comprising at least one form of venlafaxine selected from the group consisting of venlafaxine, an active metabolite of venlafaxine, a pharmaceutically acceptable salt of venlafaxine, a pharmaceutically acceptable salt of an active metabolite of venlafaxine, and combinations thereof, less than 10% of a gelling agent and a pharmaceutically acceptable excipient. The composition further comprises a modified release coating which substantially surrounds the core which provides a delayed controlled release of the at least one form of venlafaxine.

Priority: US20050686461P Applic. Date: 2005-06-02; US20050691282P Applic. Date: 2005-06-17

Inventor: ZHOU FANG [US]; OBEREGGER WERNER [CA]; MAES PAUL [FR]


Application No.: US20070098801A1  Published: 03/May/2007

Title: Particles shaped as platelets

Applicant/Assignee: JANSSEN PHARMACEUTICA N.V

Application No.: 10/571663   Filing Date: 09/Sep/2004

Abstract:The present invention relates to polymer particles shaped as platelets and to a process of manufacturing such particles. The particles according to the invention exhibit a faster rate of dissolution in aqueous media than art-known particles.

Priority: US20030501639P Applic. Date: 2003-09-10; WO2004EP52104 Applic. Date: 2004-09-09

Inventor: VERRECK GEERT [BE]; ARIEN ALBERTINA MARIA E [BE]; PEETERS JOZEF [BE]; BREWSTER MARCUS E [BE]; TOMASKO DAVID L [US]; LI HUNGBO [CA]


Application No.: US20070098824A1  Published: 03/May/2007

Title: Canola extracts containing high levels of phenolic acids

Applicant/Assignee: KGK SYNERGIZE INC

Application No.: 11/260758   Filing Date: 27/Oct/2005

Abstract:Disclosed in certain embodiments is a canola extract comprising greater than 30% sinapic acid, pharmaceutical compositions thereof, and methods thereof.

Priority:

Inventor: GUTHRIE NAJLA [CA]; GUTHRIE ROBERT A [CA]


Application No.: US20070099831A1  Published: 03/May/2007

Title: Parathyroid hormone analogues and methods of use

Applicant/Assignee:

Application No.: 11/517146   Filing Date: 06/Sep/2006

Abstract:The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose of 2 mug to 60 mug, wherein said PTH peptide analogue has a reduced phospholipase-C activity and maintains adenylate cyclase activity.

Priority: US20050714905P Applic. Date: 2005-09-06; US20060834980P Applic. Date: 2006-07-31; US20060837972P Applic. Date: 2006-08-15

Inventor: MORLEY PAUL [CA]


Application No.: US20070099883A1  Published: 03/May/2007

Title: ANHYDROUS MOMETASONE FUROATE FORMULATION

Applicant/Assignee:

Application No.: 11/539769   Filing Date: 09/Oct/2006

Abstract:A stable pharmaceutical composition of anhydrous mometasone furoate, and methods for its preparation, are described.

Priority: US20050725059P Applic. Date: 2005-10-07; US20050727334P Applic. Date: 2005-10-17

Inventor: CALIS CHERYL LYNN [US]; MAHON THOMAS D [US]


Application No.: US20070099966A1  Published: 03/May/2007

Title: Device and Method for Inhibiting AGE Complex Formation

Applicant/Assignee:

Application No.: 11/537967   Filing Date: 02/Oct/2006

Abstract:Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.

Priority: US20050724138P Applic. Date: 2005-10-05

Inventor: FABRICANT JILL D [US]


Application No.: US20070104655A1  Published: 10/May/2007

Title: Inhalable tiotropium and container therefor

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/448765   Filing Date: 08/Jun/2006

Abstract:A medical product suitable for storing and delivering a pre-metered dose of tiotropium, devices containing the same, and methods of using the same.

Priority: SE20030003269 Applic. Date: 2003-12-03; SE20030003570 Applic. Date: 2003-12-22; US2004-834037 Applic. Date: 2004-04-29

Inventor: ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]


Application No.: US20070104657A1  Published: 10/May/2007

Title: Particulate compositions for pulmonary delivery

Applicant/Assignee: ADVANCED INHALATION RESEARCH, INC

Application No.: 11/633750   Filing Date: 05/Dec/2006

Abstract:This invention concerns an improved particulate composition for delivering a drug to the pulmonary system. Applicants disclose a method of identifying an optimal form of aerodynamically light particles which are highly dispersible. The particles of the instant invention are made by creating hollow, spherical drug particles (i.e., progenitor particles) that collapse in the process of particle formation, leading to wrinkled, thin-walled drug particles of very low envelope density. Additionally, Applicants have found that such particles are especially optimal for inhaled aerosols when the surface area parameter (sigma) is greater than 2, optimally greater than 3.

Priority: US2002-300657 Applic. Date: 2002-11-20; US20010331708P Applic. Date: 2001-11-20

Inventor: BATYCKY RICHARD P [US]; EDWARDS DAVID A [US]; LIPP MICHAEL M [US]


Application No.: US20070104779A1  Published: 10/May/2007

Title: Treatment with omega-3 fatty acids and products thereof

Applicant/Assignee:

Application No.: 11/267581   Filing Date: 07/Nov/2005

Abstract:A method for reducing non-HDL cholesterol levels of a subject comprising administering a pharmaceutical composition comprising omega-3 fatty acids to the subject in an amount sufficient to reduce non-HDL cholesterol. The method may include a reduction of the triglyceride levels of the subject and, optionally, an increase in the HDL cholesterol levels of the subject. These methods can be used concurrently with hypertriglyceridemia therapy prescribed by a doctor.

Priority:

Inventor: RONGEN ROELOF M [US]; SHALWITZ ROBERT A [US]


Application No.: US20070105912A1  Published: 10/May/2007

Title: Pharmaceutical compositions comprising lercanidipine

Applicant/Assignee:

Application No.: 10/581128   Filing Date: 01/Dec/2004

Abstract:A controlled release pharmaceutical composition comprising lercanidipine dissolved or dispersed in a solid vehicle at ambient temperature, thus forming a solid dispersion, achieves delayed release of lercanidipine over an extended period of time, reduced food effect and increased bioavailability compared to commercially available lercanidipine containing products.

Priority: US20040553787P Applic. Date: 2004-03-16; DK20030001778 Applic. Date: 2003-12-01; DK20040000249 Applic. Date: 2004-02-18; WO2004DK00836 Applic. Date: 2004-12-01

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20070105927A1  Published: 10/May/2007

Title: Amorphous rizatriptan benzoate

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/584284   Filing Date: 20/Oct/2006

Abstract:Rizatriptan benzoate in an amorphous form is disclosed. Also disclosed is a process for preparing rizatriptan benzoate substantially in amorphous form comprising the steps of (a) preparing a solvent solution comprising non-amorphous rizatriptan benzoate and one or more solvents capable of dissolving the non-amorphous rizatriptan benzoate

and (b) recovering the amorphous form of rizatriptan benzoate from the solution.

Priority: IN2005MU01323 Applic. Date: 2005-10-20; US20050734561P Applic. Date: 2005-11-08

Inventor: SRIDHARAN RAMASUBRAMANIAN [IN]; NAIK SAMIR J [IN]; AHER BHUPESH V [IN]; PRADHAN NITIN SHARAD C [IN]


Application No.: US20070110678A1  Published: 17/May/2007

Title: Method for administration of tiotropium

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 11/448725   Filing Date: 08/Jun/2006

Abstract:A method for administration and preparation of pharmaceutical dry powder doses are disclosed. The metered dry powder doses are formed from a finely divided dry powder of an selected anticholinergic agent to be used in a dry powder inhaler device. The metered dry powder medicinal dose is arranged as a medicinally effective quantity of the selected medicament onto a dose bed and moisture-tight sealed by using a high barrier seal, for introduction into an inhaler device provided with an Air-razor device for obtaining a fine particle fraction, FPF, of at least 30-50% of delivered powder mass when suction through the inhaler is applied, whereby the dose is delivered to and deposited in the lung of the user during a single inhalation effort.

Priority: SE20030003270 Applic. Date: 2003-12-03; US2003-729024 Applic. Date: 2003-12-08

Inventor: ZIERENBERG BERND [DE]; MEMMESHEIMER HOLGER [DE]; LUNKENHEIMER CHRISTINE [DE]; CALANDER SVEN [SE]; NIEMI ALF [SE]; NILSSON THOMAS [SE]; MYRMAN MATTIAS [SE]


Application No.: US20070110815A1  Published: 17/May/2007

Title: Micronised azodicarbonamide, and the preparation and use thereof

Applicant/Assignee:

Application No.: 11/586723   Filing Date: 26/Oct/2006

Abstract:Azodicarbonamide (ADA) in the form of a micronised dry powder, said powder having a granulometric distribution of particles wherein the particles of the powder have a mean diameter (d50) equal to or less than 2 mum and a 90% diameter (d90) equal to or less than 4 mum.

Priority: EP20050110022 Applic. Date: 2005-10-26

Inventor: VANDEVELDE MICHEL [BE]; MARGERY HELENE [BE]


Application No.: US20070110817A1  Published: 17/May/2007

Title: Biological active blood serum obtained by electrostimulation

Applicant/Assignee: OWEN HOLDING LTD

Application No.: 10/581420   Filing Date: 20/Dec/2004

Abstract:The present invention relates to a method for preparing a blood serum product, the blood serum product and a pharmaceutical composition comprising said blood serum product as well as uses thereof in the treatment of various diseases and conditions, including epileptic seizures and apoplexy.

Priority: US20040619738P Applic. Date: 2004-10-18; WO2004EP14510 Applic. Date: 2004-12-20

Inventor: SHESTAKOV VITALI A [RU]


Application No.: US20070111953A1  Published: 17/May/2007

Title: Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease

Applicant/Assignee: KGK SYNERGIZE, INC

Application No.: 11/478970   Filing Date: 28/Jun/2006

Abstract:The present invention relates to solid compositions comprised primarily of phospholipids (also known commercially as lecithin), or enriched phospholipids, in an amount of at least 20% up to 90% by weight of the total phospholipid composition. More particularly, the present invention relates to solid phospholipid compositions that provide enhanced bioactivity of functional ingredients for the treatment, reduction and/or prevention of diseases such as hypercholesterolemia and atherosclerosis.

Priority: US20050694720P Applic. Date: 2005-06-28

Inventor: GUTHRIE NAJLA [CA]; WENDEROTH SONDRA [US]


Application No.: US20070111978A1  Published: 17/May/2007

Title: Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract

Applicant/Assignee:

Application No.: 11/595513   Filing Date: 09/Nov/2006

Abstract:Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Priority: US20050735340P Applic. Date: 2005-11-12

Inventor: DOHIL RANJAN [US]; BASTIAN JOHN [US]; ACEVES SEEMA S [US]


Application No.: US20070116664A1  Published: 24/May/2007

Title: Methods and compositions for treating hair and skin afflictions

Applicant/Assignee:

Application No.: 11/601788   Filing Date: 20/Nov/2006

Abstract:Method and composition for promoting hair growth, preventing or minimizing hair loss and treating other hair and skin afflictions are disclosed. The methods include topical application of a composition comprising at least a phyto-steroid to the skin or hair follicles being treated.

Priority: US20050738023P Applic. Date: 2005-11-21

Inventor: GONEN SHMUEL [IL]


Application No.: US20070116695A1  Published: 24/May/2007

Title: PHARMACEUTICAL PREPARATIONS FOR ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND OTHER ASSOCIATED DISORDERS

Applicant/Assignee:

Application No.: 11/533818   Filing Date: 21/Sep/2006

Abstract:A pharmaceutical preparation for the treatment of attention deficit disorders combines a therapeutically effective amount of digestive enzymes, such as chymotrypsin, and medication used to treat attention deficit disorders, such as Ritalin(R), Concert(R), Adderall(R) and Strattera(R). The preparation may be in the form of a tablet, capsule or time released formula in order to reduce the amount of pills per dosage. The pharmaceutical preparation ameliorates the symptoms of the attention deficit disorder. The preparation has a stabilizing matrix containing a solidified microcrystalline cellulose which captures and protects therapeutically effective amounts of digestive enzyme particles within the stabilizing matrix.

Priority: US20050719028P Applic. Date: 2005-09-21; US20050719255P Applic. Date: 2005-09-21; US20060744922P Applic. Date: 2006-04-15; US20060744928P Applic. Date: 2006-04-15

Inventor: FALLON JOAN M [US]


Application No.: US20070116709A1  Published: 24/May/2007

Title: Microemulsions with adsorbed macromolecules and microparticles

Applicant/Assignee:

Application No.: 11/406144   Filing Date: 18/Apr/2006

Abstract:Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(alpha-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided. Methods of stimulating an immune response, methods of immunizing a host animal against a viral, bacterial, or parasitic infection, and methods of increasing a Th1 immune response in a host animal by administering to the animal an immunogenic composition of the microparticles, and/or microemulsions of the invention, are also provided.

Priority: US2002-914279 Applic. Date: 2002-01-09; WO2000US03331 Applic. Date: 2000-02-09; US19990146391P Applic. Date: 1999-07-29; US19990161997P Applic. Date: 1999-10-28; US19990121858P Applic. Date: 1999-02-26

Inventor: O'HAGAN DEREK [US]; OTT GARY S [US]; DONNELLY JOHN [US]; KAZZAZ JINA [US]; UGOZZOLI MILDRED [US]; SINGH MANMOHAN [US]; BARACKMAN JOHN [US]


Application No.: US20070116758A1  Published: 24/May/2007

Title: Atorvastatin formulation

Applicant/Assignee:

Application No.: 11/285961   Filing Date: 23/Nov/2005

Abstract:Provided are atorvastatin compositions which reduce the effect of food on the bioavailability of atorvastatin and methods for making such compositions. Also provided are methods of reducing low density lipoprotein by administering the compositions of the invention.

Priority: US20050738828P Applic. Date: 2005-11-21

Inventor: DLUGATCH DAFNA [IL]; DOANI ZVIKA [IL]


Application No.: US20070116773A1  Published: 24/May/2007

Title: Metal nanostructures and pharmaceutical compositions

Applicant/Assignee: INTERUNIVERSITAIR MICROELEKTRONICA CENTRUM (IMEC)

Application No.: 11/479388   Filing Date: 30/Jun/2006

Abstract:A metal nanostructure is described. Such a metal nanostructure may comprise a nanometric metal core comprising gold, silver or an assembly or alloy of gold and silver, and one or more molecules attached to one or more surfaces of the nanometric metal core, where each of the molecules has the structural formula W-X-Y-Z, where W is an atom or a chemical group bound to the nanometric metal core, X is a hydrophobic spacer, Y is a hydrophilic spacer and Z is either hydrogen or a reactive group able to bind a reactive substrate or biomolecule. Such a metal nanostructure may be useful in making pharmaceutical compositions.

Priority: US20050696576P Applic. Date: 2005-07-05

Inventor: FREDERIX FILIP [BE]; VAN DE BROEK BIEKE [BE]


Application No.: US20070116786A1  Published: 24/May/2007

Title: A LIPIDIC EXTRACT FROM LEPIDIUM MEYNII AND ITS EFFECT ON THE LIBIDO

Applicant/Assignee: NATUREX

Application No.: 11/460142   Filing Date: 26/Jul/2006

Abstract:The present invention relates to compositions containing particular components that can be obtained from a plant which can have pharmaceutical applications. More particularly, the plant genus is Lepidium and the composition may contain in the range of between about 0.3% and 0.7% of benzyl isothiocyanate, b) between about 0.06% and about 0.02% of Lepidium sterol component, c) between about 1% and about 2% of a Lepidium fatty acid component, and d) about 0.006% to 0.6% or more total macamide/macaenes component as standardized with excipients.

Priority: US20050702796P Applic. Date: 2005-07-26

Inventor: ZHENG QUN Y [US]; ZHENG BO L [US]; HE KAN [US]


Application No.: US20070117815A1  Published: 24/May/2007

Title: Method of treating cancers with SAHA and pemetrexed

Applicant/Assignee:

Application No.: 11/592512   Filing Date: 03/Nov/2006

Abstract:The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

Priority: US20050733951P Applic. Date: 2005-11-04

Inventor: PLUDA JAMES [US]; FRANKEL STANLEY R [US]; RICHON VICTORIA M [US]; AVERBUCH STEVEN [US]; CHIAO JUDY H [US]


Application No.: US20070122470A1  Published: 31/May/2007

Title: New Combination Dosage Form

Applicant/Assignee:

Application No.: 11/563812   Filing Date: 28/Nov/2006

Abstract:The present invention relates to an oral pharmaceutical preparation for use in the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid. The present preparation comprises a fixed oral dosage form comprising a proton pump inhibitor in combination with acetyl salicylic acid. Furthermore, the present invention refers to a method for the manufacture thereof and the use thereof in medicine. The present invention also relates to a specific combination comprising esomeprazole, or an alkaline salt thereof or a hydrated form of any one of them, and acetyl salicylic acid for use as a medicament for the prevention of thromboembolic vascular events, such as myocardial infarction or stroke, and for the prevention and/or reduction of gastrointestinal complications associated with the use of acetyl salicylic acid.

Priority: US20050740981P Applic. Date: 2005-11-30; US20060818886P Applic. Date: 2006-07-06

Inventor: JOHANSSON DICK [SE]; SVEDBERG LARS-ERIK [SE]; NILSSON LENA [SE]


Application No.: US20070122474A1  Published: 31/May/2007

Title: Pharmaceutical preparation comprising an active dispersed on a matrix

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 11/642621   Filing Date: 21/Dec/2006

Abstract:The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation, an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohols, triglycerides, partial triglycerides and fatty acid esters.

Priority: EP20000126847 Applic. Date: 2000-12-07; US2003-433398 Applic. Date: 2003-09-11; WO2001EP14307 Applic. Date: 2001-12-06

Inventor: DIETRICH RANGO [US]; LINDER RUDOLF [US]; NEY HARTMUT [US]


Application No.: US20070122475A1  Published: 31/May/2007

Title: Taste masking composition

Applicant/Assignee:

Application No.: 11/657429   Filing Date: 24/Jan/2007

Abstract:A composition for delivery of a medicament that has a bitter taste and/or causes throat catch is provided. The composition contains Carbomer 934, Carbomer 971, Carbomer 974, PEG-5M or a mixture thereof in an amount sufficient to mask the bitter taste of the medicament and/or throat catch.

Priority: US2002-210484 Applic. Date: 2002-08-01; US20010309285P Applic. Date: 2001-08-01

Inventor: CORBO MICHAEL [US]; MIGTON JOHN [US]; PATELL MAHESH [US]


Application No.: US20070122476A1  Published: 31/May/2007

Title: Storage stable thyroxine active drug formulations and methods for their production

Applicant/Assignee: MYLAN PHARMACEUTICALS INC

Application No.: 11/699456   Filing Date: 30/Jan/2007

Abstract:This invention provides a storage-stable dosage form of a thyroxine active drug composition which exhibits an improved stability. The formulation contains a thyroxine active drug substance, an alditol, and a saccharide, and, optionally, additional pharmaceutically accepted excipients. Levothyroxine sodium is the preferred active drug substance, mannitol is the preferred alditol, and sucrose is the9 preferred saccharide. Additional preferred excipients include, for example, microcrystalline cellulose, crospovidone, magnesium stearate, colloidal silicon dioxide, and sodium lauryl sulfate.

Priority: US2005-143645 Applic. Date: 2005-06-03; US2003-443135 Applic. Date: 2003-05-22; US2001-987130 Applic. Date: 2001-11-13

Inventor: HANSHEW DWIGHT D JR [US]; WARGO DAVID J [US]


Application No.: US20070122477A1  Published: 31/May/2007

Title: Methods and articles for treating 25-hydroxyvitamin D insufficiency and deficiency

Applicant/Assignee: CYTOCHROMA, INC

Application No.: 11/549001   Filing Date: 12/Oct/2006

Abstract:A controlled-release pharmaceutical formulation including cholecalciferol and/or ergocalciferol, a method of making the formulation, and a method of administering the formulation to treat 25-hydroxyvitamin D insufficiency or deficiency, are disclosed. The composition and method of administration preferably result in delayed release of the vitamin(s) in the ileum of the small intestine and sustained, substantially constant, release of the vitamin(s) over an extended period, e.g., at least 4 hours or more. Individual and combined dosages of 500 IU to 50,000 IU per dosage form, preferably daily, are disclosed. The compositions and methods are contemplated to exhibit one or more advantages including, but not limited to efficiency of vitamin D repletion and maintenance

mitigation or avoidance of first pass effects of the Vitamin D compounds on the duodenum

mitigation or avoidance of adverse supraphysiological surges in intralumenal, intracellular and blood levels of cholecalciferol, ergocalciferol and 25-hydroxyvitamin D and their consequences

and mitigation or avoidance of serious side effects associated with Vitamin D supplementation, namely Vitamin D toxicity.

Priority: US20050725709P Applic. Date: 2005-10-12

Inventor: BISHOP CHARLES W [US]; CRAWFORD KEITH H [US]; MESSNER ERIC J [US]


Application No.: US20070122482A1  Published: 31/May/2007

Title: Method for preparing modified release pharmaceutical compositions

Applicant/Assignee:

Application No.: 10/574125   Filing Date: 04/Oct/2004

Abstract:A method for the preparation of a pharmaceutical particulate composition for modified release of one or more therapeutically, prophylactically and/or diagnostically active substances, the method involving spraying of a composition comprising an oily material on a solid composition in order to subject the solid composition to a controlled agglomeration process, whereby individual particles are aggregated into agglomerates in a controlled manner and a relatively small particle size and particle size distribution is obtained, the particulate composition comprising a sufficient amount of at least one release-rate modifying substance to provide a modified release of the active substance sufficient to provide duration of therapeutic, prophylactic and/or diagnostic effect of at least about 2 hours when the composition is exposed to an aqueous environment.

Priority: DK20030001459 Applic. Date: 2003-10-03; WO2004DK00669 Applic. Date: 2004-10-04

Inventor: HOLM PER [DK]; NORLING TOMAS [DK]


Application No.: US20070128125A1  Published: 07/Jun/2007

Title: Pharmaceutical Compositions Based on Tiotropium Salts and Salts of Salmeterol

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA KG

Application No.: 11/537333   Filing Date: 29/Sep/2006

Abstract:A pharmaceutical composition, comprising: (a) a tiotropium salt ( 1 )

and (b) a salmeterol salt ( 2 ), optionally in the form of the enantiomers, mixtures of enantiomers, or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient, and methods of treating respiratory diseases using such a pharmaceutical composition.

Priority: DE20001056104 Applic. Date: 2000-11-13; US2001-054567 Applic. Date: 2001-11-13; US20000251603P Applic. Date: 2000-12-06

Inventor: SCHMELZER CHRISTEL [DE]; NAGEL JUERGEN [DE]


Application No.: US20070128182A1  Published: 07/Jun/2007

Title: Non-Surgical Method for Preventing or Reducing the Rate of the Progression of Non-Proliferative Diabetic Retinopathy and the Treatment of Other Ocular Conditions

Applicant/Assignee:

Application No.: 11/626392   Filing Date: 24/Jan/2007

Abstract:A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

Priority: US2005-126625 Applic. Date: 2005-05-11

Inventor: BARTELS STEPHEN P [US]; MCINTIRE GREGORY L [US]; COMSTOCK TIMOTHY L [US]; LEVY BRIAN [US]


Application No.: US20070128266A1  Published: 07/Jun/2007

Title: Pharmaceutical or dietary compositions based on short-chain fatty acids and complex sugars, for intestinal disorders

Applicant/Assignee: COSMO TECHNOLOGIES LTD

Application No.: 10/588272   Filing Date: 01/Feb/2005

Abstract:Pharmaceutical and/or dietary compositions for supplying energy and eutrophication factors to the large intestine to improve its functionality and prevent the appearance of pathological conditions are described. The pharmaceutical and/or dietary compositions described are composed of one or more short-chain monocarboxylic acids or their salts, esters and/or amides, mixed with one or more soluble dietary fibres or complex sugars. These compositions are formulated by known techniques suitable for transporting the active ingredients into the colonic section of the intestine.

Priority: IT2004MI00187 Applic. Date: 2004-02-06; US20040553549P Applic. Date: 2004-03-17; WO2005EP50414 Applic. Date: 2005-02-01

Inventor: AJANI MAURO [IT]; VILLA ROBERTO [IT]; CELASCO GIUSEPPE [IT]; MORO LUIGI [IT]


Application No.: US20070128268A1  Published: 07/Jun/2007

Title: Pharmaceutical compositions comprising an antibiotic

Applicant/Assignee:

Application No.: 11/295929   Filing Date: 07/Dec/2005

Abstract:The present invention relates to cefdinir. More particularly to pharmaceutical formulations comprising cefdinir in a defined polymorphic form and processes for the preparation thereof. Furthermore, the present invention relates to processes to keep cefdinir in a defined polymorphic form.

Priority:

Inventor: JENNEWEIN HERWIG [AT]


Application No.: US20070128275A1  Published: 07/Jun/2007

Title: Trazodone composition for once a day administration

Applicant/Assignee: LABOPHARM INC LABOPHARM EUROPE LIMITED LABOPHARM (BARBADOS) LIMITED

Application No.: 11/519194   Filing Date: 11/Sep/2006

Abstract:The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.

Priority: US20050715162P Applic. Date: 2005-09-09

Inventor: GERVAIS SONIA [CA]; SMITH DAMON [CA]; RAHMOUNI MILOUD [CA]; CONTAMIN PAULINE [FR]; OUZEROUROU RACHID [CA]; MA MY L [CA]; FERRADA ANGELA [CA]; SOULHI FOUZIA [CA]


Application No.: US20070128276A1  Published: 07/Jun/2007

Title: Controlled release compositions comprising nimesulide

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 11/545718   Filing Date: 10/Oct/2006

Abstract:A controlled release composition comprising nimesulide as an active agent formulated as a gastroretentive system, preferably as a solid oral dosage form is provided, wherein the residence time of the active agent is increased in the stomach, duodenum, jejunum or ileum. The present invention also provides process of preparing such dosage form and methods of using such dosage form compositions. The dosage form compositions are preferably administered once-a-day or twice-a-day and are particularly very useful in the prophylaxis or treatment of NSAID indicated disorder(s) such as acute painful conditions like post-operative trauma, pain associated with cancer, sports injuries, migraine headache and the like, or chronic diseases such as arthritis and the like.

Priority: IN1999DE01297 Applic. Date: 1999-09-28; US2003-089020 Applic. Date: 2003-03-27; WO2000IN00094 Applic. Date: 2000-09-27

Inventor: JAIN RAJESH [IN]; JINDAL KOUR C [IN]; TALWAR MUNISH [IN]


Application No.: US20070128292A1  Published: 07/Jun/2007

Title: Novel nutraceutical and pharmaceutical compositions and their uses

Applicant/Assignee: FRESAXAL HOLDING, INC

Application No.: 10/554155   Filing Date: 22/May/2003

Abstract:The invention relates to organic chemistry area and more particularly to the polyunsaturated fatty acids area. The invention specifically relates to nutraceutical or pharmaceutical compositions rich in unsaturated fatty acids, characterized in that they contain free or combined alpha-linolenic acid, associated with fatty acids having five and six double-bonds, admixed with a diluent or vehicle suitable for oral administration. These compositions are used for preventing or treating human or animal cardio-vascular diseases, at a dose ranging from 800 to 1,000 mg of alpha-linolenic acid, from 80 to 120 mg of eicosapentaenoic acid and from 800 to 1,000 mg of docosahexaenoic acid.

Priority: FR20020006205 Applic. Date: 2002-05-22; WO2003FR01544 Applic. Date: 2003-05-22

Inventor: PREDAL LUDOVIC [FR]


Application No.: US20070129329A1  Published: 07/Jun/2007

Title: Stabilized pharmaceutical composition of pramipexole and method of preparation thereof

Applicant/Assignee: ALEMBIC LIMITED

Application No.: 11/607760   Filing Date: 01/Dec/2006

Abstract:Stabilized pharmaceutical compositions comprising pramipexole or pharmaceutically acceptable salts thereof and one or more dextrins and to methods of preparation of the same. The said stabilized composition is in form of tablets comprising pramipexole dihydrochloride, beta-cyclodextrin and one or more pharmaceutically acceptable excipients. A process for preparing the stabilized tablet composition, the process comprising dissolving pramipexole dihydrochloride along with polyvinyl pyrrolidone in suitable solvent

granulating blend of cyclodextrin and other excipients with above solution as granulating fluid

drying of above formed granules

lubricating granules with glidants and anti-adherents

compressing granules using suitable tablet equipment. A further process of preparing a stabilized tablet composition the process comprising preparing pramipexole dihydrochloride-beta-cyclodextrin inclusion complex

admixing prepared inclusion complex with other excipients

granulating using either dry granulation process or wet granulation process or direct compression

drying, sifting and lubricating, formed granules

compressing granules using suitable tablet equipment to form tablet. A method of packaging the stabilized pharmaceutical composition comprising including oxygen absorbers or inert gas in the packaging system comprising the composition

Priority: IN2005MU01492 Applic. Date: 2005-12-02

Inventor: KSHIRSAGAR RAJESH [IN]; GANDHI KRISHNAKANT [IN]; BURKUL AMOL [IN]


Application No.: US20070129444A1  Published: 07/Jun/2007

Title: Novel weight reduction composition and uses thereof

Applicant/Assignee: MALLINCKRODT INC

Application No.: 11/633698   Filing Date: 04/Dec/2006

Abstract:The present invention relates to a novel compound, N-benzylpropylhexedrine, and a process for preparing the compound. The invention also provides methods for reducing weight, decreasing appetite, inhibiting weight gain, and treating narcolepsy in patients by administering a pharmaceutical composition comprising N-benzylpropylhexedrine.

Priority: US20050742598P Applic. Date: 2005-12-06

Inventor: KALOTA DENNIS J [US]


Application No.: US20070134165A1  Published: 14/Jun/2007

Title: Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient

Applicant/Assignee: ALTANA PHARMA AG

Application No.: 11/578294   Filing Date: 19/Apr/2005

Abstract:The invention relates to a new method of treatment of respiratory diseases, in particular the treatment of asthmatic smoking patients. The method comprises the administration of a pharmaceutical composition comprising ciclesonide.

Priority: US20040563464P Applic. Date: 2004-04-20; WO2005EP51718 Applic. Date: 2005-04-19

Inventor: WURST WILHELM [DE]; BETHKE THOMAS [DE]; ENGELSTAETTER RENATE [DE]


Application No.: US20070134315A1  Published: 14/Jun/2007

Title: Orally administrable extended release pellet and tablet formulations of a highly water soluble compound

Applicant/Assignee:

Application No.: 11/296212   Filing Date: 08/Dec/2005

Abstract:Pharmaceutical compositions comprising an extended release formulation of active compounds effective in the treatment of various pathological conditions are provided. More particularly, the invention provides methods of making and using extended release formulations comprising active compounds that present formulation challenges such as short biological half-life, instability, highly water soluble and/or high dose requirements. Specifically, orally administrable extended release pellet and tablet formulations of isovaleramide are preferred.

Priority:

Inventor: VIERA MICHAEL L [US]; BHATT PADMANABH P [US]; MCKNIGHT LISA [US]; WOLDU ABRAHAM B [US]; MUHURI GOUTAM [US]


Application No.: US20070134323A1  Published: 14/Jun/2007

Title: ZIPRASIDONE SUSPENSION

Applicant/Assignee: PFIZER INC

Application No.: 11/623998   Filing Date: 17/Jan/2007

Abstract:Compositions comprising ziprasidone free base or a difficult to wet pharmaceutically acceptable ziprasidone acid addition salt, a polysorbate, and colloidal silicon dioxide form good aqueous suspensions having a useful shelf life and are easily re-suspended if settling occurs.

Priority: US2000-573312 Applic. Date: 2000-05-18; US19990136268P Applic. Date: 1999-05-27

Inventor: ARENSON DANIEL R [US]; QI HONG [US]


Application No.: US20070134328A1  Published: 14/Jun/2007

Title: OXYMORPHONE CONTROLLED RELEASE FORMULATIONS

Applicant/Assignee: ENDO PHARMACEUTICALS, INC

Application No.: 11/680432   Filing Date: 28/Feb/2007

Abstract:The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief.

Priority: US2002-190192 Applic. Date: 2002-07-03; US20010303357P Applic. Date: 2001-07-06; US20010329432P Applic. Date: 2001-10-15; US20010329444P Applic. Date: 2001-10-15; US20010329445P Applic. Date: 2001-10-15

Inventor: KAO HUAI-HUNG [US]; BAICHWAL ANAND R [US]; MCCALL TROY [US]; LEE DAVID [US]


Application No.: US20070134331A1  Published: 14/Jun/2007

Title: Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine

Applicant/Assignee: LES LABORATOIRES SERVIER

Application No.: 11/638960   Filing Date: 14/Dec/2006

Abstract:The invention relates to a coated solid orodispersible pharmaceutical composition for the administration of agomelatine by the oral, oromucosal or sublingual route.

Priority: FR20050012647 Applic. Date: 2005-12-14

Inventor: JULIEN MARC [FR]; THARRAULT FRANCOIS [FR]; PEAN JEAN-MANUEL [FR]; WUTHRICH PATRICK [FR]


Application No.: US20070134335A1  Published: 14/Jun/2007

Title: POLYPEPTIDES WITH THE CAPACITY TO ENTRAP DRUGS AND RELEASE THEM IN A CONTROLLED WAY

Applicant/Assignee:

Application No.: 11/610393   Filing Date: 13/Dec/2006

Abstract:The present application relates to new peptide polymers comprising monomeric units derived from the residues of glutamic acid, aspartic acid and lysine, or their protected derivatives, and which are functionalized through the introduction of side chains containing thiol groups or protected thiol groups. The new peptide polymers can be crosslinked in aqueous medium, and the resulting polymer matrices have the capacity to entrap drugs and, subsequently, release them in a controlled way when introduced into a physiological medium. This enables new pharmaceutical compositions to be developed for the controlled release of drugs, especially peptide- and protein-based ones.

Priority: US2005-147569 Applic. Date: 2005-06-08

Inventor: LLEDO ERNEST G [ES]; POYATOS PAU C [ES]


Application No.: US20070135336A1  Published: 14/Jun/2007

Title: Follistatin isoforms and uses thereof

Applicant/Assignee:

Application No.: 10/571837   Filing Date: 15/Sep/2004

Abstract:The present invention relates generally to regulating biological developmental process such as the biological functions involved in such developmental processes including growth and survival of an animal and particularly to methods of modifying the developmental processes and biological functions in cells. The invention also relates to methods of preventing and treating biological-development related conditions by regulating the developmental processes and modifying the biological functions in the cells.

Priority: AU20030905010 Applic. Date: 2003-09-15; WO2004AU01253 Applic. Date: 2004-09-15

Inventor: DE KRETSER DAVID [AU]; MORRISON JOHN RODERICK [AU]; LIN SHYR-YEU [TW]


Application No.: US20070135349A1  Published: 14/Jun/2007

Title: Method for increasing the serum half-life of a biologically active molecule

Applicant/Assignee:

Application No.: 11/701298   Filing Date: 31/Jan/2007

Abstract:A method is provided for preparing a biologically active molecule having an increased serum half-life. The method involves conjugating a polymer such as polyethylene glycol to the biologically active molecule. Also provided are polypeptide drugs having an increased serum half-life, e.g., human urokinase plasminogen activator (human "uPA" or "hUPA") or a fragment or derivative thereof. Pharmaceutical compositions containing such molecules and methods of using them to treat uPA-mediated and uPA receptor-mediated disorders are also provided.

Priority: US2005-113592 Applic. Date: 2005-04-25; US2002-123092 Applic. Date: 2002-04-11; US1999-263117 Applic. Date: 1999-03-05; US19980076964P Applic. Date: 1998-03-05

Inventor: DRUMMOND ROBERT J [US]; ROSENBERG STEVE [US]


Application No.: US20070135472A1  Published: 14/Jun/2007

Title: Novel crystalline forms of desloratadine and processes for their preparation

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/607229   Filing Date: 01/Dec/2006

Abstract:Novel polymorph Forms III and V of desloratadine are provided. Pharmaceutical compositions containing such polymorphs are also provided.

Priority: IN2005MU01487 Applic. Date: 2005-12-01; US20060756275P Applic. Date: 2006-01-04

Inventor: KUMAR BOBBA V S [IN]; KALE SANJAY A [IN]; CHOUDHARI RAJU B [IN]; PRADHAN NITIN S C [IN]


Application No.: US20070140980A1  Published: 21/Jun/2007

Title: Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation

Applicant/Assignee: CHIESI FARMACEUTICI S.P.A

Application No.: 10/538888   Filing Date: 17/Dec/2003

Abstract:Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is disclosed.

Priority: IT2002MI02674 Applic. Date: 2002-12-18; WO2003EP14386 Applic. Date: 2003-12-17

Inventor: CAPOCCHI ANDREA [IT]; PIVETTI FAUSTO [IT]


Application No.: US20070141022A1  Published: 21/Jun/2007

Title: POLYMERIC DELIVERY AGENTS AND DELIVERY AGENT COMPOUNDS

Applicant/Assignee: VIRGINIA COMMONWEALTH UNIVERSITY EMISPHERE TECHNOLOGIES, INC

Application No.: 11/669649   Filing Date: 31/Jan/2007

Abstract:Polymeric delivery agents, delivery agent compounds and compositions comprising them which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Priority: US2003-447608 Applic. Date: 2003-05-28; US2001-889005 Applic. Date: 2001-10-09; WO2000US00476 Applic. Date: 2000-01-07; US19990115273P Applic. Date: 1999-01-08

Inventor: MILSTEIN SAM J [US]; BARANTSEVITCH EUGENE N [US]; WANG NAI F [US]; LIAO JUN [US]; SMART JOHN E [US]; CONTICELLO RICHARD D [US]; OTTENBRITE RAPHAEL M [US]


Application No.: US20070141043A1  Published: 21/Jun/2007

Title: Non-Surgical Method for Preventing or Reducing the Rate of the Progression of Non-Proliferative Diabetic Retinopathy and the Treatment of Other Ocular Conditions

Applicant/Assignee:

Application No.: 11/626391   Filing Date: 24/Jan/2007

Abstract:A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy to the proliferative form of diabetic retinopathy comprising intravitreally administering to a patient suffering from non-proliferative diabetic retinopathy an effective amount of serine proteinase enzyme sufficient to create, without surgery, a posterior vitreal detachment to prevent or reduce the progression of proliferative diabetic retinopathy in said patient. Also disclosed is a non-surgical method of treating ocular conditions such as retinal ischemia, retinal inflammation, retinal edema tractional retinal detachment, tractional retinopathy, vitreous hemorrhage and tractional maculopathy by intravitreally administering to a patient suffering from one or more of these conditions with an effective amount of a serine proteinase enzyme to reduce or treat that particular ocular condition. Plasmin, microplasmin and miniplasmin are preferred serine proteinase enzymes and plasmin is the most preferred.

Priority: US2005-126625 Applic. Date: 2005-05-11

Inventor: BARTELS STEPHEN P [US]; MCINTIRE GREGORY L [US]; COMSTOCK TIMOTHY L [US]; LEVY BRIAN [US]


Application No.: US20070141147A1  Published: 21/Jun/2007

Title: SEQUENTIAL RELEASE PHARMACEUTICAL FORMULATIONS

Applicant/Assignee: AURIGA LABORATORIES, INC

Application No.: 11/461238   Filing Date: 31/Jul/2006

Abstract:A mixed-release tablet or capsule formulation including vehicles for the delivery of a plurality of drugs in various combinations of immediate release, extended release, and/or delayed release modes over a predetermined time period have been developed, which provide for controlled release not just of the drugs, but controlled release that is designed to create more effective coordination between the drugs being delivered. The drugs can be any medically and/or physiologically appropriate combination of drugs and active ingredients, preferably decongestant drugs, antihistamines, expectorants, antitussives, cough suppressants, and drying agents.

Priority: US20050752057P Applic. Date: 2005-12-21; US20060761766P Applic. Date: 2006-01-25; US20060791408P Applic. Date: 2006-04-13

Inventor: HEIL MATTHEW F [US]; WILSON GLYNN [US]


Application No.: US20070141149A1  Published: 21/Jun/2007

Title: Controlled-release pharmaceutical formulation

Applicant/Assignee:

Application No.: 10/583440   Filing Date: 22/Dec/2004

Abstract:In the present invention, a new pharmaceutical formulation with controlled release of the freely water soluble low-dose active substance used for at the most once daily administration is disclosed. The active substance is maintained at a suitable therapeutic concentration in the blood throughout at least a 24 hour period independent of the physiological pH value to which the pharmaceutical formulation is exposed.

Priority: SI20030000317 Applic. Date: 2003-12-23; WO2004SI00044 Applic. Date: 2004-12-22

Inventor: KUHAR POLONCA [SI]; SIRCA JUDITA [SI]


Application No.: US20070141155A1  Published: 21/Jun/2007

Title: PHARMACEUTICAL TABLETS HAVING HEIGHT GREATER THAN WIDTH

Applicant/Assignee: ACCU BREAK TECHNOLOGIES, INC

Application No.: 11/678408   Filing Date: 23/Feb/2007

Abstract:An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Priority: US20040573134P Applic. Date: 2004-05-21; WO2005US18639 Applic. Date: 2005-05-23; WO2005US18638 Applic. Date: 2005-05-23; WO2005US18633 Applic. Date: 2005-05-23; US2006-598306 Applic. Date: 2006-11-13; US2006-569343 Applic. Date: 2006-02-21; US20040573042P Applic. Date: 2004-05-21

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Application No.: US20070141158A1  Published: 21/Jun/2007

Title: Amphiphilic heparin derivative formed by coupling a heparin with a bile acid

Applicant/Assignee: ETHYPHARM

Application No.: 10/582989   Filing Date: 17/Dec/2004

Abstract:The invention relates to an amphiphilic heparin derivative formed from at least one type of partially N-desulfated heparin and at least one type of bile acid comprising one or several bile acid molecules grafted on a heparin molecule by an amide bond formed between the terminal carboxylic acid function of a bile acid and a primary heparin amine function which is initially present in the heparin or resulting from the N-desulfation. The inventive derivative is characterized in that the number of grafted bile acid molecules per 100 heparin disaccharide units ranges from 15 to 80 approximately.

Priority: FR20030015003 Applic. Date: 2003-12-19; WO2004FR03285 Applic. Date: 2004-12-17

Inventor: HOARAU DIDIER [CA]; BOUSTTA MAHFOUD [FR]; BRAUD CHRISTIAN [FR]; VERT MICHEL [FR]


Application No.: US20070141672A1  Published: 21/Jun/2007

Title: Minimalist bZIP Proteins and uses thereof

Applicant/Assignee:

Application No.: 11/592186   Filing Date: 03/Nov/2006

Abstract:The present invention provides minimalist bZIP proteins having a basic region derived from bHLH proteins fused to a leucine zipper dimerization domain derived from bZIP proteins and methods and uses thereof in the treatment of cancer. The present invention also provides pharmaceutical compositions for treating cancer.

Priority: US20050732700P Applic. Date: 2005-11-03

Inventor: SHIN JUMI [CA]


Application No.: US20070142275A1  Published: 21/Jun/2007

Title: Peptides with the capacity to bind to transforming growth factor b1 (tgf-b1)

Applicant/Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L

Application No.: 10/569012   Filing Date: 05/Jul/2004

Abstract:The described peptides possess the capacity to bind to Transforming Growth Factor TGF-beta1 (TGF-beta1), and are potential inhibitors of the biological activity of TGF-beta1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-beta1 expression.

Priority: ES20030002020 Applic. Date: 2003-08-22; WO2004ES00320 Applic. Date: 2004-07-05

Inventor: DELAS HERRERIAS JAVIER D [ES]; VAZQUEZ ANA BELEN L [ES]; SAGASTIBELZA JUAN JOSE L [ES]; VALTUENA JESUS P [ES]; CUESTA FRANCISCO B [ES]


Application No.: US20070142473A1  Published: 21/Jun/2007

Title: DOSAGE FORMS AND METHODS USING ETHACRYNIC ACID

Applicant/Assignee:

Application No.: 11/611454   Filing Date: 15/Dec/2006

Abstract:The invention is directed to a method of treating systemic arterial hypertension which preferably uses enter administration of a once-daily dose of ethacrynic acid of less than 50 mg/day to a patient afflicted with arterial hypertension. Doses of less than 25 mg/day ethacrynic acid are also indicated for treating hypertension. The invention also includes novel dosage forms comprising from 2.0 to 20 mg of ethacrynic acid.

Priority: US20050750769P Applic. Date: 2005-12-15

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Application No.: US20070148151A1  Published: 28/Jun/2007

Title: PROCESSES FOR THE MANUFACTURE AND USE OF PANCREATIN

Applicant/Assignee:

Application No.: 11/460330   Filing Date: 27/Jul/2006

Abstract:A process for the manufacture and use of pancreatin in which the concentration of one or more biological contaminants is reduced, such as viruses and/or bacteria, through heating the pancreatin at a temperature of at least 85 DEG C. for a period of less than about 48 hours.

Priority: US20050703813P Applic. Date: 2005-07-29

Inventor: FRINK MARTIN [DE]; KOELLN CLAUS-JUERGEN [DE]; BLUME HEINZ [DE]; RUST MICHAEL [DE]


Application No.: US20070148152A1  Published: 28/Jun/2007

Title: PROCESS FOR THE MANUFACTURE AND USE OF PANCREATIN MICROPELLET CORES

Applicant/Assignee:

Application No.: 11/464704   Filing Date: 15/Aug/2006

Abstract:A process for manufacturing and using pancreatin micropellet cores and pancreatin micropellets which are substantially free of synthetic oils. In one embodiment, a pharmaceutical composition is provided comprising a pancreatin micropellet with the enteric coating being designed to deliver pancreatin to the upper portion of the intestine of a mammal for release.

Priority: US20050708526P Applic. Date: 2005-08-15; US20050708692P Applic. Date: 2005-08-15

Inventor: SHLIEOUT GEORGE [DE]; KOELLN CLAUS-JUERGEN [DE]; SCZESNY FRITHJOF [DE]; ONKEN JENS [DE]; RUESING GUIDO [DE]


Application No.: US20070148153A1  Published: 28/Jun/2007

Title: CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR ACID-LABILE DRUGS

Applicant/Assignee:

Application No.: 11/464754   Filing Date: 15/Aug/2006

Abstract:An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.

Priority: US20050708526P Applic. Date: 2005-08-15; US20050708692P Applic. Date: 2005-08-15

Inventor: SHLIEOUT GEORGE [DE]; KOELLN CLAUS-JUERGEN [DE]; SCZESNY FRITHJOF [DE]; ONKEN JENS [DE]; KOERNER ANDREAS [DE]


Application No.: US20070148230A1  Published: 28/Jun/2007

Title: Medicament-containing particle and a solid preparation containing the particle

Applicant/Assignee:

Application No.: 10/582174   Filing Date: 07/Dec/2004

Abstract:The invention provides a medicament-containing particle wherein an unpleasant taste of the medicament is alleviated, which is obtainable by mixing and granulating the following ingredients: (1) the medicament with an unpleasant taste, (2) methylcellulose and (3) mannitol

and a solid preparation including the particle. The invention can make an unpleasant taste of the medicament alleviated and furthermore when the formulation including the particle is administered, the unpleasant taste can be masked and the formulation has a good dissolvability in gastrointestinal tract.

Priority: JP20030410961 Applic. Date: 2003-12-09; WO2004JP18204 Applic. Date: 2004-12-07

Inventor: FUJIWARA KEIICHI [JP]; SOGO KIYOMI [JP]; OKAMOTO SHIZUO [JP]; SHIBAMORI KOICHIRO [JP]; SHIMONO NORIHITO [JP]


Application No.: US20070148237A1  Published: 28/Jun/2007

Title: SUSTAINED-RELEASE FORMULATION OF ZONISAMIDE

Applicant/Assignee: OREXIGEN THERAPEUTICS, INC

Application No.: 11/563618   Filing Date: 27/Nov/2006

Abstract:Pharmaceutical formulations comprise sustained-release zonisamide. Methods of preparing such pharmaceutical formulations involve intermixing zonisamide with a suitable excipient configured to control the dissolution profile of the zonisamide. Methods of treatment involve administering the pharmaceutical formulations to patients in need of such treatment.

Priority: US20060835564P Applic. Date: 2006-08-04; US20060832110P Applic. Date: 2006-07-19; US20050740034P Applic. Date: 2005-11-28

Inventor: MCKINNEY ANTHONY A [US]; TOLLEFSON GARY [US]; YAU SIMON K [US]; VLADYKA RONALD S [US]; SOLTERO RICK [US]


Application No.: US20070148238A1  Published: 28/Jun/2007

Title: Dosage forms for movement disorder treatment

Applicant/Assignee: SPHERICS, INC

Application No.: 11/474116   Filing Date: 23/Jun/2006

Abstract:The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.

Priority: US20050693602P Applic. Date: 2005-06-23

Inventor: NANGIA AVINASH [US]; JACOB JULES [US]; MOSLEMY PEYMAN [US]; VERMA DAYA D [US]; HASWANI DINESH K [US]


Application No.: US20070148245A1  Published: 28/Jun/2007

Title: Compressed solid dosage forms with drugs of low solubility and process for making the same

Applicant/Assignee:

Application No.: 11/317824   Filing Date: 22/Dec/2005

Abstract:One of the objects of the present invention is directed to a process of preparing a pharmaceutical formulation of a drug of low aqueous solubility, comprising (A) fixing the drug in a strong matrix comprising at least one at least partially amorphous sugar to obtain a sugar-drug matrix

and (B) milling the sugar-drug matrix to obtain a milled sugar-drug matrix as the pharmaceutical formulation. The invention also provides the pharmaceutical formulation prepared by the process.

Priority:

Inventor: ZALIT ILAN [IL]; KOPEL MIRA [IL]


Application No.: US20070148252A1  Published: 28/Jun/2007

Title: Solid ganaxolone formulations and methods for the making and use thereof

Applicant/Assignee: MARINUS PHARMACEUTICALS

Application No.: 11/606222   Filing Date: 28/Nov/2006

Abstract:In certain embodiments, the invention is directed to composition comprising stable particles comprising ganaxolone, wherein the volume weighted median diameter (D 50 ) of the particles is from about 50 nm to about 500 nm.

Priority: US20060758171P Applic. Date: 2006-01-11; US20050740174P Applic. Date: 2005-11-28; US20050740208P Applic. Date: 2005-11-28

Inventor: SHAW KENNETH [US]; ZHANG MINGBAO [US]


Application No.: US20070149455A1  Published: 28/Jun/2007

Title: MODIFIED AND STABILIZED GDF PROPEPTIDES AND USES THEREOF

Applicant/Assignee: WYETH

Application No.: 11/614702   Filing Date: 21/Dec/2006

Abstract:Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

Priority: US2002-071499 Applic. Date: 2002-02-08; US20010267509P Applic. Date: 2001-02-08

Inventor: WOLFMAN NEIL M [US]; KHOR SOO-PEANG [US]; TOMKINSON KATHLEEN N [US]


Application No.: US20070149586A1  Published: 28/Jun/2007

Title: NEW CRYSTALLINE AND STABLE FORM OF ANDOLAST

Applicant/Assignee: ROTTAPHARM S.P.A

Application No.: 11/678277   Filing Date: 23/Feb/2007

Abstract:Described is a new crystalline Form A of Andolast disodium salt, triclinic, displaying a thermal event at 98-112 DEG C. and melting with decomposition at about 400 DEG C. (DSC). Andolast disodium Form A is a not hygroscopic solid, surprisingly stable to several humidity conditions in a temperature range acceptable for ordinary storage conditions. In addition its stability allows both chemical manufacturing and pharmaceutical manufacturing process consistency and reproducibility under conditions more viable and less expensive when compared to those used for highly hygroscopic solids.

Priority: EP20060112427 Applic. Date: 2006-04-10

Inventor: GIORDANI ANTONIO [IT]; SANTORO ANTONINO [IT]; SENIN PAOLO [IT]; GHIRRI MATTEO [IT]; MAKOVEC FRANCESCO [IT]; GILOTTA PAOLA [IT]; PERIS WALTER [IT]; CLAUDIO ROVATI LUCIO [IT]


Application No.: US20070154406A1  Published: 05/Jul/2007

Title: Spray-dried collectin compositions and process for preparing the same

Applicant/Assignee: DOBEEL CORPORATION

Application No.: 11/436377   Filing Date: 18/May/2006

Abstract:The present invention relates to a spray-dried composition comprising as an active ingredient at least one member protein of the collectin family or its functional equivalent for treating and preventing microbial infectious diseases. The present invention also relates to a method for producing the same composition. The composition produced by the method of the present invention is effective in suppressing infections caused by viruses, bacteria, fungi, and parasites. Since the composition is developed in a form suitable for inhalation, it can directly provide the active ingredient to the sites of infection from these microbes, and thus treat and prevent respiratory infections and external wounds.

Priority: WO2005KR04682 Applic. Date: 2005-12-30

Inventor: MOON HONG M [US]; YUM JUNG S [KR]; AHN BYUNG C [KR]; LEE JOO Y [KR]


Application No.: US20070154549A1  Published: 05/Jul/2007

Title: Multiparticulate formulations for oral delivery

Applicant/Assignee: VECTURA LTD

Application No.: 10/585021   Filing Date: 24/Dec/2004

Abstract:The present invention is directed to multiparticulate formulations for oral use, preferably comprising one or more therapeutically active agents. In particular, the present invention relates to fast melt formulations which are capable of masking the taste of the active agent, by virtue of one or more tastemasking measures, whilst retaining the desired drug dissolution profile and good mouthfeel. The multiparticulate formulations of the invention can be used in a multiple dose delivery device which dispenses a unit dose of the powder upon actuation, or can be packaged for dispensation in sachets or like unit dose containers.

Priority: GB20030030255 Applic. Date: 2003-12-31; WO2004GB50047 Applic. Date: 2004-12-24

Inventor: MORTON DAVID [GB]; SIMPSON DAVID [GB]; STANIFORTH JOHN [GB]


Application No.: US20070154550A1  Published: 05/Jul/2007

Title: Pharmaceutical composition comprising anticonvulsant with taste mask coating

Applicant/Assignee:

Application No.: 10/570216   Filing Date: 27/Aug/2004

Abstract:A pharmaceutical composition in the form of coated core particles comprising an anticonvulsant drug, which can be sprinkled onto food, wherein said core particles are coated with a taste mask coating which is less than 7% by weight of the pharmaceutical composition.

Priority: EP20030468006 Applic. Date: 2003-08-28; WO2004EP09588 Applic. Date: 2004-08-27

Inventor: ARTI POTDAR [IN]


Application No.: US20070160659A1  Published: 12/Jul/2007

Title: Stabilized formulations of phosphatidylserine

Applicant/Assignee:

Application No.: 10/572782   Filing Date: 08/Nov/2006

Abstract:Disclosed are stable PS preparations, in powder, liquid and dispersion forms, as well as methods of producing thereof. Most importantly, the stable PS preparations are particularly devoid of residual phospholipase D activity, and the methods of eliminating such activity are also described herein. Lastly, uses of these PS preparations in nutraceuticals or as active agents of pharmaceutical compositions are also provided herein.

Priority: IL20030158139 Applic. Date: 2003-09-25; WO2004IL00895 Applic. Date: 2004-09-26

Inventor: PLATT DORIT [IL]; SHULMAN AVIDOR [IL]; DROR GAI B [IL]; SCHEINMAN NETA [IL]; TWITO YONI [IL]; ZUABI RASSAN [IL]


Application No.: US20070160660A1  Published: 12/Jul/2007

Title: COMPOSITIONS FOR ORAL USE BASED ON S-ADENOSYLMETHIONINE AND A PROCESS FOR THEIR PREPARATION

Applicant/Assignee: TRUFFINI & REGGE' FARMACEUTICI SPA GRAAL SR:L

Application No.: 11/276900   Filing Date: 17/Mar/2006

Abstract:The present invention relates to solid dietary and/or nutraceutic pharmaceutical compositions for oral use based on SAMe, or salts thereof, in combination with inositol and/or derivatives thereof and to a process for their preparation. The present invention relates to a method of stabilising a solid composition for oral use based on SAMe or salts thereof, making use of inositol and/or derivatives thereof with the addition of magnesium oxide.

Priority: IT2006MI00026 Applic. Date: 2006-01-10

Inventor: SENECI ALESSANDRO [IT]; GIOVANNONE DANIELE [IT]; ZIO CESARE [IT]


Application No.: US20070160664A1  Published: 12/Jul/2007

Title: Pharmaceutical compositions comprising of proton pump inhibitor and prokinetic agent

Applicant/Assignee: PANACEA BIOTEC LIMITED

Application No.: 11/482186   Filing Date: 06/Jul/2006

Abstract:Oral pharmaceutical compositions and process for preparation thereof are provided comprising at least one gastric acid suppressing agent, preferably a proton pump inhibitor or its pharmaceutically acceptable salts, esters, hydrates, derivatives or prodrugs, and one or more prokinetic agent or its pharmaceutically acceptable salts, esters, hydrates, derivatives or prodrugs, optionally with other pharmaceutically acceptable excipients, characterized in that the gastric acid suppressing agent is present in a delayed release form and the prokinetic agent is present in a bimodal release form such as an immediate release form to provide an initial loading dose, and a delayed release form to provide a dose with a lag time

with the proviso that the prokinetic agent is not formulated using a hydrophilic rate controlling polymer and is not present in a sustained release form. Method of treatment of gastro esophageal reflux disease, reflux esophagitis, peptic ulcer, gastric ulcer, and other gastric acid related disorders by administering to a patient such a pharmaceutical composition in need thereof is also provided.

Priority: IN2004DE00021 Applic. Date: 2004-01-06; IN2004DE00025 Applic. Date: 2004-01-06; WO2005IN00002 Applic. Date: 2005-01-05

Inventor: JAIN RAJESH [IN]; JINDAL KOUR C [IN]; SINGH SUKHJEET [IN]


Application No.: US20070160665A1  Published: 12/Jul/2007

Title: Chlorthalidone combinations

Applicant/Assignee:

Application No.: 11/329538   Filing Date: 11/Jan/2006

Abstract:The invention relates to favourable combinations of the thiazide diuretic chlorthalidone with Angiotensin II Receptor Blockers (ARBs) for the treatment of hypertension.

Priority: WO2004EP07634 Applic. Date: 2004-07-10; US20030487835P Applic. Date: 2003-07-16

Inventor: BRAND GERRIT [CA]; BAKRIS GEORGE L [US]; DAVIDAI GIORA [US]


Application No.: US20070160671A1  Published: 12/Jul/2007

Title: Biguanide formulations

Applicant/Assignee: ANDRX CORPORATION

Application No.: 11/724931   Filing Date: 16/Mar/2007

Abstract:In certain embodiments, the invention is directed to a pharmaceutical dosage form consisting essentially of a single phase matrix comprising metformin or a pharmaceutically acceptable salt thereof and at least one controlled release excipient

said dosage form providing a mean Tmax of metformin from about 3 to about 12 hours after administration to human patients.

Priority: US2003-442692 Applic. Date: 2003-05-20; US20020382651P Applic. Date: 2002-05-23; US20020382652P Applic. Date: 2002-05-23

Inventor: CHENG XIU-XIU [US]; CHEN CHIH-MING [TW]; JAN STEVE [US]; TIAN DACHENG [US]


Application No.: US20070160675A1  Published: 12/Jul/2007

Title: Nanoparticulate and controlled release compositions comprising a cephalosporin

Applicant/Assignee: ELAN CORPORATION, PLC

Application No.: 11/478891   Filing Date: 30/Jun/2006

Abstract:The present invention provides a composition comprising cephalosporin useful in the treatment and prevention of a bacterial infection. In one embodiment, the composition comprises nanoparticulate particles comprising cephalosporin and at least one surface stabilizer. The nanoparticulate particles have an effective average particle size of less than about 2000 nm. In another embodiment, the composition comprises a modified release composition that, upon administration to a patient, delivers cephalosporin in a bimodal, multimodal or continuous manner. The invention also relates to dosage forms containing such compositions, and to methods for the treatment and prevention of a bacterial infection.

Priority: US2006-372857 Applic. Date: 2006-03-10; US2004-827689 Applic. Date: 2004-04-19; US2003-354483 Applic. Date: 2003-01-30; US2002-331754 Applic. Date: 2002-12-30; US2001-850425 Applic. Date: 2001-05-07; US2000-566636 Applic. Date: 2000-05-08; WO1999US25632 Applic. Date: 1999-11-01; US20050696117P Applic. Date: 2005-07-01; US19980106726P Applic. Date: 1998-11-02

Inventor: DEVANE JOHN G [IE]; STARK PAUL [IE]; FANNING NIALL M [IE]; REKHI GURVINDER S [US]; JENKINS SCOTT A [US]; LIVERSIDGE GARY [US]


Application No.: US20070160704A1  Published: 12/Jul/2007

Title: Colonies of nostoc commune, methods for cultivating edible nostoc commune and edible nostoc commune formulations and their use for promoting health

Applicant/Assignee:

Application No.: 10/587424   Filing Date: 03/Feb/2005

Abstract:Nostoc formulations, dietary supplements comprising the Nostoc formulations, and food products comprising Nostoc commune, (also known as Nostoc sphaericum, or Nostoc commune var. sphaericum) are disclosed. Nostoc formulations that may additionally comprise a medicinal composition are described. The present invention further relates to processes for producing these Nostoc formulations. In addition, the present invention relates to methods for promoting the health of an individual utilizing the Nostoc formulations, dietary supplements, food products and/or pharmacological compositions of the present invention. Moreover, this invention provides a method for cultivating Nostoc commune comprising (a). isolating and purifying Nostoc commune

(b). culturing the Nostoc commune

and (c). conditions suitable for optimal growth of Nostoc commune.

Priority: US20040541286P Applic. Date: 2004-02-03; US20040541290P Applic. Date: 2004-02-03; WO2005US03314 Applic. Date: 2005-02-03

Inventor: LU FAN [US]; HU QIANG [US]; HU ZHENG Y [CN]; ZHONG YANG [CN]


Application No.: US20070161551A1  Published: 12/Jul/2007

Title: Methods and compositions for the treatment of lipodystrophy

Applicant/Assignee:

Application No.: 10/586107   Filing Date: 26/Jan/2005

Abstract:The present invention is directed to methods and compositions for the treatment of lipodystrophy. The methods contemplate treatment of lipodystrophy in both HIV and non-HIV patients. More specifically, the methods are directed to a combination therapy that employs growth hormone and statins to effect treatment of lipodystrophy.

Priority: US20040549204P Applic. Date: 2004-03-01; US20040543366P Applic. Date: 2004-02-10; WO2005EP00758 Applic. Date: 2005-01-26

Inventor: DE LUCA GIAMPIERO [CH]


Application No.: US20070161617A1  Published: 12/Jul/2007

Title: Certain chemical entities, compositions and methods

Applicant/Assignee:

Application No.: 11/640438   Filing Date: 14/Dec/2006

Abstract:Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Priority: US20050751400P Applic. Date: 2005-12-15; US20060756356P Applic. Date: 2006-01-04; US20060817975P Applic. Date: 2006-06-29

Inventor: MORGAN BRADLEY P [US]; MORGANS DAVID J JR [US]; MUCI ALEX [US]; LU PU-PING [US]; KRAYNACK ERICA A [US]; TOCHIMOTO TODD [US]


Application No.: US20070166277A1  Published: 19/Jul/2007

Title: Polymeric reagents comprising a ketone or a related functional group

Applicant/Assignee:

Application No.: 11/714322   Filing Date: 06/Mar/2007

Abstract:Polymeric reagents comprising a polymer attached, either directly or through one or more atoms, to a ketone or a related functional group such as ketone hydrate, thione, monothiohydrate, dithiohydrate, hemiketal, monothiohemiketal, dithiohemiketal, ketal, or dithioketal are provided. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.

Priority: US20020437325P Applic. Date: 2002-12-31; US2003-751009 Applic. Date: 2003-12-31

Inventor: MCMANUS SAMUEL P [US]; KOZLOWSKI ANTONI [US]; SHEN XIAOMING [US]; COOK DANIEL C [US]


Application No.: US20070166370A1  Published: 19/Jul/2007

Title: Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient

Applicant/Assignee:

Application No.: 10/561700   Filing Date: 03/Jun/2004

Abstract:An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate

a population of a basic substance

and a second population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a second rate. In another embodiment, the oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a population of a pharmaceutical active

a population of a basic substance

a population of enteric coated pharmaceutical active

and a population of enteric coated basic substance. The composition can provide multiple site specific delivery of a pharmaceutical active in a rapid, delayed and/or sustained release manner into the plasma.

Priority: US20030482439P Applic. Date: 2003-06-26; US20040548903P Applic. Date: 2004-03-02; WO2004CA00825 Applic. Date: 2004-06-03

Inventor: ODIDI ISA [CA]; ODIDI AMINA [CA]


Application No.: US20070166372A1  Published: 19/Jul/2007

Title: Preparation of solid coprecipitates of amorphous valsartan

Applicant/Assignee: MAI DE LTD

Application No.: 11/641093   Filing Date: 19/Dec/2006

Abstract:A novel coprecipitate of amorphous valsartan with a pharmaceutically acceptable carrier, e.g. polyvinylpyrolidone (PVP), crosslinked-polyvinylpyrolidone, polyvinylpyrolidone vinyl acetate copolymer (PVP-VA64), a process for the preparation of said novel co-precipitate and the use of said novel coprecipitate in the treatment and/or prophylaxis of hypertension, cardiovascular diseases and conditions associated with thereof and certain complications thereof, are disclosed. A novel solid solution of amorphous valsartan with a pharmaceutically acceptable carrier, preferably with polyethyelene glycol PEG from 4000 to 20,000 of average mol. wt., a process for the preparation thereof and use are disclosed. The said novel coprecipitate of amorphous valsartan and the said novel solid solution of valsartan are stable and may be particularly suitable for pharmaceutical dosage forms.

Priority: US20060759726P Applic. Date: 2006-01-19

Inventor: HUANG HUIMIN HE [US]; HUANG CAIGU [US]


Application No.: US20070166375A1  Published: 19/Jul/2007

Title: MODIFIED RELEASE ORAL DOSAGE FORM USING CO-POLYMER OF POLYVINYL ACETATE

Applicant/Assignee: ASTRON RESEARCH LIMITED

Application No.: 11/623560   Filing Date: 16/Jan/2007

Abstract:Once a day modified release oral dosage form comprising of granules or pellets which are either compressed into tablet or filled inside the capsule, wherein the pellet has a core of active ingredient coated on non pareil seeds with a rate controlling functional coating of co-polymer of polyvinyl acetate optionally with an intermediate separating coating between the core and the functional coating layer.

Priority: IN2006MU00083 Applic. Date: 2006-01-18

Inventor: PATEL SHASHANK BABABHAI [IN]; YADAV KAMALA SULTANSINGH [IN]; MANDAL JAYANT KUMAR [IN]; MAHESHWARI KIRTI BANSIDHAR [IN]


Application No.: US20070166383A1  Published: 19/Jul/2007

Title: Anionic hydrogel matrices with ph dependent modified release as drug carriers

Applicant/Assignee: SIGMA-TAU INDUSTIRE FARMACEUTICHE RIUNITE S.P.A

Application No.: 10/596267   Filing Date: 16/Feb/2005

Abstract:Compositions with pH-dependent modified release are described, consisting of hydrogel matrices containing one or more active ingredients, in which said matrices are suitable for releasing said active ingredients in a prolonged manner in given sites of the body.

Priority: IT2004RM00168 Applic. Date: 2004-04-01; WO2005IT00081 Applic. Date: 2005-02-16

Inventor: GIAMMONA GAETANO [IT]; MANDRACCHIA DELIA [IT]


Application No.: US20070166400A1  Published: 19/Jul/2007

Title: Pharmaceutical composition comprising i.a. vitamin c, magnesium green tea extract for retarding cardiovascular disease

Applicant/Assignee:

Application No.: 10/570733   Filing Date: 18/Aug/2004

Abstract:The present invention provides pharmaceutical compositions comprising lysine, proline, arginine, vitamin C, magnesium, green tea extract, N-acetylcysteine, selenium, copper, manganese and one pharmaceutical acceptable component selected from the group consisting of a carrier, a diluent, and an excipient, wherein the pharmaceutical composition without the acceptable component contains 7-9 wt % magnesium, 20-30 wt % ascorbic acid and 11-25 wt % green tea extract A method of treting cardio-vascular diseases using the pharmaceutical compositions are also disclosed, more preferably for the treatment of post-menopausal women.

Priority: US2003-657019 Applic. Date: 2003-09-05; US2004-801262 Applic. Date: 2004-03-15; WO2004EP09263 Applic. Date: 2004-08-18

Inventor: RATH MATTHIAS [ZA]; NIEDZWIECKI ALEKSANDRA [US]; IVANOV VADIM [US]; ROOMI WAHEED [US]


Application No.: US20070167363A1  Published: 19/Jul/2007

Title: Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)

Applicant/Assignee:

Application No.: 11/504526   Filing Date: 15/Aug/2006

Abstract:In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

Priority: US1997-984476 Applic. Date: 1997-12-03; US19960032329P Applic. Date: 1996-12-03

Inventor: WOLFE M M [US]; TSENG CHI-CHUAN [US]; NEVILLE LINDA [US]


Application No.: US20070167380A1  Published: 19/Jul/2007

Title: Taste masked compositions of erythromycin a and derivatives thereof

Applicant/Assignee:

Application No.: 10/509824   Filing Date: 03/Apr/2003

Abstract:A pharmaceutical composition includes erythromycin A or a derivative thereof and alginic acid. The alginic acid provides taste masking of the erythromycin A or derivative. The erythromycin A derivative may be clarithromycin and the alginic acid may be one or both of alginic acid and its salt. The salt may be one or more of sodium alginate and calcium alginate. The pharmaceutical composition may further include one or more of a binder, a disintegrant, a flavoring agent, and a coating. The pharmaceutical composition also may include one or more active ingredients, including omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. The erythromycin A or a derivative thereof and the one or more active ingredients may be combined in a single pharmaceutical composition.

Priority: IN2002DE00426 Applic. Date: 2002-04-03; WO2003IB01221 Applic. Date: 2003-04-03

Inventor: DABRE RAHUL [IN]; NAGAPRASAD VISHNUBHOTLA [IN]; MALIK RAJIV [AT]


Application No.: US20070167489A1  Published: 19/Jul/2007

Title: Combination comprising antimuscarinic agents and PDE4 inhibitors

Applicant/Assignee:

Application No.: 11/726982   Filing Date: 23/Mar/2007

Abstract:Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary diseases.

Priority: ES20040001312 Applic. Date: 2004-05-31; US2006-375308 Applic. Date: 2006-03-14; US2005-141169 Applic. Date: 2005-05-31

Inventor: GRAS ESCARDO JORDI [ES]; LLENAS CALVO JESUS [ES]; RYDER HAMISH [ES]; ORVIZ DIAZ PIO [ES]


Application No.: US20070172459A1  Published: 26/Jul/2007

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/706088   Filing Date: 13/Feb/2007

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20070172517A1  Published: 26/Jul/2007

Title: Compositions capable of facilitation penetration across a biological barrier

Applicant/Assignee:

Application No.: 10/572249   Filing Date: 17/Sep/2004

Abstract:This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.

Priority: US2003-665184 Applic. Date: 2003-09-17; US2003-664989 Applic. Date: 2003-09-17; US20030503615P Applic. Date: 2003-09-17; WO2004IB04452 Applic. Date: 2004-09-17

Inventor: BEN-SASSON SHMUEL A [IL]; GALAMIDI-COHEN EINAT [IL]


Application No.: US20070172521A1  Published: 26/Jul/2007

Title: Levetiracetam formulations and methods for their manufacture

Applicant/Assignee:

Application No.: 11/371128   Filing Date: 07/Mar/2006

Abstract:Substantially glidant free levetiracetam compositions, pharmaceutical compositions incorporating substantially glidant free levetiracetam compositions, and methods of preparing such compositions are provided.

Priority: US20060762103P Applic. Date: 2006-01-24

Inventor: HRAKOVSKY JULIA [IL]


Application No.: US20070172525A1  Published: 26/Jul/2007

Title: Anti-diabetic combinations

Applicant/Assignee:

Application No.: 11/724486   Filing Date: 15/Mar/2007

Abstract:This invention a pharmaceutical composition comprising a DPP inhibitor and a slow release biguanide. The invention further discloses a method of administering a combination comprising a DPP inhibitor and a slow release biguanide to a mammal in need of thereof.

Priority:

Inventor: SESHA RAMESH [US]


Application No.: US20070172575A1  Published: 26/Jul/2007

Title: NUTRITIOUS EDIBLE COMPOSITIONS HAVING ZERO DIGESTIBLE CARBOHYDRATES AND HIGH PROTEINS AND PROCESSES FOR MAKING SAME

Applicant/Assignee:

Application No.: 11/164163   Filing Date: 20/Jan/2006

Abstract:A nutritious, high protein, zero carbohydrate pasta or bread is formed by combining animal protein with a binder, wherein the binder comprises substantially no digestible carbohydrates. A preferred composition comprises fish protein combined with guar gum. In an embodiment, odor, taste, texture, and color modifying ingredients are added, including for example a plant protein, ethyl maltol, salt, egg white, calcium carbonate, glycine, and/or polyphosphate.

Priority:

Inventor: GUNE SHAMIKA A [US]


Application No.: US20070173455A1  Published: 26/Jul/2007

Title: Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)

Applicant/Assignee:

Application No.: 11/504224   Filing Date: 14/Aug/2006

Abstract:In one embodiment, this invention provides an antagonist of glucose-dependent insulinotropic polypeptide (GIP) consisting essentially of a 24 amino acid polypeptide corresponding to positions 7-30 of the sequence of GIP. In another embodiment, this invention provides a method of preventing and treating obesity and non-insulin dependent diabetes mellitus (Type II) in a patient comprising administering to the patient an antagonist of glucose-dependent insulinotropic polypeptide (GIP). In yet another embodiment, this invention provides a method of improving glucose tolerance in a mammal comprising administering to the mammal an antagonist of glucose-dependent insulinotropic polypeptide (GIP).

Priority: US1997-984476 Applic. Date: 1997-12-03; US19960032329P Applic. Date: 1996-12-03

Inventor: WOLFE M M [US]; TSENG CHI-CHUAN [US]; NEVILLE LINDA [US]


Application No.: US20070178051A1  Published: 02/Aug/2007

Title: STERILIZED NANOPARTICULATE GLUCOCORTICOSTEROID FORMULATIONS

Applicant/Assignee: ELAN PHARMA INTERNATIONAL, LTD

Application No.: 11/275775   Filing Date: 27/Jan/2006

Abstract:The invention is directed sterile to compositions of glucocorticosteroids useful in the prophylaxis and chronic treatment of asthma and other allergic and inflammatory conditions in adults and pediatric patients.

Priority:

Inventor: PRUITT JOHN [US]; KEWALRAMANI RAJ [US]; SLIFER DAVID [US]; SHAW JACK M [US]; RUDDY STEPHEN B [US]


Application No.: US20070178062A1  Published: 02/Aug/2007

Title: Treatment of presbyopia with picolinic acid and its analogs

Applicant/Assignee:

Application No.: 11/544647   Filing Date: 10/Oct/2006

Abstract:Compositions and methods for inhibiting the growth of lens epithelial cells are provided. The compositions provided include a chelating agent in an amount sufficient for inhibiting the growth of lens epithelial cells. The compositions and methods provided may also be used for the treatment of disorders of the eye, especially in the treatment of presbyopia.

Priority: US20050724305P Applic. Date: 2005-10-07

Inventor: RAVI NATHAN [US]; HAMILTON PAUL D [US]


Application No.: US20070178070A1  Published: 02/Aug/2007

Title: Pharmaceutical compositions and methods for treating or preventing oxalate-related disease

Applicant/Assignee:

Application No.: 11/639388   Filing Date: 14/Dec/2006

Abstract:The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. A composition of the invention comprises an oral delivery vehicle comprising an oxalate degrading bacteria, one or more cryopreserving agents and one or more excipients. A composition of the invention is enteric coated and has a suitable shelf-life and acceptable properties to avoid negative impact from gastric fluid when it is orally administered.

Priority: WO2005US45457 Applic. Date: 2005-12-14

Inventor: KAUL POONAM [US]; SIDHU HARMEET [US]


Application No.: US20070178152A1  Published: 02/Aug/2007

Title: Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents

Applicant/Assignee:

Application No.: 11/592130   Filing Date: 03/Nov/2006

Abstract:Disclosed herein are pharmaceutical compositions comprising carboxyalkylcellulose esters for delivery of pharmaceutically active substances having low solubility in a medium such as water, an acidic aqueous buffer, a neutral aqueous buffer, or a basic aqueous buffer. Also disclosed are methods for making pharmaceutical compositions and methods of administering the compositions.

Priority: US20050733495P Applic. Date: 2005-11-04

Inventor: SHELTON MICHAEL C [US]; POSEY-DOWTY JESSICA D [US]; EDGAR KEVIN J [US]; LINGERFELT LARRY R JR [US]; KLEIN SANDRA [DE]; KIRK SHANE K [US]; DRESSMAN JENNIFER [DE]


Application No.: US20070178156A1  Published: 02/Aug/2007

Title: Pharmaceutical formulations

Applicant/Assignee:

Application No.: 10/598810   Filing Date: 11/Mar/2005

Abstract:The present invention is directed to novel pharmaceutically acceptable polymeric compositions suitable for melt extrusion and injection molding of single or multi-component pharmaceutical dosage forms comprising a plurality of drug substance containing sub-units, being capsule compartments and/or solid sub-units comprising a solid matrix of a polymer which contains a drug substance, the sub-units being connected together in the assembled dosage form.

Priority: US20040552499P Applic. Date: 2004-03-12; WO2005US08147 Applic. Date: 2005-03-11

Inventor: BROWN ADRIAN [GB]; MARGETSON DANIEL N [GB]; MATTHEWS WAYNE M [GB]; MCALLISTER STEPHEN M [GB]; RABY RONALD K JR [US]


Application No.: US20070178164A1  Published: 02/Aug/2007

Title: Pharmaceutical formulations of oxcarbazepine and methods for its preparation

Applicant/Assignee:

Application No.: 11/350606   Filing Date: 08/Feb/2006

Abstract:The present invention provides a pharmaceutical composition comprising oxcarbazepine and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution and an enhanced oxcarbazepine dissolution rate. The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multi-modal oxcarbazepine particle size distribution.

Priority: US20060764134P Applic. Date: 2006-01-31

Inventor: BLAU SIGAL [IL]


Application No.: US20070178559A1  Published: 02/Aug/2007

Title: Platelet promoting protein and the usage thereof

Applicant/Assignee:

Application No.: 11/729727   Filing Date: 29/Mar/2007

Abstract:The present invention discloses a protein that has strong affinity to thrombopoietin receptor (C-MPL) and the nucleotide sequences of the protein. The protein is capable of increasing the numbers of platelets and enhancing the blood clotting in vivo and is named as platelet promoting protein (PPP). The protein and its nucleotide sequences can be used for the treatment of blood diseases including thrombocytopenia.

Priority: CN20041080297 Applic. Date: 2004-09-30; WO2004CN01358 Applic. Date: 2004-11-26

Inventor: XU PEILIN [CN]; GE YICHEN [CN]; YANG YAN [CN]


Application No.: US20070179176A1  Published: 02/Aug/2007

Title: Monohydrated sodium salt of s-tenatoprazole and the use thereof in therapy

Applicant/Assignee: SIDEM PHARMA

Application No.: 10/561844   Filing Date: 17/Jun/2005

Abstract:The present invention relates to S-tenatoprazole monohydrated sodium salt, represented by the following formula and the use thereof in therapy for the treatment of digestive diseases.

Priority: FR20040006617 Applic. Date: 2004-06-17; WO2005FR01528 Applic. Date: 2005-06-17

Inventor: COHEN AVRAHAM [IL]; SCHUTZE FRANCOIS [FR]; CHARBIT SUZY [FR]; MARTINET FREDERIC [FR]; FICHEUX HERVE [FR]; HOMERIN MICHEL [FR]


Application No.: US20070184101A1  Published: 09/Aug/2007

Title: Stable pharmaceutical formulations of montelukast sodium

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 11/595162   Filing Date: 08/Nov/2006

Abstract:The invention encompasses stable pharmaceutical compositions comprising montelukast or salts thereof and methods of preparing the same.

Priority: US2006-431177 Applic. Date: 2006-05-09; US20060772258P Applic. Date: 2006-02-09

Inventor: HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]; BOGOMOLNY GRIGORY [IL]; DOLITZKY YEHUDIT [IL]


Application No.: US20070184103A1  Published: 09/Aug/2007

Title: Process for producing fenofibrate tablets

Applicant/Assignee: LABORATOIRES FOURNIER

Application No.: 11/723645   Filing Date: 21/Mar/2007

Abstract:The invention provides processes using suspensions to produce fenofibrate compositions. The resulting fenofibrate compositions can be made in the form of a capsule.

Priority: FR19970000479 Applic. Date: 1997-01-17; US2003-665520 Applic. Date: 2003-09-22; US2002-288425 Applic. Date: 2002-11-06; US2002-126875 Applic. Date: 2002-04-22; US2002-078500 Applic. Date: 2002-02-21; US2001-899026 Applic. Date: 2001-07-06; US2002-290333 Applic. Date: 2002-11-08; US2000-572330 Applic. Date: 2000-05-18; US1998-005128 Applic. Date: 1998-01-09

Inventor: STAMM ANDRE [FR]; SETH PAWAN [US]


Application No.: US20070184108A1  Published: 09/Aug/2007

Title: Stable pharmaceutical formulations of montelukast sodium

Applicant/Assignee:

Application No.: 11/431177   Filing Date: 09/May/2006

Abstract:The invention encompasses stable pharmaceutical compositions comprising montelukast or salts thereof and methods of preparing the same.

Priority: US20060772258P Applic. Date: 2006-02-09

Inventor: HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]; BOGOMOLNY GRIGORY [IL]; DOLITZKY YEHUDIT [IL]


Application No.: US20070184116A1  Published: 09/Aug/2007

Title: Pharmaceutical formulation containing unmilled flutamide

Applicant/Assignee:

Application No.: 10/593657   Filing Date: 17/Mar/2005

Abstract:Pharmaceutical formulation comprising crystalline and/or amorphous unmilled flutamide mixed with at least one surface-active substance.

Priority: DE200410014272 Applic. Date: 2004-03-22; WO2005EP02884 Applic. Date: 2005-03-17

Inventor: RUNGE HANS-JOACHIM [DE]; LEMBCKE ADALBERT [DE]


Application No.: US20070185177A1  Published: 09/Aug/2007

Title: Metaxalone polymorphs

Applicant/Assignee: DABUR PHARMA LTD FRESENIUS KABI ONCOLOGY LIMITED

Application No.: 11/647974   Filing Date: 29/Dec/2006

Abstract:The invention provides two crystalline forms A and B of the skeletal muscle relaxant and anxiolytic agent, Metaxalone of formula (I), and a process for preparation thereof. The two crystalline forms A and B are bioavailable. The invention further provides pharmaceutical compositions comprising the two bioavailable crystalline forms, useful for the relief of discomforts associated with acute, painful musculoskeletal conditions.

Priority: IN2005KO01196 Applic. Date: 2005-12-29

Inventor: CHATTOPADHYAY JAYANTA [IN]; SARKAR SUBRATA [IN]; MAHANTY JYAN S [IN]; HAZRA SUSANTA [IN]; MITRA MOLOY [IN]; SINGH MANOJ K [IN]


Application No.: US20070185194A1  Published: 09/Aug/2007

Title: Stable oral compositions of azithromycin monohydrate

Applicant/Assignee:

Application No.: 10/561827   Filing Date: 01/Jul/2004

Abstract:The present invention relates to stable oral compositions of azithromycin monohydrate with reduced bitterness, processes for making these compositions, and methods of using these compositions for the treatment of microbial infections. The stable oral compositions of azithromycin include an azithromycin premix, at least one pharmaceutically accepted excipient, and, optionally, at least one taste-masking agent. The azithromycin premix includes azithromycin monohydrate and at least one additive.

Priority: IN2003DE00861 Applic. Date: 2003-07-01; WO2004IB02191 Applic. Date: 2004-07-01

Inventor: MEHTA KAMAL [IN]; MATHUR RAJEEV S [IN]; PAUL SUJATA [IN]; SETHI SANJEEV K [IN]; MALIK RAJIV [IN]


Application No.: US20070189976A1  Published: 16/Aug/2007

Title: ADMINISTERING PHARMACEUTICAL COMPOSITIONS TO THE MAMMALIAN CENTRAL NERVOUS SYSTEM

Applicant/Assignee:

Application No.: 11/460194   Filing Date: 26/Jul/2006

Abstract:Methods, compositions and systems are provided for the non-invasive transnasal and transocular drug delivery to the central nervous system using eriodictyon fluid extract technology. By administration through the olfactory nerve or the optical nerve, the delivery of a biologically active substance of interest into the CNS and CSF can be enhanced through bypassing the blood-brain barrier. The invention involves the use of eriodictyon fluid extract as an excipient in compositions and systems for administering drugs to the olfactory or optical nerve.

Priority: US20050720797P Applic. Date: 2005-09-26

Inventor: PARNELL FRANCIS W [US]


Application No.: US20070190020A1  Published: 16/Aug/2007

Title: Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture

Applicant/Assignee: TEVA PHARMACEUTICAL INDUSTRIES LTD

Application No.: 11/354555   Filing Date: 14/Feb/2006

Abstract:The present invention provides pharmaceutical compositions comprising aliphatic amine polymers such as for example Sevelamer HCl as the active pharmaceutical ingredient, wherein the aliphatica amine polymers are spray granulated. The present invention further provides methods of preparing stable pharmaceutical compositions of aliphatic amine polymers such as for example Sevelamer HCl, preferably in tablets dosage forms.

Priority: WO2006US05274 Applic. Date: 2006-02-14

Inventor: HRAKOVSKY JULIA [IL]; TENENGAUZER RUTH [IL]; IOFFE ALLA [IL]; MOIN-KOTLIAR ELEONORA [IL]


Application No.: US20070190130A1  Published: 16/Aug/2007

Title: Protein hydrolysate excipients

Applicant/Assignee:

Application No.: 11/354974   Filing Date: 16/Feb/2006

Abstract:A pharmaceutical composition comprising an effective amount of a pharmaceutical active and up to about 99.8% wt/wt water soluble protein hydrolysate to total weight of composition is provided. Whey protein hydrolysate is exemplary of a suitable soluble protein hydrolysate. A method for preparing such a composition is also provided.

Priority:

Inventor: MARK WILLIAM A [US]; HALL LLOYD T [US]


Application No.: US20070190132A1  Published: 16/Aug/2007

Title: Pharmaceutical compositions for oral and topical administration

Applicant/Assignee: IVAX-CR A.S

Application No.: 11/786846   Filing Date: 13/Apr/2007

Abstract:A method of increasing viscosity of a pharmaceutical formulation for oral or topical administration comprises the steps of combining: a. an effective amount of one or more hydrophobic active ingredients

b. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids of formula (1) CH2OR-CHOR-CH20-[CH2CHOR-CH2O-]NCH2-CHOR-CH2OR (1) wherein n is an integer from 4 to 13 and R is H or CO.R' wherein R' is C8-22 saturated, unsaturated or hydroxylated alkyl and wherein at least one group R is not hydrogen

c. 5 to 50% of one or more compounds selected from polyglycerol esters of fatty acids and/or unsaturated fatty acids of formula (2) CH2OR-CHOR-CH20-[CH2CHOR-CH2O]NCH2-CHOR-CH2OR (2) wherein n is an integer from 0 to 10 and R-H or CO.R'' wherein R'' is C8-22 saturated, unsaturated or hydroxylated alkyl, and wherein while at least one group R is not hydrogen

d. 5 to 50% of one or more compounds selected from triglyceride macrogol glycerol esters, partial glycerides or fatty acids or macrogol esters of fatty acids in which the average quantity of reacted ethylene oxide in the synthesis of these substances ranges between 50 to 150 mols and concurrently the ratio between components b) and d) is from 0.1:1 to 10:1

wherein the above percentages are selected to total 100%

and wherein upon dilution with water 1:1 by volume the viscosity of the formulation increases by at least 5 times in comparison to the undiluted composition.

Priority: GB19990019288 Applic. Date: 1999-08-17; US2000-642242 Applic. Date: 2000-08-17

Inventor: ANDRYSEK TOMAS [CZ]; STUCHLIK MILAN [CZ]; VRANA ALES [CZ]; JEGOROV ALEXANDR [CZ]; STUCHLIK JOSEF [CZ]; MATHA VLADIMIR [CZ]


Application No.: US20070190133A1  Published: 16/Aug/2007

Title: Dosage forms having a microreliefed surface and methods and apparatus for their production

Applicant/Assignee:

Application No.: 11/235841   Filing Date: 27/Sep/2005

Abstract:The present invention provides an edible dosage form that incorporates optical elements (e.g., printed patterns, microrelief gratings, and/or macrorelief gratings), capable of producing unique optical effects and images in order to enable a user to better identify and differentiate the dosage forms, as well as to improve the detection of counterfeit production thereof, wherein the edible dosage forms may be made in a variety of ways to incorporate the optical elements therein.

Priority: US20040622631P Applic. Date: 2004-10-27

Inventor: BUNICK FRANK J [US]; CHEN JEN-CHI [US]


Application No.: US20070190136A1  Published: 16/Aug/2007

Title: Process for producing fenofibrate tablets

Applicant/Assignee: LABORATOIRES FOURNIER

Application No.: 11/723646   Filing Date: 21/Mar/2007

Abstract:The invention provides processes using suspensions to produce fenofibrate compositions. The resulting fenofibrate compositions can be made in the form of a tablet.

Priority: FR19970000479 Applic. Date: 1997-01-17; US2003-665520 Applic. Date: 2003-09-22; US2002-288425 Applic. Date: 2002-11-06; US2002-126875 Applic. Date: 2002-04-22; US2002-078500 Applic. Date: 2002-02-21; US2001-899026 Applic. Date: 2001-07-06; US2000-572330 Applic. Date: 2000-05-18; US1998-005128 Applic. Date: 1998-01-09; US2002-290333 Applic. Date: 2002-11-08

Inventor: STAMM ANDRE [FR]; SETH PAWAN [US]


Application No.: US20070190140A1  Published: 16/Aug/2007

Title: Pharmaceutical Composition in the Form of a Gastric-Resident Tablet Containing an Active Principle

Applicant/Assignee: SANOFI-AVENTIS

Application No.: 11/675712   Filing Date: 16/Feb/2007

Abstract:The disclosure concerns a pharmaceutical composition in the form of a gastric resident matrix tablet, comprising an active principle, characterized in that when contacted with an environment representing gastric fluid, it increases after 15 minutes in volume, by a swelling of at least 200%.

Priority: FR20040008986 Applic. Date: 2004-08-19; WO2005FR02092 Applic. Date: 2005-08-17

Inventor: ALAUX GERARD [FR]; CHOUIN ESTELLE [FR]; DUFRESNE-AROKIASSAMY NATHALIE [FR]


Application No.: US20070190143A1  Published: 16/Aug/2007

Title: Disintegrating tablets comprising licarb azepine

Applicant/Assignee:

Application No.: 10/598553   Filing Date: 21/Mar/2005

Abstract:The invention relates to pharmaceutical compositions comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide (also referred to as "licarbazepine") as drug substance.

Priority: GB20040006381 Applic. Date: 2004-03-22; GB20040006737 Applic. Date: 2004-03-25; WO2005EP02987 Applic. Date: 2005-03-21

Inventor: KALB OSKAR [DE]; WOLF MARIE-CHRISTINE [FR]


Application No.: US20070190146A1  Published: 16/Aug/2007

Title: Pharmaceutical Multilayer Tablet for Controlled Release of Active Ingredients With Highly pH-Dependent Solubility

Applicant/Assignee: SANOFI-AVENTIS

Application No.: 11/622118   Filing Date: 11/Jan/2007

Abstract:The present invention relates to a pharmaceutical controlled release multilayer tablet comprising at least two layers, at least one active ingredient with highly pH-dependent solubility, at least one pharmaceutically acceptable pH maintaining excipient and at least one pharmaceutically acceptable matrix forming excipient, characterized in that said at least one active ingredient with highly pH-dependent solubility and said at least one pharmaceutically acceptable pH maintaining excipient are respectively comprised in at least one distinct layer.

Priority: EP20040291943 Applic. Date: 2004-07-29; WO2005EP08719 Applic. Date: 2005-07-25

Inventor: ROGER BENEDICTE [FR]; BRUEL JEAN L [FR]; CUINE ALAIN [FR]


Application No.: US20070190147A1  Published: 16/Aug/2007

Title: PHARMACEUTICAL TABLETS WITH ACTIVE AND INACTIVE SEGMENTS

Applicant/Assignee: ACCU-BREAK TECHNOLOGIES, INC

Application No.: 11/693059   Filing Date: 29/Mar/2007

Abstract:An immediate release compressed pharmaceutical tablet that has two or more segments and a top and a bottom and has a height that exceeds the width of the tablet. The height is measured vertically from the top to the bottom of the tablet while it is in the tablet die in which it is fully compressed, after compression has been completed. The width is measured as the greatest horizontal dimension of the tablet at a location halfway between the top and the bottom of the tablet, except that when the horizontal cross-section of the tablet is substantially rectangular, the width is defined by locating the two shorter sides of the perimeter of the horizontal cross-section, and measuring the length of a line that is at right angle to the shorter sides.

Priority: WO2005US18633 Applic. Date: 2005-05-23; WO2005US18638 Applic. Date: 2005-05-23; WO2005US18639 Applic. Date: 2005-05-23; WO2005US18631 Applic. Date: 2005-05-23; WO2005US18632 Applic. Date: 2005-05-23; US20040573134P Applic. Date: 2004-05-21; US20040573042P Applic. Date: 2004-05-21

Inventor: SOLOMON LAWRENCE [US]; KAPLAN ALLAN S [US]


Application No.: US20070191280A1  Published: 16/Aug/2007

Title: High Purity Lipopeptides

Applicant/Assignee:

Application No.: 11/739180   Filing Date: 24/Apr/2007

Abstract:The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.

Priority: US2003-747485 Applic. Date: 2003-12-29

Inventor: KELLEHER THOMAS [US]; LAI JAN-JI [US]; DECOURCEY JOSEPH P [US]; LYNCH PAUL [US]; ZENONI MAURIZIO [IT]; TAGLIANI AURO [IT]


Application No.: US20070191321A1  Published: 16/Aug/2007

Title: Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof

Applicant/Assignee:

Application No.: 11/645807   Filing Date: 27/Dec/2006

Abstract:The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.

Priority: US20050753399P Applic. Date: 2005-12-27

Inventor: AHMED SALAH U [US]; SHAIK MADHU S [US]; GUPTA SANJEEV K [US]


Application No.: US20070191325A1  Published: 16/Aug/2007

Title: Methods for altering insulin secretion

Applicant/Assignee:

Application No.: 10/591909   Filing Date: 10/Feb/2005

Abstract:Modulation of the activity of glucocorticoid inducible kinase SGK1 in pancreatic islet cells restores insulin release. Also disclosed are methods and compounds useful for the treatment of glucocorticoid induced diabetes mellitus type-2.

Priority: EP20040005404 Applic. Date: 2004-03-08; WO2005EP01322 Applic. Date: 2005-02-10

Inventor: LANG FLORIAN [DE]


Application No.: US20070193894A1  Published: 23/Aug/2007

Title: Container for constituting a formulation in liquid form

Applicant/Assignee: IDD-EAL PATENT HOLDING COMPANY LIMITED

Application No.: 11/547709   Filing Date: 07/Apr/2005

Abstract:A container ( 70 ) for constituting a formulation in liquid form, comprises an elongate outer body ( 71 ) split into a first section ( 72 ) and a second section ( 73 ), along the longitudinal axis thereof, The container ( 70 ) has an inner chamber ( 77 ) divided into a first compartment ( 78 ) and a second compartment ( 79 ) by a seal ( 80 ). Seal ( 80 ) is movable in use between a closed position, wherein the first compartment 78 and the second compartment are sealed thereby, to an open position, wherein the first compartment ( 78 ) and the second compartment ( 79 ) are unsealed and any contents therein are free to mix together in the inner chamber ( 77 ) to form the formulation. The seal ( 80 ) is movable from the closed position to the open position by rotation of the first section ( 72 ) relative to the second section ( 73 ), and the volume of the inner chamber ( 77 ) remains unchanged following unsealing. Once the seal ( 80 ) has been moved to the open position it is retained in that position. Reversal of the rotational movement causes an outer cover ( 74 ) to become detached from a tear strip ( 75 ), permitting the outer cover ( 74 ) to be removed and the formulation to be capable of being delivered from the container ( 70 ). A formulation administered from the container ( 70 ) can ensure, for example, that a precise dose of an active ingredient is delivered to a patient, where the formulation is a pharmaceutical product.

Priority: WO2004IE00053 Applic. Date: 2004-04-08; WO2005IE00039 Applic. Date: 2005-04-07

Inventor: MACKEN MICHAEL J [IE]; O'MARA BRENDAN J [IE]


Application No.: US20070196333A1  Published: 23/Aug/2007

Title: Composition comprising mixtures of IFN-alpha subtypes

Applicant/Assignee:

Application No.: 11/360041   Filing Date: 23/Feb/2006

Abstract:A composition of human interferon-alpha (IFN-alpha) subtypes produced from human lymphoblastoid cells is disclosed. These purified IFN-alpha composition comprise higher specific activities and may be applied in the treatment of cancers, viruses, and immuno diseases.

Priority:

Inventor: LIN FU-YUNG [TW]; YANG CHIH-PING [TW]; HUANG SHIR-LY [TW]; LEE CHING-YUAN [TW]


Application No.: US20070196398A1  Published: 23/Aug/2007

Title: Fluoroquinolone fatty acid salt compositions

Applicant/Assignee:

Application No.: 11/356143   Filing Date: 17/Feb/2006

Abstract:The invention relates to pharmaceutical compositions of a fatty acid salt of a fluoroquinolone and to methods of treating a condition in an animal by administering to an animal in need thereof the pharmaceutical composition of the invention.

Priority:

Inventor: MURTHY YERRAMILLI V S [US]


Application No.: US20070196447A1  Published: 23/Aug/2007

Title: Use Of Antifungal Compositions To Treat Upper Gastrointestinal Conditions

Applicant/Assignee:

Application No.: 11/668764   Filing Date: 30/Jan/2007

Abstract:The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms.

Priority: US20060764608P Applic. Date: 2006-02-01; US20060833433P Applic. Date: 2006-07-26; US20060862149P Applic. Date: 2006-10-19

Inventor: WEG STUART L [US]


Application No.: US20070196464A1  Published: 23/Aug/2007

Title: Solid oral dosage form containing an enhancer

Applicant/Assignee: MERRION RESEARCH I LIMITED

Application No.: 11/400689   Filing Date: 07/Apr/2006

Abstract:The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to promote absorption of the bisphosphonate at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Priority: US2000-510560 Applic. Date: 2000-02-22; US19990121048P Applic. Date: 1999-02-22

Inventor: CUMMING KENNETH I [IE]; RAMTOOLA ZEBUNNISSA [IE]; LEONARD THOMAS W [US]


Application No.: US20070196472A1  Published: 23/Aug/2007

Title: PHENYLEPHRINE TANNATE AND PYRILAMINE TANNATE SALTS IN PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 11/736629   Filing Date: 18/Apr/2007

Abstract:Compositions of tannate salts of phenylephrine and pyrilamine produced by a method that allows for the in-situ conversion and incorporation of the tannate salts in a single dosage form. The conversion process includes dissolving a salts of phenylephrine and pyrilamine in a solvent and mixing with a dispersing agent and tannic acid to generate tannate salts. The tannate salts may be further processed to single dosage forms, such as tablets and suspensions.

Priority: US2001-047578 Applic. Date: 2001-10-26

Inventor: KIEL JEFFREY S [US]; THOMAS H G [US]; MANI NARASIMHAN [US]


Application No.: US20070196482A1  Published: 23/Aug/2007

Title: Sustained release torsemide dosage forms

Applicant/Assignee: PENWEST PHARMACEUTICALS CO

Application No.: 11/640083   Filing Date: 15/Dec/2006

Abstract:Disclosed in certain embodiments is a sustained release oral dosage form comprising an effective amount of torsemide or a pharmaceutically acceptable salt thereof and a sustained release excipient, wherein the dosage form provides a mean sodium (Na<+>) excretion and mean sodium (Na<+>) excretion rate as disclosed herein.

Priority: US20050750961P Applic. Date: 2005-12-16; US20050751847P Applic. Date: 2005-12-20

Inventor: SANGHVI PRADEEP [US]; KETSELA SARA [US]; SCIASCIA THOMAS [US]; JAWORSKI THEODORE J [US]


Application No.: US20070196488A1  Published: 23/Aug/2007

Title: Oral matrix formulations comprising licarbazepine

Applicant/Assignee:

Application No.: 10/598786   Filing Date: 21/Mar/2005

Abstract:The invention relates to pharmaceutical compositions comprising 10,11-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide (also referred to as "licarbazepine") as drug substance.

Priority: GB20040006379 Applic. Date: 2004-03-22; GB20040006738 Applic. Date: 2004-03-25; WO2005EP02988 Applic. Date: 2005-03-21

Inventor: KALB OSKAR [DE]; WOLF MARIE-CHRISTINE [FR]


Application No.: US20070196489A1  Published: 23/Aug/2007

Title: TASTE MASKED PHARMACEUTICAL PARTICLES

Applicant/Assignee:

Application No.: 11/696821   Filing Date: 05/Apr/2007

Abstract:Taste masked particles and chewable tablets made therefrom are disclosed. The taste masked particles comprise a core containing an active ingredient and a polymeric coating covering said core, said coating comprising a mixture of a) an enteric polymer

and b) an insoluble film forming polymer, the surface of said particle being free of active ingredient. The chewable tablets provide immediate release of the active ingredient.

Priority: US2001-878034 Applic. Date: 2001-06-08; US20000215505P Applic. Date: 2000-06-30

Inventor: MCTEIGUE DANIEL [US]; PARIKH NARENDA [US]; WYNN DAVID W [US]; PILLAI RAVIVAJ S [US]


Application No.: US20070196497A1  Published: 23/Aug/2007

Title: Pharmaceutical formulations for the prolonged release of active principle(s) and their applications

Applicant/Assignee: FLAMEL TECHNOLOGIES, INC

Application No.: 10/580023   Filing Date: 19/Nov/2004

Abstract:The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of active principle(s), particularly protein active principle(s), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of active principle(s) that makes it possible, after parenteral injection, to increase significantly the in vivo release time of a therapeutic protein while at the same time reducing the plasma concentration peak of the active protein, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance. The formulation according to the invention is an aqueous colloidal suspension of low viscosity based on submicronic particles of water-soluble biodegradable polymer PO carrying hydrophobic groups (HG), said particles being non-covalently associated with at least one active principle (AP) and forming a gelled deposit at the injection site, this gelling being caused by a protein present in the physiological medium.

Priority: FR20030050887 Applic. Date: 2003-11-21; WO2004FR50603 Applic. Date: 2004-11-19

Inventor: POULIQUEN GAUTHIER [FR]; SOULA OLIVIER [FR]; MEYRUEIX REMI [FR]; NICOLAS FLORENCE [FR]


Application No.: US20070197427A1  Published: 23/Aug/2007

Title: O,O'-AMIDOMALONATE AND N,O-AMIDOMALONATE PLATINUM COMPLEXES

Applicant/Assignee: ACCESS PHARMACEUTICALS, INC

Application No.: 11/626296   Filing Date: 23/Jan/2007

Abstract:The present invention relates to amidomalonate O,O'-Pt and N,O-Pt chelates and methods of preparing them in essentially pure form.

Priority: US2004-779186 Applic. Date: 2004-02-13; US2001-755220 Applic. Date: 2001-01-04; US20000174435P Applic. Date: 2000-01-04

Inventor: NOWOTNIK DAVID P [US]; STEWART DONALD R [US]; SOOD PAUL [US]; SHEVCHUK SERGIY V [US]; THURMOND KENNETH B II [US]


Application No.: US20070197467A1  Published: 23/Aug/2007

Title: ZAFIRLUKAST COMPOSITIONS

Applicant/Assignee:

Application No.: 11/671480   Filing Date: 06/Feb/2007

Abstract:Intimate dispersions comprising zafirlukast and hydroxypropyl cellulose.

Priority: IN2006CH00182 Applic. Date: 2006-02-06; US20060804835P Applic. Date: 2006-06-15

Inventor: RANGINENI SRINIVASULU [IN]; BHAGWATWAR HARSHAL P [IN]; DEVARAKONDA SURYA N [IN]; AGARWAL SUDEEP K [IN]


Application No.: US20070197644A1  Published: 23/Aug/2007

Title: Use of 13-HODE as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia

Applicant/Assignee: 1411198 ONTARIO LIMITED

Application No.: 11/783494   Filing Date: 10/Apr/2007

Abstract:This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury. More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperlasia and restoring vessel wall biocompatibility.

Priority: CA20002304906 Applic. Date: 2000-04-07; US2001-833257 Applic. Date: 2001-04-09

Inventor: BUCHANAN MICHAEL [CA]; HORROBIN DAVID [GB]


Application No.: US20070197649A1  Published: 23/Aug/2007

Title: Use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron

Applicant/Assignee:

Application No.: 11/708322   Filing Date: 21/Feb/2007

Abstract:A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron.

Priority: US20060775320P Applic. Date: 2006-02-22

Inventor: MUNNICH ARNOLD [FR]; SPINO MICHAEL [CA]; CABANTCHIK IOAV [IL]


Application No.: US20070197652A1  Published: 23/Aug/2007

Title: SOLID PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF THE BENIGN PROSTATIC HYPERPLASIA ITS PREPARATION PROCEDURE AND ITS THERAPEUTICAL METHOD

Applicant/Assignee:

Application No.: 11/676277   Filing Date: 17/Feb/2007

Abstract:We are hereby dealing with a solid pharmaceutical composition for the treatment of hyperplasia benign of prostate, also of a manufacturing procedure and the treatment method, where the pharmaceutical composition at least includes between 0.5 and 5 mg of a polysaccharide extract from a Gram negative bacteria wall and also pharmaceutically acceptable excipients. The aforesaid bacteria are preferably Pseudomonas Aeruginosa. Excipients can be i.e. colloidal silicic anhydride, wheat starch, micro crystalline cellulose, lactose or a combination of same. The composition may be in form of pastilles, capsules, tablets or pills.

Priority: AR2006P100573 Applic. Date: 2006-02-17

Inventor: BARREIRO HIPOLITO CARMELO MARI [AR]


Application No.: US20070202160A1  Published: 30/Aug/2007

Title: SOLID-STATE FORM OF CELECOXIB HAVING ENHANCED BIOAVAILABILITY

Applicant/Assignee: PHARMACIA CORPORATION

Application No.: 11/744603   Filing Date: 04/May/2007

Abstract:The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention. Also provided is a method of treating a medical condition or disorder in a subject where treatment with a cyclooxygenase-2 inhibitor is indicated, comprising administering, for example orally, a composition of the invention in a therapeutically effective amount.

Priority: US2005-189659 Applic. Date: 2005-07-26; US2000-730663 Applic. Date: 2000-12-06; US2000-728040 Applic. Date: 2000-12-01; US19990169856P Applic. Date: 1999-12-08

Inventor: HAGEMAN MICHAEL J [US]; HE XIAORONG [US]; KARARLI TUGRUL T [US]; MACKIN LESLEY A [US]; MIYAKE PATRICIA J [US]; ROHRS BRIAN R [US]; STEFANSKI KEVIN J [US]


Application No.: US20070202162A1  Published: 30/Aug/2007

Title: EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee:

Application No.: 11/678073   Filing Date: 23/Feb/2007

Abstract:The present invention relates to extended release pharmaceutical compositions comprising a beta-blocker drug or a pharmaceutically acceptable salt thereof, wherein said composition comprises at least two extended release portions, each portion having an in vitro dissolution profile that is different from another portion.

Priority: IN2006CH00309 Applic. Date: 2006-02-24; IN2006CH00500 Applic. Date: 2006-03-20; US20060806264P Applic. Date: 2006-06-30; US20060807570P Applic. Date: 2006-07-17

Inventor: SANKARNARAYANAN ANAND [IN]; GORE SUBHASH PANDURANG [IN]; KODIPYAKA RAVINDER [IN]; BHUSHAN INDU [IN]; MOHAN MAILATUR SIVARAMAN [IN]


Application No.: US20070202172A1  Published: 30/Aug/2007

Title: Metoprolol succinate E.R. tablets and methods for their preparation

Applicant/Assignee:

Application No.: 11/437192   Filing Date: 18/May/2006

Abstract:The present invention provides extended release pharmaceutical compositions of a beta blocker such as, but not limited to, metoprolol succinate as the active ingredient and methods of preparing such extended release pharmaceutical compositions.

Priority: US20060776706P Applic. Date: 2006-02-24

Inventor: GOLD TOMER [IL]; SHTERMAN NAVA [IL]


Application No.: US20070202182A1  Published: 30/Aug/2007

Title: Preparing solid formulation of nanoparticles of pharmaceutical ingredient, including at least micron-sized particles

Applicant/Assignee:

Application No.: 11/363129   Filing Date: 26/Feb/2006

Abstract:A slurry is prepared in which nanoparticles of a pharmaceutical ingredient have been formed within a solvent. A solid formulation of the nanoparticles of the pharmaceutical ingredient is prepared from the slurry, without employing electrostatic collection. The solid formulation of the nanoparticles includes at least micron-sized particles.

Priority:

Inventor: KANE KEVIN M [US]; FARR ISAAC [US]; FIGUEROA IDDYS D [US]


Application No.: US20070202503A1  Published: 30/Aug/2007

Title: Pharmaceutical Composition Of (+)-Erythro-Mefloquine And Its Use

Applicant/Assignee:

Application No.: 10/591158   Filing Date: 17/Mar/2005

Abstract:A pharmaceutical composition is in the form of a unit dosage comprising 1 to 60 mg (+)-erythro-mefloquine. This is intended for daily dosing.

Priority: GB20040006014 Applic. Date: 2004-03-17; WO2005GB01014 Applic. Date: 2005-03-17

Inventor: BAKER HELEN F [GB]; BANNISTER ROBIN M [GB]


Application No.: US20070203125A1  Published: 30/Aug/2007

Title: Medicament Combinations for the Treatment of Respiratory Diseases

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 11/675932   Filing Date: 16/Feb/2007

Abstract:The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R<1>, X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

Priority: EP20060110009 Applic. Date: 2006-02-16

Inventor: KONETZKI INGO [DE]; BOUYSSOU THIERRY [DE]; PESTEL SABINE [DE]; SCHNAPP ANDREAS [DE]


Application No.: US20070203198A1  Published: 30/Aug/2007

Title: Pharmaceutical composition

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 11/523771   Filing Date: 20/Sep/2006

Abstract:Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.

Priority: JP19950153500 Applic. Date: 1995-06-20; US2004-937494 Applic. Date: 2004-09-10; US2003-462793 Applic. Date: 2003-06-17; US2002-095453 Applic. Date: 2002-03-13; US2001-973689 Applic. Date: 2001-10-11; US1999-453521 Applic. Date: 1999-12-03; US1999-280710 Applic. Date: 1999-03-30; US1998-057465 Applic. Date: 1998-04-09; US1996-667979 Applic. Date: 1996-06-19

Inventor: IKEDA HITOSHI [JP]; SOHDA TAKASHI [JP]; ODAKA HIROYUKI [JP]


Application No.: US20070207191A1  Published: 06/Sep/2007

Title: PHARMACEUTICAL COMPOSITIONS AND METHODS TO ACHIEVE AND MAINTAIN A TARGETED AND STABLE COPPER STATUS AND PREVENT AND TREAT COPPER-RELATED CENTRAL NERVOUS SYSTEM DISEASES

Applicant/Assignee:

Application No.: 11/621962   Filing Date: 07/May/2007

Abstract:Compositions and methods are provided that comprise improved means to achieve and maintain a targeted level of copper status in persons in order to treat and prevent copper associated diseases.

Priority: US20060757672P Applic. Date: 2006-01-10; US20060765812P Applic. Date: 2006-02-07

Inventor: KANZER STEVE H [US]; BREWER GEORGE J [US]; STERGIS NICHOLAS [US]; ALTHAUS JOHN S [US]; BISGAIER CHARLES L [US]


Application No.: US20070207214A1  Published: 06/Sep/2007

Title: Oral pharmaceutical compositions with controlled release and prolonged absorption

Applicant/Assignee: FLAMEL TECHNOLOGIES

Application No.: 11/723553   Filing Date: 21/Mar/2007

Abstract:The invention concerns a galenic system with prolonged/controlled release of the medicinal and/or nutritional active principle, for oral administration. The aim is to provide a system enabling to obtain with one single tolerable and acceptable dose of active principle, efficient therapeutic protection over 24 hours (increasing the bioabsorption time without affecting bioavailability). To achieve this, the invention provides a composition comprising two controlled release systems associated in series, namely: individualised coated particles (microcapsules) of active principle forming an internal phase, the coating comprising a film-forming polymer P1 (ethylcellulose), a nitrogenous polymer (polyvinylpyrrolidone), a softener (castor oil) and a lubricant (magnesium stearate), and an external phase of functional carriers: polyelectrolytic hydrophilic polymer: (alginate), neutral hydrophilic polymer (hydroxypropylmethylcellulose) and a gelling additive (calcium acetate), said composition spontaneously forming in the presence of water, a cohesive and stable composite macroscopic solid, wherein the external continuous phase is a gelled matrix including the active principle microcapsules. The invention is useful for delayed oral galenic formulation of metformin.

Priority: WO2001FR02224 Applic. Date: 2001-07-10; FR20000009047 Applic. Date: 2000-07-11; US2003-332463 Applic. Date: 2003-01-09

Inventor: CASTAN CATHERINE [FR]; LEGRAND VALERIE [FR]; MEYRUEIX REMI [FR]; SOULA GERARD [FR]


Application No.: US20070212342A1  Published: 13/Sep/2007

Title: Protease compositions for the treatment of damaged tissue

Applicant/Assignee: SWISS-AMERICAN PRODUCTS, INC

Application No.: 11/642274   Filing Date: 19/Dec/2006

Abstract:The invention is directed to compositions containing one or more proteases that are beneficial in the treatment of damaged tissue, wounds and inflammation. The compositions of the invention modulate the levels and activity of proteins that are present at wound and inflammation sites and promote the repair of damaged tissue.

Priority: US20050752288P Applic. Date: 2005-12-20

Inventor: KLING WILLIAM O [US]; PARNELL LAURA K [US]; O'NEILL PHILIP J [US]


Application No.: US20070212409A1  Published: 13/Sep/2007

Title: Stable pharmaceutical compositions for 2-aza-bicyclo [3.30]-octane-3-carboxylic acid derivatives

Applicant/Assignee:

Application No.: 11/801777   Filing Date: 10/May/2007

Abstract:A stable composition of a 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivative and a method for its preparation are described. The stable composition includes an intimate admixture of the derivative and a stabilizing effective amount of a lubricant. The stable composition further includes an external excipient. A method of preparing the stable composition includes forming an intimate admixture of the derivative and a lubricant and then blending the intimate admixture with at least one excipient. Preferably the final blend is transformed into solid unit dosage form.

Priority: US2004-877027 Applic. Date: 2004-06-24; US20030482518P Applic. Date: 2003-06-26

Inventor: HRAKOVSHY JULIA [IL]; TENENGAUZER RUTH [IL]


Application No.: US20070213289A1  Published: 13/Sep/2007

Title: Method for purifying plasmid DNA

Applicant/Assignee: CENTELION

Application No.: 11/582427   Filing Date: 18/Oct/2006

Abstract:This invention provides a process for the continuous alkaline lysis of a bacterial suspension in order to harvest pDNA. It further provides for optional additional purification steps, including lysate filtration, anion exchange chromatography, triplex affinity chromatogragphy, and hydrophobic interaction chromatography. These optional purification steps can be combined with the continuous lysis in order to produce a highly purified pDNA product substantially free of gDNA, RNA, protein, endotoxin, and other contaminants.

Priority: WO2005EP05213 Applic. Date: 2005-04-19; WO2004EP11437 Applic. Date: 2004-09-17; US20040563008P Applic. Date: 2004-04-19

Inventor: BLANCHE FRANCIS [FR]; COUDER MICHEL [FR]; MAESTRALI NICOLAS [FR]; GUILLEMIN THIERRY [FR]; GAILLAC DAVID [FR]


Application No.: US20070218052A1  Published: 20/Sep/2007

Title: Novel lgG3 Antibodies for Stimulating Phagocytosis

Applicant/Assignee: LABOPRATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

Application No.: 10/575218   Filing Date: 18/Oct/2004

Abstract:The invention relates to human or humanised, chimeric, monoclonal, class IgG3 antibodies produced in a cell line of rat myeloma, especially line YB2/0. Said antibodies have a strong phagocytosis activity and can be administered for the treatment of cancers and infections.

Priority: FR20030012087 Applic. Date: 2003-10-16; WO2004FR02657 Applic. Date: 2004-10-18

Inventor: ROMEUF CHRISTOPHE D [FR]; JORIEUX SYLVIE [FR]; BOUREL DOMINIQUE [FR]; KLEIN PHILIPPE [FR]; BIHOREAU NICOLAS [FR]


Application No.: US20070218128A1  Published: 20/Sep/2007

Title: Manufacturing of Quick Release Pharmaceutical Compositions of Water Insoluble Drugs and Pharmaceutical Compositions Obtained By the Process of the Invention

Applicant/Assignee:

Application No.: 11/631091   Filing Date: 28/Jun/2005

Abstract:It has been found that pharmaceutical compositions comprising water insoluble drugs can be manufactured and formulated in a manner ensuring fast dissolution in gastric fluid. Advantageously, the manufacturing process provides a significantly improved stability, thus resulting in compositions that may have a longer shelf life than conventionally formulated and processed drugs.

Priority: DK20040001021 Applic. Date: 2004-06-29; WO2005DK00435 Applic. Date: 2005-06-28

Inventor: BERTELSEN POUL [DK]


Application No.: US20070218129A1  Published: 20/Sep/2007

Title: Solid Dispersible and/or Orodispersible Non-Filmy Containing at Least One Type of Active Substance Pharmaceutical Composition and Method for the Preparation Thereof

Applicant/Assignee: PHARMINNOVATION

Application No.: 10/567345   Filing Date: 05/Aug/2004

Abstract:The invention relates to an immediate release dispersible and orodispersible solid pharmaceutical composition having the form of particles with a size lower than 710 mum, containing the metformin active ingredient, characterized in that it comprises: a) from 65% to 90% in weight of the metformin active ingredient, optionally under the form of a salt, or a combination of the metformin active ingredient with a hypoglycemic active ingredient

b) from 0.5 to 4% in weight of a binding agent or a combination of binding agents

c) from 1% to 12% in weight of a disintegrating agent or a combination of disintegrating agents

d) from 0% to 10% in weight of a diluting agent or a combination of diluting agents

e) from 0.05% to 3% in weight of a sweetening agent or a combination of sweetening agents

and f) one or more additional excipients, the weight percentages being expressed based on the total weight of said composition.

Priority: FR20030050403 Applic. Date: 2003-08-06; WO2004FR50376 Applic. Date: 2004-08-05

Inventor: BESSE JEROME [FR]


Application No.: US20070218135A1  Published: 20/Sep/2007

Title: Sustained release matrix pharmaceutical composition

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/717980   Filing Date: 14/Mar/2007

Abstract:A sustained release pharmaceutical composition in solid dosage form is provided comprising (a) a therapeutically effective amount of one or more active pharmaceutical agents

(b) a first high viscosity release retarding cellulose ether

and (c) a second high viscosity release retarding cellulose ether, wherein the first and second high viscosity release retarding cellulose ethers are of the same material.

Priority: IN2006MU00366 Applic. Date: 2006-03-14; US20060832379P Applic. Date: 2006-07-21

Inventor: MUKHARYA AMIT [IN]; CHANDAK ABHAYKUMAR M [IN]; KRISHNAN ANANDI [IN]


Application No.: US20070218142A1  Published: 20/Sep/2007

Title: Pharmaceutical Formulations For The Prolonged Release Of Interleukins And Their Therapeutic Applications

Applicant/Assignee:

Application No.: 10/580035   Filing Date: 19/Nov/2004

Abstract:The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of an interleukin (IL) (and one or more other possible active principles), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of interleukin(s) (and one or more other possible active principles) that makes it possible, after parenteral injection, significantly to increase the in vivo release time of the IL while at the same time reducing the plasma concentration peak of this IL, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance. The formulation according to the invention is an aqueous colloidal suspension of low viscosity based on submicronic particles of water-soluble biodegradable polymer PO carrying hydrophobic groups (HG), said particles being non-covalently associated with at least one interleukin (and one or more other possible active principles) and forming a gelled deposit at the injection site, this gelling being caused by a protein present in the physiological medium.

Priority: FR20030050888 Applic. Date: 2003-11-21; WO2004FR50607 Applic. Date: 2004-11-19

Inventor: BIGNON SOPHIE [FR]; MEYRUEIX REMI [FR]; SOULA OLIVIER [FR]


Application No.: US20070219119A1  Published: 20/Sep/2007

Title: Method of Treatment of Tendonitis by Administration of Streptolysin O

Applicant/Assignee: MILKHAUS LABORATORY, INC

Application No.: 11/688596   Filing Date: 20/Mar/2007

Abstract:The invention provides a method for administering streptolysin O for treatment of various conditions including connective tissue disorders, reproductive fibroses and conditions mediated by the CD44 receptor. The invention also provides methods for protecting nerve cells from the effects of neurotoxic agents by the administration of streptolysin O.

Priority: US2004-764161 Applic. Date: 2004-01-23; US2003-349606 Applic. Date: 2003-01-23

Inventor: MCMICHAEL JOHN [US]


Application No.: US20070219175A1  Published: 20/Sep/2007

Title: Controlled Release Pharmaceutical Composition Comprising An Acid-Insoluble And A Bioadhesive Polymer

Applicant/Assignee: PANACEA BIOTEC LTD

Application No.: 10/551058   Filing Date: 05/Jan/2005

Abstract:Rapidly disintegrating oral controlled release pharmaceutical compositions and process for preparation of such compositions are provided. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably amoxicillin either alone or in combination with other antibiotic(s). The controlled release compositions comprise at least one active ingredient, and a polymer system comprising of at least two polymers which retard the release of the active ingredient in the stomach while providing rapid release of the said active ingredient in the alkaline contents of small intestine, optionally with other pharmaceutically acceptable excipients. The compositions provide therapeutically effective levels of the active ingredient for extended periods of time, and possess bioadhesive properties.

Priority: IN2004DE00022 Applic. Date: 2004-01-06; IN2004DE00027 Applic. Date: 2004-01-06; WO2005IN00005 Applic. Date: 2005-01-05

Inventor: JAIN RAJESH [IN]; JINDAL KOUR C [IN]; SINGH SUKHJEET [IN]


Application No.: US20070224129A1  Published: 27/Sep/2007

Title: Anti-misuse microparticulate oral pharmaceutical form

Applicant/Assignee: FLAMEL TECHNOLOGIES, INC

Application No.: 11/439432   Filing Date: 24/May/2006

Abstract:The present invention relates to solid microparticulate oral pharmaceutical forms whose composition and structure make it possible to avoid misuse of the pharmaceutical active principle (AP) they contain. The object of the present invention is to prevent solid oral drugs from being misappropriated for any use other than the therapeutic use(s) officially approved by the competent public health authorities. In other words, the object is to avoid the voluntary or involuntary misuse of solid oral drugs. The invention relates to a solid oral pharmaceutical form which is characterized in that it contains anti-misuse means, in that at least part of the AP it comprises is contained in coated microparticles for modified release of the AP, and in that the coated microparticles of AP have a coating layer (Ra) which assures the modified release of the AP and simultaneously imparts crushing resistance to the coated microparticles of AP so as to avoid misuse.

Priority: FR20050053437 Applic. Date: 2005-11-10; US20050735182P Applic. Date: 2005-11-10

Inventor: GUIMBERTEAU FLORENCE [FR]; DARGELAS FREDERIC [FR]


Application No.: US20070224260A1  Published: 27/Sep/2007

Title: Dosage Form Having Polymorphic Stability

Applicant/Assignee: DR. REDDY'S LABORATORIES, INC

Application No.: 10/599907   Filing Date: 14/Apr/2005

Abstract:Mini-tablets comprising a drug substance are formed by compression, using forces sufficiently low to preserve the polymorphic form of the drug. The mini-tablets can be administered directly, filled into capsules, etc.

Priority: IN2004CH00346 Applic. Date: 2004-04-15; US20040600332P Applic. Date: 2004-08-09; WO2005US12544 Applic. Date: 2005-04-14

Inventor: MEHTA PAVAK R [IN]; BHUSHAN INDU [IN]; CHOWDARY PASULA B [IN]; KRISHNAN KIRAN [US]; MOHAN MAILATUR S [IN]


Application No.: US20070224266A1  Published: 27/Sep/2007

Title: Descarbonylethoxyloratadine containing pharmaceutical composition

Applicant/Assignee: PHARMASCIENCE INC

Application No.: 11/642545   Filing Date: 21/Dec/2006

Abstract:A pharmaceutical composition wherein the pharmaceutically active ingredient (i.e. drug component) comprises Descarbonylethoxyloratadine and which further comprises an acidic element and a pharmaceutically acceptable stabilizer element.

Priority: CA20062541045 Applic. Date: 2006-03-24

Inventor: AURORA JACK [CA]; DAVE BRIJESH KUMAR [CA]


Application No.: US20070224267A1  Published: 27/Sep/2007

Title: Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity

Applicant/Assignee:

Application No.: 11/751245   Filing Date: 21/May/2007

Abstract:The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of painful conditions in the oral and pharyngeal cavity.

Priority: DE20021008313 Applic. Date: 2002-02-27; US2005-185558 Applic. Date: 2005-07-20; US2003-376349 Applic. Date: 2003-02-27; US20020386164P Applic. Date: 2002-06-05

Inventor: PSCHORN UWE [DE]; VIX JEAN-MICHEL [DE]; ESPERESTER ANKE [DE]


Application No.: US20070231368A1  Published: 04/Oct/2007

Title: PHARMACEUTICAL FORMULATIONS OF 6-11 BICYCLIC MACROLIDE DERIVATIVE KNOWN AS EDP-182 AND METHODS FOR PREPARATION THEREOF

Applicant/Assignee: ENANTA PHARMACEUTICALS, INC

Application No.: 11/693309   Filing Date: 29/Mar/2007

Abstract:The present invention provides pharmaceutical compositions and formulations comprising a therapeutically effectively of EDP-182 and the methods of formulation preparations. The present invention provides methods of treating bacterial infections by administering the pharmaceutical compositions to a subject in need of such treatment.

Priority: US20060787621P Applic. Date: 2006-03-30

Inventor: WANG MICHELLE [US]; SUN RONGQI [US]; OR YAT SUN [US]; WANG ZHE [US]


Application No.: US20070231374A1  Published: 04/Oct/2007

Title: Composition Comprising Ether Lipid

Applicant/Assignee:

Application No.: 10/572306   Filing Date: 17/Sep/2004

Abstract:The invention provides a composition suitable for administration to a mammalian, particularly human, subject wherein the composition comprises an active agent and an amphilic component (containing at least one amphiphile) wherein at least a portion of the amphiphilic component is an ether-linked lipid and wherein the composition includes a non-lamellar phase, preferably in the form of particles, or forms a non-lamellar phase on contact with an aqueous liquid. The aqueous liquid may be a body fluid. The invention also provides pharmaceutical and cosmetic formulations comprising the compositions and methods for their formation.

Priority: GB20030022033 Applic. Date: 2003-09-19; WO2004GB03965 Applic. Date: 2004-09-17

Inventor: TIBERG FREDRIK [SE]; BARAUSKAS JUSTAS [SE]; LARSSON KARE [SE]


Application No.: US20070231385A1  Published: 04/Oct/2007

Title: Controlled Release Pharmaceutical Composition and a Process for Preparing the Same

Applicant/Assignee: LUPIN LIMITED

Application No.: 10/574320   Filing Date: 29/Sep/2004

Abstract:A three-drug antiretrovial pharmaceutical composition having a selective combination of a controlled release active formulation and an immediate release active formulation for once daily administration. The composition provides desired dosages of the actives lamivudine, zidovudine or pharmaceutically acceptable derivatives thereof, and the immediate release formulation including at least one selective Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI), preferably nevirapine or a pharmaceutically acceptable derivative thereof along with pharmaceutically acceptable excipients. The once daily composition would favour patient compliance and effective treatment. A method of reducing the pill burden in a patient suffering from HIV infection and/or Acquired Immunodeffieciency Syndrome by administering a once daily dose of the three-drug antiretroviral pharmaceutical composition.

Priority: IN2003MU00417 Applic. Date: 2003-10-01; WO2004IN00306 Applic. Date: 2004-09-29

Inventor: SEN HIMADRI [IN]; JAYANTHI SURYAKUMAR [IN]; RAGHAVAN VINEETH [IN]; ARRA GANGA S [IN]


Application No.: US20070231386A1  Published: 04/Oct/2007

Title: Novel Pharmaceutical Formulation Containing a Biguanide and an Agiotension Antagonist

Applicant/Assignee: ANDRX LABS, LLC

Application No.: 11/628066   Filing Date: 27/May/2005

Abstract:A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.

Priority: US20040575259P Applic. Date: 2004-05-28; WO2005US18939 Applic. Date: 2005-05-27

Inventor: HAHN ELIOT F [US]


Application No.: US20070232537A1  Published: 04/Oct/2007

Title: INTRANASAL PYY FORMULATIONS WITH IMPROVED TRANSMUCOSAL PHARMACOKINETICS

Applicant/Assignee: NASTECH PHARMACEUTICAL COMPANY INC

Application No.: 11/613109   Filing Date: 19/Dec/2006

Abstract:What is described is an aqueous Y2 receptor-binding peptide formulation for enhanced intranasal delivery of a Y2 receptor-binding peptide, comprising said Y2 receptor-binding peptide, a buffer salt, and having a pH between about 3.0 and about 6.0, wherein said buffer salt comprises a net single ionogenic moiety with a pKa within two pH units of the pH of the formulation.

Priority: US20050751598P Applic. Date: 2005-12-19

Inventor: COSTANTINO HENRY R [US]; KLEPPE MARY S [US]; COHEN ANNEMARIE S [US]; SILENO ANTHONY P [US]


Application No.: US20070232638A1  Published: 04/Oct/2007

Title: Opiopathies

Applicant/Assignee:

Application No.: 11/395242   Filing Date: 03/Apr/2006

Abstract:The present invention provides novel methods for classifying, diagnosing and/or treating a group of human and veterinary ailments involving endogenous opioid concentrations. Also provided is a novel use for an existing class of compounds, the opioids, to treat opiopathic ailments, particularly paresis/paralysis, pseudo-atrophy and/or opiopathic pain, and in the manufacture of pharmaceutical and veterinary formulations therefor. The invention also relates to neuropathic, polyneuropathic, neurologic and neurogenic ailments typically characterized by paresis/paralysis. These ailments can involve an abnormal concentration of one or more endogenous opioids, or the blockade, underexpression or overexpression of one or more opioid receptors. In that regard, the invention encompasses therapeutic uses, methods and compositions employing opiates and/or their receptors. In particular, the invention relates to certain laboratory testing methods, clinical testing methods, research and development methods, business methods, methods of treatment, novel therapeutic uses, and human and veterinary pharmaceutical dosage forms, dosing regimens and formulations, especially those pertaining to opiopathy (particularly hypo-opiopathy).

Priority:

Inventor: BROOKS-KORN HOWARD [US]


Application No.: US20070232695A1  Published: 04/Oct/2007

Title: Gelled Periodontal Anesthetic Preparation

Applicant/Assignee: COLLEGIUM PHARMACEUTICAL, INC

Application No.: 11/534552   Filing Date: 22/Sep/2006

Abstract:A composition for anesthetizing oral or buccal tissues, especially periodontal pockets, is provided. The composition has a high concentration of topical anesthetic carried in a non-aqueous liquid vehicle containing a gelling agent. The anesthetics are optionally stabilized in the solution by ion-exchange complexation. The composition can anesthetize the gingivae for an extended period, such as 30 minutes or longer. Preferred anesthetics include tetracaine, benzocaine, butamben, and mixtures of these.

Priority: US2005-046608 Applic. Date: 2005-01-28; US20040539677P Applic. Date: 2004-01-28; US20050720153P Applic. Date: 2005-09-23

Inventor: HIRSH MARK [US]; HIRSH JANE C [US]; TRUMBORE MARK W [US]


Application No.: US20070232819A1  Published: 04/Oct/2007

Title: Oral Pharmaceutical Composition for Targeted Transport of a Platinum Complex Into the Colorectal Region, Method for Producing and Use as Medicament Thereof

Applicant/Assignee: PLIVA-LACHEMA A.S

Application No.: 11/574929   Filing Date: 14/Sep/2005

Abstract:An oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, includes a mixture of platinum complex of general formula I wherein A each independently is an -NH3 group or an amino group containing 1 to 18 carbon atoms, B each independently is a halogen atom, a hydroxy group or a -O-C(O)-R group wherein R each independently is hydrogen atom or an alkyl, alkenyl, aryl, aralkyl, alkylamino or alkoxy group containing 1 to 10 carbon atoms or functional derivatives of these groups, and X each independently is a halogen atom or a monocarboxylate group containing 1 to 20 carbon atoms, or X together form a dicarboxylate group containing 2 to 20 carbon atoms, and at least one excipient selected from the group including a saccharide, oligosaccharide, polysaccharide, modified polysaccharide mucopolysaccharide, protein, oligoprotein, polyprotein,

mucoprotein, peptide, oligopeptide and polypeptide, and optionally a lubricant and/or disintegrant, which mixture is optionally compressed into a tablet or contained in a capsule, and this tablet or capsule is optionally coated with a biodegradable layer and/or an outer pH-sensitive colonic layer, and a method of manufacturing and using the composition for treatment of colorectal carcinoma.

Priority: CZ20040000964 Applic. Date: 2004-09-14; WO2005CZ00070 Applic. Date: 2005-09-14

Inventor: FRANC ALES [CZ]; SOVA PETR [CZ]


Application No.: US20070238697A1  Published: 11/Oct/2007

Title: Pharmaceutical compositions and methods relating to fucans

Applicant/Assignee: UNIVERSITY OF BRITISH COLUMBIA

Application No.: 11/634526   Filing Date: 05/Dec/2006

Abstract:Compositions, methods and the like comprising fucans such as fucoidan to treat surgical adhesions, arthritis, and psoriasis.

Priority: US2004-958759 Applic. Date: 2004-10-05; US2002-232850 Applic. Date: 2002-08-28; US20010315362P Applic. Date: 2001-08-29

Inventor: JACKSON JOHN K [CA]; BURT HELEN M [CA]


Application No.: US20070238707A1  Published: 11/Oct/2007

Title: Solid Oral Dosage Form Containing an Enhancer

Applicant/Assignee: MERRION RESEARCH II LIMITED MERRION RESEARCH III LIMITED

Application No.: 11/733007   Filing Date: 09/Apr/2007

Abstract:The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Priority: US20060791231P Applic. Date: 2006-04-07

Inventor: LEONARD THOMAS W [US]


Application No.: US20070238716A1  Published: 11/Oct/2007

Title: STATIN STABILIZING DOSAGE FORMULATIONS

Applicant/Assignee:

Application No.: 11/686284   Filing Date: 14/Mar/2007

Abstract:The present invention relates to pharmaceutical formulations containing 7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methylphenylamino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid, or pharmaceutically acceptable salts thereof, and a stabilizing agent.

Priority: IN2006DE00700 Applic. Date: 2006-03-14

Inventor: MURTHY AYANAMPUDI S R [IN]; RAO KORLAPATI V [IN]; BOKALIAL RANADEEP [IN]; KAUSHIK RITU [IN]; KAUSHIK SUCHITRA [IN]


Application No.: US20070240236A1  Published: 11/Oct/2007

Title: O-GLYCANS IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE AND CANCERS

Applicant/Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATION

Application No.: 11/696599   Filing Date: 04/Apr/2007

Abstract:The present invention provides preventive approaches and treatments for an inflammatory bowel disorder (e.g., Crohn's disease or ulcerative colitis) or a gastrointestinal tumor (e.g., a colorectal cancer) comprising administering an O-glycan composition (e.g., mucins) to a subject, such as a human patient. In addition, the present invention also provides transgenic mice that fail to synthesize core 1-derived or core 3-derived O-glycans.

Priority: US20060789499P Applic. Date: 2006-04-05

Inventor: XIA LIJUN [US]


Application No.: US20070243234A1  Published: 18/Oct/2007

Title: Microscopic Tagging System for Security Identification

Applicant/Assignee:

Application No.: 11/578695   Filing Date: 31/Oct/2005

Abstract:A microscopic tagging material is provided comprised of a material to which has imparted at least two degrees of identification selected from the group consisting of physical configuration, elemental analysis, functional analysis, and polymeric composition analysis. The material may be a polymeric material, and the tagging material may comprise cut sections of an extruded polymer or polymer composition. The tagging material may be used as an authenticating means for a variety of compositions, coatings and/or products, such as food or drug products.

Priority: US20040622800P Applic. Date: 2004-10-29; US20050722011P Applic. Date: 2005-09-30; WO2005US39435 Applic. Date: 2005-10-31

Inventor: GABRIELE PETER [US]; FLEMMENS MICHAEL [US]; ROBERTSON JEFFREY [US]


Application No.: US20070243249A1  Published: 18/Oct/2007

Title: Novel formulation of pyridoxal-5'-phosphate and method of preparation

Applicant/Assignee:

Application No.: 11/288971   Filing Date: 28/Nov/2005

Abstract:A pyridoxal-5'-phosphate pharmaceutical formulation suitable for oral administration is provided comprising a dissolution profile, when measured in a standard dissolution apparatus, according to the United States Pharmacopoeia dissolution test, at 37 DEG C. in a 0.05M phosphate buffered solution having a pH of 6.8 at 75 rpm, as follows: (a) greater than about 30% at 15 minutes, (b) greater than about 85% at 30 minutes, (c), greater than about 90% at 45 minutes, or (d) greater than about 95% at 60 minutes. Additionally, in vivo oral intake of between 15 and 60 mg/kg of a pyridoxal-5'-phosphate pharmaceutical formulation can produce a maximum plasma level (Cmax) of between about 1 mg/L and 8 mg/L. A pharmaceutical formulation provided comprises (a) a core, wherein said core comprises pyridoxal-5'-phosphate or a pharmaceutically acceptable salt thereof

(b) a sub-coat surrounding the core

and (c) an enteric coat surrounding the sub-coat.

Priority: US20040630574P Applic. Date: 2004-11-26; US20050690127P Applic. Date: 2005-06-14

Inventor: FRIESEN ALBERT D [CA]; CARTER JOHN [CA]


Application No.: US20070248565A1  Published: 25/Oct/2007

Title: PHARMACEUTICAL PREPARATIONS COMPRISING CORTICOSTEROIDS AND ANTIINFECTIVE AGENTS

Applicant/Assignee: CHANDAVARKAR, NANDAN MOHAN

Application No.: 11/770357   Filing Date: 28/Jun/2007

Abstract:The invention consists of a stable preparation of a combination drug, comprising of an anti-inflammatory agent and an anti-infective agent. The anti-inflammatory agent in this invention is a corticosteroid, and the anti-infective agent is a derivative of quinolone, amino-glycoside or their pharmaceutically acceptable salts. The combination drug essentially comprises of i) an anti-inflammatory agent which is a corticosteroid, ii) an anti-infective agent selected from the group comprising of derivatives of quinolone, aminoglycoside and their pharmaceutically acceptable salts

iii) a complexation enhancing polymer

iv) a solubiliser exhibiting an inclusion phenomenon, along with pharmaceutically acceptable excipients with a suitable carrier system.

Priority: IN2000MU01018 Applic. Date: 2000-11-15; IN2001MU01077 Applic. Date: 2001-11-09; US2003-416837 Applic. Date: 2003-10-20; WO2001IN00199 Applic. Date: 2001-11-12

Inventor: CHANDAVARKAR MOHAN A [IN]; CHANDAVARKAR NANDAN M [IN]; CHANDRASHEKHAR MAINDE [IN]


Application No.: US20070248664A1  Published: 25/Oct/2007

Title: Oral Antimicrobial Pharmaceutical Compositions

Applicant/Assignee: COSMO TECHNOLOGIES LTD

Application No.: 11/571044   Filing Date: 03/May/2005

Abstract:The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon.

Priority: IT2004MI01295 Applic. Date: 2004-06-25; WO2005EP52025 Applic. Date: 2005-05-03

Inventor: AIANI MAURO [IT]; BOZZELLA ROBERTA [IT]; CELASCO GIUSEPPE [IT]; VILLA ROBERTO [IT]


Application No.: US20070248665A1  Published: 25/Oct/2007

Title: Compositions comprising co-precipitate of eplerenone and a water-soluble excipient

Applicant/Assignee:

Application No.: 11/409270   Filing Date: 24/Apr/2006

Abstract:Solid compositions for oral administration comprising a co-precipitate of eplerenone and a water-soluble excipient.

Priority:

Inventor: SHERMAN BERNARD C [CA]


Application No.: US20070248669A1  Published: 25/Oct/2007

Title: Oral sustained release formulation

Applicant/Assignee:

Application No.: 11/410017   Filing Date: 25/Apr/2006

Abstract:The present invention relates to an oral sustained release formulation comprising a core, a medicinal layer containing vanlafaxine or a pharmaceutically acceptable salt of venlafaxine and a release-modulating layer containing a release-modulating agent. The present invention also relates to a method for preparing an oral sustained release formulation, and to a pharmaceutical composition containing the oral sustained release formulation prepared by the method.

Priority:

Inventor: HSIAO FANG-HSIUNG [TW]; CHANGCHIEN YA-CHING [TW]


Application No.: US20070248679A1  Published: 25/Oct/2007

Title: VACCINE

Applicant/Assignee: GLAXO GROUP LIMITED

Application No.: 11/734464   Filing Date: 12/Apr/2007

Abstract:The invention relates to polynucleotides for DNA vaccination which polynucleotides encode an HIV envelope protein or fragment or immunogenic derivative fused to an additional HIV protein selected from a non-structural protein or capsid protein or fragment or immunogenic derivative thereof. Preferably the HIV envelope molecule is gp120 and preferred fusions include one or more of HIV Nef, Gag, RT or Tat. Preferably the HIV envelope molecule is non-glycosylated in mammalian cells.

Priority: GB20020025786 Applic. Date: 2002-11-05; US2005-533841 Applic. Date: 2005-11-23; WO2003EP12429 Applic. Date: 2003-11-03

Inventor: ERTL PETER F [GB]


Application No.: US20070248684A1  Published: 25/Oct/2007

Title: Pharmaceutical formulations of oxcarbazepine and methods for its preparation

Applicant/Assignee:

Application No.: 11/701180   Filing Date: 31/Jan/2007

Abstract:The present invention provides a pharmaceutical composition comprising oxcarbazepine and at least one pharmaceutical excipient, wherein the oxcarbazepine in the composition has a broad particle size distribution. The broad particle size distribution of oxcarbazepine in the pharmaceutical composition is preferably a multi-modal oxcarbazepine particle size distribution, preferably with an enhanced oxcarbazepine dissolution rate.

Priority: US2006-113506 Applic. Date: 2006-02-08; US20060764134P Applic. Date: 2006-01-31; US20060860333P Applic. Date: 2006-11-20; US20070897361P Applic. Date: 2007-01-24

Inventor: BLAU SIGAL [IL]; ZALIT ILAN [IL]; KOLATKAR GERSHON [IL]; AZARIA CAROLINA A [IL]


Application No.: US20070248687A1  Published: 25/Oct/2007

Title: Method and Composition for Modulation of Systemic Inflammatory Responses Syndrome (Sirs)

Applicant/Assignee:

Application No.: 11/660089   Filing Date: 16/Aug/2005

Abstract:The present invention relates to pharmaceutical composition comprising animal venom and using same in a method for the treatment of Systemic Inflammatory Response Syndrome (SIRS) and related pathologies.

Priority: US20040601648P Applic. Date: 2004-08-16; WO2005IL00890 Applic. Date: 2005-08-16

Inventor: SORKINE PATRICK [IL]; FROKLIS INNA [IL]; LOCKER CHAIM [IL]


Application No.: US20070248698A1  Published: 25/Oct/2007

Title: Obesity and Metabolic Syndrome Treatment with Tanshinone Derivatives Which Increase Metabolic Activity

Applicant/Assignee: KT&G CO., LTD.,

Application No.: 10/584983   Filing Date: 30/Dec/2004

Abstract:The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.

Priority: KR20030099658 Applic. Date: 2003-12-30; KR20030099657 Applic. Date: 2003-12-30; KR20030099556 Applic. Date: 2003-12-30; KR20030099557 Applic. Date: 2003-12-30; KR20040036195 Applic. Date: 2004-05-21; KR20040036197 Applic. Date: 2004-05-21; KR20040050200 Applic. Date: 2004-06-30; WO2004KR03546 Applic. Date: 2004-12-30

Inventor: KWAK TAEHWAN [KR]; PARK MYUNGGYU [KR]


Application No.: US20070249668A1  Published: 25/Oct/2007

Title: CONTROL OF ATP RELEASE BY RED BLOOD CELLS AND THERAPEUTIC APPLICATIONS THEREOF

Applicant/Assignee:

Application No.: 11/695102   Filing Date: 02/Apr/2007

Abstract:The invention is based upon the discovery that red blood cells contain phosphodiesterase 3B (PDE3B), and that inhibition of that phosphodiesterase allows for an enhanced accumulation of cAMP and subsequent release of ATP. It was further discovered that RBCs treated with insulin accumulate significantly less cAMP and release significantly less ATP than normal RBCs. Likewise, RBCs of patients suffering from type 2 diabetes (hyperinsulinemia) accumulate significantly less cAMP and release significantly less ATP than normal RBCs. It was further discovered that prostaglandin analogues synergistically work with phosphodiesterase 3B inhibitors to improve or increase cAMP accumulation and ATP release by RBCs. Thus the invention is directed to compositions and methods for improving ATP release by RBCs, via administering PDE3B inhibitor or a combination of PDE3B inhibitor and prostaglandin analogue.

Priority: US20060788584P Applic. Date: 2006-04-01

Inventor: SPRAGUE RANDY [US]; STUMPF MADELYN [US]


Application No.: US20070253913A1  Published: 01/Nov/2007

Title: Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation

Applicant/Assignee:

Application No.: 11/717276   Filing Date: 13/Mar/2007

Abstract:Pharmaceutical aerosol formulations of dihydroergotamine, or pharmaceutically acceptable salts thereof, to administer dry powders and propellant suspensions via pulmonary aerosol or nasal spray inhalation. Such formulations may be used for the treatment of various disease states and conditions, including, but not limited to, migraine headaches. The dihydroergotamine particles are produced using a supercritical fluid process. The aerosol formulations disclosed have superior stability, purity and comprise particle of respirable size particularly suitable for pulmonary delivery.

Priority: WO2004US29632 Applic. Date: 2004-09-10; US20030501938P Applic. Date: 2003-09-10

Inventor: MOHSEN NAHED [US]; ARMER THOMAS A [US]; PAVKOV RICHARD M [CH]


Application No.: US20070253945A1  Published: 01/Nov/2007

Title: Chalaropsis Lysozyme Protein and its Method of Use in Anti-Bacterial Applications

Applicant/Assignee: NEW CENTURY PHARMACEUTICALS, INC

Application No.: 10/566243   Filing Date: 30/Jul/2004

Abstract:A Chalaropsis lysozyme (Lysozyme Ch) is provided which has a corrected amino acid sequence and which can be utilized to prepare recombinant proteins having higher activity than those proteins prepared using the incorrect sequence. Methods are also provided to reduce immunogenicity or increase half-life of the lysozyme. The lysozyme Ch of the present invention will be extremely useful in killing bacteria, particularly resistance strains such as MRSA and VISA, and the enzyme can be utilized in a variety of settings wherein bacterial infection has been a particular problem such as the hospital setting or in veterinary applications, and can also be used as an effective means of combating bioterror agents.

Priority: US20030490984P Applic. Date: 2003-07-30; WO2004US24414 Applic. Date: 2004-07-30

Inventor: WANG ZHONGMIN [US]; CARTER DANIEL C [US]


Application No.: US20070254028A1  Published: 01/Nov/2007

Title: Granules Comprising a Nsaid and a Sugar Alcohol Made by Melt Extrusion

Applicant/Assignee: RECKITT BENCKISER HEALTHCARE (UK) LIMITED

Application No.: 11/659974   Filing Date: 08/Aug/2005

Abstract:A pharmaceutical composition comprising a granular component comprising a plurality of solidified melt granules of a sugar alcohol having a salt of non-steroidal anti-inflammatory drug (NSAID salt) contained therein.

Priority: GB20040017939 Applic. Date: 2004-08-12; GB20040017942 Applic. Date: 2004-08-12; WO2005GB03077 Applic. Date: 2005-08-08

Inventor: SHERRY ROBERT [GB]


Application No.: US20070254035A1  Published: 01/Nov/2007

Title: Preparing Active Polymer Extrudates

Applicant/Assignee:

Application No.: 10/576909   Filing Date: 22/Oct/2004

Abstract:Process for preparing active polymer extrudate comprising polymer matrix and guest matter, the process comprising contacting a polymer substrate and guest matter with a plasticising fluid under dense phase, sub critical or supercritical plasticising conditions of elevated temperature and/or pressure to plasticise the polymer substrate and incorporate guest matter and extruding polymer substrate incorporating guest matter under dense phase, sub critical or supercritical conditions via an extrusion orifice into a collection zone or a mould with simultaneous or subsequent release of pressure, whereby extrudate is obtained comprising a solid admixture of polymer matrix and guest matter in form conferred by the orifice or the mould

a novel extrudate

composition thereof and apparatus for the preparation thereof, and use thereof in fibre processing techniques, medical applications such as in delivery of drugs and other agents such as imaging and diagnostic agents, tissue engineering, and as medical devices or aids such as delivery devices or aids for drugs, imaging and diagnostic agents, as tissue engineering devices or aids such as sutures, and the like

as an anti-microbial for example having bacteria-static or -cidal activity

as a natural or synthetic barrier capable of immobilising e.g. naturally occurring or artificially introduced poisons or toxins by e.g. absorption, interaction or reaction

in agrochemical or crop protection applications

in the processing of thermally labile fibres for use in dying, textiles, electronics etc below the polymer Tg, Tm or viscosity

in incorporation of dyes and other thermally labile materials into polymers that cannot be formed by traditional processes e.g. melt extrusion and the like

or in incorporation of surfactants into fibres to control polymer properties.

Priority: GB20030024720 Applic. Date: 2003-10-23; GB20040003361 Applic. Date: 2004-02-14; WO2004GB04470 Applic. Date: 2004-10-22

Inventor: HAO JIANYUAN [GB]; WHITAKER MARTIN J [GB]; SHAKESHEFF KEVIN M [GB]; HOWDLE STEVEN M [GB]


Application No.: US20070254838A1  Published: 01/Nov/2007

Title: Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules

Applicant/Assignee:

Application No.: 11/656921   Filing Date: 22/Jan/2007

Abstract:Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.

Priority: US2003-658834 Applic. Date: 2003-09-08; US20030457135P Applic. Date: 2003-03-21; US20020409898P Applic. Date: 2002-09-09

Inventor: GANTIER RENE [FR]; VEGA MANUEL [FR]; DRITTANTI LILA [FR]; GUYON THIERRY [FR]


Application No.: US20070254962A1  Published: 01/Nov/2007

Title: METHODS OF ADMINISTERING ANTI-INFLAMMATORY CYCLOOXYGENASE-2 SELECTIVE INHIBITORS

Applicant/Assignee: BIOACTIVES, INC

Application No.: 11/736551   Filing Date: 17/Apr/2007

Abstract:Disclosed are novel anti-inflammatory pharmaceutical compositions and related methods that exhibit potent and selective inhibition of the cycloooxygenase-2 (COX-2) enzyme. The formulation can comprise a hops extract that exhibits COX-2 selectivity as defined by dividing the IC50 COX-2/IC50COX-1 concentrations that are determined by testing with the William Harvey Whole Blood Assay (WHMA), and can fall within the range of 0.011 to 0.2. Such compositions may also optionally contain high levels of alpha acids and low levels of beta acids, some flavonoid compounds, and virtually no essential oils. Such compositions are useful for treating conditions that manifest as inflammatory pain, or are impacted by the COX-2 enzyme. The recited compositions are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects.

Priority: US2006-452095 Applic. Date: 2006-06-12; US2003-340183 Applic. Date: 2003-01-09

Inventor: KUHRTS ERIC [US]


Application No.: US20070256687A1  Published: 08/Nov/2007

Title: Enhanced Medical Product

Applicant/Assignee:

Application No.: 11/629803   Filing Date: 01/Jun/2005

Abstract:The invention relates to a method for enclosing a metered, dry powder medication dose comprising at least one active pharmaceutical ingredient (API) and a metered dose of at least one dry powder excipient in a common space of a dose container. The deposited doses in the common dose container constitute a medical product. The method and the medical product are effective in raising the emitted medication dose output and improving the therapeutic efficacy when the doses are delivered together from a dry powder inhaler.

Priority: SE20040001612 Applic. Date: 2004-06-18; WO2005SE00822 Applic. Date: 2005-06-01

Inventor: NIEMI ALF [SE]; CALANDER SVEN [SE]; KAX LARS [SE]


Application No.: US20070259045A1  Published: 08/Nov/2007

Title: Alcohol Resistant Dosage Forms

Applicant/Assignee: EURO-CELTIQUE S.A

Application No.: 11/574778   Filing Date: 27/Jan/2006

Abstract:Disclosed in certain embodiments is a controlled release dosage form comprising a matrix comprising a pharmaceutically acceptable salt of an opioid analgesic in a controlled release material

wherein less than 25% of the opioid salt is released after 1 hour of in-vitro dissolution of the dosage form in 900 ml of Simulated Gastric Fluid with 20% ethanol using a USP Apparatus I (basket) apparatus at 100 rpm at 37 degrees C. DEG .

Priority: GB20050001638 Applic. Date: 2005-01-28; WO2005GB50014 Applic. Date: 2005-02-11; US20050670506P Applic. Date: 2005-04-12; US20050730339P Applic. Date: 2005-10-26; WO2006EP00727 Applic. Date: 2006-01-27

Inventor: MANNION RICHARD O [US]; MCKENNA WILLIAM H [US]; O'DONNELL EDWARD P [US]; DANAGHER HELEN K [GB]; HAYES GEOFFREY G [GB]; MOHAMMAD HASSAN [GB]; PRATER DEREK A [GB]; TAMBER HARJIT [GB]; MALCOLM WALDEN [GB]; WHITELOCK STEVE [GB]; FLEISCHER WOLFGANG [DE]; HAHN UDO [DE]; SPITZLEY CHRISTOF [DE]; LEUNER CHRISTIAN [DE]


Application No.: US20070259062A1  Published: 08/Nov/2007

Title: Composition containing an extract of rubi fructus for preventing and treaing anxiety, depression and dementia and improving memory

Applicant/Assignee:

Application No.: 11/648325   Filing Date: 29/Dec/2006

Abstract:Disclosed is a composition containing an extract of Rubi Fructus for preventing and treating anxiety, depression and dementia and improving memory. The composition can be used as drugs and dietary supplements which induce prophylactic and therapeutic effects on anxiety, depression and dementia as well as memory-improving effect in the modems afflicted with the modification of neurotransmitter releases and brain damage caused by external environmental factors including various kinds of stresses, menopause, drinking alcohols, smoking cigarettes and others.

Priority: KR20060041105 Applic. Date: 2006-05-08

Inventor: KIM SUNG-JIN [KR]


Application No.: US20070259857A1  Published: 08/Nov/2007

Title: Amorphous form of Olanzapine

Applicant/Assignee:

Application No.: 10/561009   Filing Date: 15/Jun/2004

Abstract:The present invention relates to an amorphous form of olanzapine Formula (I): and a process for its preparation. The present invention further relates to a pharmaceutical composition comprising an amorphous form of olanzapine (I). The pharmaceutical composition may be used, in particular, for the treatment of psychiatric, psychological or psychotic disorders, anxiety disorders, or gastrointestinal or functional bowel disorders. The present invention also relates to a method of treating said disorders.

Priority: GB20030014149 Applic. Date: 2003-06-18; WO2004GB02579 Applic. Date: 2004-06-15

Inventor: GRAY JASON [GB]


Application No.: US20070264202A1  Published: 15/Nov/2007

Title: Pharmaceutical Composition Comprising an Isomer of Betamimetic Agent and an Anti-Cholinergic Agent

Applicant/Assignee: CIPLA LIMITED

Application No.: 11/574902   Filing Date: 09/Sep/2005

Abstract:A pharmaceutical composition in a dosage form suitable for inhalation comprises a therapeutically isomer of a betamimetic agent or a salt, solvate, ester, derivative, or polymorph thereof substantially free of the less therapeutically effective isomer(s) of said agent and optionally an anti-cholinergic agent or a salt, solvate, ester, derivative, isomer or polymorph thereof. A preferred composition comprises R-salbutamol sulphate and ipratropium bromide. Methods of making the compositions of the invention are also provided.

Priority: IN2004MU00970 Applic. Date: 2004-09-09; IN2004MU01004 Applic. Date: 2004-09-17; IN2004MU01077 Applic. Date: 2004-10-08; IN2004MU01088 Applic. Date: 2004-10-11; IN2004MU01089 Applic. Date: 2004-10-11; IN2005MU00093 Applic. Date: 2005-01-31; IN2005MU00222 Applic. Date: 2005-02-28; WO2005GB03475 Applic. Date: 2005-09-09

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]


Application No.: US20070264271A1  Published: 15/Nov/2007

Title: Potent Immunostimulatory from Microalgae

Applicant/Assignee: THE UNIVERSITY OF MISSISSIPPI

Application No.: 11/697038   Filing Date: 05/Apr/2007

Abstract:Immunostimulatory polysaccharides can be preferentially extracted from food-grade microalgae using an aqueous ethanol extraction procedure. The resulting preparations exhibit extremely potent immunostimulatory activity. The preferential extraction of these immunostimulatory polysaccharides is dependent on the concentration of ethanol used and the extraction temperature. The most efficient conditions are 50% ethanol concentration at temperatures between 60 DEG and 70 DEG C. The isolated polysaccharide preparations are potentially useful as a botanical or pharmaceutical preparation to improve immune function.

Priority: US2003-332323 Applic. Date: 2003-02-03; WO2001US21770 Applic. Date: 2001-07-10; US20000217001P Applic. Date: 2000-07-10

Inventor: ELSOHLY MAHMOUD [US]; ROSS SAMIR [US]; PASCO DAVID S [US]; PUGH NIRMAL D [US]; ELSOHLY HALA N [US]


Application No.: US20070264317A1  Published: 15/Nov/2007

Title: Imiquimod cream formulation

Applicant/Assignee: PERRIGO ISRAEL PHARMACEUTICALS LTD

Application No.: 11/433471   Filing Date: 15/May/2006

Abstract:Novel compositions containing imiquimod which are suitable for use in the treatment of skin disorders are disclosed. The compositions comprise micronized imiquimod and pharmaceutically acceptable excipients.

Priority:

Inventor: YOSHA IDO [IL]; TSAHOR HILA [IL]; TIKHONENKO TATIANA [IL]; NAIM RONEN [IL]


Application No.: US20070264328A1  Published: 15/Nov/2007

Title: Continuous melt spheronization apparatus and process for the production of pharmaceutical pellets

Applicant/Assignee: AMERICAN LEISTRITZ EXTRUDER CORP PHARMACEUTICAL TECHNOLOGY SOLUTIONS, LLC

Application No.: 11/434041   Filing Date: 15/May/2006

Abstract:Spherically-shaped pharmaceutical pellets are produced using a novel spheronization apparatus in a continuous melt spheronization process in which an active pharmaceutical agent is blended with various excipients, fed to an extruder, cut and subsequently fed to the novel spheronizer for continuously producing uniform, spherically-shaped pellets. The pellets may be further coated so as to provide immediate or various modified release characteristics.

Priority:

Inventor: GHEBRE-SELLASSIE ISAAC [US]; MARTIN CHARLES [US]; ELLIOT BERT [US]


Application No.: US20070264329A1  Published: 15/Nov/2007

Title: CALCIUM COMPOSITIONS

Applicant/Assignee: DRUGTECH CORPORATION

Application No.: 11/746832   Filing Date: 10/May/2007

Abstract:Compositions comprising calcium carbonate and processes for making such compositions are provided. The invention provides a granulation comprising about 95% to about 99% by weight calcium carbonate, about 0.5% to about 5% by weight of a binder and about 0.03% to about 3% by weight of a porosity increasing agent. A pharmaceutical or nutritional composition prepared from such a granulation comprises about 90% to about 99% by weight calcium carbonate, about 0.03% to about 3% by weight of a porosity increasing agent, and about 1% to about 10% by weight of other excipients. The composition provides a smaller tablet than conventional calcium carbonate compositions, for improved ease of swallowing.

Priority: US20060800178P Applic. Date: 2006-05-12

Inventor: STOTLER DENIS [US]; FREEBERSYSER STEVEN R [US]; LEVINSON R SAUL [US]


Application No.: US20070265203A1  Published: 15/Nov/2007

Title: METHODS AND COMPOSITIONS FOR MODULATION OF BLOOD-NEURAL BARRIER

Applicant/Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH

Application No.: 11/736499   Filing Date: 17/Apr/2007

Abstract:Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-alpha antagonist.

Priority: US20060792318P Applic. Date: 2006-04-17; US20060828506P Applic. Date: 2006-10-06

Inventor: ERIKSSON ULF [SE]; LAWRENCE DANIEL [US]; SU ENMING J [US]; STRICKLAND DUDLEY [US]; YEPES MANUEL [US]; FREDRIKSSON LINDA [SE]


Application No.: US20070265234A1  Published: 15/Nov/2007

Title: METHODS FOR STABILIZING OXIDATIVELY UNSTABLE COMPOSITIONS

Applicant/Assignee:

Application No.: 11/686988   Filing Date: 16/Mar/2007

Abstract:Ophthalmic compositions and methods of preparing such compositions are disclosed.

Priority: US20060783557P Applic. Date: 2006-03-17

Inventor: MAHADEVAN SHIVKUMAR [US]; MOLOCK FRANK [US]; KHANOLKAR VANDEETA [US]


Application No.: US20070265235A1  Published: 15/Nov/2007

Title: Methods for treating or preventing disorders using ecdysteroid compositions

Applicant/Assignee:

Application No.: 11/799598   Filing Date: 02/May/2007

Abstract:This invention relates to methods and compositions which are useful in the modulation of endogenous growth hormone levels in a mammal. Also included are methods of treating a mammal which include the administration of said compositions.

Priority: US20060800844P Applic. Date: 2006-05-09

Inventor: GORELIK-FELDMAN JONATHAN [US]; RASKIN ILYA [US]


Application No.: US20070265329A1  Published: 15/Nov/2007

Title: Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)

Applicant/Assignee:

Application No.: 11/433917   Filing Date: 12/May/2006

Abstract:A pharmaceutical composition for the sustained release of an effective amount of a selective 5-hydroxytryptamine 3 (5-HT3) receptor antagonist for the prevention, reduction or alleviation of acute and delayed chemotherapy-induced nausea and vomiting (CINV) following a course of emetogenic chemotherapy, wherein the composition is administered by subcutaneous injection, the composition comprising a 5-HT3 receptor antagonist, a semi-solid delivery vehicle and a pharmaceutically acceptable liquid excipient

wherein the composition, when administered in a single dosage, provides a controlled release of the 5-HT3 receptor antagonist and prolonging the release of the 5-HT3 receptor antagonist that tracks the profile of the incidence of vomiting.

Priority:

Inventor: DEVANG SHAH T [US]; BARR JOHN [US]; BAXTER BRIAN [US]; HELLER JORGE [US]


Application No.: US20070269465A1  Published: 29/Jun/2006

Title: Anesthetic composition for topical administration

Applicant/Assignee:

Application No.: 10/562392   Filing Date: 01/Jun/2004

Abstract:It comprises a mixture of lidocaine, prilocaine and tetracaine, or their pharmaceutically acceptable salts. The preferred composition comprises the following components in the indicated approximate w/w percentages: 1.5% of lidocaine base

1.5% of prilocaine base

4% of tetracaine base

10% of methylpynrolidone

2% of dimethyl sulfoxide

0.08% of topical hyaluronidase

1.5% of guar gum

1% of Tween-20

0.5% of Tween-80, and the necessary amount of water to 100%. It exhibits a a high concentration on skin, a deep anesthetic effect and a significantly more rapid onset of the anesthetic effect than comparable transdermal anesthetics.

Priority: ES20030001548 Applic. Date: 2003-06-19; WO2004EP50967 Applic. Date: 2004-06-01

Inventor: FITA FERNANDO B [ES]


Application No.: US20070269481A1  Published: 22/Nov/2007

Title: Biomimetic Scaffolds

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 11/668448   Filing Date: 29/Jan/2007

Abstract:The invention provides a composition comprising a nanofiber polymer in which the fibers of the nanofiber polymer are aligned, and a molecule is covalently attached, either directly or through a linker, to the nanofiber polymer. This molecule is capable of either covalently or non-covalently attaching to a member selected from an extracellular matrix component, a growth factor, and combinations thereof. The invention also provides methods of making the composition and methods of using the compositions to add new tissue to a subject, such as a human.

Priority: US20060861780P Applic. Date: 2006-11-30; US20060804350P Applic. Date: 2006-06-09; US20060763111P Applic. Date: 2006-01-27

Inventor: LI SONG [US]; PATEL SHYAM [US]; HASHI CRAIG [US]; HUANG NGAN F [US]; KURPINSKI KYLE [US]


Application No.: US20070269494A1  Published: 22/Nov/2007

Title: Compositions and methods for enhancing active agent absorption

Applicant/Assignee: NEXUS PHARMA, INC

Application No.: 11/804646   Filing Date: 18/May/2007

Abstract:Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.

Priority: US20060747900P Applic. Date: 2006-05-22

Inventor: SHIH CHUNG [US]


Application No.: US20070269500A1  Published: 22/Nov/2007

Title: Compositions and methods for enhancing active agent absorption

Applicant/Assignee: NEXUS PHARMA, INC

Application No.: 11/805202   Filing Date: 21/May/2007

Abstract:Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.

Priority: US20060747900P Applic. Date: 2006-05-22

Inventor: SHIH CHUNG [US]


Application No.: US20070269511A1  Published: 22/Nov/2007

Title: SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN

Applicant/Assignee: WARNER-LAMBERT COMPANY LLC

Application No.: 11/555988   Filing Date: 02/Nov/2006

Abstract:A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

Priority: US20050732589P Applic. Date: 2005-11-02

Inventor: BOCKBRADER HOWARD N [US]; CHO YUN H [US]; DIAZ SANTIAGO STEVEN [US]; MAHJOUR MAJID [US]; REYNOLDS THOMAS D [US]; SHAO PUSHPA G [US]; SHAO ZEZHI J [US]; WAN JIANSHENG [US]


Application No.: US20070269517A1  Published: 22/Nov/2007

Title: Pharmaceutical Formulations for the Prolonged Release of Interferons and Their Therapeutic Applications

Applicant/Assignee: FLAMEL TECHNOLOGIES, INC

Application No.: 10/580037   Filing Date: 19/Nov/2004

Abstract:The present invention relates to novel pharmaceutical formulations based on stable, fluid aqueous colloidal suspensions for the prolonged release of an interferon (IFN) (and one or more other possible active principles), and to the applications, especially therapeutic applications, of these formulations. The object of the invention is to propose a fluid pharmaceutical formulation for the prolonged release of interferon(s) (and one or more other possible active principles) that makes it possible, after parenteral injection, significantly to increase the in vivo release time of the interferons while at the same time reducing the plasma concentration peak of this IFN, said formulation furthermore being stable on storage and also being biocompatible, biodegradable, non-toxic and non-immunogenic and having a good local tolerance. The formulation according to the invention is an aqueous colloidal suspension of low viscosity based on submicronic particles of water-soluble biodegradable polymer PO carrying hydrophobic groups (HG), said particles being non-covalently associated with at least one interferon (and one or more other possible active principles) and forming a gelled deposit at the injection site, this gelling being caused by a protein present in the physiological medium.

Priority: FR20030050886 Applic. Date: 2003-11-21; WO2004FR50605 Applic. Date: 2004-11-19

Inventor: POULIQUEN GAUTHIER [FR]; MEYRUEIX REMI [FR]; SOULA OLIVIER [FR]


Application No.: US20070269543A1  Published: 22/Nov/2007

Title: Use of Red Nocardia Rubric Cell Wall Skeleton in the Preparation of Medicament for Treating Cervical Precancerous Lesion

Applicant/Assignee: SHENYANG SUNBELLCOM BIO-PHARMACEUTICAL CO., LTD

Application No.: 11/750529   Filing Date: 18/May/2007

Abstract:The use of Red Nocardia Rubric Cell Wall Skeleton in the preparation of medicaments for treating cervical precancerous lesion is disclosed in the present application.

Priority: CN20061082627 Applic. Date: 2006-05-19

Inventor: ZHANG CE [US]; ZHANG YI [US]; HONG XIAOMING [US]; ZHANG GUOYING [US]; ZHAO JIAN [US]


Application No.: US20070270341A1  Published: 22/Nov/2007

Title: Parathyroid hormone analogues and methods of use

Applicant/Assignee:

Application No.: 11/650918   Filing Date: 05/Jan/2007

Abstract:The present invention is directed to novel methods of treating a subject with a bone deficit disorder. The methods generally include administering to a subject in need thereof a pharmaceutically acceptable formulation comprising a parathyroid hormone (PTH) peptide analogue in a daily dose sufficient to result in an effective pharmacokinetic profile and maintained adenylate cyclase activity, while simultaneously reducing undesirable side effects.

Priority: US2006-517146 Applic. Date: 2006-09-06; US20050714905P Applic. Date: 2005-09-06; US20060834980P Applic. Date: 2006-07-31; US20060837972P Applic. Date: 2006-08-15

Inventor: MORLEY PAUL [CA]; STOGNIEW MARTIN [US]; MACDONALD BRIAN [US]


Application No.: US20070270392A1  Published: 22/Nov/2007

Title: Use of a Cyclopentenone Prostaglandin for Delaying the Onset and/or Preventing the Continuation of Labour

Applicant/Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITED

Application No.: 10/581389   Filing Date: 29/Mar/2004

Abstract:The present invention provides the use of a cyclopentenone prostaglandin in the manufacture of a medicament for delaying the onset and/or preventing the continuation of labour in a female. Preferably the cyclopentenone prostaglandin prevents and/or reduces an inflammatory response in the reproductive system of a female. Preferably, the cyclopentenone prostaglandin is 15-deoxy-Delta<12,14>-prostaglandin J2 or prostaglandin A1, or a precursor thereof. The invention further provides a pharmaceutical composition comprising cyclopentenone prostaglandin and methods of use thereof.

Priority: GB20030027975 Applic. Date: 2003-12-02; WO2004GB01380 Applic. Date: 2004-03-29

Inventor: BENNETT PHILLIP R [GB]; LINDSTROM TAMSIM [GB]


Application No.: US20070270496A1  Published: 22/Nov/2007

Title: Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system

Applicant/Assignee: EPITECH GROUP S.R.L

Application No.: 11/724501   Filing Date: 14/Mar/2007

Abstract:The present invention relates to a pharmaceutical composition consisting of amides of mono- and di-carboxylic acids and hydroxystilbenes, and may be used for the treatment of pathologies caused, sustained and/or characterised by an abnormal general response of the immune system, in both humans and animals.

Priority: EP20060425206 Applic. Date: 2006-03-28

Inventor: DELLA VALLE FRANCESCO [IT]; DELLA VALLE MARIA F [IT]; MARCOLONGO GABRIELE [IT]; RAVAGNAN GIANPIERO [IT]; DI MARZO VINCENZO [IT]


Application No.: US20070275052A1  Published: 29/Nov/2007

Title: Pharmaceutical compositions containing sterol inhibitors

Applicant/Assignee: GLENMARK PHARMACEUTICALS LIMITED

Application No.: 11/805752   Filing Date: 24/May/2007

Abstract:Pharmaceutical compositions containing ezetimibe or its pharmaceutically acceptable salt that is substantially free of microcrystalline cellulose or crystalline cellulose are disclosed. Also disclosed are pharmaceutical compositions containing micronized particles of ezetimibe.

Priority: IN2006MU00790 Applic. Date: 2006-05-24; US20060848042P Applic. Date: 2006-09-26

Inventor: MAHAJAN ABHAY [IN]; MEHTA KAMAL [IN]


Application No.: US20070275057A1  Published: 29/Nov/2007

Title: Formulation and Process for the Preparation of Modafinil

Applicant/Assignee: HIKMA PHARMACEUTICALS

Application No.: 11/776012   Filing Date: 11/Jul/2007

Abstract:The present invention provides pharmaceutical tablets comprising modafinil particles, processes for preparing such pharmaceutical tablets, and methods of treating a disease or disorder using the pharmaceutical tablet of the invention. In particular, the pharmaceutical tablet of the invention comprises modafinil particles and one or more pharmaceutically acceptable excipients, wherein the modafinil particles have a size distribution such that at least about 65% of the modafinil particles have a diameter greater than 220 microns and the tablet is bioequivalent to PROVIGIL(R). The pharmaceutical tablet of the invention is prepared by a dry granulation method.

Priority:

Inventor: SHAWER MOHANNAD [JO]; SALLAM ALSAYED A [JO]; JAWHARI DALIA [JO]


Application No.: US20070275067A1  Published: 29/Nov/2007

Title: Compression Coated Tablet Comprising Sumatriptan

Applicant/Assignee: NORTON HEALTHCARE LTD

Application No.: 10/585547   Filing Date: 08/Jan/2005

Abstract:The present invention provides a pharmaceutical composition for oral administration, comprising a core of active ingredient and an outer non-active layer formed on the core by application of pressure.

Priority: GB20040000452 Applic. Date: 2004-01-09; WO2005US00500 Applic. Date: 2005-01-08

Inventor: DOSHI HITESHKUMAR [IN]; ELCHIDANA PARIZAD [IN]; JOG SUNIL [IN]; SONAJE DEEPAK [IN]


Application No.: US20070275071A1  Published: 29/Nov/2007

Title: Use of Microparticles for Antigen Delivery

Applicant/Assignee: ISTITUTO SUPERIORE DI SANITA

Application No.: 10/577974   Filing Date: 03/Nov/2004

Abstract:The invention relates to microparticles that may be used for antigen delivery and vaccine immunization strategies. The invention in particular relates to microparticles that are useful in the prophylaxis and treatment of human immunodeficiency virus (HIV) infections.

Priority: GB20030025624 Applic. Date: 2003-11-03; WO2004EP12421 Applic. Date: 2004-11-03

Inventor: ENSOLI BARBARA [IT]; CAPUTO ANTONELLA [IT]; LAUS MICHELE [IT]; TONDELLI LUISA [IT]; SPARNACCI KATIA [IT]; GAVIOLI RICCARDO [IT]


Application No.: US20070275074A1  Published: 29/Nov/2007

Title: Controlled agglomeration

Applicant/Assignee: LIFECYCLE PHARMA A/S

Application No.: 11/711965   Filing Date: 27/Feb/2007

Abstract:A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a therapeutically and/or prophylactically active substance which has a relatively low aqueous solubility and/or which is subject to chemical decomposition. The process comprising i) spraying a first composition comprising a carrier, which has a melting point of about 5 DEG C. or more which is present in the first composition in liquid form, on a second composition comprising a material in solid form, the second composition having a temperature of at the most a temperature corresponding to the melting point of the carrier and/or the carrier composition and ii) mixing or others means of mechanical working the second composition onto which the first composition is sprayed to obtain the particulate material.

Priority: DK20010001071 Applic. Date: 2001-07-06; WO2002DK00472 Applic. Date: 2002-07-05; US2004-482558 Applic. Date: 2004-07-26

Inventor: HOLM PER [DK]; BURR ANDERS [DK]; ELEMA MICHIEL O [DK]; MOLLGAARD BIRGITTE [DK]; HOLM JANNIE E [DK]; SCHULTZ KIRSTEN [DK]


Application No.: US20070275993A1  Published: 29/Nov/2007

Title: Combinations Of An Anti Emetic Agent And An Enkephalinase Inhibitor

Applicant/Assignee:

Application No.: 10/587899   Filing Date: 14/Feb/2005

Abstract:The present invention concerns new combinations of an anti-emetic agent and an enkephalinase inhibitor, the uses of said combinations for treating diarrhea and/or gastroenteritis.

Priority: EP20040290384 Applic. Date: 2004-02-12; WO2005IB00351 Applic. Date: 2005-02-14

Inventor: SCHWARTZ JEAN-CHARLES [FR]; LECOMTE JEANNE-MARIE [FR]


Application No.: US20070281000A1  Published: 06/Dec/2007

Title: Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof

Applicant/Assignee:

Application No.: 11/446336   Filing Date: 02/Jun/2006

Abstract:The present invention provides stable pharmaceutical compositions comprising moisture sensitive drugs, in particular an angiotensin converting enzyme (ACE) inhibitor such as Cilazapril, as the active ingredient, and at least one pharmaceutical excipient, wherein the active pharmaceutical ingredient is wet granulated with a solution of at least one pharmaceutical excipient, and methods for preparing such stable pharmaceutical compositions.

Priority:

Inventor: FOX MICHAEL [IL]


Application No.: US20070281013A1  Published: 06/Dec/2007

Title: Prednisolone salt formulations

Applicant/Assignee: CIMA LABS, INC

Application No.: 11/638216   Filing Date: 13/Dec/2006

Abstract:The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The dosage forms include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.

Priority: US20060810015P Applic. Date: 2006-06-01

Inventor: HABIB WALID [US]; KOTHARI BHAVESHKUMAR [US]


Application No.: US20070281014A1  Published: 06/Dec/2007

Title: Prednisolone salt formulations

Applicant/Assignee: CIMA LABS, INC

Application No.: 11/638260   Filing Date: 13/Dec/2006

Abstract:The present invention relates to tablets containing prednisolone salts and in particular prednisolone sodium phosphates. The tablets include ODTs and non-ODTs, effervescent tablets and noneffervescent tablets and tablets meeting certain performance criteria.

Priority: US20060810015P Applic. Date: 2006-06-01

Inventor: HABIB WALID [US]; KOTHARI BHAVESHKUMAR [US]


Application No.: US20070281020A1  Published: 06/Dec/2007

Title: PHARMACEUTICAL COMPOSITIONS FOR SUSTAINED RELEASE OF PHENYLEPHRINE

Applicant/Assignee:

Application No.: 11/756774   Filing Date: 01/Jun/2007

Abstract:The invention discloses a pharmaceutical composition comprising phenylephrine in a sustained-release formulation alone or in combination with another active such as an antihistamine, an analgesic, an antipyretic or a non-steroidal anti-inflammatory agent or a mixture of two or more other actives. In a preferred embodiment, the composition comprises a solid dosage form with hydroxypropyl methylcellulose and carboxymethyl cellulose sodium as a matrix for sustained release of phenylephrine. Phenylephrine is released over a prolonged period of time by the solid dosage form essentially independent of pH.

Priority: US20060810019P Applic. Date: 2006-06-01

Inventor: ULLOA SERGIO R [MX]; VILLACAMPA RAMOS JOSE DE JESUS [MX]; JUAREZ VARGAS LUIS J [MX]


Application No.: US20070281960A1  Published: 06/Dec/2007

Title: Anti-Histaminic Composition

Applicant/Assignee:

Application No.: 11/572175   Filing Date: 18/Jul/2005

Abstract:A stable pharmaceutical composition comprises desloratadine or a pharmaceutically acceptable salt, solvate, derivative, polymorph, hydrate or enantiomer thereof, and a carrier comprising at least one polyol. Preferred compositions comprise, in addition to desloratadine, from 50 to 80% polyol, from 5 to 15% disintegrating agent, and from 0.01 to 0.5% antioxidant and/or a chelating agent, all by weight of the composition. The polyol may be used to stabilise a pharmaceutical composition comprising desloratadine. A process for making a stable pharmaceutical composition comprising desloratadine and one or more polyols, optionally together with other pharmaceutically acceptable excipients comprises blending the ingredients and formulating them so as to form said composition.

Priority: IN2004MU00765 Applic. Date: 2004-07-16; WO2005GB02828 Applic. Date: 2005-07-18

Inventor: LULLA AMAR [IN]; MALHOTRA GEENA [IN]; ANAND SANKARNARAYANAN [IN]


Application No.: US20070281964A1  Published: 06/Dec/2007

Title: Novel Crystalline Polymorphs of Clopidogrel

Applicant/Assignee: GENERICS [UK] LIMITED

Application No.: 10/571419   Filing Date: 09/Sep/2004

Abstract:The present invention relates to novel crystalline forms of the platelet aggregation inhibitor (+)-(S)-methyl-2-(2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate, clopidogrel (1), in the form of hydrogen bromide salts, identified as polymorph forms 1, 2 and 3. The present invention further relates to processes for preparing such forms, pharmaceutical compositions comprising such forms, and uses for such forms and compositions. The pharmaceutical compositions may be used, in particular, for inhibiting platelet aggregation or for treating, preventing or managing thrombosis, atherothrombosis, an atherothrombotic event, ischaemic stroke, myocardial infarction, non-Q-wave myocardial infarction, atherosclerosis, peripheral arterial disease, or unstable angina. The present invention also relates to methods of treating said disorders. Formula (1).

Priority: GB20030021256 Applic. Date: 2003-09-11; WO2004GB03867 Applic. Date: 2004-09-09

Inventor: ARUL RAMAKRISHNAN [IN]; RAWAT AJAY S [IN]; GADAKAR MAHESHKUMAR [IN]; RAO RAJESH [IN]; PISE ABHINAY [IN]; GRAY JASON [DE]


Application No.: US20070282004A1  Published: 06/Dec/2007

Title: Use of a Cyclopentenone Prostaglandin for Delaying for the Onset and/or Preventing the Continuation of Labour

Applicant/Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITED

Application No.: 10/581532   Filing Date: 02/Dec/2004

Abstract:The present invention provides the use of a cyclopentenone prostaglandin in the manufacture of a medicament for delaying the onset and/or preventing the continuation of labour in a female. Preferably the cyclopentenone prostaglandin prevents and/or reduces an inflammatory response in the reproductive system of a female. Preferably, the cyclopentenone prostaglandin is 15-deoxy-Delta<12,14>-prostaglandin J2 or prostaglandin A1, or a precursor thereof. The invention further provides a pharmaceutical composition comprising cyclopentenone prostaglandin and methods of use thereof.

Priority: GB20030027975 Applic. Date: 2003-12-02; WO2004GB01380 Applic. Date: 2004-03-29; WO2004GB05087 Applic. Date: 2004-12-02

Inventor: BENNETT PHILLIP R [GB]; LINDSTROM TAMSIN [GB]


Application No.: US20070282009A1  Published: 06/Dec/2007

Title: Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

Applicant/Assignee: PFIZER INC

Application No.: 11/799447   Filing Date: 30/Apr/2007

Abstract:A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.

Priority: US2002-066091 Applic. Date: 2002-02-01; US2001-918127 Applic. Date: 2001-07-30; US20000223279P Applic. Date: 2000-08-03

Inventor: CREW MARSHALL D [US]; CURATOLO WILLIAM J [US]; FRIESEN DWAYNE T [US]; GUMKOWSKI MICHAEL J [US]; LORENZ DOUGLAS A [US]; NIGHTLINGALE JAMES A S [US]; RUGGERI ROGER B [US]; SHANKER RAVI M [US]


Application No.: US20070286901A1  Published: 13/Dec/2007

Title: Novel Pharmaceutical Formulation of Cefixime for Enhanced Bioavailability

Applicant/Assignee: LUPIN LTD

Application No.: 11/579988   Filing Date: 10/May/2004

Abstract:A chewable tablet comprising Cefixime having a mean particle size between 20 mu and 120 mu wherein the said composition demonstrates bioequivalence to a suspension of Cefixime trihydrate. The process of preparation of the chewable tablet comprises the steps of optionally micronizing Cefixime such that the mean particle size of the Cefixime particles is between 20 mu and 120 mu, blending with other excipients, roll compaction, milling to form granules, blending to form a secondary blend and compression of the secondary blend to form tablets.

Priority: WO2004IN00128 Applic. Date: 2004-05-10

Inventor: WAGH SANJAY [IN]; AGA HIDAYTULLA [IN]; AVACHAT MAKARAND [IN]; SEN HIMADRI [IN]


Application No.: US20070286914A1  Published: 13/Dec/2007

Title: HIGH MOLECULAR WEIGHT POLYSACCHARIDE FRACTION FROM ALOE VERA WITH IMMUNOSTIMULATORY ACTIVITY

Applicant/Assignee: THE UNIVERSITY OF MISSISSIPPI UNIVERSITY OF MISSISSIPPI

Application No.: 11/622509   Filing Date: 12/Jan/2007

Abstract:A complex, water soluble polysaccharide fraction having potent immunostimulatory activity isolated from Aloe vera. The polysaccharide fraction has an apparent molecular weight above 2 million daltons. Its major glycosyl components are glucose, galactose, mannose and arabinose. The invention further includes pharmaceutical compositions containing the instant polysaccharide fraction, optionally in combination with acceptable pharmaceutical carriers and/or excipents. These pharmaceutical compositions may be used to provide immunostimulation to an individual in need of such treatment by administering to such an individual an effective amount of the composition. The polysaccharide fraction is also useful as a component of dietary supplements and as a standardization component of commercial Aloe products.

Priority: US2003-332408 Applic. Date: 2003-08-13; WO2001US21596 Applic. Date: 2001-07-09; US20000217002P Applic. Date: 2000-07-10

Inventor: PASCO DAVID S [US]; PUGH NIRMAL D [US]; ELSOHLY MAHMOUD [US]; ROSS SAMIR [US]


Application No.: US20070287675A1  Published: 13/Dec/2007

Title: Enhanced Delivery of Drug Compositions to Treat Life Threatening Infections

Applicant/Assignee: THE DOW CHEMICAL COMPANY BOARD OF REGENTS UNIVERSITY OF TEXAS SYSTEM

Application No.: 11/660012   Filing Date: 26/Aug/2005

Abstract:Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (Cmax) of at least about 0.25 mug/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.

Priority: US20040605179P Applic. Date: 2004-08-27; WO2005US30543 Applic. Date: 2005-08-26

Inventor: HITT JAMES E [US]; ROGERS TRUE L [US]; SCHERZER BRIAN D [US]; GILLESPIE IAN B [US]; GARCIA PAULA C [US]; BECK NICHOLAS S [US]; TUCKER CHRISTOPHER J [US]; YOUNG TIMOTHY J [US]; HAYES DAVID A [US]; WILLIAMS III ROBERT O [US]; JOHNSTON KEITH P [US]; MCCONVILLE JASON T [US]; PETERS JAY I [US]; TALBERT ROBERT [US]; BURGESS DAVID S [US]


Application No.: US20070289258A1  Published: 20/Dec/2007

Title: Individualized pharmaceutical selection and packaging

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE

Application No.: 11/453571   Filing Date: 14/Jun/2006

Abstract:The present disclosure relates to methods and systems that may be used for individualized selection of one or more pharmaceutical agents and packaging of the one or more pharmaceutical agents.

Priority:

Inventor: JUNG EDWARD K Y [US]; LEVIEN ROYCE A [US]; LORD ROBERT W [US]; MALAMUD MARK A [US]; RINALDO JOHN D [US]; WOOD LOWELL L [US]


Application No.: US20070292454A1  Published: 20/Dec/2007

Title: Therapeutic calcium phosphate particles and methods of manufacture and use

Applicant/Assignee:

Application No.: 11/732596   Filing Date: 03/Apr/2007

Abstract:Novel calcium phosphate core particles, methods of making them, and methods of using them as vaccine adjuvants, as cores, as carriers of biologically active material, and as controlled release matrices for biologically active material are disclosed. The core particles may have a surface modifying agent and/or biologically active material, such as antigenic material or natural immunoenhancing factor, polynucleotide material, or therapeutic proteins or peptides, partially coating the particle or impregnated therein. The core particles have a diameter between about 300 nm and about 4000 nm, more particularly between about 300 nm and about 2000 nm, and even more particularly between about 300 nm and about 1000 nm, are substantially spherical in shape, and have a substantially smooth surface

Priority: US2001-794576 Applic. Date: 2001-02-27; US2000-496771 Applic. Date: 2000-02-03; US19990118356P Applic. Date: 1999-02-03; US19990118364P Applic. Date: 1999-02-03; US19990118355P Applic. Date: 1999-02-03

Inventor: BELL STEVE J [US]; MORCOL TULIN [US]; HE QING [US]


Application No.: US20070292500A1  Published: 20/Dec/2007

Title: Novel Extended Release Composition of Venlafaxine Hydrochloride Containing Polyvinyl Acetate

Applicant/Assignee: LUPIN LTD

Application No.: 11/597460   Filing Date: 21/May/2004

Abstract:Extended release pharmaceutical composition of Venlafaxine hydrochloride comprising a pharmaceutically acceptable capsule containing minitablets. The minitablets comprise from about 20% to about 70% by weight effective amount of Venlafaxine hydrochloride, polyvinyl acetate, one or more pharmaceutically acceptable excipients. The minitablets have diameter from about 1 mm to 5 mm and are coated with a release controlling composition.

Priority: WO2004IN00140 Applic. Date: 2004-05-21

Inventor: WAGH SANJAY [IN]; AGA HIDAYTULLA [IN]; SEN HIMADRI [IN]


Application No.: US20070292505A1  Published: 20/Dec/2007

Title: Controlled release alfuzosin hydrochloride formulation

Applicant/Assignee: ABRIKA PHARMACEUTICALS, INC

Application No.: 11/453651   Filing Date: 15/Jun/2006

Abstract:In certain embodiments the invention is directed to a single layer controlled release pharmaceutical formulation comprising a tablet consisting of a single layer matrix comprising a therapeutically effective amount of alfuzosin or a pharmaceutically acceptable salt thereof dispersed in a controlled release material, wherein the formulation following single dose administration under fed conditions exhibits a mean time to maximum plasma concentration of about 3 hours to about 14 hours.

Priority:

Inventor: YANG TIANRUN [US]; WENG TIMOTHY [US]


Application No.: US20070292506A1  Published: 20/Dec/2007

Title: SUSTAINED RELEASE FORMULATIONS

Applicant/Assignee: AMGEN INC

Application No.: 11/847984   Filing Date: 30/Aug/2007

Abstract:The present invention relates broadly to the field of sustained release formulations. More specifically, the invention describes compositions and methods relating to formulating proteins and/or peptides with purified gallic acid esters. In one example, the gallic acid ester is PentaGalloylGlucose (PGG) and in anther example the gallic acid ester is epigallocatechin gallate (EGCG).

Priority: US2005-114473 Applic. Date: 2005-04-25; US20040565247P Applic. Date: 2004-04-23

Inventor: GOLDENBERG MERRILL S [US]; GU JIAN H [US]


Application No.: US20070292511A1  Published: 20/Dec/2007

Title: Duloxetine hydrochloride delayed release formulations

Applicant/Assignee:

Application No.: 11/805395   Filing Date: 22/May/2007

Abstract:Delayed release formulations of duloxetine hydrochloride and methods for its manufacture are described. A preferred formulation includes an inert core, a drug layer comprising duloxetine hydrochloride, a separating layer and an enteric layer comprising at least one of methacrylic acid copolymer and hydroxypropyl methyl cellulose phthalate.

Priority: US20060802849P Applic. Date: 2006-05-22

Inventor: KOLATKAR GERSHON [IL]; ZISMAN ERELA [IL]


Application No.: US20070293458A1  Published: 20/Dec/2007

Title: Prevention of nuclear, solar, and other radiation-induced tissue damage

Applicant/Assignee: IP-6 RESEARCH INC

Application No.: 11/453843   Filing Date: 16/Jun/2006

Abstract:Inositol hexaphosphate (IP-6) is a polyphosphorylated carbohydrate with potent antioxidant activity to prevent active oxygen species-mediated mutagenesis, cell injury and carcinogenesis. IP-6 also activates DNA repair mechanisms. Sublethal radiation causes DNA damage through the formation of free radicals, reactive oxygen species, and pyrimidine crosslinks leading to cellular proliferation, cell cycle arrest and apoptosis. In the skin it results in the induction of skin cancer, premature skin aging, immuno-suppression, inflammation, and cell death. Likewise sublethal exposure to ionizing radiation as in nuclear blasts (war-time, accidental, terrorist-induced etc), cosmic radiation, etc. also causes the same spectrum of damage to the cells and the organisms with acute symptoms and eventual high risk of many cancers. IP-6 and/or inositol and their pharmaceutically acceptable salts and derivatives, including pyrophosphates and citrate derivatives, significantly counteract the harmful effects of radiation, affecting cell cycle progression in a protective manner (more cells in the protective GI phase) as well as decreasing apoptosis and caspase-3 activation. Various salts of IP-6 are used with comparable efficacy and the combination of IP-6+inositol affords the best protection against radiation-induced cell injury. Thus IP-6 and inositol are effective agents for protection against nuclear, solar and other radiation injuries.

Priority:

Inventor: SHAMSUDDIN ABULKALAM M [US]; VUCENIK IVANA [US]


Application No.: US20070293576A1  Published: 20/Dec/2007

Title: Pharmaceutical Methods, Dosing Regimes And Dosage Forms For The Treatment Of Alzheimer's Disease

Applicant/Assignee: MYRIAD GENETICS, INCORPORATED

Application No.: 11/745928   Filing Date: 08/May/2007

Abstract:In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 mug per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.

Priority: US2004-889971 Applic. Date: 2004-07-12; US20030486769P Applic. Date: 2003-07-11; US20030517666P Applic. Date: 2003-11-05; US20040560685P Applic. Date: 2004-04-07

Inventor: HOBDEN ADRIAN [US]; ZAVITZ KENTON [US]; MATHER GARY [US]; HENDRIX SUZANNE [US]


Application No.: US20070298101A1  Published: 27/Dec/2007

Title: Controlled-Release Formulation Comprising Tamsulosin Hydrochloride

Applicant/Assignee: INSTYTUT FARMACEUTYCZNY

Application No.: 11/573562   Filing Date: 12/Aug/2005

Abstract:Taught herein is a solid, oral, controlled-release pharmaceutical composition of tamsulosin hydrochloride in the form of an enteric-coated tablet, wherein tamsulosin hydrochloride is homogenously dispersed within a matrix consisting of a mixture of a fatty component and a hydrophilic component, together with at least one diluent, and optionally other pharmaceutically acceptable excipients, exhibiting the following dissolution profile of tamsulosin hydrochloride, as measured in a Type II paddle apparatus in accordance with the dissolution testing method specified in the European Pharmacopoeia, i.e., at 37+-0.5 DEG C. and 100 rpm in a 0.1 N HCl buffer for 2 hours, followed by pH 7.2 buffer for the rest of the test: 10-40% dissolution during first 2 hours (in HCl), 35-70% dissolution after 3 h (in pH 7.2 buffer system), not less than 70% dissolution of the declared content after 5 h (in pH 7.2 buffer system).

Priority: PL20040369566 Applic. Date: 2004-08-12; WO2005PL00052 Applic. Date: 2005-08-12

Inventor: WIACKOWSKI LECH [PL]; WIACKOWSKA BEATA [PL]; SZELEJEWSKI WIESLAW [PL]; ZAREMBA ANDRZEJ [PL]; PESTA-DYNDA EDYTA [PL]; MARCHLEWSKA-CELA ZOFIA [PL]


Application No.: US20070298102A1  Published: 27/Dec/2007

Title: Extended Release Pharmaceutical Composition of Celecoxib

Applicant/Assignee:

Application No.: 11/791122   Filing Date: 23/Nov/2005

Abstract:The invention concerns new pharmaceutical agents comprising the known medicinal celecoxib for oral administration and adapted to release the celecoxib in a controlled manner over an extended period, typically for a period of up 10-12 hours or more. The invention also includes a method for the production of the new pharmaceutical agents and a method for their use to achieve the desirable therapeutic effects of celecoxib, for example in the management of pain.

Priority: GB20040025728 Applic. Date: 2004-11-23; GB20050015315 Applic. Date: 2005-07-27; WO2005GB04500 Applic. Date: 2005-11-23

Inventor: DUMICIC ALEKSANDRA [HR]


Application No.: US20070298108A1  Published: 27/Dec/2007

Title: Pharmaceutical Formulation

Applicant/Assignee:

Application No.: 10/590889   Filing Date: 28/Feb/2005

Abstract:Composition were developed which stabilize an active pharmaceutical ingredient in polymorph form susceptible to degradation or interconversion into other polymorph forms, where stabilizing substance is conveniently among silicon dioxide, silicified microcrystalline cellulose, magnesium oxide and polyethylene glycol.

Priority: SI20040000067 Applic. Date: 2004-03-01; WO2005EP02108 Applic. Date: 2005-02-28

Inventor: SVETE PETER [SI]; GRAHEK ROK [SI]; HUMAR VLASTA [SI]; HUSU-KOVACEVIC BREDA [SI]; JERALA-STRUKELJ ZDENKA [SI]


Application No.: US20070298116A1  Published: 27/Dec/2007

Title: Amorphous, spray-dried powders having a reduced moisture content and a high long term stability

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG

Application No.: 10/915298   Filing Date: 10/Aug/2004

Abstract:The present invention relates to spray-dried amorphous powders which contain a pharmaceutical active substance and a matrix-forming agent, preferably a polymer, sugar or sugar alcohol in an amount of >=20-60% (w/w). The powders have a moisture content which is less than 1.2% (w/w), preferably less than 1% (w/w). The present invention also relates to special methods of preparing such powders and methods of administering them by inhalation.

Priority: DE20031039197 Applic. Date: 2003-08-22; US20030503115P Applic. Date: 2003-09-15

Inventor: BECHTOLD-PETERS KAROLINE [DE]; FRIESS WOLFGANG [DE]; SCHUELE STEFANIE [DE]; BASSARAB STEFAN [DE]; GARIDEL PATRICK [DE]; SCHULTZ-FADEMRECHT TORSTEN [DE]


Application No.: US20070299008A1  Published: 27/Dec/2007

Title: Transport Protein Which Is Used To Introduce Chemical Compounds Into Nerve Cells

Applicant/Assignee:

Application No.: 11/661849   Filing Date: 06/Sep/2005

Abstract:The invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum. The protein binds specifically to nerve cells with a higher affinity as the native neurotoxin. The invention also relates to a method for the production of transport protein, the nucleic acids coding for the transport protein, the transport protein containing pharmaceutical and cosmetic compositions and use thereof.

Priority: DE200410043009 Applic. Date: 2004-09-06; WO2005EP09554 Applic. Date: 2005-09-06

Inventor: RUMMEL ANDREAS [DE]


Application No.: US20070299021A1  Published: 27/Dec/2007

Title: Modified Tailed Oligonucleotides

Applicant/Assignee:

Application No.: 10/524724   Filing Date: 18/Aug/2003

Abstract:A nucleic acid molecule comprising first and second domains, said first domain being capable of forming a first specific binding pair with a target sequence of a target RNA species, said second domain consisting of a sequence which forms a second specific binding pair with at least one RNA processing or translation factor, said target sequence being sufficiently close on said target RNA species to an RNA processing or translation site for processing or translation at said site to be enhanced by the action of the factor bound to the second domain.

Priority: GB20020019143 Applic. Date: 2002-08-16; WO2003GB03612 Applic. Date: 2003-08-18

Inventor: DUNCKLEY MATTHEW G [GB]; EPERON IAN C [GB]; MUNTONI FRANCESCO [GB]

US Patent Applications in Excipients, Delivery and Release of
Pharmaceutical Compositions and Actives Published from 2001 to 2007
US Applications Published in 2008
US Applications Published from 2004 to 2005
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
US PROVISIONAL PATENT APPLICATIONS IN EXCIPIENTS, DELIVERY AND RELEASE OF PHARMACEUTICAL COMPOSITIONS PUBLISHED FROM 2006 TO 2007
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications. Salient search terms
included pharmaceutical formulations, excipients, strips, gums, cellulose, lozenge, tablets, capsules, suppositories; solid dosage, nasal inhalation; time, control or sustained drug release;
polysaccharides, polymeric excipients, hyaluronic acid, micro- and nano-spheres, carbomer, povidone, polyacrylates, polymerthacrylates; emulsions; enemas, vaginal, rectal, nasal, ocular
or buccal administration of medications, etc.
Clck to enlarge and view details